{"items": "674", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street", "url": "https://www.fool.com/investing/2024/01/18/these-could-be-the-biggest-nasdaq-100-winners-in-2/", "time_published": "20240118T105000", "authors": ["Keith Speights"], "summary": "Nice gains could be on the way for three stocks if analysts are right.", "banner_image": "https://g.foolcdn.com/editorial/images/761429/woman-streaming-on-tv-with-popcorn.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.217821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.12645", "ticker_sentiment_score": "0.181314", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHTR", "relevance_score": "0.30928", "ticker_sentiment_score": "0.30766", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PARA", "relevance_score": "0.063425", "ticker_sentiment_score": "-0.088878", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.063425", "ticker_sentiment_score": "0.228081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.475618", "ticker_sentiment_score": "0.338854", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Moves -0.37%: What You Should Know", "url": "https://www.zacks.com/stock/news/2211737/biogen-inc-biib-stock-moves--037-what-you-should-know", "time_published": "20240117T225019", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) closed the most recent trading day at $245.27, moving -0.37% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default353.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.117211, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.684485", "ticker_sentiment_score": "0.195683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DoubleVerify Digital Ad Tools Scale Up At Meta Platforms", "url": "https://www.investors.com/research/ibd-stock-of-the-day/dv-stock-doubleverify-meta-platform-digital-ad-partnership-goes-live/", "time_published": "20240117T172300", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "DoubleVerify ( DV ) is the IBD Stock of the Day as the specialist in digital advertising verification forges an entry point from a cup-with-handle base. Bank of America and BMO Capital Markets recently initiated coverage of DV stock with buy and outperform ratings, respectively.", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-17-2024DV.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.143279, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.100729", "ticker_sentiment_score": "0.189215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.199859", "ticker_sentiment_score": "0.23886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DV", "relevance_score": "0.745397", "ticker_sentiment_score": "0.388504", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.100729", "ticker_sentiment_score": "0.060706", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCOR", "relevance_score": "0.100729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.050465", "ticker_sentiment_score": "0.016997", "ticker_sentiment_label": "Neutral"}, {"ticker": "IAS", "relevance_score": "0.100729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZCRF", "relevance_score": "0.050465", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.050465", "ticker_sentiment_score": "0.336707", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alzheimer's Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36655498/alzheimers-disease-diagnostics-treatment-market-revenues-to-reach-us-11-9-billion-by-2030-market-s", "time_published": "20240117T100000", "authors": ["Globe Newswire"], "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate ( CAGR ) of 8.9%, reaching a value of US$11.9 billion by the end of 2030, up from US$6.5 billion ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.329342, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.01403", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.01403", "ticker_sentiment_score": "0.076513", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.028056", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.01403", "ticker_sentiment_score": "0.16322", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.028056", "ticker_sentiment_score": "-0.053084", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042073", "ticker_sentiment_score": "0.148051", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.111877", "ticker_sentiment_score": "0.14894", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gitlab Profitability On Fast Track Amid Market Share Gains", "url": "https://www.investors.com/research/ibd-stock-of-the-day/gtlb-stock-gitlab-profitability-on-fast-track-amid-market-share-gains/", "time_published": "20240116T201900", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Gitlab ( GTLB ) is the IBD Stock Of The Day as the company emerges as a strong player in a fast-growing software market and GTLB stock inflects to consistent quarterly profits. Founded in 2014, GitLab helps customers develop software and deploy new applications in a secure process.", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-16-2024GTLB.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.304482, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.099271", "ticker_sentiment_score": "0.00864", "ticker_sentiment_label": "Neutral"}, {"ticker": "PATH", "relevance_score": "0.099271", "ticker_sentiment_score": "-0.009671", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.099271", "ticker_sentiment_score": "-0.11781", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLB", "relevance_score": "0.881063", "ticker_sentiment_score": "0.471087", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.049732", "ticker_sentiment_score": "0.074334", "ticker_sentiment_label": "Neutral"}, {"ticker": "FROG", "relevance_score": "0.099271", "ticker_sentiment_score": "0.03251", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.099271", "ticker_sentiment_score": "0.03251", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.049732", "ticker_sentiment_score": "0.336595", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BIIB, ZTS, EXAS: Which \"Strong Buy\" Healthcare Stock is Best?", "url": "https://markets.businessinsider.com/news/stocks/biib-zts-exas-which-strong-buy-healthcare-stock-is-best-1032965194", "time_published": "20240113T222408", "authors": ["Tipranks"], "summary": "In 2023, the only thing nearly as hot as generative AI technologies like ChatGPT were GLP-1 injections ( weight-loss drugs like Ozempic ) . GLP-1 may not be the most significant healthcare breakthrough of all time, but it certainly represents one of its most profitable in a while.", "banner_image": "https://blog.tipranks.com/wp-content/uploads/2024/01/image-341-1024x339.png?utm_source=markets.businessinsider.com&utm_medium=referral", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.213068, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZTS", "relevance_score": "0.200688", "ticker_sentiment_score": "0.210098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.278109", "ticker_sentiment_score": "0.219781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.31583", "ticker_sentiment_score": "0.198498", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight", "url": "https://www.prnewswire.com/news-releases/gene-therapy-global-market-is-projected-to-grow-at-a-cagr-of-19-by-2028-predicts-delveinsight-302033381.html", "time_published": "20240112T220100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "LAS VEGAS, Jan. 12, 2024 /PRNewswire/ -- DelveInsight's Gene Therapy Market Insights report provides the current and forecast market analysis, individual leading gene therapy companies' market shares, challenges, gene therapy market drivers, barriers, trends, and key market gene therapy ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.060694", "ticker_sentiment_score": "-0.036112", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.060694", "ticker_sentiment_score": "0.078001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.030369", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.030369", "ticker_sentiment_score": "0.096229", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.060694", "ticker_sentiment_score": "0.055", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.030369", "ticker_sentiment_score": "0.096229", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.030369", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.090931", "ticker_sentiment_score": "0.00954", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRLN", "relevance_score": "0.060694", "ticker_sentiment_score": "-0.036112", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.030369", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.030369", "ticker_sentiment_score": "0.096229", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXEO", "relevance_score": "0.030369", "ticker_sentiment_score": "0.096229", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.090931", "ticker_sentiment_score": "0.00954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIOX", "relevance_score": "0.030369", "ticker_sentiment_score": "-0.05095", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030369", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Interest Rates Matter In Possible DocuSign, Software Buyouts", "url": "https://www.investors.com/news/technology/how-interest-rates-matter-in-possible-docusign-software-buyouts/", "time_published": "20240112T195200", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "DocuSign's ( DOCU ) possible sale to a private equity firm could be a precursor to more deals but perhaps not at big premiums, said an Evercore ISI analyst. DOCU stock rose for a second day in a row amid reports it could be acquired.", "banner_image": "https://www.investors.com/wp-content/uploads/2018/09/stock-DocuSign-10-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.147686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.204936", "ticker_sentiment_score": "0.050998", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.805954", "ticker_sentiment_score": "0.060157", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.103331", "ticker_sentiment_score": "0.364434", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why Regeneron Just Hit A Record High - Again", "url": "https://www.investors.com/news/technology/regn-stock-hits-a-record-high-again-as-it-tacks-on-new-wins/", "time_published": "20240112T182200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "REGN Stock Hits A Record High - Again - As It Tacks On New Wins Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.259275, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.346108", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.123844", "ticker_sentiment_score": "0.02857", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.06211", "ticker_sentiment_score": "0.115369", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.06211", "ticker_sentiment_score": "0.337735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.06211", "ticker_sentiment_score": "0.190789", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/24/01/36615264/evolving-landscape-for-alzheimers-blood-tests-gains-momentum-amid-inaccuracy-concerns", "time_published": "20240112T181714", "authors": ["Vandana Singh"], "summary": "A new era in Alzheimer's diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medicine pioneered blood tests capable of detecting sticky amyloid plaques, a key Alzheimer's indicator.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/dementia-Photo-by-Gerd-Altmann-via-Pixab.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0975, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.155954", "ticker_sentiment_score": "0.144892", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.096036", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.155954", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.078354", "ticker_sentiment_score": "0.193429", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.155954", "ticker_sentiment_score": "0.252164", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Shift4 Wins Price Target Hikes From Truist, Goldman Sachs", "url": "https://www.investors.com/research/ibd-stock-of-the-day/four-stock-shift4-wins-price-target-hikes-from-truist-goldman-sachs/", "time_published": "20240112T172500", "authors": ["REINHARDT KRAUSE", "Investor's Business Daily"], "summary": "Shift4 Payments ( FOUR ) is the IBD Stock Of The Day as the financial technology company wins price target hikes for FOUR stock. On the stock market today, FOUR stock rose around 1% to 75.69. Shift4 stock has gained about 2% in 2024. FOUR stock has climbed 25% over the past 52 weeks.", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-12-2024FOUR.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.280462, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TOST", "relevance_score": "0.125134", "ticker_sentiment_score": "0.063244", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.062761", "ticker_sentiment_score": "0.337867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOUR", "relevance_score": "0.41849", "ticker_sentiment_score": "0.210389", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GigaCloud Stock Takes A Breather After A Big Run Of More Than 200%", "url": "https://www.investors.com/news/technology/gct-stock/", "time_published": "20240111T204200", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "GCT Stock: How GigaCloud Expanded Into Large Parcel E-Commerce Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-ecommerce-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Earnings", "relevance_score": "0.917436"}], "overall_sentiment_score": 0.181583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.116067", "ticker_sentiment_score": "0.040043", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.058188", "ticker_sentiment_score": "0.337168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "W", "relevance_score": "0.116067", "ticker_sentiment_score": "0.040043", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/24/01/36601102/1000-invested-in-this-stock-20-years-ago-would-be-worth-6-100-today", "time_published": "20240111T203115", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 2.08% on an annualized basis producing an average annual return of 9.48%. Currently, Biogen has a market capitalization of $36.66 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "C4  ( CCCC )  Up 6% on Restructuring Plan to Curb Cash Burn", "url": "https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn", "time_published": "20240111T164400", "authors": ["Zacks Equity Research"], "summary": "The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.089571, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.108222", "ticker_sentiment_score": "0.056455", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.119641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.054236", "ticker_sentiment_score": "0.052814", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.413708", "ticker_sentiment_score": "0.050021", "ticker_sentiment_label": "Neutral"}]}, {"title": "Salesforce Upgraded On Software Price Increase Boost", "url": "https://www.investors.com/news/technology/crm-stock-salesforce-stock-upgraded-on-price-increase-boost/", "time_published": "20240111T154100", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "CRM Stock: Salesforce Upgraded On Price Increase Boost Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Salesforce-06-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.282679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.142565", "ticker_sentiment_score": "0.413891", "ticker_sentiment_label": "Bullish"}]}, {"title": "Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36580897/analyst-assesses-cell-programming-focused-ginkgo-bioworks-positioning-amid-revenue-", "time_published": "20240110T192943", "authors": ["Vandana Singh"], "summary": "Wednesday, Ginkgo Bioworks Holdings Inc DNA released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. Preliminary cell engineering and biosecurity revenue are expected to be within the disclosed guidance range of $145 million-$150 million and up ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/dna.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222569, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DNA", "relevance_score": "0.355588", "ticker_sentiment_score": "0.160827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.241684", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.241684", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prothena's  ( PRTA )  Update on Pipeline Progress Disappoints", "url": "https://www.zacks.com/stock/news/2208432/prothenas-prta-update-on-pipeline-progress-disappoints", "time_published": "20240110T170600", "authors": ["Zacks Equity Research"], "summary": "Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRTA", "relevance_score": "0.382088", "ticker_sentiment_score": "0.184408", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.056808", "ticker_sentiment_score": "-0.024017", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.113329", "ticker_sentiment_score": "-0.02735", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.169279", "ticker_sentiment_score": "0.106826", "ticker_sentiment_label": "Neutral"}]}, {"title": "Comparing Biogen With Industry Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/24/01/36578930/comparing-biogen-with-industry-competitors-in-biotechnology-industry", "time_published": "20240110T160038", "authors": ["Benzinga Insights"], "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen BIIB and its primary competitors in the Biotechnology industry.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.043121, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.127456", "ticker_sentiment_score": "-0.051505", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.529659", "ticker_sentiment_score": "0.082668", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Buying Juniper Networks Means For HPE Stock", "url": "https://www.investors.com/news/technology/what-buying-juniper-networks-means-for-hpe-stock/", "time_published": "20240110T155600", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Hewlett Packard Enterprise's ( HPE ) $14 billion all-cash acquisition of Juniper Networks ( JNPR ) will shake-up the computer networking market, giving Cisco Systems ( CSCO ) and others a more formidable rival, analysts say.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-HPE-SanJose-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.132035, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.058903", "ticker_sentiment_score": "0.076989", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.058903", "ticker_sentiment_score": "0.013043", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.117486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.058903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.175433", "ticker_sentiment_score": "0.142502", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.058903", "ticker_sentiment_score": "0.015006", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNPR", "relevance_score": "0.288214", "ticker_sentiment_score": "0.090234", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.058903", "ticker_sentiment_score": "0.119504", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.058903", "ticker_sentiment_score": "0.337242", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Continues Its 225% Winning Streak With A Sales Beat", "url": "https://www.investors.com/news/technology/tgtx-stock-continues-its-surge-after-ms-drug-crushes-sales-estimates/", "time_published": "20240110T143300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "TGTX Stock Continues Its 225% Surge After MS Drug Crushes Sales Estimates Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/09/Stock-DrugPillsCapsuls-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.179146, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGTX", "relevance_score": "0.775204", "ticker_sentiment_score": "0.241411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.137671", "ticker_sentiment_score": "0.406953", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference", "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-provides-business-updates-at-jp-morgan-healthcare-conference-302031259.html", "time_published": "20240110T123500", "authors": ["Ginkgo Bioworks"], "summary": "Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business", "banner_image": "https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.990999"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.219116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.027476", "ticker_sentiment_score": "0.004673", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.190524", "ticker_sentiment_score": "0.121595", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.082299", "ticker_sentiment_score": "0.146189", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.05492", "ticker_sentiment_score": "0.142845", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027476", "ticker_sentiment_score": "0.096738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug Discovery Informatics Market Set to Surge at 10.9% CAGR, to Reach USD 6.8 billion by 2031 | Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/24/01/g36571592/drug-discovery-informatics-market-set-to-surge-at-10-9-cagr-to-reach-usd-6-8-billion-by-2031-trans", "time_published": "20240110T090642", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global drug discovery informatics market is estimated to flourish at a CAGR of 10.9% from 2023 to 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.417591, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.032251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WUXAY", "relevance_score": "0.032251", "ticker_sentiment_score": "0.143898", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASTF", "relevance_score": "0.032251", "ticker_sentiment_score": "0.084129", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.064449", "ticker_sentiment_score": "0.071327", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.032251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFY", "relevance_score": "0.032251", "ticker_sentiment_score": "0.143898", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.064449", "ticker_sentiment_score": "0.248632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CERT", "relevance_score": "0.064449", "ticker_sentiment_score": "0.248632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRL", "relevance_score": "0.032251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMGTF", "relevance_score": "0.096542", "ticker_sentiment_score": "0.080315", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.064449", "ticker_sentiment_score": "0.289891", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Registers a Bigger Fall Than the Market: Important Facts to Note", "url": "https://www.zacks.com/stock/news/2207796/biogen-inc-biib-registers-a-bigger-fall-than-the-market-important-facts-to-note", "time_published": "20240109T225020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default130.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.21786, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.5633", "ticker_sentiment_score": "0.281167", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "China approves Alzheimer's drug Leqembi developed by Eisai and Biogen", "url": "https://www.scmp.com/news/china/science/article/3247845/china-joins-us-and-japan-approving-alzheimers-drug-leqembi-developed-eisai-and-biogen", "time_published": "20240109T220016", "authors": ["Yuke Xie"], "summary": "China has approved the sale of Leqembi, an antibody that has shown to slow progression of the disease for people in the early stages of Alzheimer's. The drug will be launched in the third quarter.", "banner_image": "https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2024/01/09/b9908c0a-6426-4d26-b4a0-845d40607cf3_91574aa5.jpg", "source": "South China Morning Post", "category_within_source": "Companies", "source_domain": "www.scmp.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.045237, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.270773", "ticker_sentiment_score": "0.157222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.09186", "ticker_sentiment_score": "0.055046", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.09186", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines - C4 Therapeutics  ( NASDAQ:CCCC ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36565423/c4-therapeutics-announces-2024-priorities-and-extended-cash-runway-to-advance-portfolio-of-targete", "time_published": "20240109T210100", "authors": ["Globe Newswire"], "summary": "Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.135502, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.025514", "ticker_sentiment_score": "0.050263", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.152178", "ticker_sentiment_score": "0.124314", "ticker_sentiment_label": "Neutral"}]}, {"title": "Palo Alto Networks Pushes AI-Driven Cybersecurity Automation", "url": "https://www.investors.com/research/ibd-stock-of-the-day/panw-stock-palo-alto-networks-pushes-ai-driven-cybersecurity-automation/", "time_published": "20240109T201400", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Palo Alto Networks ( PANW ) is the IBD Stock of the Day as the cybersecurity leader's shares bounce off the 10-week moving average and forge a new entry point. PANW stock jumped 111% in 2023, a move that has some analysts questioning its valuation. On the stock market today, shares rose 3.6% to ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-9-24PANW.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.232183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.091509", "ticker_sentiment_score": "0.135399", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.091509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHKP", "relevance_score": "0.091509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.091509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.04583", "ticker_sentiment_score": "0.147248", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.04583", "ticker_sentiment_score": "0.335683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.671437", "ticker_sentiment_score": "0.288645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top-Notch Biotech Soars - Again - On Rumored Novartis Buyout", "url": "https://www.investors.com/news/technology/cytk-stock-rockets-as-novartis-reportedly-nears-a-buyout-deal/", "time_published": "20240108T191200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "CYTK Stock Rockets As Novartis Reportedly Nears A Buyout Deal Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/07/Stock-Cytokinetics-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.301308, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.762438", "ticker_sentiment_score": "0.381648", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.186738", "ticker_sentiment_score": "0.480646", "ticker_sentiment_label": "Bullish"}]}, {"title": "How To Buy Hot And Promising - But Uncertain - Biotech Stocks", "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/", "time_published": "20240108T173400", "authors": ["Investor's Business Daily", "MATTHEW GALGANI"], "summary": "A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-petridishmolecule-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.972476"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.268824, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.083541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.166169", "ticker_sentiment_score": "0.070153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.166169", "ticker_sentiment_score": "0.200529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.166169", "ticker_sentiment_score": "0.200529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRTX", "relevance_score": "0.246999", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.400052", "ticker_sentiment_score": "0.433085", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.166169", "ticker_sentiment_score": "0.070153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.246999", "ticker_sentiment_score": "0.430266", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.166169", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Slumps As Its Biggest Moneymaker Falls Short", "url": "https://www.investors.com/news/technology/regn-stock-slumps-as-us-eylea-sales-disappoint-exel-stock-slammed-on-guidance/", "time_published": "20240108T145100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "REGN Stock Slumps As U.S. Eylea Sales Disappoint, EXEL Stock Slammed On Guidance Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/Stock-Regeneron02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.149157, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.615462", "ticker_sentiment_score": "-0.308546", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXEL", "relevance_score": "0.722944", "ticker_sentiment_score": "-0.179488", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.172097", "ticker_sentiment_score": "0.458082", "ticker_sentiment_label": "Bullish"}]}, {"title": "Two Biotechs Roughly Double After Snagging Splashy Takeover Deals", "url": "https://www.investors.com/news/technology/amam-stock-harp-stock-catapult-after-snagging-jnj-merck-buyouts/", "time_published": "20240108T141900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "AMAM Stock, HARP Stock Catapult After Snagging J&J, Merck Buyouts Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.210915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.529185", "ticker_sentiment_score": "0.18163", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HARP", "relevance_score": "0.334762", "ticker_sentiment_score": "0.110142", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.131349", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXNX", "relevance_score": "0.436009", "ticker_sentiment_score": "0.214449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.114682", "ticker_sentiment_score": "0.37702", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.227007", "ticker_sentiment_score": "0.160288", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Beleaguered Big Pharma Merck Finally Staging A Comeback?", "url": "https://www.investors.com/news/technology/merck-stock-is-it-finally-time-for-this-2023-laggard-to-stage-a-comeback/", "time_published": "20240108T140005", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Merck Stock: Is It Finally Time For This 2023 Laggard To Stage A Comeback? Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-merckhq-rahway-03-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": -0.023982, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.175433", "ticker_sentiment_score": "-0.153983", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DSKYF", "relevance_score": "0.175433", "ticker_sentiment_score": "-0.153983", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVO", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.117998", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.058903", "ticker_sentiment_score": "0.337242", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Denali Therapeutics  ( NASDAQ:DNLI ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36531655/denali-therapeutics-announces-key-anticipated-2024-milestones-and-priorities-to-further-advance-it", "time_published": "20240108T130000", "authors": ["Globe Newswire"], "summary": "Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readiness Advance broad clinical-stage portfolio of seven therapeutic product candidates across neurodegeneration ( ALS, Parkinson's disease, MS, FTD-GRN ) , lysosomal storage disease ( MPS II, MPS ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.052144, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.076455", "ticker_sentiment_score": "0.0479", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.045918", "ticker_sentiment_score": "0.049457", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.076455", "ticker_sentiment_score": "0.022497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases", "url": "https://www.prnewswire.com/news-releases/ionis-poised-for-continued-momentum-in-2024-with-product-launches-and-key-advances-in-robust-pipeline-of-investigational-medicines-for-serious-diseases-302028429.html", "time_published": "20240108T120300", "authors": ["Inc.", "Ionis Pharmaceuticals"], "summary": "Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of ... PR ...", "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.076847", "ticker_sentiment_score": "0.049882", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.115048", "ticker_sentiment_score": "0.092309", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.038468", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - Caribou Biosciences  ( NASDAQ:CRBU ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36525999/caribou-biosciences-appoints-tim-kelly-as-chief-technology-officer-and-highlights-multiple-clinica", "time_published": "20240107T160000", "authors": ["Globe Newswire"], "summary": "-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrolling ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.157276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXBDF", "relevance_score": "0.030102", "ticker_sentiment_score": "0.102787", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIXX", "relevance_score": "0.030102", "ticker_sentiment_score": "0.102787", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.075161", "ticker_sentiment_score": "0.094267", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045139", "ticker_sentiment_score": "0.113397", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.015054", "ticker_sentiment_score": "0.093924", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss", "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/", "time_published": "20240105T180100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.130124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.404098", "ticker_sentiment_score": "0.232614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.350564", "ticker_sentiment_score": "0.141762", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.120431", "ticker_sentiment_score": "0.106572", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.060388", "ticker_sentiment_score": "0.337437", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Top 10% Stock Is Playing A Game Of Whiplash", "url": "https://www.investors.com/news/technology/kymr-stock-whiplash-shares-surge-then-topple-after-275-million-offering/", "time_published": "20240105T151600", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "KYMR Stock Whiplash: Shares Surge, Then Topple After $275 Million Offering Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-kymera-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}], "overall_sentiment_score": -0.024361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.524949", "ticker_sentiment_score": "0.247639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.143216", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.16171", "ticker_sentiment_score": "0.092165", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.081276", "ticker_sentiment_score": "-0.145926", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.081276", "ticker_sentiment_score": "0.345837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.143216", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stran & Company Appoints Ian Thomas Wall as Chief Information Officer", "url": "https://www.globenewswire.com/news-release/2024/01/04/2804023/0/en/Stran-Company-Appoints-Ian-Thomas-Wall-as-Chief-Information-Officer.html", "time_published": "20240104T140000", "authors": ["Inc.", "Stran & Company"], "summary": "Quincy, MA, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Stran & Company, Inc. ( \"Stran\" or the \"Company\" ) ( NASDAQ: SWAG. SWAGW ) , a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b48087c7-1d09-44f4-b051-176a3ab4efaf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.285414, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04794", "ticker_sentiment_score": "0.073616", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAG", "relevance_score": "0.369456", "ticker_sentiment_score": "0.569935", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.04794", "ticker_sentiment_score": "0.073616", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.", "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets", "time_published": "20240104T123000", "authors": ["Globe Newswire"], "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.287429, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.039745", "ticker_sentiment_score": "0.095935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.158", "ticker_sentiment_score": "0.04959", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform - PR Newswire", "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-program-with-biogen-to-boost-productivity-of-gene-therapy-manufacturing-platform-302025717.html", "time_published": "20240104T120000", "authors": [], "summary": "Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.213907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DNA", "relevance_score": "0.371523", "ticker_sentiment_score": "0.304868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.096283", "ticker_sentiment_score": "0.159307", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH MONOCLONAL ANTIBODIES MAY SLOW DISEASE PROGRESSION", "url": "https://www.newswire.ca/news-releases/potential-breakthrough-for-alzheimer-s-treatment-focused-ultrasound-combined-with-monoclonal-antibodies-may-slow-disease-progression-839028810.html", "time_published": "20240104T120000", "authors": ["Insightec"], "summary": "POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1699588/4172473/Insightec_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.299139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.046452", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046452", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( NASDAQ:BIIB )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2024/01/04/biogen-nasdaqbiib-upgraded-to-buy-by-stocknews-com.html", "time_published": "20240104T075242", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Biogen ( NASDAQ:BIIB - Free Report ) from a hold rating to a buy rating in a report released on Wednesday morning. BIIB has been the topic of several other research reports.", "banner_image": "https://www.marketbeat.com/logos/biogen-inc-logo.jpg?v=20221024141534", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.289804, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.103331", "ticker_sentiment_score": "0.220411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.103331", "ticker_sentiment_score": "0.220411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.051774", "ticker_sentiment_score": "0.031825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.805954", "ticker_sentiment_score": "0.453307", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Sees a More Significant Dip Than Broader Market: Some Facts to Know", "url": "https://www.zacks.com/stock/news/2205288/biogen-inc-biib-sees-a-more-significant-dip-than-broader-market-some-facts-to-know", "time_published": "20240103T225020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default153.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.208852, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.573651", "ticker_sentiment_score": "0.283813", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20240103T112007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.279971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.230782", "ticker_sentiment_score": "0.218856", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 - Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36394374/upward-trajectory-for-biotechpharma-m-a-sector-trends-towards-pre-pandemic-levels-forecasts-posit", "time_published": "20231229T120452", "authors": ["Vandana Singh"], "summary": "According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/29/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.32803, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.266008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALPMF", "relevance_score": "0.081276", "ticker_sentiment_score": "0.223002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMGN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.166513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.16171", "ticker_sentiment_score": "0.238233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CERE", "relevance_score": "0.16171", "ticker_sentiment_score": "0.224966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.316846", "ticker_sentiment_score": "0.316063", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.081276", "ticker_sentiment_score": "0.217853", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRTX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.399542", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.16171", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.16171", "ticker_sentiment_score": "0.332796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.459624", "ticker_sentiment_score": "0.611513", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Declines While Market Improves: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2203359/biogen-inc-biib-stock-declines-while-market-improves-some-information-for-investors", "time_published": "20231228T225020", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.219439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.531019", "ticker_sentiment_score": "0.241213", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement", "url": "https://www.prnewswire.com/news-releases/neurosense-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-302022851.html", "time_published": "20231227T220000", "authors": ["NeuroSense"], "summary": "CAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( \"NeuroSense\" or the \"Company\" ) , a company developing treatments for severe neurodegenerative diseases, today announced that it has received a notification from the Listing Qualifications Department ...", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.004807, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.067919", "ticker_sentiment_score": "-0.024226", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.032452", "ticker_sentiment_label": "Neutral"}]}, {"title": "Understanding Biogen's Position In Biotechnology Industry Compared To Competitors - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/12/36399366/understanding-biogens-position-in-biotechnology-industry-compared-to-competitors", "time_published": "20231227T160039", "authors": ["Benzinga Insights"], "summary": "In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen BIIB and its primary competitors in the Biotechnology industry.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.078769, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.125789", "ticker_sentiment_score": "-0.051184", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.571381", "ticker_sentiment_score": "0.12016", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/12/36389293/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-800-today", "time_published": "20231226T190027", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 3.19% on an annualized basis producing an average annual return of 10.72%. Currently, Biogen has a market capitalization of $37.79 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2202108/fluor-corporation-and-align-technology-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20231226T134500", "authors": ["Zacks Equity Research"], "summary": "Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.998932"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.195928, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.071075", "ticker_sentiment_score": "0.085648", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTR", "relevance_score": "0.047418", "ticker_sentiment_score": "0.108779", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.094669", "ticker_sentiment_score": "0.030919", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.071075", "ticker_sentiment_score": "0.085648", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACM", "relevance_score": "0.047418", "ticker_sentiment_score": "0.108779", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.094669", "ticker_sentiment_score": "0.081917", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRL", "relevance_score": "0.047418", "ticker_sentiment_score": "0.108779", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLR", "relevance_score": "0.16487", "ticker_sentiment_score": "0.204894", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.071075", "ticker_sentiment_score": "0.042296", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.071075", "ticker_sentiment_score": "-0.004048", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.02372", "ticker_sentiment_score": "0.099398", "ticker_sentiment_label": "Neutral"}]}, {"title": "Recap 2023: From postpartum depression to Alzheimer's disease, here are some crucial USFDA approvals this year", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/recap-2023-from-postpartum-depression-to-alzheimers-disease-here-are-some-crucial-usfda-approvals-this-year/3347615/", "time_published": "20231226T081111", "authors": ["Sushmita Panda"], "summary": "The United States Food and Drug Administration ( FDA ) approves a wide range of innovative drugs and products that play a crucial role in improved patient outcomes. Based on the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/pills-g5a602a81d_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.375576, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALPMF", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSRGF", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.080188", "ticker_sentiment_score": "0.168534", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Where To Invest Your 401 ( K ) ", "url": "https://www.kiplinger.com/retirement/401ks/where-to-invest-your-401k", "time_published": "20231225T170013", "authors": ["Nellie S. Huang"], "summary": "These days, 401 ( k ) plans make it relatively easy to save for retirement, but the task of figuring out which funds to invest in is still tricky. A good target-date fund is an easy box to check - and most plans offer one. Low-cost index funds are another no-brainer.", "banner_image": "https://cdn.mos.cms.futurecdn.net/zN3tuwiHZ3YvvYxLNgSy2G-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.247887, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.063258", "ticker_sentiment_score": "0.037124", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.063258", "ticker_sentiment_score": "0.010014", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.042196", "ticker_sentiment_score": "0.047582", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.042196", "ticker_sentiment_score": "0.160021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.042196", "ticker_sentiment_score": "0.160021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.042196", "ticker_sentiment_score": "0.160021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSC", "relevance_score": "0.042196", "ticker_sentiment_score": "-0.005885", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Ginkgo Bioworks Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/12/24/could-ginkgo-bioworks-stock-help-you-become-a-mill/", "time_published": "20231224T131000", "authors": ["David Jagielski"], "summary": "It's easy to see a way for this to be a huge business in the future, but the path ahead of it is by no means a smooth one.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758862%2Fginkgo-bioworks-active-programs.png&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.291738, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DNA", "relevance_score": "0.315628", "ticker_sentiment_score": "0.334277", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.064797", "ticker_sentiment_score": "0.086356", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064797", "ticker_sentiment_score": "0.086356", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.064797", "ticker_sentiment_score": "0.086356", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bristol Myers  ( BMY )  to Buy Karuna Therapeutics for $14B", "url": "https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b", "time_published": "20231222T161300", "authors": ["Zacks Equity Research"], "summary": "Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.172453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KDNY", "relevance_score": "0.066047", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.196344", "ticker_sentiment_score": "0.205598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CERE", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.011271", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.131643", "ticker_sentiment_score": "-0.014174", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.131643", "ticker_sentiment_score": "0.184825", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.066047", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.196344", "ticker_sentiment_score": "0.208624", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024", "url": "https://www.zacks.com/stock/news/2201572/3-beaten-down-biotech-stocks-to-buy-for-a-turnaround-in-2024", "time_published": "20231222T144600", "authors": ["Sundeep Ganoria"], "summary": "Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.165017, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.176502", "ticker_sentiment_score": "0.161578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.132855", "ticker_sentiment_score": "0.050293", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.21961", "ticker_sentiment_score": "0.036706", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.132855", "ticker_sentiment_score": "-0.004879", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.176502", "ticker_sentiment_score": "0.228523", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis  ( IONS ) , AstraZeneca's Eplontersen Receives FDA Nod", "url": "https://www.zacks.com/stock/news/2201529/ionis-ions-astrazenecas-eplontersen-receives-fda-nod", "time_published": "20231222T143400", "authors": ["Zacks Equity Research"], "summary": "FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.137041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.160633", "ticker_sentiment_score": "0.198852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONS", "relevance_score": "0.238913", "ticker_sentiment_score": "0.099539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.521961", "ticker_sentiment_score": "0.243374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.387674", "ticker_sentiment_score": "0.139475", "ticker_sentiment_label": "Neutral"}]}, {"title": "Postpartum Depression Market Size Is Expected To Reach A Value Of $36.9 Billion By 2028 At A CAGR Of 32% As Per The Business Research Company's Postpartum Depression Global Market Report 2024", "url": "https://www.benzinga.com/pressreleases/23/12/g36347132/postpartum-depression-market-size-is-expected-to-reach-a-value-of-36-9-billion-by-2028-at-a-cagr-o", "time_published": "20231221T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Postpartum Depression Global Market Report 2024, the postpartum depression market has witnessed exponential growth, surging from $9.17 billion in 2023 to a projected $12.15 billion in 2024, showcasing a remarkable ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.022229, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.066055", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.066055", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36344473/looking-into-biogens-recent-short-interest", "time_published": "20231221T144521", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has risen 7.8% since its last report. The company recently reported that it has 2.83 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.12 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.", "url": "https://www.fool.com/investing/2023/12/21/looking-to-invest-in-next-big-craze-like-ozempic/", "time_published": "20231221T143000", "authors": ["Alex Carchidi"], "summary": "Diabetes and weight-loss drugs won't be the hottest category of medicines forever.", "banner_image": "https://g.foolcdn.com/editorial/images/758645/investor-thinks-while-looking-out-a-window.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.088101, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.049322", "ticker_sentiment_score": "0.052428", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma", "url": "https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html", "time_published": "20231220T120001", "authors": ["Annika Kim Constantino"], "summary": "Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107347356-1702499004188-gettyimages-1839792823-roy-notitle231211_np5rX.jpeg?v=1702499083&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.016958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.053992", "ticker_sentiment_score": "0.045817", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.08091", "ticker_sentiment_score": "-0.013704", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027011", "ticker_sentiment_score": "0.172126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.091089", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.107736", "ticker_sentiment_score": "0.068154", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08091", "ticker_sentiment_score": "0.132047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.08091", "ticker_sentiment_score": "0.05643", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - PR Newswire", "url": "https://www.prnewswire.com/news-releases/deka-biosciences-adds-industry-veterans-to-its-executive-leadership-team-and-board-of-directors-302019378.html", "time_published": "20231219T190900", "authors": [], "summary": "Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.137095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAG", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.030348", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRAX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.022424", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Out Licenses Europe Rights for HAE Drug to Otsuka", "url": "https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka", "time_published": "20231219T154500", "authors": ["Zacks Equity Research"], "summary": "Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.140302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.358669", "ticker_sentiment_score": "0.100847", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.290607", "ticker_sentiment_score": "0.227701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.423843", "ticker_sentiment_score": "0.161527", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Centralized Marketing Authorizations of Generic Versions of TECFIDERA\u00ae are Revoked by the European Commission - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36300699/centralized-marketing-authorizations-of-generic-versions-of-tecfidera-are-revoked-by-the-european-", "time_published": "20231219T123021", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass., Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA\u00ae ( dimethyl fumarate ) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.11574, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.053153", "ticker_sentiment_score": "0.069705", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.053153", "ticker_sentiment_score": "0.069705", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.005", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.536645", "ticker_sentiment_score": "0.160579", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen's  ( BIIB )  Rare Disease Drug Skyclarys Gets CHMP Nod in EU", "url": "https://www.zacks.com/stock/news/2199443/biogens-biib-rare-disease-drug-skyclarys-gets-chmp-nod-in-eu", "time_published": "20231218T145700", "authors": ["Zacks Equity Research"], "summary": "Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTCT", "relevance_score": "0.315975", "ticker_sentiment_score": "0.169223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADMA", "relevance_score": "0.315975", "ticker_sentiment_score": "0.177391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.315975", "ticker_sentiment_score": "-0.027516", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.183895", "ticker_sentiment_score": "0.091158", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotech Stocks Most Wall Street Analysts Are Bullish About", "url": "https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about", "time_published": "20231218T140100", "authors": ["Ekta Bagri"], "summary": "Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.26846, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRSP", "relevance_score": "0.149424", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITCI", "relevance_score": "0.112357", "ticker_sentiment_score": "0.110298", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.037563", "ticker_sentiment_score": "0.202684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CERE", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.075043", "ticker_sentiment_score": "0.061531", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTX Celebrates Resilience and Innovation in North Texas Biosciences Ecosystem", "url": "https://www.prnewswire.com/news-releases/biontx-celebrates-resilience-and-innovation-in-north-texas-biosciences-ecosystem-302017055.html", "time_published": "20231215T193800", "authors": ["BioNTX"], "summary": "DALLAS, Dec. 15, 2023 /PRNewswire/ -- BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success.", "banner_image": "https://mma.prnewswire.com/media/2001725/BIONTX_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.510159, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.205807", "ticker_sentiment_score": "0.240955", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CHMP Issues Positive Opinion for Biogen's SKYCLARYS\u00ae  ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36257323/chmp-issues-positive-opinion-for-biogens-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedr", "time_published": "20231215T140525", "authors": ["Globe Newswire"], "summary": "Friedreich's ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen's growing portfolio in rare diseases and focus on addressing unmet needs of patients living with neuromuscular diseases CAMBRIDGE, Mass., Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.050848, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.033006", "ticker_sentiment_score": "0.146177", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.033006", "ticker_sentiment_score": "0.146177", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.259382", "ticker_sentiment_score": "0.080298", "ticker_sentiment_label": "Neutral"}]}, {"title": "CHMP Issues Positive Opinion for Biogen's SKYCLARYS\u00ae  ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease", "url": "https://www.globenewswire.com/news-release/2023/12/15/2797103/0/en/CHMP-Issues-Positive-Opinion-for-Biogen-s-SKYCLARYS-omaveloxolone-the-First-Therapy-to-Treat-Friedreich-s-Ataxia-a-Rare-Neurodegenerative-Disease.html", "time_published": "20231215T140500", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) recommended marketing authorization for SKYCLARYS\u00ae ( omaveloxolone ) for the treatment of Friedreich's ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.077122, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.033006", "ticker_sentiment_score": "0.065779", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.033006", "ticker_sentiment_score": "0.065779", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.22792", "ticker_sentiment_score": "0.091747", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Things to know for Dec. 15: Israel, Vaccines, European Union, Storms, Train collision", "url": "https://www.cnn.com/2023/12/15/us/5-things-to-know-for-dec-15-israel-vaccines-european-union-storms-train-collision/index.html", "time_published": "20231215T114000", "authors": ["Alexandra Banner"], "summary": "Some of America's legacy airlines are hiring aggressively and adjusting flight schedules to accommodate staffing shortages as they prepare to to fly around 2.8 million passengers a day during the end-of-year holiday rush. Here's what else you need to know to Get Up to Speed and On with Your Day.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231208191257-hidden-treasures-hk-wakesurfing-video-cover.jpg?c=16x9&q=w_850,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.02407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.081691", "ticker_sentiment_score": "0.132696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.040899", "ticker_sentiment_score": "0.028801", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040899", "ticker_sentiment_score": "0.028801", "ticker_sentiment_label": "Neutral"}]}, {"title": "First postpartum depression pill now available in the US, drugmakers say", "url": "https://www.cnn.com/2023/12/14/health/postpartum-depression-pill-zurzuvae/index.html", "time_published": "20231215T040400", "authors": ["Jacqueline Howard"], "summary": "The first oral pill approved in the United States to treat postpartum depression is now available by prescription, according to the drugmakers. The US Food and Drug Administration approved the therapy, called Zurzuvae, in August.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230804095045-03-postpartum-depression-pill-zuranolone.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.034103, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.052226", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.052226", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.104228", "ticker_sentiment_score": "0.049715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.104228", "ticker_sentiment_score": "0.130792", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html", "time_published": "20231214T221500", "authors": [], "summary": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDPQ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTGN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.22385", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "ZURZUVAE\u2122  ( zuranolone )  CIV, a Landmark Oral Treatment for Women with Postpartum Depression  ( PPD ) , is Now Available in the U.S. - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36232867/zurzuvae-zuranolone-civ-a-landmark-oral-treatment-for-women-with-postpartum-depression-ppd-is-now-", "time_published": "20231214T113000", "authors": ["Globe Newswire"], "summary": "ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.017174, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.01441", "ticker_sentiment_score": "0.058508", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.01441", "ticker_sentiment_score": "0.058508", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.086297", "ticker_sentiment_score": "0.05475", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.14333", "ticker_sentiment_score": "0.052345", "ticker_sentiment_label": "Neutral"}]}, {"title": "ZURZUVAE\u2122  ( zuranolone )  CIV, a Landmark Oral Treatment for Women with Postpartum Depression  ( PPD ) , is Now Available in the U.S.", "url": "https://www.globenewswire.com/news-release/2023/12/14/2796102/0/en/ZURZUVAE-zuranolone-CIV-a-Landmark-Oral-Treatment-for-Women-with-Postpartum-Depression-PPD-is-Now-Available-in-the-U-S.html", "time_published": "20231214T113000", "authors": ["Biogen Inc."], "summary": "ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.039144, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.014612", "ticker_sentiment_score": "0.058602", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.014612", "ticker_sentiment_score": "0.058602", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.058401", "ticker_sentiment_score": "0.118242", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.130926", "ticker_sentiment_score": "0.061208", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. Neurologists Eagerly Await Promising Oral Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement", "url": "https://www.benzinga.com/pressreleases/23/12/g36222947/u-s-neurologists-eagerly-await-promising-oral-brutons-tyrosine-kinase-inhibitors-in-multiple-scler", "time_published": "20231213T190351", "authors": ["Globe Newswire"], "summary": "Exton, PA, Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Several clinical trials are underway for Bruton's tyrosine kinase inhibitors ( BTKi ) targeting relapsing and progressive multiple sclerosis ( RMS/PPMS ) .", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.243631, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.052455", "ticker_sentiment_score": "-0.013", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052455", "ticker_sentiment_score": "-0.013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/12/36218811/industry-comparison-evaluating-biogen-against-competitors-in-biotechnology-industry", "time_published": "20231213T160049", "authors": ["Benzinga Insights"], "summary": "In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Biogen BIIB in relation to its major competitors in the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.118475, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.051247", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.572601", "ticker_sentiment_score": "0.193461", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eisai to launch Alzheimer's drug Leqembi in Japan on Dec 20", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-launch-alzheimers-drug-leqembi-japan-dec-20-2023-12-13/", "time_published": "20231213T085300", "authors": ["Reuters"], "summary": "Eisai to launch Alzheimer's drug Leqembi in Japan on Dec ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OAYYXJV7MFNPRFTBFUEG4CYWVI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.114087, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.535653", "ticker_sentiment_score": "0.109875", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.192694", "ticker_sentiment_score": "0.136769", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.374312", "ticker_sentiment_score": "0.149528", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity", "url": "https://www.zacks.com/stock/news/2196695/the-zacks-analyst-blog-highlights-biogen-prothena-ac-immunes-and-vaxxinity", "time_published": "20231212T141000", "authors": ["Zacks Equity Research"], "summary": "Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.191433, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACIU", "relevance_score": "0.128592", "ticker_sentiment_score": "-0.017717", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.212674", "ticker_sentiment_score": "0.08018", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.037015", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.04303", "ticker_sentiment_score": "0.124792", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.170878", "ticker_sentiment_score": "0.131235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development", "url": "https://www.benzinga.com/pressreleases/23/12/g36194201/vanqua-bio-advances-clinical-candidate-for-parkinsons-disease-expands-leadership-team-to-support-f", "time_published": "20231212T123000", "authors": ["Globe Newswire"], "summary": "CHICAGO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase ( GCase ) , will enter clinical development in the first quarter of 2024, with an initial ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.192865, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYTK", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.047092", "ticker_sentiment_score": "0.088836", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.047092", "ticker_sentiment_score": "0.094795", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/12/12/sangamo-therapeutics-nasdaqsgmo-research-coverage-started-at-stocknews-com.html", "time_published": "20231212T062045", "authors": ["Defense World Staff"], "summary": "Equities research analysts at StockNews.com began coverage on shares of Sangamo Therapeutics ( NASDAQ:SGMO - Get Free Report ) in a note issued to investors on Tuesday. The brokerage set a \"sell\" rating on the biopharmaceutical company's stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.168554, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.790817", "ticker_sentiment_score": "0.265475", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.055621", "ticker_sentiment_score": "0.055882", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.055621", "ticker_sentiment_score": "0.055882", "ticker_sentiment_label": "Neutral"}, {"ticker": "M", "relevance_score": "0.055621", "ticker_sentiment_score": "-0.011001", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.055621", "ticker_sentiment_score": "0.055882", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055621", "ticker_sentiment_score": "0.105872", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/12/36185858/1000-invested-in-this-stock-20-years-ago-would-be-worth-7-200-today", "time_published": "20231211T213052", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 2.89% on an annualized basis producing an average annual return of 10.34%. Currently, Biogen has a market capitalization of $35.73 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Alzheimer's Disease Space Evolves in 2023: Stocks in Focus", "url": "https://www.zacks.com/stock/news/2196083/alzheimers-disease-space-evolves-in-2023-stocks-in-focus", "time_published": "20231211T140600", "authors": ["Ekta Bagri"], "summary": "The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.201058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACIU", "relevance_score": "0.136888", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.181819", "ticker_sentiment_score": "0.109759", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.061265", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.04583", "ticker_sentiment_score": "0.124967", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.136888", "ticker_sentiment_score": "0.191134", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs - BioXcel Therapeutics  ( NASDAQ:BTAI ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36173480/bioxcel-therapeutics-strengthens-clinical-development-leadership-to-advance-late-stage-programs", "time_published": "20231211T120000", "authors": ["Globe Newswire"], "summary": "Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- BioXcel Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.07528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BTAI", "relevance_score": "0.371892", "ticker_sentiment_score": "0.211654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.025761", "ticker_sentiment_score": "0.072552", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.025761", "ticker_sentiment_score": "0.072552", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025761", "ticker_sentiment_score": "0.038005", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond", "url": "https://www.fool.com/investing/2023/12/09/2-popular-stocks-to-avoid-like-the-plague-in-2024/", "time_published": "20231209T185200", "authors": ["Prosper Junior Bakiny"], "summary": "These stocks aren't worth the risk.", "banner_image": "https://media.ycharts.com/charts/94f176b8227cf3f81b6d053a6ca0781c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.160495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACB", "relevance_score": "0.375722", "ticker_sentiment_score": "0.208505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.193465", "ticker_sentiment_score": "0.008012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Biogen Inc.  ( BIIB )  Up 6.4% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2195589/why-is-biogen-inc-biib-up-64-since-last-earnings-report", "time_published": "20231208T163042", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default20.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.059351, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.030641", "ticker_sentiment_score": "0.051863", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.030641", "ticker_sentiment_score": "0.051863", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.030641", "ticker_sentiment_score": "0.055617", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.091743", "ticker_sentiment_score": "0.043911", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.355164", "ticker_sentiment_score": "0.134467", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?", "url": "https://www.fool.com/investing/2023/12/08/abbvies-on-an-acquisition-binge-could-your-favorit/", "time_published": "20231208T103800", "authors": ["Cory Renauer"], "summary": "Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757472%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.105364, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CERE", "relevance_score": "0.204072", "ticker_sentiment_score": "0.003284", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.253514", "ticker_sentiment_score": "0.005928", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.04259", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.051551", "ticker_sentiment_score": "-0.011015", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051551", "ticker_sentiment_score": "0.18687", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights", "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html", "time_published": "20231208T071400", "authors": ["Coherent Market Insights"], "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.", "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.196644, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints", "url": "https://www.prnewswire.com/news-releases/neurosenses-phase-2b-als-trial-achieves-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-302005837.html", "time_published": "20231205T130000", "authors": ["NeuroSense"], "summary": "CAMBRIDGE, Mass., Dec. 5, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( \"NeuroSense\" ) , a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy ...", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.047833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.101797", "ticker_sentiment_score": "-0.046828", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.226536", "ticker_sentiment_score": "-0.04247", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023", "url": "https://www.prnewswire.com/news-releases/neurosense-to-report-phase-2b-als-topline-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-on-december-5-2023-302005044.html", "time_published": "20231204T210100", "authors": ["NeuroSense"], "summary": "NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.019217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.043421", "ticker_sentiment_score": "-0.037602", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.214557", "ticker_sentiment_score": "-0.01196", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Earns Sell Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/12/04/sangamo-therapeutics-nasdaqsgmo-earns-sell-rating-from-analysts-at-stocknews-com.html", "time_published": "20231204T062444", "authors": ["Defense World Staff"], "summary": "Sangamo Therapeutics ( NASDAQ:SGMO ) Earns Sell Rating from ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.150865, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.819522", "ticker_sentiment_score": "0.21229", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.05339", "ticker_sentiment_score": "0.023965", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.05339", "ticker_sentiment_score": "0.023965", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.05339", "ticker_sentiment_score": "0.023965", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.05339", "ticker_sentiment_score": "0.150707", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-size-to-grow-by-usd-65-13-billion-from-2022-2027-aquestive-therapeutics-inc-bausch-health-companies-inc-biogen-inc-and-more-among-the-major-companies-in-the-market--technavio-302002042.html", "time_published": "20231201T183000", "authors": [], "summary": "Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.213768, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCLI", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTLHF", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.11894", "ticker_sentiment_score": "0.013603", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "NPNKF", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.059636", "ticker_sentiment_score": "0.014995", "ticker_sentiment_label": "Neutral"}]}, {"title": "Annovis Bio  ( ANVS )  Stock Surges 38% in a Month: Here's Why", "url": "https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-heres-why", "time_published": "20231201T161200", "authors": ["Zacks Equity Research"], "summary": "Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.235366", "ticker_sentiment_score": "0.116995", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.235366", "ticker_sentiment_score": "0.069513", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.324902", "ticker_sentiment_score": "0.006998", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.142565", "ticker_sentiment_score": "0.146836", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html", "time_published": "20231201T073500", "authors": [], "summary": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.290604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIC", "relevance_score": "0.048523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}]}, {"title": "Codexis to Host Virtual KOL Event on its ECO Synthesis\u2122 Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023 - Codexis  ( NASDAQ:CDXS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35989473/codexis-to-host-virtual-kol-event-on-its-eco-synthesis-platform-and-the-future-of-rnai-therapeutic", "time_published": "20231128T210524", "authors": ["Globe Newswire"], "summary": "REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.101388, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.02849", "ticker_sentiment_score": "0.073265", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.02849", "ticker_sentiment_score": "0.073265", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXS", "relevance_score": "0.628066", "ticker_sentiment_score": "0.143855", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRRO", "relevance_score": "0.02849", "ticker_sentiment_score": "0.009195", "ticker_sentiment_label": "Neutral"}, {"ticker": "WVE", "relevance_score": "0.02849", "ticker_sentiment_score": "0.009195", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.056943", "ticker_sentiment_score": "0.037981", "ticker_sentiment_label": "Neutral"}, {"ticker": "PROK", "relevance_score": "0.02849", "ticker_sentiment_score": "0.073265", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.02849", "ticker_sentiment_score": "0.073265", "ticker_sentiment_label": "Neutral"}]}, {"title": "Codexis to Host Virtual KOL Event on its ECO Synthesis\u2122 Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023", "url": "https://www.globenewswire.com/news-release/2023/11/28/2787362/24825/en/Codexis-to-Host-Virtual-KOL-Event-on-its-ECO-Synthesis-Platform-and-the-Future-of-RNAi-Therapeutics-Manufacturing-on-December-8-2023.html", "time_published": "20231128T210500", "authors": ["Codexis", "Inc."], "summary": "REDWOOD CITY, Calif., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- Codexis, Inc. ( NASDAQ: CDXS ) , a leading enzyme engineering company, today announced it will host a virtual key opinion leader ( KOL ) event focused on its Enzyme-Catalyzed Oligonucleotide ( ECO ) Synthesis\u2122 platform and the broader RNA ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/ebbfa755-c2db-4783-aace-43c700ba3369", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.106183, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.028972", "ticker_sentiment_score": "0.073454", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.028972", "ticker_sentiment_score": "0.073454", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXS", "relevance_score": "0.636117", "ticker_sentiment_score": "0.144829", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRRO", "relevance_score": "0.028972", "ticker_sentiment_score": "0.009224", "ticker_sentiment_label": "Neutral"}, {"ticker": "WVE", "relevance_score": "0.028972", "ticker_sentiment_score": "0.009224", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.057907", "ticker_sentiment_score": "0.037994", "ticker_sentiment_label": "Neutral"}, {"ticker": "PROK", "relevance_score": "0.028972", "ticker_sentiment_score": "0.073454", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028972", "ticker_sentiment_score": "0.073454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Comparative Study: Biogen And Industry Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/11/35982754/comparative-study-biogen-and-industry-competitors-in-biotechnology-industry", "time_published": "20231128T160018", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.13338, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.050816", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.516883", "ticker_sentiment_score": "0.167844", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/il/news-releases/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-301999234.html", "time_published": "20231128T134500", "authors": ["NeuroSense"], "summary": "\u2022 Topline clinical secondary efficacy results and primary safety endpoints from Phase ALS trial ( PARADIGM ) expected in early \u2022 Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue ...", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.113423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.022202", "ticker_sentiment_score": "0.151982", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRSN", "relevance_score": "0.110666", "ticker_sentiment_score": "-0.025967", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-301999234.html", "time_published": "20231128T134500", "authors": ["NeuroSense"], "summary": "\u2022 Topline clinical secondary efficacy results and primary safety endpoints from Phase ALS trial ( PARADIGM ) expected in early \u2022 Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue ...", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.113423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.022202", "ticker_sentiment_score": "0.151982", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRSN", "relevance_score": "0.110666", "ticker_sentiment_score": "-0.025967", "ticker_sentiment_label": "Neutral"}]}, {"title": "Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer", "url": "https://www.globenewswire.com/news-release/2023/11/27/2786524/0/en/Terns-Pharmaceuticals-Mourns-the-Loss-of-Senthil-Sundaram-Former-Chief-Executive-Officer.html", "time_published": "20231127T210500", "authors": ["Terns Pharmaceuticals", "Inc."], "summary": "FOSTER CITY, Calif., Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( \"Terns\" or the \"Company\" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/00cb412c-d8d1-4c3f-9839-803cd3024504", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.09716, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TERN", "relevance_score": "0.217508", "ticker_sentiment_score": "-0.117196", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.073321", "ticker_sentiment_score": "0.039356", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.073321", "ticker_sentiment_score": "0.039356", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.146025", "ticker_sentiment_score": "0.049104", "ticker_sentiment_label": "Neutral"}]}, {"title": "Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer - Terns Pharma  ( NASDAQ:TERN ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35968012/terns-pharmaceuticals-mourns-the-loss-of-senthil-sundaram-former-chief-executive-officer", "time_published": "20231127T210500", "authors": ["Globe Newswire"], "summary": "FOSTER CITY, Calif., Nov. 27, 2023 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( \"Terns\" or the \"Company\" ) TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today announced that ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.072936, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TERN", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.159868", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.070105", "ticker_sentiment_score": "0.039219", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.070105", "ticker_sentiment_score": "0.039219", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.139669", "ticker_sentiment_score": "0.047874", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware Appoints John A. Cunningham, COO of VRARA and Former Unity Executive, to International Advisory Board for U.S. Expansion Drive", "url": "https://www.globenewswire.com/news-release/2023/11/27/2785842/0/en/Virtualware-Appoints-John-A-Cunningham-COO-of-VRARA-and-Former-Unity-Executive-to-International-Advisory-Board-for-U-S-Expansion-Drive.html", "time_published": "20231127T064500", "authors": ["VIRTUALWARE 2007 SA"], "summary": "BILBAO, Spain and MIAMI, November 27, 2023.- Virtualware, a European leader in Virtual Reality solutions, has appointed VR and AR industry leader John A. Cunningham to its International Advisory Board in a move that marks a significant step in Virtualware's U.S. market expansion.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/6aee44c0-62ac-4f66-9be0-b3578d202005", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.176107, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.042122", "ticker_sentiment_score": "0.103523", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.042122", "ticker_sentiment_score": "0.157011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBDSF", "relevance_score": "0.042122", "ticker_sentiment_score": "0.103523", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.042122", "ticker_sentiment_score": "0.103523", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042122", "ticker_sentiment_score": "0.103523", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.042122", "ticker_sentiment_score": "0.103523", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/26/sangamo-therapeutics-nasdaqsgmo-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231126T081448", "authors": ["Defense World Staff"], "summary": "Sangamo Therapeutics ( NASDAQ:SGMO ) Now Covered by Analysts ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.120193, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.789652", "ticker_sentiment_score": "0.201075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.018856", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.049939", "ticker_sentiment_score": "0.018856", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.018856", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.049939", "ticker_sentiment_score": "0.018856", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSBC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.176207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.049939", "ticker_sentiment_score": "0.105246", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals", "time_published": "20231124T141000", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.225302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.127795", "ticker_sentiment_score": "0.105904", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.171316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0854", "ticker_sentiment_score": "0.090184", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.021388", "ticker_sentiment_score": "0.106821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright", "url": "https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright", "time_published": "20231122T130700", "authors": ["Ekta Bagri"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.111281", "ticker_sentiment_score": "0.139072", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.172148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.066908", "ticker_sentiment_score": "0.125817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.022326", "ticker_sentiment_score": "0.154669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o", "time_published": "20231121T201625", "authors": ["Vandana Singh"], "summary": "Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins ( white matter ) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/21/aapharma_5.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.087042, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACIU", "relevance_score": "0.229149", "ticker_sentiment_score": "0.303386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.07556", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.229149", "ticker_sentiment_score": "0.303386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VAXX", "relevance_score": "0.229149", "ticker_sentiment_score": "0.303386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.048396", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.07556", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/18/sangamo-therapeutics-nasdaqsgmo-now-covered-by-analysts-at-stocknews-com.html", "time_published": "20231118T081644", "authors": ["Defense World Staff"], "summary": "Sangamo Therapeutics ( NASDAQ:SGMO ) Now Covered by Analysts ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.195428, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.81111", "ticker_sentiment_score": "0.308024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.058188", "ticker_sentiment_score": "0.040999", "ticker_sentiment_label": "Neutral"}, {"ticker": "JCI", "relevance_score": "0.058188", "ticker_sentiment_score": "-0.013006", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.058188", "ticker_sentiment_score": "0.040999", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.058188", "ticker_sentiment_score": "0.040999", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.058188", "ticker_sentiment_score": "0.040999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.058188", "ticker_sentiment_score": "0.12399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prothena  ( PRTA )  Pipeline Shows Promise in a Tough AD Market", "url": "https://www.zacks.com/stock/news/2186212/prothena-prta-pipeline-shows-promise-in-a-tough-ad-market", "time_published": "20231117T183500", "authors": ["Zacks Equity Research"], "summary": "Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.138529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRTA", "relevance_score": "0.558244", "ticker_sentiment_score": "0.078006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.061315", "ticker_sentiment_score": "-0.078544", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.122269", "ticker_sentiment_score": "-0.093569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.299478", "ticker_sentiment_score": "0.067233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exclusive: Manufacturer Lonza says it will not fill obesity drug syringes", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/manufacturer-lonza-says-it-will-not-fill-obesity-drug-syringes-2023-11-17/", "time_published": "20231117T134900", "authors": ["Ludwig Burger", "Paul Arnold"], "summary": "The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/KA4L3IWZZBMZHI5IPSSDRGTPCA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.05673, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.056143", "ticker_sentiment_score": "0.051907", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.056143", "ticker_sentiment_score": "0.18296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.056143", "ticker_sentiment_score": "0.0659", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.056143", "ticker_sentiment_score": "0.007003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.056143", "ticker_sentiment_score": "0.0659", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:CHF", "relevance_score": "0.056143", "ticker_sentiment_score": "-0.045913", "ticker_sentiment_label": "Neutral"}]}, {"title": "The War In Alzheimer's Treatment Is Just Beginning", "url": "https://www.investors.com/news/technology/biotech-stocks-the-war-in-alzheimers-treatment-is-just-beginning-why-there-is-still-hope/", "time_published": "20231117T131500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks: The Race For An Alzheimer's Cure Takes Off Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/A1jump2c-112023-1024x384.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.123012, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VAXX", "relevance_score": "0.067871", "ticker_sentiment_score": "-0.096986", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.033966", "ticker_sentiment_score": "-0.089096", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.067871", "ticker_sentiment_score": "0.189791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHPEF", "relevance_score": "0.016987", "ticker_sentiment_score": "-0.009199", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.05093", "ticker_sentiment_score": "0.057996", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABOS", "relevance_score": "0.033966", "ticker_sentiment_score": "0.068935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.05093", "ticker_sentiment_score": "-0.09242", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.135252", "ticker_sentiment_score": "0.103934", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033966", "ticker_sentiment_score": "-0.088133", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.21806", "ticker_sentiment_score": "0.140978", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/11/35836598/heres-how-much-1000-invested-in-biogen-20-years-ago-would-be-worth-today", "time_published": "20231116T200016", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 9.84%. Currently, Biogen has a market capitalization of $33.56 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is The Alzheimer's Drug Leqembi Eligible For Medicare Coverage?", "url": "https://www.forbes.com/health/medicare/leqembi-medicare/", "time_published": "20231116T125921", "authors": ["Caren Weiner"], "summary": "Medicare Coverage For Leqembi: What To Know - Forbes Health Forbes ...", "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/health/wp-content/uploads/2022/11/Screen-Shot-2022-11-21-at-9.47.54-AM.png", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.226263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.143415", "ticker_sentiment_score": "0.188774", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.143415", "ticker_sentiment_score": "0.206992", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.143415", "ticker_sentiment_score": "0.206992", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eli Lilly plans new 2 billion euro German plant", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-new-2-bln-euro-german-plant-source-2023-11-16/", "time_published": "20231116T112500", "authors": ["Andreas Rinke", "Rene Wagner", "Klaus Lauer"], "summary": "Eli Lilly plans single-digit billion dollar new German plant ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/AVII7E2CZ5PZ3MJ5RTH67AGZWI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.096354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.078611", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.078611", "ticker_sentiment_score": "-0.050654", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.078611", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.078611", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/11/35780726/industry-comparison-evaluating-biogen-against-competitors-in-biotechnology-industry", "time_published": "20231114T160019", "authors": ["Benzinga Insights"], "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Biogen BIIB alongside its primary competitors in ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.111974, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.121343", "ticker_sentiment_score": "-0.050354", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.554751", "ticker_sentiment_score": "0.141136", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Early-Stage Genetic Disorder Data Shows Promise", "url": "https://www.zacks.com/stock/news/2183312/ionis-ions-early-stage-genetic-disorder-data-shows-promise", "time_published": "20231113T144600", "authors": ["Zacks Equity Research"], "summary": "Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.342093", "ticker_sentiment_score": "-0.067359", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.342093", "ticker_sentiment_score": "0.13504", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.342093", "ticker_sentiment_score": "0.048762", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.420083", "ticker_sentiment_score": "0.216924", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nereid Therapeutics Appoints Michael Kauffman as CEO", "url": "https://www.prnewswire.com/news-releases/nereid-therapeutics-appoints-michael-kauffman-as-ceo-301986045.html", "time_published": "20231113T130000", "authors": ["Nereid Therapeutics"], "summary": "Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid's work to advance multiple programs towards the clinic", "banner_image": "https://mma.prnewswire.com/media/2274425/Nereid_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.268922, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KZR", "relevance_score": "0.063763", "ticker_sentiment_score": "0.040012", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSTM", "relevance_score": "0.063763", "ticker_sentiment_score": "0.040012", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACET", "relevance_score": "0.063763", "ticker_sentiment_score": "0.040012", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.063763", "ticker_sentiment_score": "0.040012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fosun Pharma to deliver China-made surgical robots in key medical milestone", "url": "https://www.scmp.com/business/china-business/article/3241245/fosun-pharma-prepares-deliver-da-vinci-surgical-robots-make-advanced-medical-treatment-affordable", "time_published": "20231112T081406", "authors": ["Daniel Ren"], "summary": "The Fosun Group is looking to make another major leap in the healthcare industry as it prepares to deliver locally-made surgical robots to hospitals.", "banner_image": "https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2023/11/12/b53b0b69-dd22-4e24-8057-5215d3549ce1_800c4d68.jpg", "source": "South China Morning Post", "category_within_source": "Economy", "source_domain": "www.scmp.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.232756, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOSUF", "relevance_score": "0.279015", "ticker_sentiment_score": "0.200829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOMO", "relevance_score": "0.056943", "ticker_sentiment_score": "0.078004", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.113597", "ticker_sentiment_score": "0.1186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFOSF", "relevance_score": "0.056943", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.056943", "ticker_sentiment_score": "-0.090936", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.056943", "ticker_sentiment_score": "0.082934", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.235", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen  ( NASDAQ:BIIB )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/12/biogen-nasdaqbiib-stock-rating-lowered-by-stocknews-com.html", "time_published": "20231112T065444", "authors": ["Defense World Staff"], "summary": "Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by StockNews.com from a \"buy\" rating to a \"hold\" rating in a note issued to investors on Friday. BIIB has been the subject of several other reports.", "banner_image": "https://www.marketbeat.com/logos/biogen-inc-logo.jpg?v=20221024141534", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.236959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.058047", "ticker_sentiment_score": "0.027993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.058047", "ticker_sentiment_score": "0.027993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNS", "relevance_score": "0.058047", "ticker_sentiment_score": "0.027993", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.058047", "ticker_sentiment_score": "0.109027", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLUG", "relevance_score": "0.058047", "ticker_sentiment_score": "0.109027", "ticker_sentiment_label": "Neutral"}, {"ticker": "HBNC", "relevance_score": "0.115787", "ticker_sentiment_score": "0.204271", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.873767", "ticker_sentiment_score": "0.400757", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/11/12/sangamo-therapeutics-nasdaqsgmo-coverage-initiated-at-stocknews-com.html", "time_published": "20231112T063446", "authors": ["Defense World Staff"], "summary": "Sangamo Therapeutics ( NASDAQ:SGMO ) Coverage Initiated at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.233499, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.778186", "ticker_sentiment_score": "0.366488", "ticker_sentiment_label": "Bullish"}, {"ticker": "TFC", "relevance_score": "0.054114", "ticker_sentiment_score": "0.063857", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.054114", "ticker_sentiment_score": "0.063857", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.054114", "ticker_sentiment_score": "0.063857", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBS", "relevance_score": "0.107978", "ticker_sentiment_score": "0.240697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHW", "relevance_score": "0.107978", "ticker_sentiment_score": "0.240697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.018", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLUG", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.018", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.054114", "ticker_sentiment_score": "0.127763", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome", "url": "https://www.prnewswire.com/news-releases/ionis-shares-positive-clinical-update-from-ongoing-trial-of-ion582-for-angelman-syndrome-301985239.html", "time_published": "20231111T163000", "authors": ["Inc.", "Ionis Pharmaceuticals"], "summary": "\u2022 Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 \u2022 ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the study", "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.158974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.122269", "ticker_sentiment_score": "0.132275", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.081691", "ticker_sentiment_score": "0.096292", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Pauses As Yields Rebound: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/", "time_published": "20231110T120000", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/01/INCOME_yield_013017_shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.017348, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.091746", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.070037", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.070036", "ticker_sentiment_score": "0.075537", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.162489", "ticker_sentiment_score": "-0.016092", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOUR", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.161943", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FN", "relevance_score": "0.046724", "ticker_sentiment_score": "0.060043", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.093289", "ticker_sentiment_score": "0.005589", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.006543", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.077475", "ticker_sentiment_label": "Neutral"}, {"ticker": "FANG", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GFS", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.093289", "ticker_sentiment_score": "0.02077", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.116461", "ticker_sentiment_score": "0.016621", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOSL", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.093289", "ticker_sentiment_score": "0.042954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSY", "relevance_score": "0.046724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIOD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.073194", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.116461", "ticker_sentiment_score": "-0.038586", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.085312", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?", "url": "https://www.fool.com/investing/2023/11/10/the-alzheimers-drug-market-is-heating-up-should-yo/", "time_published": "20231110T115000", "authors": ["Alex Carchidi"], "summary": "The real competitive battle is about to begin, and it will last a long time.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.217491, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.18967", "ticker_sentiment_score": "0.122235", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.235823", "ticker_sentiment_score": "0.097212", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Analysts Revise Their Forecasts On Biogen After Q3 Results - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35708707/these-analysts-revise-their-forecasts-on-biogen-after-q3-results", "time_published": "20231109T184950", "authors": ["Lisa Levin"], "summary": "Biogen Inc BIIB reported better-than-expected third-quarter earnings. Biogen posted quarterly sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency ( CC ) . Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/biogen_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.096301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WFC", "relevance_score": "0.38588", "ticker_sentiment_score": "-0.052037", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.976726", "ticker_sentiment_score": "-0.159635", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stock Market News for Nov 9, 2023", "url": "https://www.zacks.com/stock/news/2181656/stock-market-news-for-nov-9-2023", "time_published": "20231109T143000", "authors": ["Zacks Equity Research"], "summary": "U.S. stock closed mostly higher on Wednesday, with the S&P 500 and Nasdaq extending their longest winning streak in more than two years as investors weighed comments from Federal Reserve officials on future interest rates path.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.160894, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIVN", "relevance_score": "0.142989", "ticker_sentiment_score": "0.020307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.213048", "ticker_sentiment_score": "0.167923", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2181433/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates", "time_published": "20231109T120500", "authors": ["Ekta Bagri"], "summary": "Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.162975, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.431956", "ticker_sentiment_score": "0.165788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHGI", "relevance_score": "0.041394", "ticker_sentiment_score": "0.044537", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.283635", "ticker_sentiment_score": "0.121678", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.204763", "ticker_sentiment_score": "0.141619", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082677", "ticker_sentiment_score": "0.100716", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYEN", "relevance_score": "0.359592", "ticker_sentiment_score": "0.096383", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.041394", "ticker_sentiment_score": "0.096085", "ticker_sentiment_label": "Neutral"}]}, {"title": "TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS", "url": "https://www.newswire.ca/news-releases/treefrog-therapeutics-reinforces-executive-committee-with-three-new-members-801014367.html", "time_published": "20231109T103200", "authors": ["TreeFrog Therapeutics"], "summary": "Jaime Arango, Chief Financial Officer, Jens Schr\u00f6der as Chief Medical Officer and Rachel Mooney, Chief Communications Officer", "banner_image": "https://mma.prnewswire.com/media/2272329/treefrog_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.108931, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.102888", "ticker_sentiment_score": "0.077031", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.204072", "ticker_sentiment_score": "0.035991", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/08/biogen-biib-q3-2023-earnings-call-transcript/", "time_published": "20231108T191520", "authors": ["Motley Fool Transcribing"], "summary": "BIIB earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.004732", "ticker_sentiment_score": "0.229245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.004732", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.004732", "ticker_sentiment_score": "0.093858", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.066178", "ticker_sentiment_score": "0.081263", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.023659", "ticker_sentiment_score": "0.065434", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.047296", "ticker_sentiment_score": "0.101222", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.004732", "ticker_sentiment_score": "0.033251", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.004732", "ticker_sentiment_score": "0.033251", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sage Therapeutics  ( SAGE )  Q3 Earnings Lag Estimates, Down 5%", "url": "https://www.zacks.com/stock/news/2181116/sage-therapeutics-sage-q3-earnings-lag-estimates-down-5", "time_published": "20231108T181100", "authors": ["Zacks Equity Research"], "summary": "Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.009585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.3007", "ticker_sentiment_score": "-0.075896", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.43768", "ticker_sentiment_score": "0.083905", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.153145", "ticker_sentiment_score": "0.083164", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.252463", "ticker_sentiment_score": "0.161541", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGIOF", "relevance_score": "0.05133", "ticker_sentiment_score": "0.086485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35673203/biogen-revises-annual-forecast-as-reata-m-a-and-alzheimers-drug-expenses-hit-bottomline-stock-sli", "time_published": "20231108T174320", "authors": ["Vandana Singh"], "summary": "Biogen Inc BIIB posted Q3 FY23 sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency ( CC ) . Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97. Multiple sclerosis revenue of $1.16 billion decreased by 14% ( down 12% CC ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/08/biib.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.316726"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.00953, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.183895", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.755086", "ticker_sentiment_score": "0.00399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Earnings Data Deluge", "url": "https://www.zacks.com/stock/news/2180976/earnings-data-deluge", "time_published": "20231108T160000", "authors": ["Zacks Equity Research"], "summary": "Pre-market indices are gamely climbing again this morning, after starting early-morning trading in the red. Currently, the Dow is +45 points, the S&P 500 +5, the market-leading Nasdaq +6 and even the small-cap Russell 2000 is in the green, +0.4 points.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ac/4283.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.15391, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.160099", "ticker_sentiment_score": "0.024645", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.160099", "ticker_sentiment_score": "0.047371", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.160099", "ticker_sentiment_score": "0.198434", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARM", "relevance_score": "0.160099", "ticker_sentiment_score": "0.047371", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.160099", "ticker_sentiment_score": "0.21827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DIS", "relevance_score": "0.160099", "ticker_sentiment_score": "0.047371", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pre-Markets Keep Streak Alive; RL, BIIB Beat", "url": "https://www.zacks.com/stock/news/2180968/pre-markets-keep-streak-alive-rl-biib-beat", "time_published": "20231108T154200", "authors": ["Mark Vickery"], "summary": "The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ac/4283.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.151485, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.15697", "ticker_sentiment_score": "0.025686", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.046777", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.15697", "ticker_sentiment_score": "0.196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.046777", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.15697", "ticker_sentiment_score": "0.215609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DIS", "relevance_score": "0.15697", "ticker_sentiment_score": "0.046777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB )  Beats on Q3 Earnings & Sales, Cuts EPS View", "url": "https://www.zacks.com/stock/news/2180965/biogen-biib-beats-on-q3-earnings-sales-cuts-eps-view", "time_published": "20231108T153100", "authors": ["Zacks Equity Research"], "summary": "Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999483"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.117025, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.157483", "ticker_sentiment_score": "0.136764", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.118452", "ticker_sentiment_score": "0.094624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.07913", "ticker_sentiment_score": "0.041555", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.308891", "ticker_sentiment_score": "0.198618", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ranking the biggest winners, and losers, in the current economy", "url": "https://www.businessinsider.com/news-today-november-8-economy-rankings-boomers-gen-z-millennials-2023-11", "time_published": "20231108T130000", "authors": ["Dan DeFrancesco"], "summary": "The latest news, headlines, and business stories for November 8 - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.014537, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.061003", "ticker_sentiment_score": "-0.050092", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.061003", "ticker_sentiment_score": "-0.050101", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.061003", "ticker_sentiment_score": "-0.050092", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIS", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.047548", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.061003", "ticker_sentiment_score": "-0.050092", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures subdued ahead of Powell's remarks", "url": "https://www.reuters.com/markets/us/futures-take-breather-ahead-powell-remarks-2023-11-08/", "time_published": "20231108T124700", "authors": ["Amruta Khandekar", "Shristi A"], "summary": "A trader works on the floor at the New York Stock Exchange ( NYSE ) in New York City, U.S., October 27, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4QXBW6RP45FBRHDZQXLNRGX5UY.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": -0.00483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LCID", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.158196", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPR", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.186819", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIVN", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.158196", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HRGLF", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.005216", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.241904", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.077094", "ticker_sentiment_score": "0.148013", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTWO", "relevance_score": "0.077094", "ticker_sentiment_score": "0.23679", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "S&P 500, Nasdaq Set For Muted Open Today: What's Moving Stock Futures? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35669834/us-stocks-set-to-open-flat-after-hot-7-day-rally-traders-sharpen-focus-on-powells-speech-disney-ear", "time_published": "20231108T121210", "authors": ["Shanthi Rexaline"], "summary": "Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell's speech for insights into possible rate cuts. Media earnings, including Walt Disney Co. DIS, take center stage in the earnings ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/stock-charts-1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.019414, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BKRIF", "relevance_score": "0.040416", "ticker_sentiment_score": "-0.196596", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GPRO", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLG", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAM", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0465", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.040416", "ticker_sentiment_score": "0.06538", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.040416", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LITE", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAZR", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYND", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSAT", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.040416", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEAS", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSR", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0465", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRB", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTWO", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.080728", "ticker_sentiment_score": "0.15706", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment", "url": "https://www.marketwatch.com/story/biogen-quarterly-results-top-estimates-despite-complex-launch-of-new-alzheimers-treatment-3b16535c", "time_published": "20231108T121000", "authors": ["Eleanor Laise"], "summary": "Company focuses on new products in Alzheimer's, postpartum depression as multiple sclerosis product revenues decline ...", "banner_image": "https://images.mktw.net/im-448250/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.176999, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.276648", "ticker_sentiment_score": "0.280715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.669671", "ticker_sentiment_score": "0.273489", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen cuts annual profit forecast on persistent higher costs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-cuts-annual-profit-forecast-persistent-higher-costs-2023-11-08/", "time_published": "20231108T120300", "authors": ["Reuters"], "summary": "Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/55H44PU3TBL3TI5DOA2Z6ZWB74.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.151075", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.755086", "ticker_sentiment_score": "0.063556", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Cuts Profit Outlook As Leqembi Expenses Mount", "url": "https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q3-2023/", "time_published": "20231108T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biogen Stock: Drugmaker Tops Earnings Views, But Cuts Profit Guide Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-biogen-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.084864, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.725935", "ticker_sentiment_score": "0.295705", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Just turned 50? Here's where Howard Marks suggests investing for the next 10 years.", "url": "https://www.marketwatch.com/story/just-turned-50-heres-where-howard-marks-suggests-investing-for-the-next-10-years-d3e489ef", "time_published": "20231108T114900", "authors": ["Barbara Kollmeyer"], "summary": "From Hong Kong, Oaktree's Howard Marks and some other top investors discuss where a 50-year old might want to put money for the next decade.", "banner_image": "https://images.mktw.net/im-883282?width=700&height=462", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.140635, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.035555", "ticker_sentiment_score": "-0.005721", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.07104", "ticker_sentiment_score": "0.106397", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.07104", "ticker_sentiment_score": "0.106397", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNUT", "relevance_score": "0.035555", "ticker_sentiment_score": "0.171295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIVN", "relevance_score": "0.07104", "ticker_sentiment_score": "0.106397", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNBR", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.114287", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.035555", "ticker_sentiment_score": "-0.005721", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.104564", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.104564", "ticker_sentiment_label": "Neutral"}, {"ticker": "GCMG", "relevance_score": "0.035555", "ticker_sentiment_score": "0.035913", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.104564", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOD", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.114287", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07104", "ticker_sentiment_score": "-0.104564", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.035555", "ticker_sentiment_score": "-0.027399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2180608/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe", "time_published": "20231108T112004", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.175411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.254973", "ticker_sentiment_score": "0.091126", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}]}, {"title": "New postpartum depression drug gets almost $16,000 price tag, raising questions about access", "url": "https://www.cnn.com/2023/11/07/health/postpartum-depression-drug-price-tag/index.html", "time_published": "20231107T235035", "authors": ["Meg Tirrell"], "summary": "A newly approved medication to treat postpartum depression will cost $15,900 per 14-day course, before insurance, when it reaches the market later this year, raising concerns among doctors and researchers that some patients may have trouble paying for the drug.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230921152319-mother-baby-postpartum-depression-wellness-stock-restricted.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.024372, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.035241", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.035241", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.035241", "ticker_sentiment_score": "0.039857", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.105449", "ticker_sentiment_score": "0.04818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sentiment Check: Market Under Pressure as Positive Feelings Dip Following Hawkish Remarks from Fed Official", "url": "https://www.benzinga.com/markets/23/11/35661550/sentiment-check-market-under-pressure-as-positive-feelings-dip-following-hawkish-remarks-from-fed-of", "time_published": "20231107T220839", "authors": ["Schwab Center for Financial Research"], "summary": "( Tuesday market open ) ) Five Federal Reserve officials are speaking today, but words from another Fed policymaker yesterday helped lead to early losses on Wall Street. Stocks fell in premarket trading on ideas that the battle against inflation may not be won and rate hikes may not be over.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/07/screenshot_2023-11-07_at_4.52.35_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.038682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TD", "relevance_score": "0.10579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.042421", "ticker_sentiment_score": "0.062698", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.042421", "ticker_sentiment_score": "0.052988", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.10579", "ticker_sentiment_score": "0.015397", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.042421", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.123705", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.042421", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.063594", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.084722", "ticker_sentiment_score": "0.05653", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.042421", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.063594", "ticker_sentiment_score": "0.067112", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.161099", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "BIIB: Biogen  ( BIIB )  Earnings Spotlight: Is the Biotech Stock a Buy or Sell?", "url": "https://stocknews.com/news/biib-gild-jazz-alks-biogen-biib-earnings-spotlight-is-the-biotech-stock-a-buy/", "time_published": "20231107T170210", "authors": ["StockNews.com Staff"], "summary": "BIIB: Biogen ( BIIB ) Earnings Spotlight: Is the Biotech Stock a Buy or ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/iSto_GreenStockChart_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.093338, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.038101", "ticker_sentiment_score": "0.101926", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.526355", "ticker_sentiment_score": "0.189417", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eisai expects Alzheimer's drug to rake in revenue of $66.5 mln by March", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-expects-alzheimers-drug-rake-revenue-665-mln-by-march-2023-11-07/", "time_published": "20231107T141100", "authors": ["Reuters"], "summary": "The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/WJN2W7Z2CJO67DLBB2W34JMWBE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.278969, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.769861", "ticker_sentiment_score": "0.523429", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.451494", "ticker_sentiment_score": "0.553956", "ticker_sentiment_label": "Bullish"}, {"ticker": "FOREX:JPY", "relevance_score": "0.235823", "ticker_sentiment_score": "0.159959", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen-Sage Therapeutics postpartum depression pill priced at $15,900", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-sage-therapeutics-postpartum-depression-pill-priced-15900-2023-11-07/", "time_published": "20231107T135100", "authors": ["Reuters"], "summary": "Biogen-Sage Therapeutics postpartum depression pill priced at ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/55H44PU3TBL3TI5DOA2Z6ZWB74.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.095654, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.436009", "ticker_sentiment_score": "-0.082393", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.436009", "ticker_sentiment_score": "-0.052356", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Biogen  ( BIIB )  Might Surprise This Earnings Season", "url": "https://www.zacks.com/stock/news/2179917/why-biogen-biib-might-surprise-this-earnings-season", "time_published": "20231107T133200", "authors": ["Zacks Equity Research"], "summary": "Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.463498, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.906257", "ticker_sentiment_score": "0.608664", "ticker_sentiment_label": "Bullish"}]}, {"title": "Wall Street extends winning streak; eyes Fed speakers, Treasury auctions", "url": "https://www.moneycontrol.com/news/business/markets/wall-street-extends-winning-streak-eyes-fed-speakers-treasury-auctions-11680071.html", "time_published": "20231107T004842", "authors": [], "summary": "Equities last week posted their biggest weekly percentage gain in about a year, as a weaker-than-expected U.S. payrolls report on Friday sent Treasury yields lower on the view the Fed was done hiking interest rates and could start cutting them next year.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2018/12/Wall-Street.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.028702, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DISH", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.118398", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.068306", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35626255/looking-into-biogens-recent-short-interest", "time_published": "20231106T180026", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has fallen 7.62% since its last report. The company recently reported that it has 2.64 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.95 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Countdown to Biogen Inc.  ( BIIB )  Q3 Earnings: A Look at Estimates Beyond Revenue and EPS", "url": "https://www.zacks.com/stock/news/2179432/countdown-to-biogen-inc-biib-q3-earnings-a-look-at-estimates-beyond-revenue-and-eps", "time_published": "20231106T170200", "authors": ["Zacks Equity Research"], "summary": "Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default78.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.107166, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.319725", "ticker_sentiment_score": "0.041567", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly chief scientific officer 'extremely optimistic' that major new Alzheimer's breakthrough is coming", "url": "https://www.marketwatch.com/story/eli-lilly-chief-scientific-officer-extremely-optimistic-that-major-new-alzheimers-breakthrough-is-coming-79003fcc", "time_published": "20231106T160500", "authors": ["Eleanor Laise"], "summary": "Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner-and that an overlooked class of medicines could become the GLP-1 drugs of the future. If he's right, Eli Lilly & Co.'s LLY, remarkable winning streak won't fizzle any time soon.", "banner_image": "https://images.mktw.net/im-857606/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.125979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.365524", "ticker_sentiment_score": "0.148178", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.075754", "ticker_sentiment_score": "0.013501", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.113418", "ticker_sentiment_score": "0.152012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.075754", "ticker_sentiment_score": "0.013501", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.075754", "ticker_sentiment_score": "0.154848", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen  ( BIIB )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2179003/biogen-biib-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231106T132600", "authors": ["Zacks Equity Research"], "summary": "Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.158783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.222022", "ticker_sentiment_score": "-0.020454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.134339", "ticker_sentiment_score": "0.052317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.04497", "ticker_sentiment_score": "0.073593", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.348103", "ticker_sentiment_score": "0.222584", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Appoints Monish Patolawala to its Board of Directors - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35617358/biogen-appoints-monish-patolawala-to-its-board-of-directors", "time_published": "20231106T123000", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass., Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ( \"3M\" ) , to the Company's Board of Directors ( the \"Board\" ) , effective January 1, 2024.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.113525, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GIC", "relevance_score": "0.032736", "ticker_sentiment_score": "0.077136", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.032736", "ticker_sentiment_score": "-0.017798", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.032736", "ticker_sentiment_score": "0.062843", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.032736", "ticker_sentiment_score": "0.062843", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.032736", "ticker_sentiment_score": "0.097269", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.097987", "ticker_sentiment_score": "0.063491", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.288138", "ticker_sentiment_score": "0.240823", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures edge up on rate cut hopes; Fed speakers awaited", "url": "https://www.reuters.com/markets/us/futures-edge-up-rate-cut-hopes-fed-speakers-awaited-2023-11-06/", "time_published": "20231106T110300", "authors": ["Reuters"], "summary": "Futures edge up on rate cut hopes. Fed speakers awaited ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LDNTKV6G3JMU7NMA5Z3B5CSCPU.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.15216, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.085629", "ticker_sentiment_score": "0.083129", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDD", "relevance_score": "0.085629", "ticker_sentiment_score": "0.083129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BILI", "relevance_score": "0.085629", "ticker_sentiment_score": "0.083129", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.085629", "ticker_sentiment_score": "0.069751", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.085629", "ticker_sentiment_score": "0.083129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.085629", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.085629", "ticker_sentiment_score": "0.069751", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's how America's economy could begin to weaken | Business", "url": "https://edition.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html", "time_published": "20231105T123000", "authors": ["Bryan Mena"], "summary": "Here's how America's economy could begin to weaken CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1693347660.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.026507, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CG", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWSAL", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.060085", "ticker_sentiment_score": "0.116097", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.207743", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBD", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.059033", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHAL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.037723", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's how America's economy could begin to weaken | Business", "url": "https://www.cnn.com/2023/11/05/business/stocks-week-ahead-how-us-economy-weakens/index.html", "time_published": "20231105T123000", "authors": ["Bryan Mena"], "summary": "Here's how America's economy could begin to weaken ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1693347660.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.026507, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CG", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWSAL", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.060085", "ticker_sentiment_score": "0.116097", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030064", "ticker_sentiment_score": "0.01712", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.207743", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBD", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.059033", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHAL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.037723", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.030064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030064", "ticker_sentiment_score": "-0.051893", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html", "time_published": "20231103T223500", "authors": [], "summary": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.217263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.045255", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mild Jobs Report Puts More Pressure On Falling Yields as Stocks On Pace For Best Week In A Year - Apple  ( NASDAQ:AAPL ) , Walt Disney  ( NYSE:DIS ) ", "url": "https://www.benzinga.com/markets/23/11/35597954/mild-jobs-report-puts-more-pressure-on-falling-yields-as-stocks-on-pace-for-best-week-in-a-year", "time_published": "20231103T174516", "authors": ["Schwab Center for Financial Research"], "summary": "( Friday market open ) A mild October U.S. jobs report Friday doesn't appear likely to dent recent market optimism about interest rates. The benchmark 10-year Treasury note yield fell another 10 basis points immediately after the data, potentially loosening pressure on stocks.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shutterstock_1723527190_17.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.055611, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.042048", "ticker_sentiment_score": "0.085772", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.104866", "ticker_sentiment_score": "0.071795", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.042048", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.042048", "ticker_sentiment_score": "0.104984", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.042048", "ticker_sentiment_score": "0.085772", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.042048", "ticker_sentiment_score": "0.104984", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.021031", "ticker_sentiment_score": "0.072576", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMND", "relevance_score": "0.042048", "ticker_sentiment_score": "0.104984", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.042048", "ticker_sentiment_score": "0.085772", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.042048", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.042048", "ticker_sentiment_score": "0.104984", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.08398", "ticker_sentiment_score": "0.064132", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042048", "ticker_sentiment_score": "-0.185859", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ionis  ( IONS )  Q3 Loss Wider Than Expected, Sales Beat Estimates", "url": "https://www.zacks.com/stock/news/2178101/ionis-ions-q3-loss-wider-than-expected-sales-beat-estimates", "time_published": "20231103T134400", "authors": ["Zacks Equity Research"], "summary": "Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.054714, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.20279", "ticker_sentiment_score": "-0.008397", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALX", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.112424", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.152821", "ticker_sentiment_score": "0.062683", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.300088", "ticker_sentiment_score": "0.116073", "ticker_sentiment_label": "Neutral"}]}, {"title": "Editas Medicine Announces Third Quarter 2023 Results and Business Updates", "url": "https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html", "time_published": "20231103T110000", "authors": ["Editas Medicine", "Inc."], "summary": "Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology ( ASH ) Annual Meeting and in a ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.159874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EDIT", "relevance_score": "0.515103", "ticker_sentiment_score": "0.226113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.053035", "ticker_sentiment_score": "0.065926", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGTA", "relevance_score": "0.026532", "ticker_sentiment_score": "0.061065", "ticker_sentiment_label": "Neutral"}]}, {"title": "Take Five: You  ( may )  have arrived at your destination", "url": "https://www.reuters.com/business/take-five/global-markets-themes-graphic-2023-11-03/", "time_published": "20231103T083800", "authors": ["Reuters"], "summary": "LONDON, Nov 3 ( Reuters ) - Next week will have plenty to keep financial market traders and investors busy, including whether the Federal Reserve really has hit peak rates, another possible rate rise in Australia, a batch of European bank earnings and the continuing conflict in Gaza.", "banner_image": "https://graphics.reuters.com/GLOBAL-MARKETS/THEMES/akvearynjvr/chart.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.098635, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALIZF", "relevance_score": "0.046006", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.046006", "ticker_sentiment_score": "0.068571", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046006", "ticker_sentiment_score": "0.068571", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:AUD", "relevance_score": "0.046006", "ticker_sentiment_score": "0.084667", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.137409", "ticker_sentiment_score": "-0.040805", "ticker_sentiment_label": "Neutral"}]}, {"title": "Treasuries, Stocks Extend Gains Following Fed Meeting as Apple, Jobs Report Loom - ConocoPhillips  ( NYSE:COP ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/markets/23/11/35571776/treasuries-stocks-extend-gains-following-fed-meeting-as-apple-jobs-report-loom", "time_published": "20231102T174043", "authors": ["Schwab Center for Financial Research"], "summary": "( Thursday market open ) The World Series is over, but Wall Street remains in the thick of this week's triple play of a Fed meeting, Apple ( NASDAQ: AAPL ) earnings and Friday's October jobs report. So far, stocks are building up a lead as worries lessen about future Federal Reserve rate hikes.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/02/shutterstock_534465157_8.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.009665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.045353", "ticker_sentiment_score": "0.26219", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.045353", "ticker_sentiment_score": "0.086519", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.157778", "ticker_sentiment_score": "-0.029655", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.045353", "ticker_sentiment_score": "0.086519", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.045353", "ticker_sentiment_score": "0.086519", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.045353", "ticker_sentiment_score": "0.055727", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.045353", "ticker_sentiment_score": "0.086519", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.045353", "ticker_sentiment_score": "0.055727", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.045353", "ticker_sentiment_score": "-0.187044", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MAR", "relevance_score": "0.045353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/11/35546123/heres-how-much-you-would-have-made-owning-biogen-stock-in-the-last-15-years", "time_published": "20231101T183016", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 1.68% on an annualized basis producing an average annual return of 12.42%. Currently, Biogen has a market capitalization of $34.40 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fed in Sight: Rate Pause Widely Expected As Market Warily Watches Rising Yields, Dollar - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/23/11/35545121/fed-in-sight-rate-pause-widely-expected-as-market-warily-watches-rising-yields-dollar", "time_published": "20231101T175229", "authors": ["Schwab Center for Financial Research"], "summary": "( Wednesday market open ) November dawns after major indexes finished October with consecutive gains for the first time in two weeks. Stocks lost ground in premarket trading Wednesday, however, as investors awaited results from today's Federal Reserve meeting that's widely expected to bring a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/screenshot_2023-11-01_at_10.47.08_pm_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999687"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.024039, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.043698", "ticker_sentiment_score": "0.151218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.043698", "ticker_sentiment_score": "0.086164", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.108958", "ticker_sentiment_score": "-0.067511", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.043698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.043698", "ticker_sentiment_score": "0.086164", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.065506", "ticker_sentiment_score": "0.153167", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIVN", "relevance_score": "0.043698", "ticker_sentiment_score": "0.086164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.043698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.043698", "ticker_sentiment_score": "0.086164", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.043698", "ticker_sentiment_score": "-0.186486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:JPY", "relevance_score": "0.108958", "ticker_sentiment_score": "0.033955", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.021857", "ticker_sentiment_score": "0.027793", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release", "url": "https://www.zacks.com/stock/news/2176407/biogen-inc-biib-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release", "time_published": "20231101T140119", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default233.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.158799, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MNKD", "relevance_score": "0.174587", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.259267", "ticker_sentiment_score": "0.13811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer", "url": "https://www.globenewswire.com/news-release/2023/11/01/2771019/0/en/Sensei-Biotherapeutics-Appoints-Stephanie-Krebs-MS-MBA-as-Chief-Business-Officer.html", "time_published": "20231101T113000", "authors": ["Sensei Biotherapeutics"], "summary": "BOSTON, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( Nasdaq: SNSE ) , a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3b05eb20-243f-4173-a4ae-7c39a6a8a81d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.024119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.043898", "ticker_sentiment_score": "0.103483", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.043898", "ticker_sentiment_score": "0.103483", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNSE", "relevance_score": "0.21686", "ticker_sentiment_score": "0.043511", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer - Sensei Biotherapeutics  ( NASDAQ:SNSE ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35533717/sensei-biotherapeutics-appoints-stephanie-krebs-ms-mba-as-chief-business-officer", "time_published": "20231101T113000", "authors": ["Globe Newswire"], "summary": "BOSTON, Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. SNSE, a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.02167, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.042647", "ticker_sentiment_score": "0.102191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042647", "ticker_sentiment_score": "0.102191", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNSE", "relevance_score": "0.25168", "ticker_sentiment_score": "0.048854", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics  ( NASDAQ:SGMO )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/01/sangamo-therapeutics-nasdaqsgmo-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231101T083045", "authors": ["Defense World Staff"], "summary": "Sangamo Therapeutics ( NASDAQ:SGMO ) Coverage Initiated by ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.210128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.789652", "ticker_sentiment_score": "0.331254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.000993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.049939", "ticker_sentiment_score": "0.000993", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.000993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.049939", "ticker_sentiment_score": "0.128204", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2175072/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20231031T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.216666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.175433", "ticker_sentiment_score": "0.221938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Rises But Trails Market: What Investors Should Know", "url": "https://www.zacks.com/stock/news/2174831/biogen-inc-biib-rises-but-trails-market-what-investors-should-know", "time_published": "20231030T214520", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default51.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.116958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.45825", "ticker_sentiment_score": "0.110032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Assessing Biogen's Performance Against Competitors In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/10/35494535/assessing-biogens-performance-against-competitors-in-biotechnology-industry", "time_published": "20231030T160046", "authors": ["Benzinga Insights"], "summary": "Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Biogen BIIB in comparison to its major ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.098317, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.061473", "ticker_sentiment_score": "0.018018", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.462743", "ticker_sentiment_score": "0.185643", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Biogen's Alzheimer's Treatment Results Sent Its Rival Crashing 15%", "url": "https://www.investors.com/news/technology/biogen-stock-drags-rival-prothena-down-on-mixed-alzheimers-treatment-results/", "time_published": "20231026T182700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biogen Stock Drags Rival Prothena Down 15% On Mixed ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/07/Stock-biogen-10-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.106293, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.260189", "ticker_sentiment_score": "0.133361", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.624172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.493442", "ticker_sentiment_score": "0.055496", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172563/crispr-crsp-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T122200", "authors": ["Zacks Equity Research"], "summary": "Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.119254, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.184834", "ticker_sentiment_score": "0.115115", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.184834", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.244723", "ticker_sentiment_score": "0.152148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.244723", "ticker_sentiment_score": "-0.027788", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly  ( LLY )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172391/eli-lilly-lly-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T114000", "authors": ["Zacks Equity Research"], "summary": "On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.10472, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.417304", "ticker_sentiment_score": "0.022949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.050098", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.216473", "ticker_sentiment_score": "0.025286", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.216473", "ticker_sentiment_score": "-0.026882", "ticker_sentiment_label": "Neutral"}]}, {"title": "More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study", "url": "https://www.cnbc.com/2023/10/25/alzheimers-drug-leqembi-shows-promise-as-injection.html", "time_published": "20231025T224526", "authors": ["Annika Kim Constantino"], "summary": "Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1698273926&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.036234, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.413425", "ticker_sentiment_score": "0.362893", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.214304", "ticker_sentiment_score": "0.236084", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Injected version of Eisai/Biogen Alzheimer's drug effective, side effects higher", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/injected-version-eisaibiogen-alzheimers-drug-effective-side-effects-higher-2023-10-25/", "time_published": "20231025T213000", "authors": ["Deena Beasley", "Julie Steenhuysen"], "summary": "The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/IZAVM6OBWBKH5DTDXLKSQZK4LA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.431065", "ticker_sentiment_score": "-0.040431", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.075635", "ticker_sentiment_score": "0.108141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen and Eisai release new Alzheimer's drug data that may support wider uptake", "url": "https://www.marketwatch.com/story/biogen-and-eisai-release-new-alzheimers-drug-data-that-may-support-wider-uptake-40d2d151", "time_published": "20231025T212800", "authors": ["Eleanor Laise"], "summary": "Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.", "banner_image": "https://images.mktw.net/im-696087/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.083728, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.224903", "ticker_sentiment_score": "0.003554", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.524949", "ticker_sentiment_score": "0.059391", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.524949", "ticker_sentiment_score": "0.059391", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eisai Presents New LEQEMBI\u00ae  ( lecanemab-irmb )  Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease  ( CTAD )  Conference - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35427706/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-study-r", "time_published": "20231025T212600", "authors": ["Globe Newswire"], "summary": "TOKYO and CAMBRIDGE, England, Oct. 25, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.009589, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.009256", "ticker_sentiment_score": "0.053538", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.018511", "ticker_sentiment_score": "0.071019", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.009256", "ticker_sentiment_score": "0.065996", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.228202", "ticker_sentiment_score": "0.10615", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.119876", "ticker_sentiment_score": "0.032771", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eisai Presents New LEQEMBI\u00ae  ( lecanemab-irmb )  Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease  ( CTAD )  Conference", "url": "https://www.globenewswire.com/news-release/2023/10/25/2767024/0/en/Eisai-Presents-New-LEQEMBI-lecanemab-irmb-Investigational-Subcutaneous-Formulation-Interim-Study-Results-and-Clinical-Improvement-Data-in-Earlier-Stages-of-Early-Alzheimer-s-Diseas.html", "time_published": "20231025T212600", "authors": ["Biogen Inc."], "summary": "Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics ( AUC ) 11% Higher, And Similar ARIA Rates To IV ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.040719, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.216296", "ticker_sentiment_score": "0.094428", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.009125", "ticker_sentiment_score": "0.079", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.109165", "ticker_sentiment_score": "0.04029", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35419274/biogen-says-new-data-shows-promise-for-potential-new-generation-of-treatments-in-early-alzheimer", "time_published": "20231025T162008", "authors": ["Nabaparna Bhattacharya"], "summary": "Biogen Inc. BIIB reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide ( ASO ) therapy targeting tau, in mild Alzheimer's disease ( AD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/25/biib_2.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.011977, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.574235", "ticker_sentiment_score": "0.147322", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Data from Biogen's Investigational Antisense Oligonucleotide  ( ASO )  Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease", "url": "https://www.globenewswire.com/news-release/2023/10/25/2766721/0/en/New-Data-from-Biogen-s-Investigational-Antisense-Oligonucleotide-ASO-Targeting-Tau-Shows-Promise-for-Potential-New-Generation-of-Treatments-in-Early-Alzheimer-s-Disease.html", "time_published": "20231025T145100", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., Oct. 25, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide ( ASO ) therapy targeting tau, in mild Alzheimer's disease ( AD ) .", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.064877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.035345", "ticker_sentiment_score": "0.066463", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.035345", "ticker_sentiment_score": "0.066463", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.27704", "ticker_sentiment_score": "0.090909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks to own ahead of a rally that this $15 billion fund house says is coming soon", "url": "https://www.marketwatch.com/story/stocks-to-own-ahead-of-a-rally-that-this-15-billion-fund-house-says-is-coming-soon-adffe026", "time_published": "20231025T120700", "authors": ["Barbara Kollmeyer"], "summary": "Sit Investment Associates, Roger Sit, says a short sharp recession is coming, along with a stock rally and lots of opportunities to own names across the board.", "banner_image": "https://images.mktw.net/im-874884?width=700&height=302", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.086559, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "J", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.199451", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.107495", "ticker_sentiment_score": "0.029475", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLT", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNX", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTRYF", "relevance_score": "0.035929", "ticker_sentiment_score": "-0.161194", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FDX", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WHR", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.107495", "ticker_sentiment_score": "0.165941", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MP", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOH", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "PH", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRC", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.142989", "ticker_sentiment_score": "0.158804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2171289/amgen-amgn-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231025T112600", "authors": ["Zacks Equity Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.203947, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.219312", "ticker_sentiment_score": "0.114532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.215777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.272181", "ticker_sentiment_score": "0.030414", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.272181", "ticker_sentiment_score": "0.036737", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week - Stitch Fix  ( NASDAQ:SFIX ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/10/35399377/an-oversold-small-cap-industrial-that-insiders-are-buying-ahead-of-earnings-this-week", "time_published": "20231024T164130", "authors": ["David Pinsen"], "summary": "In a post last month, we wrote about the power of RSI ( Relative Strength Index ) as a technical indicator ( Relative Strength Index ) in relation to Stitch Fix, Inc. SFIX A technical indicator to keep in mind for earnings trades. https://t.co/g6zISKkVmc$BIG $SFIX", "banner_image": "https://cdn.benzinga.com/files/oversold.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.218262, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SFIX", "relevance_score": "0.196344", "ticker_sentiment_score": "0.205598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.196344", "ticker_sentiment_score": "0.109088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock News - InMed Pharmaceuticals Inc.'s  ( NASDAQ: INM )  INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies", "url": "https://www.investorideas.com/news/2023/biotech/10241NASDAQ-INM.asp", "time_published": "20231024T145024", "authors": [], "summary": "Pharma Stock News - InMed Pharmaceuticals Inc.'s ( NASDAQ: INM ... ...", "banner_image": null, "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.097336, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INM", "relevance_score": "0.468029", "ticker_sentiment_score": "0.212879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.031159", "ticker_sentiment_score": "-0.10684", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.031159", "ticker_sentiment_score": "-0.10684", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  to Report Q3 Earnings: Here's What to Expect", "url": "https://www.zacks.com/stock/news/2170681/pfizer-pfe-to-report-q3-earnings-heres-what-to-expect", "time_published": "20231024T113900", "authors": ["Zacks Equity Research"], "summary": "Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.057075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.188928", "ticker_sentiment_score": "0.102132", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.234911", "ticker_sentiment_score": "0.026995", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.489057", "ticker_sentiment_score": "0.065703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.234911", "ticker_sentiment_score": "0.032619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.047654", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Biogen Inc.  ( BIIB )  Fell More Than Broader Market", "url": "https://www.zacks.com/stock/news/2170464/heres-why-biogen-inc-biib-fell-more-than-broader-market", "time_published": "20231023T215019", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.188943, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.519002", "ticker_sentiment_score": "0.272314", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/roche-settles-us-patent-lawsuit-against-biogen-over-blockbuster-arthritis-drug-2023-10-23/", "time_published": "20231023T192700", "authors": ["Blake Brittain"], "summary": "The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/e80269c0-8a61-4e5d-afa1-d2c4740ed247.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.011896, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHGCF", "relevance_score": "0.136113", "ticker_sentiment_score": "0.083968", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.507107", "ticker_sentiment_score": "-0.025708", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's in Store for Bristol-Myers  ( BMY )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2170140/whats-in-store-for-bristol-myers-bmy-in-q3-earnings", "time_published": "20231023T124700", "authors": ["Zacks Equity Research"], "summary": "Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999974"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235812, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.11324", "ticker_sentiment_score": "0.060688", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.17719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.150592", "ticker_sentiment_score": "0.046863", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.22421", "ticker_sentiment_score": "0.260342", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck  ( MRK )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2170134/merck-mrk-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231023T112500", "authors": ["Zacks Equity Research"], "summary": "Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.153023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.206245", "ticker_sentiment_score": "-0.024239", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.305058", "ticker_sentiment_score": "0.100231", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.052112", "ticker_sentiment_score": "0.171568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.256179", "ticker_sentiment_score": "-0.02884", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Initiates Coverage on Sangamo Therapeutics  ( NASDAQ:SGMO ) ", "url": "https://www.defenseworld.net/2023/10/22/stocknews-com-initiates-coverage-on-sangamo-therapeutics-nasdaqsgmo.html", "time_published": "20231022T054324", "authors": ["Defense World Staff"], "summary": "StockNews.com Initiates Coverage on Sangamo Therapeutics ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=SGMO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.213152, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.821747", "ticker_sentiment_score": "0.354217", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.051111", "ticker_sentiment_score": "0.025958", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.051111", "ticker_sentiment_score": "0.025958", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.051111", "ticker_sentiment_score": "0.025958", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051111", "ticker_sentiment_score": "0.160402", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novartis  ( NVS )  to Report Q3 Earnings: What's in the Offing?", "url": "https://www.zacks.com/stock/news/2169736/novartis-nvs-to-report-q3-earnings-whats-in-the-offing", "time_published": "20231020T142000", "authors": ["Zacks Equity Research"], "summary": "Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default89.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.237467, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.257895", "ticker_sentiment_score": "0.260712", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.130689", "ticker_sentiment_score": "0.066913", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.130689", "ticker_sentiment_score": "0.064556", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.130689", "ticker_sentiment_score": "0.0516", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.043738", "ticker_sentiment_score": "0.06155", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anti-obesity drugs are an investable \"fountain of youth\" for baby boomers", "url": "https://www.investorideas.com/news/2023/biotech/10191RichardMills-Anti-Obesity-Drugs.asp", "time_published": "20231019T182325", "authors": [], "summary": "Anti-obesity drugs are an investable \"fountain of youth\" for baby ... ...", "banner_image": "https://aheadoftheherd.com/app/uploads/2023/10/ozempic-effect.png", "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.041022, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MO", "relevance_score": "0.013409", "ticker_sentiment_score": "-0.079627", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.013409", "ticker_sentiment_score": "0.055477", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.026815", "ticker_sentiment_score": "0.098503", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMS", "relevance_score": "0.013409", "ticker_sentiment_score": "0.048388", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.013409", "ticker_sentiment_score": "0.048388", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.013409", "ticker_sentiment_score": "-0.034385", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.013409", "ticker_sentiment_score": "0.048388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.013409", "ticker_sentiment_score": "0.055477", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.013409", "ticker_sentiment_score": "0.00788", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.013409", "ticker_sentiment_score": "0.098089", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.013409", "ticker_sentiment_score": "0.055477", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.013409", "ticker_sentiment_score": "0.095434", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.026815", "ticker_sentiment_score": "0.036404", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.026815", "ticker_sentiment_score": "-0.027861", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sage's  ( SAGE )  Huntington's Disease Drug Gets FDA's Orphan Tag", "url": "https://www.zacks.com/stock/news/2169138/sages-sage-huntingtons-disease-drug-gets-fdas-orphan-tag", "time_published": "20231019T161600", "authors": ["Sundeep Ganoria"], "summary": "The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.038676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DCPH", "relevance_score": "0.175009", "ticker_sentiment_score": "-0.010166", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.662054", "ticker_sentiment_score": "0.154879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.287537", "ticker_sentiment_score": "0.0913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.231884", "ticker_sentiment_score": "0.102378", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease  ( CTAD )  2023 Meeting - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35326238/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimers-disease-ctad-2023-meeting", "time_published": "20231019T113000", "authors": ["Globe Newswire"], "summary": "Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease Additional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBI\u00ae ( lecanemab-irmb )", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.109396, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.032871", "ticker_sentiment_score": "0.065737", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.032871", "ticker_sentiment_score": "0.065737", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.195287", "ticker_sentiment_score": "0.038625", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.349665", "ticker_sentiment_score": "0.092957", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease  ( CTAD )  2023 Meeting", "url": "https://www.globenewswire.com/news-release/2023/10/19/2763066/0/en/Biogen-to-Present-New-Data-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2023-Meeting.html", "time_published": "20231019T113000", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease ( CTAD ) meeting taking place October 24-27 in Boston, Mass.", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.13056, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.033609", "ticker_sentiment_score": "0.06596", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.033609", "ticker_sentiment_score": "0.06596", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.166858", "ticker_sentiment_score": "0.067168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.326499", "ticker_sentiment_score": "0.111515", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/10/35318992/1000-invested-in-biogen-20-years-ago-would-be-worth-this-much-today", "time_published": "20231018T210033", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 3.66% on an annualized basis producing an average annual return of 11.04%. Currently, Biogen has a market capitalization of $38.16 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "5 Biotech Stocks Set to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2168288/5-biotech-stocks-set-to-outpace-q3-earnings-estimates", "time_published": "20231018T152000", "authors": ["Zacks Equity Research"], "summary": "Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.170488, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.30569", "ticker_sentiment_score": "0.052098", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.353418", "ticker_sentiment_score": "-0.064866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.353418", "ticker_sentiment_score": "0.073833", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.399734", "ticker_sentiment_score": "0.11986", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.353418", "ticker_sentiment_score": "0.115454", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Struggling Stocks Investors Shouldn't Buy on the Dip", "url": "https://www.fool.com/investing/2023/10/18/3-struggling-stocks-investors-shouldnt-buy-on-the/", "time_published": "20231018T122300", "authors": ["David Jagielski"], "summary": "These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": -0.103294, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.103331", "ticker_sentiment_score": "0.144206", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.051774", "ticker_sentiment_score": "-0.153538", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.025926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Falls More Steeply Than Broader Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2167530/biogen-inc-biib-falls-more-steeply-than-broader-market-what-investors-need-to-know", "time_published": "20231017T215020", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.986564"}], "overall_sentiment_score": 0.098662, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.520477", "ticker_sentiment_score": "0.1729", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech", "url": "https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html", "time_published": "20231016T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.069381, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.032245", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077426", "ticker_sentiment_score": "-0.029504", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONCT", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "APVO", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRE", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/10/35270983/inquiry-into-biogens-competitor-dynamics-in-biotechnology-industry", "time_published": "20231016T160046", "authors": ["Benzinga Insights"], "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Biogen BIIB alongside its primary competitors in ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.186064, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.063594", "ticker_sentiment_score": "0.018037", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.47672", "ticker_sentiment_score": "0.242597", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/government/23/10/35245698/improved-alzheimers-diagnosis-access-cms-expands-amyloid-pet-scan-usage", "time_published": "20231013T191042", "authors": ["Vandana Singh"], "summary": "The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomography ( PET ) scans, a non-invasive brain scan crucial for identifying amyloid plaques, a telltale sign of Alzheimer's.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/13/dementia-photo_by_gerd_altmann_via_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.254307", "ticker_sentiment_score": "0.182864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.128822", "ticker_sentiment_score": "0.114567", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.254307", "ticker_sentiment_score": "0.182864", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wall Street Analysts See a 25.44% Upside in Biogen Inc.  ( BIIB ) : Can the Stock Really Move This High?", "url": "https://www.zacks.com/stock/news/2165588/wall-street-analysts-see-a-2544-upside-in-biogen-inc-biib-can-the-stock-really-move-this-high", "time_published": "20231013T135505", "authors": ["Zacks Equity Research"], "summary": "The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.236408, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.286864", "ticker_sentiment_score": "0.368762", "ticker_sentiment_label": "Bullish"}]}, {"title": "GILD: How to Enhance Your Own Strategies with POWR Ratings", "url": "https://stocknews.com/news/gild-amgn-uthr-biib-regn-how-to-enhance-your-own-strategies-with-powr-ratings/", "time_published": "20231012T162947", "authors": ["StockNews.com Staff"], "summary": "One thing Wall Street is never short of is ideas. Technical strategies, fundamental strategies, seasonal investing, and the list goes on and on and on.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/06/shutterstock_530971462-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}], "overall_sentiment_score": 0.16666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.035035", "ticker_sentiment_score": "0.006888", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.139467", "ticker_sentiment_score": "0.121564", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.173832", "ticker_sentiment_score": "0.036379", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.241512", "ticker_sentiment_score": "0.114", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.207868", "ticker_sentiment_score": "0.139319", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/news/large-cap/23/10/35199963/is-there-a-blood-test-for-alzheimers-progress-underway-but-not-quite-ready", "time_published": "20231011T182704", "authors": ["Vandana Singh"], "summary": "Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are in development, none are approved by regulators or insurance reimbursement.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/11/dementia-photo_by_gerd_altmann_via_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.005294", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.012987", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.012987", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.229149", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTRX", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.0034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Biogen Inc.  ( BIIB )  Beat Estimates Again in Its Next Earnings Report?", "url": "https://www.zacks.com/stock/news/2164465/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report", "time_published": "20231011T161011", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default333.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.334096, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.418689", "ticker_sentiment_score": "0.518363", "ticker_sentiment_label": "Bullish"}]}, {"title": "Blood tests needed for widespread Alzheimer's diagnosis on the way", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/blood-tests-needed-widespread-alzheimers-diagnosis-way-2023-10-11/", "time_published": "20231011T113600", "authors": ["Deena Beasley"], "summary": "[1/3] A view shows tests for patients suffering from Alzheimer's disease at the Memory Centre Department of Readaptation and Geriatrics of the University Hospital ( HUG ) , in Geneva, Switzerland, June 6, 2023. REUTERS/Denis Balibouse/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EJ4XVCXTRFPEZOEJML2CXR554M.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122516, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DGX", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.04557", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.088799", "ticker_sentiment_score": "-0.001058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044469", "ticker_sentiment_score": "-0.054621", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTRX", "relevance_score": "0.044469", "ticker_sentiment_score": "0.045597", "ticker_sentiment_label": "Neutral"}]}, {"title": "LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35164150/lumind-ceo-at-odds-with-neurologists-over-alzheimers-drugs-made-by-biogen-eli-lilly", "time_published": "20231010T163526", "authors": ["Vandana Singh"], "summary": "Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd ESALY/ Biogen Inc's BIIB and Eli Lilly And Co's LLY. The former biotech executive is also hoping to include people with Down syndrome in Alzheimer's ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/10/aapharma_4.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.066268, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.405651", "ticker_sentiment_score": "0.14946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.277433", "ticker_sentiment_score": "0.112842", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.277433", "ticker_sentiment_score": "0.033717", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mana.bio Advances AI-Based Lipid Nanoparticle  ( LNP )  Platform to Accelerate \"Programmable Drug Delivery\" for RNA and Gene Therapies", "url": "https://www.prnewswire.com/news-releases/manabio-advances-ai-based-lipid-nanoparticle-lnp-platform-to-accelerate-programmable-drug-delivery-for-rna-and-gene-therapies-301952340.html", "time_published": "20231010T163000", "authors": ["Mana.bio"], "summary": "Mana.bio Advances AI-Based Lipid Nanoparticle ( LNP ) Platform to Accelerate \"Programmable Drug Delivery\" for RNA ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2242153/MANA_BIO_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.275223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.068797", "ticker_sentiment_score": "0.08833", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "STOK", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer - Medicenna Therapeutics  ( NASDAQ:MDNA ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35158239/medicenna-therapeutics-appoints-humphrey-gardner-m-d-as-chief-medical-officer", "time_published": "20231010T110753", "authors": ["Globe Newswire"], "summary": "TORONTO and HOUSTON, Oct. 10, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( \"Medicenna\" or the \"Company\" ) MDNAMDNA, a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.171183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVLO", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.102013", "ticker_sentiment_score": "0.123332", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051111", "ticker_sentiment_score": "0.00497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer", "url": "https://www.globenewswire.com/news-release/2023/10/10/2757337/0/en/Medicenna-Therapeutics-Appoints-Humphrey-Gardner-M-D-as-Chief-Medical-Officer.html", "time_published": "20231010T110700", "authors": ["Medicenna Therapeutics Corp."], "summary": "Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions Dr. Gardner brings over 30 years of experience leading clinical development to ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1644a38b-bed9-4a76-96fa-d57dd028e650", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.175941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVLO", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.204936", "ticker_sentiment_score": "0.190836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.051774", "ticker_sentiment_score": "0.004975", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Equity Research Report Recommends 'Buy' Rating for Virtualware  ( EPA:MLVIR )  with \u20ac10 Price Target", "url": "https://www.globenewswire.com/news-release/2023/10/10/2757117/0/en/New-Equity-Research-Report-Recommends-Buy-Rating-for-Virtualware-EPA-MLVIR-with-10-Price-Target.html", "time_published": "20231010T054500", "authors": ["VIRTUALWARE 2007 SA"], "summary": "New York and Bilbao, Spain, 10, October.- Litchfield Hills Research initiated coverage of Virtualware ( ENXTPA: MLVIR ) with a 'Buy' rating and \u20ac10 ( $10.56 ) price target, according to an equity research report published and distributed Monday.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13948b91-ce96-426f-b8a7-b1586665fb52", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.178587, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.047278", "ticker_sentiment_score": "0.097811", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.047278", "ticker_sentiment_score": "0.097811", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.047278", "ticker_sentiment_score": "0.097811", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.047278", "ticker_sentiment_score": "0.097811", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.047278", "ticker_sentiment_score": "0.097811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Advances But Underperforms Market: Key Facts", "url": "https://www.zacks.com/stock/news/2162963/biogen-inc-biib-advances-but-underperforms-market-key-facts", "time_published": "20231009T215020", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.215825, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.584103", "ticker_sentiment_score": "0.336573", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bristol Myers  ( BMY )  to Acquire Mirati Therapeutics for $5.8 B", "url": "https://www.zacks.com/stock/news/2162756/bristol-myers-bmy-to-acquire-mirati-therapeutics-for-58-b", "time_published": "20231009T142400", "authors": ["Zacks Equity Research"], "summary": "Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.119149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRTX", "relevance_score": "0.091684", "ticker_sentiment_score": "0.134407", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.137148", "ticker_sentiment_score": "0.151625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.354952", "ticker_sentiment_score": "0.335439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KDNY", "relevance_score": "0.045918", "ticker_sentiment_score": "-0.101506", "ticker_sentiment_label": "Neutral"}]}, {"title": "LANGaware Strengthens Advisory Board with Michel Vounatsos, Former Biogen CEO and Strategic Visionary", "url": "https://www.prnewswire.com/news-releases/langaware-strengthens-advisory-board-with-michel-vounatsos-former-biogen-ceo-and-strategic-visionary-301950283.html", "time_published": "20231009T120000", "authors": ["LANGaware"], "summary": "NEW YORK, Oct. 9, 2023 /PRNewswire/ -- LANGaware, a pioneering tech company at the forefront of AI-driven cognitive and mental health diagnostics, is delighted to announce the appointment of Michel Vounatsos to their advisory board.", "banner_image": "https://mma.prnewswire.com/media/2236589/LANGaware___Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.469701, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.157483", "ticker_sentiment_score": "0.108438", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves TOFIDENCE\u2122  ( tocilizumab-bavi )  a Biosimilar of ACTEMRA\u00ae developed by Bio-Thera Solutions", "url": "https://www.prnewswire.com/news-releases/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions-301950199.html", "time_published": "20231008T084500", "authors": ["Ltd", "Bio-Thera Solutions"], "summary": "\u2022 TOFIDENCE is Bio-Thera's first product approved by USFDA. \u2022 TOFIDENCE is the first monoclonal antibody drug researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in \u2022 TOFIDENCE is the first biosimilar to Actemra approved by USFDA", "banner_image": "https://mma.prnewswire.com/media/2184516/Bio_Thera_Solutions_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.1491", "ticker_sentiment_score": "0.104231", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's The Point This Obesity-Focused Stock Of The Day Becomes Actionable", "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-the-point-at-which-this-ibd-stock-of-the-day-could-become-actionable-again/", "time_published": "20231006T163700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Eli Lilly Stock: The Point At Which This IBD Stock Of The Day Could ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/sotd-10-6-23-1.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}], "overall_sentiment_score": 0.108716, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.828099", "ticker_sentiment_score": "0.211705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.043579", "ticker_sentiment_score": "0.037994", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNTH", "relevance_score": "0.215319", "ticker_sentiment_score": "0.048003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.087027", "ticker_sentiment_score": "0.066449", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8 - VanEck Gold Miners ETF  ( ARCA:GDX ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/23/10/35109444/an-oversold-gold-miner-with-strong-fundamentals-its-relative-strength-index-is-below-20-and-its-piot", "time_published": "20231005T135803", "authors": ["David Pinsen"], "summary": "On Zero Hedge on Monday, contributing editor \"Quoth The Raven\" suggested \"paying urgent attention to gold miners\": As everybody knows, one of my favorite assets on the board right now for buying is gold miners.", "banner_image": "https://cdn.benzinga.com/files/intergold.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.282899, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.152499", "ticker_sentiment_score": "0.062346", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.152499", "ticker_sentiment_score": "0.062346", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.076602", "ticker_sentiment_score": "0.215568", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Public reimbursement for biosimilar BYOOVIZ\u2122 to treat serious retinal disorders now secured in four provinces and two national benefits programs", "url": "https://www.newswire.ca/news-releases/public-reimbursement-for-biosimilar-byooviz-tm-to-treat-serious-retinal-disorders-now-secured-in-four-provinces-and-two-national-benefits-programs-817633984.html", "time_published": "20231004T110000", "authors": ["Biogen Canada"], "summary": "Public reimbursement for biosimilar BYOOVIZ\u2122 to treat serious retinal disorders now secured in four provinces and two ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2238276/Biogen_Canada_Public_reimbursement_for_biosimilar_BYOOVIZ__to_tr.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.338403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.05749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.171282", "ticker_sentiment_score": "0.263662", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.436009", "ticker_sentiment_score": "0.557652", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Much Will Your Medicare Part B Premiums Increase Next Year?", "url": "https://www.fool.com/retirement/2023/10/04/how-much-medicare-part-b-premiums-increase/", "time_published": "20231004T093000", "authors": ["Keith Speights"], "summary": "Part B premiums declined this year, but don't expect such good news for 2024.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749386%2Fretired-couple-computer-screen.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01948, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.131082", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.062926", "ticker_sentiment_score": "-0.131082", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35064710/1000-invested-in-this-stock-20-years-ago-would-be-worth-7-800-today", "time_published": "20231003T140026", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 20 years by 3.54% on an annualized basis producing an average annual return of 10.81%. Currently, Biogen has a market capitalization of $36.49 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2158859/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20231002T215019", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.106713, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.554916", "ticker_sentiment_score": "0.214534", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio", "url": "https://www.prnewswire.com/news-releases/parkinsons-disease-psychosis-market-is-likely-to-increase-at-a-steady-growth-rate-by-2032-estimates-delveinsight--key-companies-working-to-develop-therapies---vanda-kyowa-kirin-sage-athira-aptinyx-cogstate-agenebio-301941331.html", "time_published": "20231002T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.204202, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIVI", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.027508", "ticker_sentiment_score": "0.073271", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.054983", "ticker_sentiment_score": "0.104827", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWF", "relevance_score": "0.027508", "ticker_sentiment_score": "0.096754", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.027508", "ticker_sentiment_score": "0.096754", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHA", "relevance_score": "0.027508", "ticker_sentiment_score": "0.096754", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.054983", "ticker_sentiment_score": "0.057847", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNPUF", "relevance_score": "0.027508", "ticker_sentiment_score": "0.049131", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.027508", "ticker_sentiment_score": "0.049131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.027508", "ticker_sentiment_score": "0.096754", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.082393", "ticker_sentiment_score": "0.094921", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.027508", "ticker_sentiment_score": "0.096754", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027508", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves Biogen's TOFIDENCE\u2122  ( tocilizumab-bavi ) , a Biosimilar Referencing ACTEMRA\u00ae", "url": "https://www.globenewswire.com/news-release/2023/09/29/2752273/0/en/FDA-Approves-Biogen-s-TOFIDENCE-tocilizumab-bavi-a-Biosimilar-Referencing-ACTEMRA.html", "time_published": "20230929T200600", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., Sept. 29, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced that the U.S. Food and Drug Administration ( FDA ) has approved TOFIDENCE ( tocilizumab-bavi ) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.051982, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.029399", "ticker_sentiment_score": "-0.027325", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.029399", "ticker_sentiment_score": "0.064614", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.029399", "ticker_sentiment_score": "0.064614", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.341699", "ticker_sentiment_score": "0.225364", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves Biogen's TOFIDENCE\u2122  ( tocilizumab-bavi ) , a Biosimilar Referencing ACTEMRA\u00ae - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g35011402/fda-approves-biogens-tofidence-tocilizumab-bavi-a-biosimilar-referencing-actemra", "time_published": "20230929T200600", "authors": ["Globe Newswire"], "summary": "TOFIDENCE ( BIIB800 ) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 ( GLOBE NEWSWIRE ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.054172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.025406", "ticker_sentiment_score": "-0.042326", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.025406", "ticker_sentiment_score": "0.063176", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.025406", "ticker_sentiment_score": "0.063176", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.321135", "ticker_sentiment_score": "0.173813", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Suven Pharma gets a new board as Advent International completes stake buy", "url": "https://www.business-standard.com/companies/news/suven-pharma-gets-a-new-board-as-advent-international-completes-stake-buy-123092901342_1.html", "time_published": "20230929T163118", "authors": ["Sohini Das"], "summary": "As US-based private equity ( PE ) firm Advent International completed the acquisition of a majority stake in Hyderabad-based Suven Pharma, it announced a change in the pharma company's board.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-09/05/full/1693933453-2949.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.176713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEP", "relevance_score": "0.079921", "ticker_sentiment_score": "0.044652", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079921", "ticker_sentiment_score": "0.029415", "ticker_sentiment_label": "Neutral"}, {"ticker": "DEO", "relevance_score": "0.079921", "ticker_sentiment_score": "0.044652", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sangamo Therapeutics 10% Owner Sold $3.00M In Company Stock - Sangamo Therapeutics  ( NASDAQ:SGMO ) ", "url": "https://www.benzinga.com/news/23/09/35004871/sangamo-therapeutics-10-owner-sold-3-00m-in-company-stock", "time_published": "20230929T150145", "authors": ["Benzinga Insights"], "summary": "BIOGEN INC, 10% Owner at Sangamo Therapeutics SGMO, reported a large insider sell on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that INC sold 6,000,000 shares of Sangamo Therapeutics.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.17144, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.485711", "ticker_sentiment_score": "0.283665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware's VIROO capabilities shown at NATO Exercise", "url": "https://www.globenewswire.com/news-release/2023/09/29/2751745/0/en/Virtualware-s-VIROO-capabilities-shown-at-NATO-Exercise.html", "time_published": "20230929T053900", "authors": ["VIRTUALWARE 2007 SA"], "summary": "Bilbao, Spain, September 29.- Virtualware ( EPA: MLVIR ) , the European leader in the virtual reality industry, has participated at the NATO Air Operation exercise focused on chemical, biological, radiological, and nuclear ( CBRN ) Def interoperability to present the VR training project for the ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13948b91-ce96-426f-b8a7-b1586665fb52", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.09457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.113299", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.113299", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.113299", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.045396", "ticker_sentiment_score": "0.113299", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.045396", "ticker_sentiment_score": "0.113299", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Biogen Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/09/28/is-biogen-stock-a-buy-now/", "time_published": "20230928T140700", "authors": ["Prosper Junior Bakiny"], "summary": "It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.", "banner_image": "https://media.ycharts.com/charts/5740e8bfae6508ed2970aec4017d6d1d.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.075455, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.040276", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.096872", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.501398", "ticker_sentiment_score": "0.072025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Inks New Deal With Roche to Develop Novel RNA Drugs", "url": "https://www.zacks.com/stock/news/2157174/ionis-ions-inks-new-deal-with-roche-to-develop-novel-rna-drugs", "time_published": "20230928T140600", "authors": ["Zacks Equity Research"], "summary": "Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2110.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.27838", "ticker_sentiment_score": "0.130759", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.27838", "ticker_sentiment_score": "0.150773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.382088", "ticker_sentiment_score": "0.203331", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Intercept Pharmaceuticals  ( ICPT )  Surges on Acquisition Deal", "url": "https://www.zacks.com/stock/news/2156244/intercept-pharmaceuticals-icpt-surges-on-acquisition-deal", "time_published": "20230927T140200", "authors": ["Zacks Equity Research"], "summary": "Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.132473, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ICPT", "relevance_score": "0.136113", "ticker_sentiment_score": "0.280993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETON", "relevance_score": "0.136113", "ticker_sentiment_score": "0.07192", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.136113", "ticker_sentiment_score": "0.142503", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.202932", "ticker_sentiment_score": "0.194798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KDNY", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.103323", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Meets Rare Disease Drug Study Goal, Stock Up 8.5%", "url": "https://www.zacks.com/stock/news/2156308/ionis-ions-meets-rare-disease-drug-study-goal-stock-up-85", "time_published": "20230927T135800", "authors": ["Zacks Equity Research"], "summary": "Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028602, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.276491", "ticker_sentiment_score": "0.132036", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.168099", "ticker_sentiment_score": "0.124396", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.3796", "ticker_sentiment_score": "0.222398", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors", "url": "https://www.prnewswire.com/news-releases/chroma-medicine-strengthens-leadership-with-the-appointment-of-biotech-business-leader-michael-a-kelly-to-its-board-of-directors-301939429.html", "time_published": "20230927T110000", "authors": ["Chroma Medicine"], "summary": "Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1690088/Chroma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.260958, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.089462", "ticker_sentiment_score": "0.005256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEO", "relevance_score": "0.089462", "ticker_sentiment_score": "0.005256", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOOM", "relevance_score": "0.089462", "ticker_sentiment_score": "0.005256", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.089462", "ticker_sentiment_score": "0.005256", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.089462", "ticker_sentiment_score": "0.005256", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder", "url": "https://www.investors.com/news/technology/ionis-stock-ionis-stock-gains-olezarsen-body-fat/", "time_published": "20230926T155400", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Ionis Pharmaceuticals ( IONS ) on Tuesday said Olezarsen, an experimental drug in late-stage patient trials, succeeded in reducing abnormally high levels of body fat in patients with a rare genetic disorder. Ionis stock broke out on the news.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/Stock-IonisHQ-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.021939, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.265378", "ticker_sentiment_score": "-0.129658", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.502207", "ticker_sentiment_score": "0.185605", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.388879", "ticker_sentiment_score": "-0.17433", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biogen Completes Acquisition of Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34906129/biogen-completes-acquisition-of-reata-pharmaceuticals", "time_published": "20230926T125954", "authors": ["Globe Newswire"], "summary": "Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS\u00ae ( omaveloxolone ) , the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.092299, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.032961", "ticker_sentiment_score": "-0.017832", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.032961", "ticker_sentiment_score": "0.065765", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.032961", "ticker_sentiment_score": "0.065765", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.131284", "ticker_sentiment_score": "0.071851", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.259037", "ticker_sentiment_score": "0.15009", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eisai's Alzheimer's drug wins approval in Japan, following US", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/eisais-alzheimers-drug-wins-approval-in-japan-following-us/3255107/", "time_published": "20230926T070106", "authors": ["Bloomberg"], "summary": "Eisai Co.'s breakthrough Alzheimer's disease drug won clearance from Japanese regulators after the medicine was fully cleared in the US in July.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/pill-g3fe14fdf6_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.659096", "ticker_sentiment_score": "0.209245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.031089", "ticker_sentiment_label": "Neutral"}]}, {"title": "After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen", "url": "https://apnews.com/article/japan-alzheimers-drug-eisai-approved-f866aeb9dd3591d1dd9e41d265115b5f", "time_published": "20230926T061900", "authors": ["MARI YAMAGUCHI"], "summary": "After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen The Associated Press ...", "banner_image": "https://dims.apnews.com/dims4/default/52452b4/2147483647/strip/true/crop/4000x2250+0+187/resize/1440x810!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F1d%2Fa7%2Fccebd998b7e16bd4e1292e973479%2F5d88378e635e464599248b0ea7518fee", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.069402, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.344074", "ticker_sentiment_score": "0.287134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.118064", "ticker_sentiment_score": "0.179402", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sandoz receives European Commission approval for Tyruko\u00ae  ( natalizumab ) , first and only biosimilar for multiple sclerosis in Europe", "url": "https://www.globenewswire.com/news-release/2023/09/26/2749144/0/en/Sandoz-receives-European-Commission-approval-for-Tyruko-natalizumab-first-and-only-biosimilar-for-multiple-sclerosis-in-Europe.html", "time_published": "20230926T051500", "authors": ["Novartis Pharma AG"], "summary": "Basel, September 26, 2023 - Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Commission ( EC ) granted marketing authorization for the first and only biosimilar Tyruko\u00ae ( natalizumab ) , developed by Polpharma Biologics.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/82c7b5ec-a7bf-4160-88e4-e12876be166e", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.177655, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.033052", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2155109/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230925T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.123274, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.593715", "ticker_sentiment_score": "0.286564", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34861916/japans-regulatory-authority-approves-biogeneisais-alzheimer-treatment-leqembi", "time_published": "20230925T144144", "authors": ["Vandana Singh"], "summary": "Eisai Co Ltd ESALY ESALF and Biogen Inc BIIB announced that humanized anti-soluble aggregated amyloid-beta ( A\u03b2 ) monoclonal antibody Leqembi Intravenous Infusion ( 200 mg, 500mg, lecanemab ) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/25/aapharma_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222776, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.364275", "ticker_sentiment_score": "0.19546", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.364275", "ticker_sentiment_score": "0.10874", "ticker_sentiment_label": "Neutral"}]}, {"title": "Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Editas Medicine  ( NASDAQ:EDIT ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34863723/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-", "time_published": "20230925T130000", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc. EDIT, a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.306904, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EDIT", "relevance_score": "0.540534", "ticker_sentiment_score": "0.528723", "ticker_sentiment_label": "Bullish"}, {"ticker": "MGTA", "relevance_score": "0.065506", "ticker_sentiment_score": "0.036029", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.065506", "ticker_sentiment_score": "0.052049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRNX", "relevance_score": "0.065506", "ticker_sentiment_score": "0.052049", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.130571", "ticker_sentiment_score": "0.136534", "ticker_sentiment_label": "Neutral"}]}, {"title": "Japan approves Alzheimer treatment Leqembi by Eisai and Biogen", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/japan-approves-alzheimer-treatment-leqembi-by-eisai-biogen-2023-09-25/", "time_published": "20230925T051600", "authors": ["Reuters"], "summary": "The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS /File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/WMLAU5VT7BLK7CPRH5Q5R7FL6M.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.608634", "ticker_sentiment_score": "0.239897", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.184366", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "LEQEMBI\u00ae Intravenous Infusion  ( Lecanemab )  Approved for the Treatment of Alzheimer's Disease in Japan - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34847116/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan", "time_published": "20230925T050257", "authors": ["Globe Newswire"], "summary": "TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.043036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.011733", "ticker_sentiment_score": "0.054707", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.023464", "ticker_sentiment_score": "0.073389", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.011733", "ticker_sentiment_score": "0.067034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.2978", "ticker_sentiment_score": "0.18051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.18602", "ticker_sentiment_score": "0.053692", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG", "url": "https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html", "time_published": "20230921T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.337142, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MESO", "relevance_score": "0.068177", "ticker_sentiment_score": "-0.133049", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCLX", "relevance_score": "0.02275", "ticker_sentiment_score": "-0.104786", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's a rapid-fire update on all 35 stocks in the Club's portfolio, including a new buy", "url": "https://www.cnbc.com/2023/09/21/rapid-fire-update-on-all-35-stocks-in-jim-cramers-club-portfolio.html", "time_published": "20230921T192259", "authors": ["Kevin Stankiewicz"], "summary": "Jim Cramer ran through all 35 Club stocks during our September Monthly Meeting on Thursday.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107200467-1677528554270-NUP_200782_00122.jpg?v=1695324179&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.209065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.099394", "ticker_sentiment_score": "0.095909", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "NATI", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWK", "relevance_score": "0.019928", "ticker_sentiment_score": "0.080807", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMR", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIN", "relevance_score": "0.059736", "ticker_sentiment_score": "0.08825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXD", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.07959", "ticker_sentiment_score": "0.090866", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTRA", "relevance_score": "0.039844", "ticker_sentiment_score": "0.086994", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34764319/biib-analyzing-biogens-short-interest", "time_published": "20230920T141520", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has risen 3.39% since its last report. The company recently reported that it has 3.14 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.06 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2152141/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230918T215020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $253.30, marking a -0.58% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default166.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.186311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.617188", "ticker_sentiment_score": "0.296886", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, RETA, VRTV, HCCI", "url": "https://www.benzinga.com/pressreleases/23/09/g34702887/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-reta-vrtv-hcci", "time_published": "20230918T205947", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.331688, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HCCI", "relevance_score": "0.266101", "ticker_sentiment_score": "0.213604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.067727", "ticker_sentiment_score": "0.119871", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.266101", "ticker_sentiment_score": "0.234832", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.266101", "ticker_sentiment_score": "0.237454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTV", "relevance_score": "0.266101", "ticker_sentiment_score": "0.21949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.120965", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html", "time_published": "20230918T083500", "authors": [], "summary": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.157274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CPRI, RETA - Capri Holdings  ( NYSE:CPRI ) , American National  ( NASDAQ:AMNB ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34633215/shareholder-investigation-halper-sadeh-llc-investigates-amnb-cpri-reta", "time_published": "20230915T214401", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American National Bankshares Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.076847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NKSH", "relevance_score": "0.155451", "ticker_sentiment_score": "0.157066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.155451", "ticker_sentiment_score": "0.101048", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPR", "relevance_score": "0.155451", "ticker_sentiment_score": "0.013441", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNB", "relevance_score": "0.155451", "ticker_sentiment_score": "0.157066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CPRI", "relevance_score": "0.155451", "ticker_sentiment_score": "0.013441", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMNB", "relevance_score": "0.155451", "ticker_sentiment_score": "0.157066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.155451", "ticker_sentiment_score": "0.157066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.155451", "ticker_sentiment_score": "0.101048", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34624241/100-invested-in-biogen-15-years-ago-would-be-worth-this-much-today", "time_published": "20230915T173025", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 3.36% on an annualized basis producing an average annual return of 12.4%. Currently, Biogen has a market capitalization of $37.04 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Moves -0.19%: What You Should Know", "url": "https://www.zacks.com/stock/news/2148040/biogen-inc-biib-stock-moves--019-what-you-should-know", "time_published": "20230912T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.115767, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.658245", "ticker_sentiment_score": "0.103347", "ticker_sentiment_label": "Neutral"}]}, {"title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - VRTV, HCCI, RETA, ACER", "url": "https://www.benzinga.com/pressreleases/23/09/g34500168/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-vrtv-hcci-reta-acer", "time_published": "20230912T180253", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.333856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HCCI", "relevance_score": "0.266828", "ticker_sentiment_score": "0.21406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACER", "relevance_score": "0.266828", "ticker_sentiment_score": "0.271614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZVRA", "relevance_score": "0.067919", "ticker_sentiment_score": "0.139072", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.266828", "ticker_sentiment_score": "0.237955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTV", "relevance_score": "0.266828", "ticker_sentiment_score": "0.219957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.120992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sitting Around For Too Many Hours Can Boost Your Dementia Risk-Here's What Researchers Recommend", "url": "https://www.forbes.com/sites/willskipworth/2023/09/12/sitting-around-for-too-many-hours-can-boost-your-dementia-risk-heres-what-researchers-recommend/", "time_published": "20230912T150000", "authors": ["William Skipworth"], "summary": "A new study found that people with too much sedentary time have an increased risk of developing dementia.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64ff81a1a02bfabe9df9e2cb/0x0.jpg?format=jpg&crop=4103,2310,x0,y204,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.07405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.051999", "ticker_sentiment_score": "0.029997", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051999", "ticker_sentiment_score": "0.029997", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: 3 Biotech Gainers to Consider", "url": "https://stocknews.com/news/regn-biib-regn-reta-3-biotech-gainers-to-consider/", "time_published": "20230911T164719", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Biogen Inc. ( BIIB ) , and United Therapeutics Corporation ( UTHR ) could be worth buying.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.216037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.265217", "ticker_sentiment_score": "0.381353", "ticker_sentiment_label": "Bullish"}, {"ticker": "DBTX", "relevance_score": "0.06001", "ticker_sentiment_score": "0.291226", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.089909", "ticker_sentiment_score": "0.064947", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.089909", "ticker_sentiment_score": "0.075774", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.236684", "ticker_sentiment_score": "0.142313", "ticker_sentiment_label": "Neutral"}]}, {"title": "Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer - Madrigal Pharmaceuticals  ( NASDAQ:MDGL ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34434144/madrigal-pharmaceuticals-appoints-bill-sibold-as-chief-executive-officer", "time_published": "20230911T110000", "authors": ["Globe Newswire"], "summary": "CONSHOHOCKEN, Pa., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis ( NASH ) , today announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.210952, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDGL", "relevance_score": "0.253426", "ticker_sentiment_score": "0.149063", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042953", "ticker_sentiment_score": "0.057112", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.253426", "ticker_sentiment_score": "0.110468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?", "url": "https://www.fool.com/investing/2023/09/09/does-biogens-latest-15-billion-dollar-move-make-it/", "time_published": "20230909T114500", "authors": ["Alex Carchidi"], "summary": "Buying a biotech is a good move, but it might not be enough to entice investors.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.193395, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.187705", "ticker_sentiment_score": "0.185881", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.365166", "ticker_sentiment_score": "0.267121", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alector  ( ALEC )  Up 7% on Finishing Enrolment in Alzheimer Study", "url": "https://www.zacks.com/stock/news/2146781/alector-alec-up-7-on-finishing-enrolment-in-alzheimer-study", "time_published": "20230908T161000", "authors": ["Zacks Equity Research"], "summary": "Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.181653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.295155", "ticker_sentiment_score": "0.138053", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.350564", "ticker_sentiment_score": "0.321404", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALEC", "relevance_score": "0.675301", "ticker_sentiment_score": "0.329413", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.179788", "ticker_sentiment_score": "0.168865", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Ionis Pharmaceuticals  ( IONS )  Up 1.4% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2146705/why-is-ionis-pharmaceuticals-ions-up-14-since-last-earnings-report", "time_published": "20230908T153027", "authors": ["Zacks Equity Research"], "summary": "Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default246.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.117935, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.049526", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.243864", "ticker_sentiment_score": "0.167708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "0.125135", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.147818", "ticker_sentiment_score": "0.021972", "ticker_sentiment_label": "Neutral"}]}, {"title": "Scientists Finally Discover Why Exercise Cuts Alzheimer's Risk, Study Says", "url": "https://www.forbes.com/sites/willskipworth/2023/09/08/scientists-finally-discover-why-exercise-cuts-alzheimers-risk-study-says/", "time_published": "20230908T150000", "authors": ["William Skipworth"], "summary": "Researchers have identified a hormone called irisin that reduces a protein widely believed to cause Alzheimer's disease-more proof that the best known way to combat the disease is by staying active.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f9fd0a1989d006addcb95b/0x0.jpg?format=jpg&crop=4896,2754,x0,y183,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.07887", "ticker_sentiment_score": "-0.002055", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07887", "ticker_sentiment_score": "-0.002055", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group", "url": "https://www.zacks.com/stock/news/2146643/the-zacks-analyst-blog-highlights-humana-cintas-biogen-royal-caribbean-cruises-and-markel-group", "time_published": "20230908T132400", "authors": ["Zacks Equity Research"], "summary": "Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1345.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.299456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.276648", "ticker_sentiment_score": "0.051319", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.140485", "ticker_sentiment_score": "0.037704", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTAS", "relevance_score": "0.404563", "ticker_sentiment_score": "0.324122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.341857", "ticker_sentiment_score": "0.23324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MKL", "relevance_score": "0.140485", "ticker_sentiment_score": "0.037704", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for Humana, Cintas & Biogen", "url": "https://www.zacks.com/research-daily/2146023/top-analyst-reports-for-humana-cintas-biogen", "time_published": "20230907T211700", "authors": ["Mark Vickery"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.36611, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CTAS", "relevance_score": "0.288893", "ticker_sentiment_score": "0.413341", "ticker_sentiment_label": "Bullish"}, {"ticker": "HUM", "relevance_score": "0.098255", "ticker_sentiment_score": "0.014538", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.195025", "ticker_sentiment_score": "0.276419", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Prothena  ( PRTA )  Skyrockets 88.7% in 12 Months: Here's Why", "url": "https://www.zacks.com/stock/news/2146171/prothena-prta-skyrockets-887-in-12-months-heres-why", "time_published": "20230907T160000", "authors": ["Zacks Equity Research"], "summary": "Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.044978", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.347058", "ticker_sentiment_score": "0.370312", "ticker_sentiment_label": "Bullish"}, {"ticker": "ESALF", "relevance_score": "0.051221", "ticker_sentiment_score": "0.33079", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.102231", "ticker_sentiment_score": "0.289694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.152821", "ticker_sentiment_score": "0.10643", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Denali Therapeutics Inc.  ( DNLI )  Down 0.1% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2146141/why-is-denali-therapeutics-inc-dnli-down-01-since-last-earnings-report", "time_published": "20230907T153049", "authors": ["Zacks Equity Research"], "summary": "Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.12729, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.080728", "ticker_sentiment_score": "0.25985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.387674", "ticker_sentiment_score": "0.139069", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should BNY Mellon US Mid Cap Core Equity ETF  ( BKMC )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2145779/should-bny-mellon-us-mid-cap-core-equity-etf-bkmc-be-on-your-investing-radar", "time_published": "20230907T102005", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.16155, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MORN", "relevance_score": "0.064276", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.128135", "ticker_sentiment_score": "0.060442", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.128135", "ticker_sentiment_score": "0.060442", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2145683/biogen-inc-biib-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230906T215021", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) closed at $263.72 in the latest trading session, marking a -0.97% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.122899, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.665097", "ticker_sentiment_score": "0.096533", "ticker_sentiment_label": "Neutral"}]}, {"title": "Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst - Denali Therapeutics  ( NASDAQ:DNLI ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34287817/denali-therapeutics-breakthrough-blood-brain-barrier-platform-a-game-changer-in-neu", "time_published": "20230906T184528", "authors": ["Vandana Singh"], "summary": "B Riley Securities initiated coverage on Denali Therapeutics Inc DNLI with a Buy rating and a price target of $38.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/06/dnli.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.210215, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.29234", "ticker_sentiment_score": "-0.189865", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DNLI", "relevance_score": "0.426225", "ticker_sentiment_score": "0.133125", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Wednesday", "url": "https://www.cnbc.com/2023/09/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday-.html", "time_published": "20230906T130822", "authors": ["Jim Cramer"], "summary": "Equities are lower in premarket trading Wednesday, while Arm Holdings' roadshow ahead of a planned initial public offering is impressive.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107290745-1692802098753-gettyimages-1619153799-ARM_IPO.jpeg?v=1694005702&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.076538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TJX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "D", "relevance_score": "0.068306", "ticker_sentiment_score": "0.112032", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.024715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.068306", "ticker_sentiment_score": "0.078215", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.17828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHTR", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.3583", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.028359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - NEWR, AMNB, DBTX, RETA", "url": "https://www.benzinga.com/pressreleases/23/09/g34257451/alert-the-m-a-class-action-firm-continues-investigating-the-merger-newr-amnb-dbtx-reta", "time_published": "20230905T234611", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.344643, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NEWR", "relevance_score": "0.266828", "ticker_sentiment_score": "0.241955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.135347", "ticker_sentiment_score": "0.197052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.266828", "ticker_sentiment_score": "0.237955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.161474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.067919", "ticker_sentiment_score": "0.119896", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.266828", "ticker_sentiment_score": "0.235329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.266828", "ticker_sentiment_score": "0.31425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.161474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.120992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Competing in These 3 Markets Could Send Eli Lilly Stock Soaring", "url": "https://www.fool.com/investing/2023/09/05/competing-in-these-3-markets-could-send-eli-lilly/", "time_published": "20230905T140000", "authors": ["Alex Carchidi"], "summary": "Each market presents the opportunity for multiple catalysts as well as more sales.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.045819, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.053749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.455978", "ticker_sentiment_score": "0.10002", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.053749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's  ( BIIB )  Stock Outperforms Industry YTD: Here's Why", "url": "https://www.zacks.com/stock/news/2144831/biogens-biib-stock-outperforms-industry-ytd-heres-why", "time_published": "20230905T134000", "authors": ["Zacks Equity Research"], "summary": "While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.215518, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.282886", "ticker_sentiment_score": "0.090556", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.282886", "ticker_sentiment_score": "0.234859", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.172097", "ticker_sentiment_score": "-0.002936", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.531326", "ticker_sentiment_score": "0.229629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 Stock Buys With Fat Profit Margins", "url": "https://www.forbes.com/sites/johndorfman/2023/09/04/livent-snapon-5-stock-buys-with-fat-profit-margins/", "time_published": "20230905T000617", "authors": ["John Dorfman"], "summary": "These stocks have large profit margins, which can be a sign that a company has a unique product or is significantly ahead of its competitors.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f5515956808567d1b0157e/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.12549, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMAT", "relevance_score": "0.111488", "ticker_sentiment_score": "0.08058", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTMD", "relevance_score": "0.111488", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CF", "relevance_score": "0.111488", "ticker_sentiment_score": "0.050372", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.055881", "ticker_sentiment_score": "0.142267", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.055881", "ticker_sentiment_score": "0.081883", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.111488", "ticker_sentiment_score": "0.08058", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.055881", "ticker_sentiment_score": "0.081883", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNA", "relevance_score": "0.220809", "ticker_sentiment_score": "0.07839", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.111488", "ticker_sentiment_score": "0.08058", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOG", "relevance_score": "0.166551", "ticker_sentiment_score": "-0.098993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055881", "ticker_sentiment_score": "0.142267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big Companies-From CVS To Yellow Corp.-Laid Off More Than 65,000 This Summer", "url": "https://www.forbes.com/sites/brianbushard/2023/09/04/big-companies-from-cvs-to-yellow-corp-laid-off-more-than-65000-this-summer/", "time_published": "20230904T193011", "authors": ["Brian Bushard"], "summary": "The biggest layoffs this summer came at Yellow Corp., CVS Health, KPMG, Biogen and Binance.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f62ff564af86a8b085cc97/0x0.jpg?format=jpg&crop=3000,1686,x0,y156,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.261005, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.122581", "ticker_sentiment_score": "-0.12815", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.082164", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELL", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.014204", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.082164", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKLA", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCWX", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.114068", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34213020/1000-invested-in-biogen-15-years-ago-would-be-worth-this-much-today", "time_published": "20230904T183022", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 12.94%. Currently, Biogen has a market capitalization of $38.69 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Neuromyelitis Optica Spectrum Disorder Market to grow by USD 173.48 million from 2022 to 2027 | The growing ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/neuromyelitis-optica-spectrum-disorder-market-to-grow-by-usd-173-48-million-from-2022-to-2027--the-growing-geriatric-population-drives-growth---technavio-301915605.html", "time_published": "20230901T224500", "authors": [], "summary": "Neuromyelitis Optica Spectrum Disorder Market to grow by USD 173.48 million from 2022 to 2027 | The growing ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.163139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGTX", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGCF", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HBMHF", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTLHF", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.047185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sage Therapeutics  ( SAGE )  Plunges 46% in a Month: Here's Why", "url": "https://www.zacks.com/stock/news/2143923/sage-therapeutics-sage-plunges-46-in-a-month-heres-why", "time_published": "20230901T172700", "authors": ["Zacks Equity Research"], "summary": "The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.20344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ANIP", "relevance_score": "0.314151", "ticker_sentiment_score": "0.226785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.61919", "ticker_sentiment_score": "0.407531", "ticker_sentiment_label": "Bullish"}, {"ticker": "ANVS", "relevance_score": "0.21258", "ticker_sentiment_score": "0.060633", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.21258", "ticker_sentiment_score": "0.121483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/anti-rheumatic-market-to-grow-exponentially-by-2029--brandessence-market-research-301915970.html", "time_published": "20230901T143400", "authors": ["Brandessence Market Research And Consulting Private Limited"], "summary": "LONDON, Sept. 1, 2023 /PRNewswire/ -- Rheumatoid arthritis ( RA ) is a highly prevalent auto-immune ailment. This disease predominantly affects our joints, mainly that of hands and feet. It occurs when the immune system begins attacking the healthy tissues.", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.110872, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPIX", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.027382", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.054732", "ticker_sentiment_score": "0.131821", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects", "url": "https://www.zacks.com/commentary/2143430/5-biotech-stocks-to-buy-as-new-drug-approvals-drive-industry-prospects", "time_published": "20230901T131800", "authors": ["Ekta Bagri"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.184163, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.145437", "ticker_sentiment_score": "0.105338", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.024372", "ticker_sentiment_score": "0.080027", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.024372", "ticker_sentiment_score": "0.080027", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.024372", "ticker_sentiment_score": "0.055127", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.024372", "ticker_sentiment_score": "0.055127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIP", "relevance_score": "0.073024", "ticker_sentiment_score": "0.08328", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.097259", "ticker_sentiment_score": "0.088129", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.04872", "ticker_sentiment_score": "0.019905", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.024372", "ticker_sentiment_score": "0.055127", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34171679/biib-analyzing-biogens-short-interest", "time_published": "20230901T131520", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has fallen 11.61% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 2.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2143281/biogen-inc-biib-gains-as-market-dips-what-you-should-know", "time_published": "20230831T214517", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.134345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.606946", "ticker_sentiment_score": "0.233452", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sage, Struggling With Depression Flop, Cuts Workforce By 40%", "url": "https://www.investors.com/news/technology/sage-stock-could-a-workforce-cut-lift-its-depression/", "time_published": "20230831T151000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Sage Stock: Could A Workforce Cut Lift Its Depression? Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-sagetherapeutics-02-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": -0.093677, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMAM", "relevance_score": "0.075397", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.150122", "ticker_sentiment_score": "-0.332492", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.429845", "ticker_sentiment_score": "-0.069269", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2142663/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230830T215019", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default334.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.160676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.606946", "ticker_sentiment_score": "0.241862", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Blood test for Parkinson's disease promising in early study", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/blood-test-parkinsons-disease-promising-early-study-2023-08-30/", "time_published": "20230830T181200", "authors": ["Nancy Lapid"], "summary": "Aug 30 ( Reuters ) - An experimental blood test that detected Parkinson's disease in a preliminary study could become the first specific tool for diagnosing the devastating neurodegenerative condition, researchers said on Wednesday.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4QXBW6RP45FBRHDZQXLNRGX5UY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.136798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABCM", "relevance_score": "0.113062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.113062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.113062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Albert Maasland, Former CAB and Saxo Bank UK CEO, joins Virtualware's International Advisory Board", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734030/0/en/Albert-Maasland-Former-CAB-and-Saxo-Bank-UK-CEO-joins-Virtualware-s-International-Advisory-Board.html", "time_published": "20230830T060000", "authors": ["VIRTUALWARE 2007 SA"], "summary": "London and Bilbao, Spain, August 30, 2023.- Spanish Virtual Reality company Virtualware ( MLVIR.PA ) has appointed Albert C. Maasland, former CEO of Crown Agents Bank and former CEO of Saxo Bank UK, to its International Advisory Board, in a decision that will reinforce the company's position as a ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13948b91-ce96-426f-b8a7-b1586665fb52", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.19158, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCBFF", "relevance_score": "0.051774", "ticker_sentiment_score": "0.093523", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTHIF", "relevance_score": "0.051774", "ticker_sentiment_score": "0.114497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.051774", "ticker_sentiment_score": "0.114497", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.051774", "ticker_sentiment_score": "0.093523", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.051774", "ticker_sentiment_score": "0.114497", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.051774", "ticker_sentiment_score": "0.114497", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.051774", "ticker_sentiment_score": "0.114497", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34097085/shareholder-investigation-halper-sadeh-llc-investigates-dbtx-amed-reta-surf", "time_published": "20230829T163452", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128205, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SURF", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMED", "relevance_score": "0.255641", "ticker_sentiment_score": "0.157578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.129516", "ticker_sentiment_score": "0.091303", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.185732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.129516", "ticker_sentiment_score": "0.185732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.129516", "ticker_sentiment_score": "0.091303", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g34095921/moore-kuehn-encourages-amed-dbtx-reta-and-surf-investors-to-contact-law-firm", "time_published": "20230829T154747", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.200602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.02614", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.213988", "ticker_sentiment_score": "0.311241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMED", "relevance_score": "0.213988", "ticker_sentiment_score": "0.311241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHRS", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBTX", "relevance_score": "0.107978", "ticker_sentiment_score": "0.267137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.107978", "ticker_sentiment_score": "0.210957", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Roche's  ( RHHBY )  Evrysdi Gets Label Expansion in EU for Newborns", "url": "https://www.zacks.com/stock/news/2142071/roches-rhhby-evrysdi-gets-label-expansion-in-eu-for-newborns", "time_published": "20230829T153900", "authors": ["Zacks Equity Research"], "summary": "Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.235661, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.153961", "ticker_sentiment_score": "0.19757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.229149", "ticker_sentiment_score": "0.163422", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Buy: Biogen vs. Eli Lilly", "url": "https://www.fool.com/investing/2023/08/29/better-buy-biogen-vs-eli-lilly/", "time_published": "20230829T140700", "authors": ["Prosper Junior Bakiny"], "summary": "This battle of biotech giants has a clear winner.", "banner_image": "https://media.ycharts.com/charts/8788a5006dcd88a2e55605d386dfc22a.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.249145, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.571178", "ticker_sentiment_score": "0.379726", "ticker_sentiment_label": "Bullish"}, {"ticker": "RETA", "relevance_score": "0.05257", "ticker_sentiment_score": "0.040754", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.608634", "ticker_sentiment_score": "0.207174", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity", "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html", "time_published": "20230829T120000", "authors": ["Ginkgo Bioworks"], "summary": "Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2196137/Ginkgo_Bioworks___Google_Cloud_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.19802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.598427", "ticker_sentiment_score": "0.24733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOMMF", "relevance_score": "0.039353", "ticker_sentiment_score": "0.153924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.117678", "ticker_sentiment_score": "0.136676", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.039353", "ticker_sentiment_score": "0.153924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSUMF", "relevance_score": "0.039353", "ticker_sentiment_score": "0.153924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.039353", "ticker_sentiment_score": "0.153924", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/n34086282/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engin", "time_published": "20230829T120000", "authors": ["PRNewswire"], "summary": "Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud's Vertex AI platform", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.225226, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.659644", "ticker_sentiment_score": "0.303482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOMMF", "relevance_score": "0.027164", "ticker_sentiment_score": "0.147098", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.108344", "ticker_sentiment_score": "0.139933", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.027164", "ticker_sentiment_score": "0.147098", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.027164", "ticker_sentiment_score": "0.147098", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027164", "ticker_sentiment_score": "0.147098", "ticker_sentiment_label": "Neutral"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - SCU, AMNB, NEWR, RETA", "url": "https://www.benzinga.com/pressreleases/23/08/g34080066/alert-the-m-a-class-action-firm-continues-investigating-the-merger-scu-amnb-newr-reta", "time_published": "20230828T215105", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.3447, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCU", "relevance_score": "0.270523", "ticker_sentiment_score": "0.234378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEWR", "relevance_score": "0.270523", "ticker_sentiment_score": "0.244531", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.137278", "ticker_sentiment_score": "0.198552", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.270523", "ticker_sentiment_score": "0.240493", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RITM", "relevance_score": "0.068896", "ticker_sentiment_score": "0.118064", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNB", "relevance_score": "0.068896", "ticker_sentiment_score": "0.161671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.270523", "ticker_sentiment_score": "0.317482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.068896", "ticker_sentiment_score": "0.161671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.068896", "ticker_sentiment_score": "0.121133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novartis'  ( NVS )  Sandoz Gets FDA Nod for Tysabri's Biosimilar", "url": "https://www.zacks.com/stock/news/2141397/novartis-nvs-sandoz-gets-fda-nod-for-tysabris-biosimilar", "time_published": "20230828T145700", "authors": ["Zacks Equity Research"], "summary": "Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.183884, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRO", "relevance_score": "0.115787", "ticker_sentiment_score": "0.062321", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.115787", "ticker_sentiment_score": "0.062321", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.229149", "ticker_sentiment_score": "0.06697", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street Thinks This Tiny Biotech Company Could Soar Soon", "url": "https://www.fool.com/investing/2023/08/28/wall-street-thinks-this-tiny-biotech-company-could/", "time_published": "20230828T123000", "authors": ["George Budwell"], "summary": "An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745581%2Fresearcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.204223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.055621", "ticker_sentiment_score": "0.157909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.110973", "ticker_sentiment_score": "0.079156", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/multiple-sclerosis-market-in-the-us-to-grow-by-usd-3-95-billion-from-2021-to-2026--rising-prevalence-of-multiple-sclerosis-will-drive-growth---technavio-301909378.html", "time_published": "20230826T003000", "authors": [], "summary": "Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.302792, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCPF", "relevance_score": "0.059785", "ticker_sentiment_score": "0.140023", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.178021", "ticker_sentiment_score": "0.217977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.059785", "ticker_sentiment_score": "0.185027", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sandoz receives FDA approval for Tyruko\u00ae  ( natalizumab-sztn ) , first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis", "url": "https://www.globenewswire.com/news-release/2023/08/25/2731654/0/en/Sandoz-receives-FDA-approval-for-Tyruko-natalizumab-sztn-first-and-only-FDA-approved-biosimilar-for-relapsing-forms-of-multiple-sclerosis.html", "time_published": "20230825T051500", "authors": ["Novartis Pharma AG"], "summary": "Basel, August 25, 2023 - Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration ( FDA ) has approved its biosimilar Tyruko\u00ae ( natalizumab-sztn ) , developed by Polpharma Biologics.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e53d40db-990b-4c71-a22a-b5a107ded595", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.0737, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.024724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Down 0.2% Since Last Earnings Report: Can It Rebound?", "url": "https://www.zacks.com/stock/news/2140375/biogen-inc-biib-down-02-since-last-earnings-report-can-it-rebound", "time_published": "20230824T153041", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default51.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99915"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.036098, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.0367", "ticker_sentiment_score": "0.057454", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.354572", "ticker_sentiment_score": "0.154249", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?", "url": "https://www.fool.com/investing/2023/08/24/is-sage-therapeutics-stock-in-trouble-dropping-50/", "time_published": "20230824T091000", "authors": ["David Jagielski"], "summary": "The pharmaceutical company's growth prospects have taken a big hit.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744779%2Fchart-showing-cash-burn-versus-cash-and-investments-on-hand.png&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.225593, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.411176", "ticker_sentiment_score": "-0.241161", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.159745", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "These Are The 5 Best Stocks Of The Year", "url": "https://www.investors.com/research/here-are-best-performing-stocks-of-2023-with-gains-as-high-as-345/", "time_published": "20230822T120000", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "Best Stocks: These Are The Top 5 Of The Year Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/IT02-REATApharmaceuticals-02-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999162"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.329699, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.234119", "ticker_sentiment_score": "0.349803", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.118354", "ticker_sentiment_score": "0.508817", "ticker_sentiment_label": "Bullish"}, {"ticker": "SMCI", "relevance_score": "0.118354", "ticker_sentiment_score": "0.064515", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.176717", "ticker_sentiment_score": "0.095898", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRT", "relevance_score": "0.234119", "ticker_sentiment_score": "0.153815", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IRON", "relevance_score": "0.118354", "ticker_sentiment_score": "0.061742", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.176717", "ticker_sentiment_score": "0.162786", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMNB, RETA, CIR, PRDS", "url": "https://www.benzinga.com/pressreleases/23/08/g33974061/alert-the-m-a-class-action-firm-continues-investigating-the-merger-amnb-reta-cir-prds", "time_published": "20230821T213521", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.340291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRDS", "relevance_score": "0.263942", "ticker_sentiment_score": "0.230547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.133841", "ticker_sentiment_score": "0.195895", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.263942", "ticker_sentiment_score": "0.235964", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIR", "relevance_score": "0.263942", "ticker_sentiment_score": "0.232018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.263942", "ticker_sentiment_score": "0.311713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.120888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight", "url": "https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html", "time_published": "20230821T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.05963, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNPX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARM", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.048671", "ticker_sentiment_score": "-0.012897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVCTF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCPF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.048671", "ticker_sentiment_score": "0.037506", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGM", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELEV", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBRX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRYIF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.048671", "ticker_sentiment_score": "0.037506", "ticker_sentiment_label": "Neutral"}, {"ticker": "QEBR", "relevance_score": "0.07295", "ticker_sentiment_score": "-0.035688", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLOSF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMAC", "relevance_score": "0.024347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBIO", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "URGN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.048671", "ticker_sentiment_score": "-0.031649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRVS", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AURA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORYZF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Earthstone Energy, Inc.  ( NYSE - ESTE ) , Fiesta Restaurant Group, Inc.  ( Nasdaq - FRGI ) , Veritiv Corporation  ( NYSE - VRTV ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33964496/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-earthstone-en", "time_published": "20230821T142745", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.995973"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QSR", "relevance_score": "0.076358", "ticker_sentiment_score": "0.258176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PR", "relevance_score": "0.497733", "ticker_sentiment_score": "0.32485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.226301", "ticker_sentiment_score": "0.067163", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.076358", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTV", "relevance_score": "0.298567", "ticker_sentiment_score": "0.276759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSTGF", "relevance_score": "0.076358", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.226301", "ticker_sentiment_score": "0.20402", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESTE", "relevance_score": "0.434763", "ticker_sentiment_score": "0.285731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FRGI", "relevance_score": "0.076358", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bethany L. Sensenig Joins Supernus' Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/08/21/2728720/19871/en/Bethany-L-Sensenig-Joins-Supernus-Board-of-Directors.html", "time_published": "20230821T130000", "authors": ["Supernus Pharmaceuticals", "Inc."], "summary": "ROCKVILLE, Md., Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Bethany L.", "banner_image": "https://ml.globenewswire.com/Resource/Download/1fc58442-511b-40c2-a8c0-f1e78b8437b4", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.225929, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NMTR", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.002939", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.003533", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUPN", "relevance_score": "0.170275", "ticker_sentiment_score": "0.131693", "ticker_sentiment_label": "Neutral"}]}, {"title": "Japan health ministry panel recommends approval of Alzheimer's treatment Leqembi", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/japan-health-ministry-panel-recommends-approval-alzheimers-treatment-leqembi-2023-08-21/", "time_published": "20230821T125400", "authors": ["Reuters"], "summary": "Japan health ministry panel recommends approval of Alzheimer's treatment ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ALSSEKTCOJOHDEI5BYCOY4N2IM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.27917, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.509589", "ticker_sentiment_score": "0.346299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.269776", "ticker_sentiment_score": "0.271837", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, AEL, PRDS, CELL - American Equity Inv  ( NYSE:AEL ) , PhenomeX  ( NASDAQ:CELL ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33953862/shareholder-investigation-halper-sadeh-llc-investigates-reta-ael-prds-cell", "time_published": "20230820T194013", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 20, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.170112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNRE", "relevance_score": "0.10607", "ticker_sentiment_score": "0.14516", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRDS", "relevance_score": "0.10607", "ticker_sentiment_score": "0.151771", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.10607", "ticker_sentiment_score": "0.084268", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEL", "relevance_score": "0.10607", "ticker_sentiment_score": "0.14516", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRKR", "relevance_score": "0.10607", "ticker_sentiment_score": "0.090783", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELL", "relevance_score": "0.210274", "ticker_sentiment_score": "0.134915", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAM", "relevance_score": "0.10607", "ticker_sentiment_score": "0.14516", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.10607", "ticker_sentiment_score": "0.084268", "ticker_sentiment_label": "Neutral"}]}, {"title": "SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm", "url": "https://www.prnewswire.com/news-releases/sage-investigation-notice-robbins-geller-rudman--dowd-llp-announces-investigation-into-sage-therapeutics-inc-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-301904886.html", "time_published": "20230819T181500", "authors": ["Robbins Geller Rudman & Dowd LLP"], "summary": "SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage ... PR ...", "banner_image": "https://mma.prnewswire.com/media/198876/robbins_geller_rudman_and_dowd_llp_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.002433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.603594", "ticker_sentiment_score": "-0.181276", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.084423", "ticker_sentiment_score": "-0.115848", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc.  ( Nasdaq - FRGI ) , Veritiv Corporation  ( NYSE - VRTV ) , New Relic, Inc.  ( NYSE - NEWR ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33900603/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-fiesta-restau", "time_published": "20230817T192923", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.274359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QSR", "relevance_score": "0.086556", "ticker_sentiment_score": "0.264278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.255641", "ticker_sentiment_score": "0.074053", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.33628", "ticker_sentiment_score": "0.258518", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTV", "relevance_score": "0.33628", "ticker_sentiment_score": "0.301775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSTGF", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.255641", "ticker_sentiment_score": "0.224143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FRGI", "relevance_score": "0.086556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2137310/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20230817T102007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.297511, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.176287", "ticker_sentiment_score": "0.279847", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware partners with VRLOGIC to leverage its VR CAVEs business with VIROO.", "url": "https://www.globenewswire.com/news-release/2023/08/17/2727034/0/en/Virtualware-partners-with-VRLOGIC-to-leverage-its-VR-CAVEs-business-with-VIROO.html", "time_published": "20230817T095100", "authors": ["VIRTUALWARE 2007 SA"], "summary": "Spanish technology company Virtualware ( EPA: MLVIR ) , one of the European leaders in the virtual reality industry, recently signed a partnership agreement with the German company VRLOGIC GmbH to leverage its VR CAVEs business with VIROO.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13948b91-ce96-426f-b8a7-b1586665fb52", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.223677, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.049732", "ticker_sentiment_score": "0.098234", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.049732", "ticker_sentiment_score": "0.098234", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.049732", "ticker_sentiment_score": "0.098234", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.049732", "ticker_sentiment_score": "0.098234", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.049732", "ticker_sentiment_score": "0.098234", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/il/news-releases/neurosense-announces-second-quarter-2023-financial-results-and-provides-business-update-301902486.html", "time_published": "20230816T130000", "authors": ["NeuroSense"], "summary": "CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( NASDAQ: NRSN ) ( \"NeuroSense\" ) , a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.115841, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.064973", "ticker_sentiment_score": "0.056318", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.161494", "ticker_sentiment_score": "-0.02639", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/neurosense-announces-second-quarter-2023-financial-results-and-provides-business-update-301902486.html", "time_published": "20230816T130000", "authors": ["NeuroSense"], "summary": "CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( NASDAQ: NRSN ) ( \"NeuroSense\" ) , a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.", "banner_image": "https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.115841, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.064973", "ticker_sentiment_score": "0.056318", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.161494", "ticker_sentiment_score": "-0.02639", "ticker_sentiment_label": "Neutral"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - PRDS, CIR, RETA, AMNB", "url": "https://www.benzinga.com/pressreleases/23/08/g33849414/alert-the-m-a-class-action-firm-continues-investigating-the-merger-prds-cir-reta-amnb", "time_published": "20230814T220000", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.340291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRDS", "relevance_score": "0.263942", "ticker_sentiment_score": "0.230547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.133841", "ticker_sentiment_score": "0.195895", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.263942", "ticker_sentiment_score": "0.235964", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIR", "relevance_score": "0.263942", "ticker_sentiment_score": "0.232018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.263942", "ticker_sentiment_score": "0.311713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067158", "ticker_sentiment_score": "0.120888", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33837974/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-500-today", "time_published": "20230814T160027", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 3.21% on an annualized basis producing an average annual return of 11.96%. Currently, Biogen has a market capitalization of $39.45 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Biotech Stocks Poised to Beat Q2 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2136103/3-biotech-stocks-poised-to-beat-q2-earnings-estimates", "time_published": "20230814T111500", "authors": ["Ekta Bagri"], "summary": "We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.16367, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KOD", "relevance_score": "0.290853", "ticker_sentiment_score": "0.213162", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEGN", "relevance_score": "0.330102", "ticker_sentiment_score": "0.182724", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRTX", "relevance_score": "0.210092", "ticker_sentiment_score": "0.186048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GSK", "relevance_score": "0.084871", "ticker_sentiment_score": "0.143272", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042496", "ticker_sentiment_score": "0.136604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management - Medicenna Therapeutics  ( NASDAQ:MDNA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33825888/medicenna-establishes-boston-presence-appoints-brent-meadows-as-chief-business-officer-and-bolster", "time_published": "20230814T110025", "authors": ["Globe Newswire"], "summary": "Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer ( CBO ) , bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.176334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDNA", "relevance_score": "0.029728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.029728", "ticker_sentiment_score": "0.040437", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.059415", "ticker_sentiment_score": "0.022992", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.059415", "ticker_sentiment_score": "0.022992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management", "url": "https://www.globenewswire.com/news-release/2023/08/14/2724250/0/en/Medicenna-Establishes-Boston-Presence-Appoints-Brent-Meadows-as-Chief-Business-Officer-and-Bolsters-Management.html", "time_published": "20230814T110000", "authors": ["Medicenna Therapeutics Corp."], "summary": "TORONTO and HOUSTON, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( \"Medicenna\" or \"the Company\" ) ( NASDAQ: MDNA TSX: MDNA ) , a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer ( \"CBO\" ) , as part of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1644a38b-bed9-4a76-96fa-d57dd028e650", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.183492, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDNA", "relevance_score": "0.107656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.035983", "ticker_sentiment_score": "0.041706", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.071892", "ticker_sentiment_score": "0.023106", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.071892", "ticker_sentiment_score": "0.023106", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insight: What happens when a $2 million gene therapy is not enough", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/what-happens-when-2-million-gene-therapy-is-not-enough-2023-08-12/", "time_published": "20230812T090500", "authors": ["Deena Beasley"], "summary": "[1/5] Elizabeth Kutschke spends time at the park with her 2-year-old son, Ben, who was diagnosed with spinal muscular atrophy, an inherited disorder which is the leading genetic cause of death in infancy globally and leaves children too weak to walk, talk, swallow or even breathe, in Oak Park,...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RYOJVKI2TFJJ3MZWJAFAVE4YNU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.024097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.020146", "ticker_sentiment_score": "-0.069129", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.04028", "ticker_sentiment_score": "-0.126611", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.020146", "ticker_sentiment_score": "0.035661", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Sage Therapeutics Slumped This Week", "url": "https://www.fool.com/investing/2023/08/11/why-shares-of-sage-therapeutics-slumped-this-week/", "time_published": "20230811T152353", "authors": ["Jim Halley"], "summary": "The company got bad news from the FDA and saw increased losses.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743206%2Fone-hundred-dollar-bill-cash-money-dividend-income-invest-wages-salary-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.111545, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.13459", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.265378", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.123342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News", "url": "https://www.zacks.com/stock/news/2135802/biotech-stock-roundup-sage-grtx-plunge-on-setback-regn-to-buy-dbtx-more-news", "time_published": "20230811T143400", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.104054, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.069869", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.039878", "ticker_sentiment_score": "-0.028661", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTX", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.033262", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.041673", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Beaten-Down Stocks That Still Aren't Worth Buying", "url": "https://www.fool.com/investing/2023/08/11/2-beaten-down-stocks-that-still-arent-worth-buying/", "time_published": "20230811T125000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies aren't bargains at all.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.058384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.377142", "ticker_sentiment_score": "0.008088", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.056011", "ticker_sentiment_score": "-0.111", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.326643", "ticker_sentiment_score": "0.067541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Denali  ( DNLI )  Q2 Earnings Beat on Higher Collaboration Revenues", "url": "https://www.zacks.com/stock/news/2135288/denali-dnli-q2-earnings-beat-on-higher-collaboration-revenues", "time_published": "20230810T160200", "authors": ["Zacks Equity Research"], "summary": "Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/33314.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.077496, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.201523", "ticker_sentiment_score": "0.01123", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.434349", "ticker_sentiment_score": "0.180364", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.250386", "ticker_sentiment_score": "0.060107", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.250386", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Q2 Loss Narrows Y/Y, Sales Surpass Estimates", "url": "https://www.zacks.com/stock/news/2135191/ionis-ions-q2-loss-narrows-yy-sales-surpass-estimates", "time_published": "20230810T153100", "authors": ["Zacks Equity Research"], "summary": "Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.089595, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.172713", "ticker_sentiment_score": "0.108308", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.172713", "ticker_sentiment_score": "-0.080687", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.297404", "ticker_sentiment_score": "0.056876", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?", "url": "https://www.fool.com/investing/2023/08/10/could-6-point-5-billion-acquisition-help-biogen/", "time_published": "20230810T130000", "authors": ["David Jagielski"], "summary": "The company's rare disease portfolio may soon get an upgrade.", "banner_image": "https://media.ycharts.com/charts/ee11bcbb99f9607cc509ea738c8bf292.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.05085, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.061315", "ticker_sentiment_score": "0.102122", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.061315", "ticker_sentiment_score": "-0.075003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.461699", "ticker_sentiment_score": "0.006151", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, AEL, NLTX, RETA - NexTier Oilfield  ( NYSE:NEX ) , American Equity Inv  ( NYSE:AEL ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33688724/shareholder-investigation-halper-sadeh-llc-investigates-nex-ael-nltx-reta", "time_published": "20230810T005716", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: NexTier Oilfield Solutions Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.111707, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BNRE", "relevance_score": "0.116348", "ticker_sentiment_score": "0.150363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEX", "relevance_score": "0.116348", "ticker_sentiment_score": "0.093838", "ticker_sentiment_label": "Neutral"}, {"ticker": "NLTX", "relevance_score": "0.116348", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.116348", "ticker_sentiment_score": "0.087101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEL", "relevance_score": "0.116348", "ticker_sentiment_score": "0.150363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PTEN", "relevance_score": "0.116348", "ticker_sentiment_score": "0.093838", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAM", "relevance_score": "0.116348", "ticker_sentiment_score": "0.150363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.116348", "ticker_sentiment_score": "0.087101", "ticker_sentiment_label": "Neutral"}]}, {"title": "More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection", "url": "https://www.fool.com/investing/2023/08/09/more-alzheimers-treatments-are-coming-this-company/", "time_published": "20230809T135300", "authors": ["David Jagielski"], "summary": "Alzheimer's is a huge problem, and earlier detection could make a big difference.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742979%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.147333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DGX", "relevance_score": "0.273552", "ticker_sentiment_score": "0.306111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.069697", "ticker_sentiment_score": "0.209286", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "With an Acquisition on the Way, Is Biogen Stock a Buy?", "url": "https://www.fool.com/investing/2023/08/09/with-an-acquisition-on-the-way-is-biogen-stock-a/", "time_published": "20230809T123000", "authors": ["Prosper Junior Bakiny"], "summary": "Can the biotech finally get back in the good graces of investors?", "banner_image": "https://media.ycharts.com/charts/7d7303b8491c5372569b24a2e3b66982.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.138656, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.31482", "ticker_sentiment_score": "0.207371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.582526", "ticker_sentiment_score": "0.310217", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eli Lilly Has Tentpoles In Weight Loss And Alzheimer's; But Is It A Buy?", "url": "https://www.investors.com/news/technology/eli-lilly-stock-buy-now/", "time_published": "20230809T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Eli Lilly Has Tentpoles In Weight Loss And Alzheimer's. But Is It A Buy? Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Eli-Lilly-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.166399, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.026474", "ticker_sentiment_score": "0.022403", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.680543", "ticker_sentiment_score": "0.300199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.026474", "ticker_sentiment_score": "-0.142778", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.001124", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.026474", "ticker_sentiment_score": "0.155279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.079304", "ticker_sentiment_score": "0.218136", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax Earnings Call Reveals Surprise Profit, But Stocks Still Slide", "url": "https://www.forbes.com/sites/qai/2023/08/09/novavax-earnings-call-reveals-surprise-profit-but-stocks-still-slide/", "time_published": "20230809T111456", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "It's not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64d374fd54a6981499b1ea3f/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.102418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.067347", "ticker_sentiment_score": "0.082229", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.033703", "ticker_sentiment_score": "-0.052441", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.033703", "ticker_sentiment_score": "-0.235169", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVAX", "relevance_score": "0.553082", "ticker_sentiment_score": "0.140567", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.033703", "ticker_sentiment_score": "-0.052441", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.091998", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.052593", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.033703", "ticker_sentiment_score": "-0.052441", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.073705", "ticker_sentiment_label": "Neutral"}]}, {"title": "BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/08/09/2721423/0/en/BiomX-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html", "time_published": "20230809T103000", "authors": ["BiomX"], "summary": "Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2545774a-e366-4eba-a284-7aca7de3708d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.106444, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMRN", "relevance_score": "0.023579", "ticker_sentiment_score": "0.032015", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.023579", "ticker_sentiment_score": "0.032015", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies Working in Market - Roche, Acticor Biotech, Genentech, Mallinckrodt, AbbVie, Janssen, Bristol Myers Squibb, Bayer", "url": "https://www.prnewswire.com/news-releases/ischemic-stroke-market-is-likely-to-increase-at-a-steady-growth-rate-examines-delveinsight--key-companies-working-in-market---roche-acticor-biotech-genentech-mallinckrodt-abbvie-janssen-bristol-myers-squibb-bayer-301895355.html", "time_published": "20230808T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177836, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.024622", "ticker_sentiment_score": "0.0624", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLOSF", "relevance_score": "0.024622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.049221", "ticker_sentiment_score": "0.053506", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMAC", "relevance_score": "0.098255", "ticker_sentiment_score": "0.04861", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHX", "relevance_score": "0.049221", "ticker_sentiment_score": "0.053496", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.049221", "ticker_sentiment_score": "0.012825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.073773", "ticker_sentiment_score": "0.045349", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation  ( Nasdaq - SATS ) , Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) , Amedisys, Inc.  ( Nasdaq - AMED ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33644967/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-echostar-corp", "time_published": "20230808T203358", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., Aug. 08, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.997902"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.178446, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SOVO", "relevance_score": "0.078354", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.232069", "ticker_sentiment_score": "0.291904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMED", "relevance_score": "0.306007", "ticker_sentiment_score": "0.142929", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.232069", "ticker_sentiment_score": "0.068524", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.078354", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DISH", "relevance_score": "0.508878", "ticker_sentiment_score": "0.183796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SATS", "relevance_score": "0.508878", "ticker_sentiment_score": "0.177172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.232069", "ticker_sentiment_score": "0.208011", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking Into Biogen's Recent Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33628115/looking-into-biogens-recent-short-interest", "time_published": "20230808T130032", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has risen 24.07% since its last report. The company recently reported that it has 2.57 million shares sold short, which is 2.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Sage Therapeutics a Contrarian Buy?", "url": "https://www.fool.com/investing/2023/08/08/is-sage-therapeutics-a-contrarian-buy/", "time_published": "20230808T130000", "authors": ["George Budwell"], "summary": "A regulatory setback weighed heavily on the drugmaker's shares Monday.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743149%2Fdepression.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.09766, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.81358", "ticker_sentiment_score": "0.16371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.244109", "ticker_sentiment_score": "-0.046036", "ticker_sentiment_label": "Neutral"}]}, {"title": "DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday - Axsome Therapeutics  ( NASDAQ:AXSM ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33624476/draftkings-to-rally-over-38-here-are-10-other-analyst-forecasts-for-tuesday", "time_published": "20230808T114336", "authors": ["Lisa Levin"], "summary": "Piper Sandler raised the price target for Chegg, Inc. CHGG from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market trading. Atlantic Equities cut Biogen Inc. BIIB price target from $282 to $275.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/08/draftkings_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.174053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.28442", "ticker_sentiment_score": "0.555079", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.191929", "ticker_sentiment_score": "0.084764", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.191929", "ticker_sentiment_score": "0.180225", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DDOG", "relevance_score": "0.28442", "ticker_sentiment_score": "0.11518", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAY", "relevance_score": "0.28442", "ticker_sentiment_score": "0.414427", "ticker_sentiment_label": "Bullish"}, {"ticker": "GS", "relevance_score": "0.191929", "ticker_sentiment_score": "0.312574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.28442", "ticker_sentiment_score": "0.084549", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.28442", "ticker_sentiment_score": "0.154739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOVO", "relevance_score": "0.28442", "ticker_sentiment_score": "0.243286", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENTA", "relevance_score": "0.28442", "ticker_sentiment_score": "-0.168126", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GENI", "relevance_score": "0.28442", "ticker_sentiment_score": "-0.17909", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CHGG", "relevance_score": "0.28442", "ticker_sentiment_score": "0.139152", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVN", "relevance_score": "0.28442", "ticker_sentiment_score": "0.11518", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.28442", "ticker_sentiment_score": "0.006401", "ticker_sentiment_label": "Neutral"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - PACW, INPX, AMNB, RETA", "url": "https://www.benzinga.com/pressreleases/23/08/g33610103/alert-the-m-a-class-action-firm-continues-investigating-the-merger-pacw-inpx-amnb-reta", "time_published": "20230807T210000", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.344705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.272788", "ticker_sentiment_score": "0.319454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.138464", "ticker_sentiment_score": "0.199482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.272788", "ticker_sentiment_score": "0.242042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.161798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BANC", "relevance_score": "0.138464", "ticker_sentiment_score": "0.199482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.272788", "ticker_sentiment_score": "0.319454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.161798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.121224", "ticker_sentiment_label": "Neutral"}, {"ticker": "INPX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.162347", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead - Sage Therapeutics  ( NASDAQ:SAGE ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33604705/what-more-can-support-biogensages-zuranolone-resubmission-analysts-see-uncertain-ro", "time_published": "20230807T174405", "authors": ["Vandana Singh"], "summary": "The FDA approved Sage Therapeutics Inc SAGE and Biogen Inc's BIIB Zurzuvae ( zuranolone ) 50 mg for adults with postpartum depression ( PPD ) but issued a Complete Response Letter for the New Drug Application for zuranolone for major depressive disorder.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/07/sage_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.028933, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.199649", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.363388", "ticker_sentiment_score": "-0.144019", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says - Axsome Therapeutics  ( NASDAQ:AXSM ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33601230/fdas-rejection-of-sagebiogens-zuranolone-boosts-prospects-for-axsomes-auvelity-anal", "time_published": "20230807T160656", "authors": ["Vandana Singh"], "summary": "Axsome Therapeutics Inc AXSM reported Q2 sales of $46.7 million, beating the consensus of $40.19 million. The company reported a Q2 EPS loss of $ ( 1.54 ) , missing the consensus of $ ( 1.24 ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/07/axsm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026367, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.372647", "ticker_sentiment_label": "Bearish"}, {"ticker": "AXSM", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.067142", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.372647", "ticker_sentiment_label": "Bearish"}]}, {"title": "Why Sage Therapeutics Stock Is Crashing Today", "url": "https://www.fool.com/investing/2023/08/07/why-sage-therapeutics-stock-is-crashing-today/", "time_published": "20230807T154432", "authors": ["Keith Speights"], "summary": "Sage's regulatory win wasn't enough to offset an even bigger regulatory loss.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.016871, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.386875", "ticker_sentiment_score": "-0.11616", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.386875", "ticker_sentiment_score": "-0.159288", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stock Market Glad To Start A New Week; Warren Buffett Berkshire Stock Rises", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-glad-to-start-a-new-week-warren-buffett-stock-rises-on-profit-news/", "time_published": "20230807T145900", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Glad To Start A New Week. Warren Buffett Berkshire Stock Rises Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/A1MAIN-doggy-102519-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.103412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.113597", "ticker_sentiment_score": "0.017364", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOVO", "relevance_score": "0.113597", "ticker_sentiment_score": "0.138692", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.169676", "ticker_sentiment_score": "0.171718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELAN", "relevance_score": "0.113597", "ticker_sentiment_score": "0.232727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.056943", "ticker_sentiment_score": "0.015038", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.056943", "ticker_sentiment_score": "0.223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.18986", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.056943", "ticker_sentiment_score": "0.122338", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.113597", "ticker_sentiment_score": "0.162166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.113597", "ticker_sentiment_score": "0.140926", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.217537", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.169676", "ticker_sentiment_score": "-0.237489", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stock Market Glad To Start A New Week; Warren Buffett Berkshire Stock Rises", "url": "https://www.investors.com/research/stock-market-glad-to-start-a-new-week-warren-buffett-stock-rises-on-profit-news/", "time_published": "20230807T145900", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Glad To Start A New Week. Warren Buffett Berkshire Stock Rises Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/A1MAIN-doggy-102519-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.103412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.113597", "ticker_sentiment_score": "0.017364", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOVO", "relevance_score": "0.113597", "ticker_sentiment_score": "0.138692", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.169676", "ticker_sentiment_score": "0.171718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELAN", "relevance_score": "0.113597", "ticker_sentiment_score": "0.232727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.056943", "ticker_sentiment_score": "0.015038", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.056943", "ticker_sentiment_score": "0.223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.18986", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.056943", "ticker_sentiment_score": "0.122338", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.113597", "ticker_sentiment_score": "0.162166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.113597", "ticker_sentiment_score": "0.140926", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.217537", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.169676", "ticker_sentiment_score": "-0.237489", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug", "url": "https://www.cnbc.com/2023/08/07/sage-therapeutics-plunges-after-fda-decision-on-depression-drug.html", "time_published": "20230807T145226", "authors": ["Annika Kim Constantino"], "summary": "The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107282724-1691416994265-gettyimages-1232777091-PGONCHAR_W8860.jpeg?v=1691419946&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.224207, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "WFC", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.165443", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SAGE", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.084191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.342487", "ticker_sentiment_score": "-0.19103", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Sage Therapeutics' stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder", "url": "https://www.marketwatch.com/story/sage-therapeutics-stock-craters-49-after-fda-approves-zuranolone-for-postpartum-depression-but-not-major-depressive-disorder-2648cefa", "time_published": "20230807T144600", "authors": ["Ciara Linnane"], "summary": "The good news on postpartum depression was offset by disappointment about major depressive disorder, which would be a far greater opportunity.", "banner_image": "https://images.mktw.net/im-830844/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.132535, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.217834", "ticker_sentiment_score": "-0.099739", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.055109", "ticker_sentiment_score": "-0.129849", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.109956", "ticker_sentiment_score": "0.153158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.256977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.321673", "ticker_sentiment_score": "0.162009", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Stories Monday, Aug 7: PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories - Apple  ( NASDAQ:AAPL ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/cryptocurrency/23/08/33602277/paypal-unveils-usd-backed-stablecoin-trucking-firm-yellow-corp-files-for-bankruptcy-fda-ap", "time_published": "20230807T143422", "authors": ["Vandana Singh"], "summary": "In a significant move to bolster the adoption of digital tokens for transactions, PayPal Holdings Inc PYPL announced Monday the launch of a new U.S. dollar-denominated stablecoin. The digital coin, issued by Paxos Trust Co., is underpinned by U.S. dollar deposits, short-term Treasuries, and other ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/07/pypl.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999999"}], "overall_sentiment_score": -0.007216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.128135", "ticker_sentiment_score": "0.195378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.128135", "ticker_sentiment_score": "0.04412", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.128135", "ticker_sentiment_score": "0.054465", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELL", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.27794", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBS", "relevance_score": "0.128135", "ticker_sentiment_score": "0.119572", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.034944", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042876", "ticker_sentiment_score": "0.08893", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.14363", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.128135", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.042876", "ticker_sentiment_score": "0.016756", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOGO", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.098371", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELAN", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.076953", "ticker_sentiment_label": "Neutral"}, {"ticker": "THS", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.020251", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.034944", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.128135", "ticker_sentiment_score": "0.195378", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharma Earnings Reports Are Moving The Markets And AI Shakes Up The Emerging Tech Space - AI Newsletter August 5th", "url": "https://www.forbes.com/sites/qai/2023/08/07/pharma-earnings-reports-are-moving-the-markets-and-ai-shakes-up-the-emerging-tech-spaceforbes-ai-newsletter-august-5th/", "time_published": "20230807T141624", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "Subscribe to the Forbes AI newsletter to stay in the loop and get AI-backed investing insights, the latest news and more delivered directly to your inbox every weekend.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64d0fc60aad203763e16bfb6/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998932"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.182086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.043579", "ticker_sentiment_score": "0.032128", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.087027", "ticker_sentiment_score": "0.136134", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRVN", "relevance_score": "0.087027", "ticker_sentiment_score": "0.105503", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.043579", "ticker_sentiment_score": "0.03166", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.043579", "ticker_sentiment_score": "0.007952", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043579", "ticker_sentiment_score": "0.152827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.043579", "ticker_sentiment_score": "0.007952", "ticker_sentiment_label": "Neutral"}, {"ticker": "EEFT", "relevance_score": "0.087027", "ticker_sentiment_score": "0.234932", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.043579", "ticker_sentiment_score": "0.007952", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGTX", "relevance_score": "0.130217", "ticker_sentiment_score": "0.069125", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSTM", "relevance_score": "0.087027", "ticker_sentiment_score": "0.150273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.087027", "ticker_sentiment_score": "0.033382", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This Biotech Lost Half Its Value On An FDA Approval", "url": "https://www.investors.com/news/technology/sage-stock-why-the-biotech-lost-half-its-value-after-the-fda-approved-its-depression-drug/", "time_published": "20230807T132000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Sage Stock: Why The Biotech Lost Half Its Value After The FDA Approved Its Depression Drug Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-sagetherapeutics-02-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": -0.12084, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.279502", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.067054", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sage Therapeutics and Biogen Stocks Are Falling - What's Going On? - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33595528/fda-approves-sage-therapeuticsbiogens-zuranolone-for-one-type-of-depression-rejects-for-another", "time_published": "20230807T125748", "authors": ["Vandana Singh"], "summary": "The FDA approved Sage Therapeutics Inc SAGE and Biogen Inc's BIIB Zurzuvae ( zuranolone ) 50 mg for adults with postpartum depression ( PPD ) . Zurzuvae is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/07/sage.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.017041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.40348", "ticker_sentiment_score": "0.069703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.519739", "ticker_sentiment_score": "0.065282", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lupin Pharmaceuticals Just Recalled Two Birth Control Pills - Did It Affect The Stock?", "url": "https://www.forbes.com/sites/qai/2023/08/07/lupin-pharmaceuticals-just-recalled-two-birth-control-pillsdid-it-affect-the-stock/", "time_published": "20230807T121959", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "Despite the news, Lupin's share price rose 4% on earnings results and has increased 47% in ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64d0e0f0129ef649e1034c65/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.998932"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.082029, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033562", "ticker_sentiment_score": "-0.0158", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033562", "ticker_sentiment_score": "-0.077014", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.033562", "ticker_sentiment_score": "0.10067", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.067064", "ticker_sentiment_score": "0.105488", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen, Sage face uphill battle with postpartum depression pill", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-sage-face-uphill-battle-with-postpartum-depression-pill-2023-08-07/", "time_published": "20230807T113500", "authors": ["Mariam Sunny", "Bhanvi Satija"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/24e53264-190b-4097-835a-edeca236a9f4.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.116648, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.059851", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.541149", "ticker_sentiment_score": "-0.118908", "ticker_sentiment_label": "Neutral"}]}, {"title": "Major US health systems expect to offer Alzheimer's drug Leqembi in a few months", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/major-us-health-systems-expect-offer-alzheimers-drug-leqembi-few-months-2023-08-07/", "time_published": "20230807T101600", "authors": ["Deena Beasley", "Julie Steenhuysen"], "summary": "The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File photo", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/U3AAZDXUPRIUNCIYPD4GHM72CA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.056887, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.250386", "ticker_sentiment_score": "0.039363", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.022781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Retirees' Biggest Social Security News of the Year Is Less Than 10 Weeks Away", "url": "https://www.fool.com/retirement/2023/08/07/retirees-biggest-social-security-news-of-the-year/", "time_published": "20230807T100000", "authors": ["Keith Speights"], "summary": "You'll soon find out how much fizz is in your Social Security COLA for 2024.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741854%2Folder-woman-looking-at-calendar.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014269, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.069294", "ticker_sentiment_score": "-0.058183", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.069294", "ticker_sentiment_score": "-0.058183", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA - EQRx  ( NASDAQ:EQRX ) , New Relic  ( NYSE:NEWR ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33589244/lifshitz-law-pllc-announces-investigations-of-eqrx-rvmd-newr-and-reta", "time_published": "20230806T001300", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 05, 2023 ( GLOBE NEWSWIRE ) -- Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.20711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EQRX", "relevance_score": "0.403913", "ticker_sentiment_score": "0.270951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TPG", "relevance_score": "0.084423", "ticker_sentiment_score": "0.034441", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.659949", "ticker_sentiment_score": "0.35648", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.084423", "ticker_sentiment_score": "0.037647", "ticker_sentiment_label": "Neutral"}]}, {"title": "What To Know About Zuranolone-The First FDA-Approved Oral Pill For Postpartum Depression", "url": "https://www.forbes.com/sites/tylerroush/2023/08/05/what-to-know-about-zuranolone-the-first-fda-approved-oral-pill-for-postpartum-depression/", "time_published": "20230805T182634", "authors": ["Ty Roush"], "summary": "About one in seven women experience postpartum depression after giving birth.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64ce93b99afc8170a7364b32/0x0.jpg?format=jpg&crop=5361,3017,x0,y0,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.070842, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.040967", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.040967", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves first postpartum depression pill in the US", "url": "https://www.cnn.com/2023/08/04/health/fda-approves-first-postpartum-depression-pill-in-the-us/index.html", "time_published": "20230805T155600", "authors": ["Jacqueline Howard"], "summary": "The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for postpartum depression, a serious mental illness that can develop in about 1 in 7 new mothers ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230725151910-01-postpartum-depression-pill-zuranolone.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.194462, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.022368", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.022368", "ticker_sentiment_score": "0.182765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.044718", "ticker_sentiment_score": "-0.016001", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Fantastic Growth Stocks to Buy in August", "url": "https://www.fool.com/investing/2023/08/05/3-fantastic-growth-stocks-to-buy-in-august/", "time_published": "20230805T105500", "authors": ["Keith Speights", "and Prosper Junior Bakiny", "David Jagielski"], "summary": "These stocks could be poised to soar.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742339%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.271353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.344473", "ticker_sentiment_score": "0.196689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.262052", "ticker_sentiment_score": "0.324917", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.176502", "ticker_sentiment_score": "0.079316", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044469", "ticker_sentiment_score": "0.167724", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US approves first pill to treat postpartum depression", "url": "https://www.aljazeera.com/news/2023/8/5/us-approves-first-pill-to-treat-postpartum-depression", "time_published": "20230805T064726", "authors": ["Al Jazeera"], "summary": "Zurzuvae is expected to be commercially available later this year. Health regulators in the United States have approved the first pill to treat postpartum depression, offering a lifeline to the as many as one in seven new mothers who suffer from the condition each year.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/08/AP23215650492512-1691215478.jpg?resize=770%2C513&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.036173, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.165031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.468029", "ticker_sentiment_score": "0.015338", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.468029", "ticker_sentiment_score": "0.015338", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves ZURZUVAE\u2122  ( zuranolone ) , the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder - Sage Therapeutics  ( NASDAQ:SAGE ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33585905/fda-approves-zurzuvae-zuranolone-the-first-and-only-oral-treatment-approved-for-women-with-postpar", "time_published": "20230805T024132", "authors": ["Globe Newswire"], "summary": "Postpartum depression ( PPD ) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": -0.009826, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.012618", "ticker_sentiment_score": "0.19227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.075595", "ticker_sentiment_score": "0.051305", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.113181", "ticker_sentiment_score": "0.078266", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves ZURZUVAE\u2122  ( zuranolone ) , the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder", "url": "https://www.globenewswire.com/news-release/2023/08/05/2719329/0/en/FDA-Approves-ZURZUVAE-zuranolone-the-First-and-Only-Oral-Treatment-Approved-for-Women-with-Postpartum-Depression-and-Issues-a-Complete-Response-Letter-for-Major-Depressive-Disorder.html", "time_published": "20230805T024100", "authors": ["Biogen Inc."], "summary": "Postpartum depression ( PPD ) approval based on results from two Phase 3 clinical trials. in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": -0.041718, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012473", "ticker_sentiment_score": "0.057593", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.012473", "ticker_sentiment_score": "0.057593", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.049861", "ticker_sentiment_score": "0.087001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.099528", "ticker_sentiment_score": "0.059654", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves first-ever pill for postpartum depression in new mothers", "url": "https://www.marketwatch.com/story/fda-approves-first-ever-pillfor-postpartum-depression-in-new-mothers-185ecf81", "time_published": "20230804T234000", "authors": ["Rachel Koning Beals"], "summary": "Biogen and Sage Therapeutics are behind the first FDA-approved pill for treating postpartum depression.", "banner_image": "https://images.mktw.net/im-830415/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.233717, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.199037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.294682", "ticker_sentiment_score": "-0.004313", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA approves Biogen-Sage Therapeutics pill for clinical depression", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biogen-sage-therapeutics-pill-clinical-depression-2023-08-04/", "time_published": "20230804T231100", "authors": ["Reuters"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo/File Photo Aug 4 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/55SBVFB7TROATMBPHXGQQPVRAY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.049625, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.388879", "ticker_sentiment_score": "0.109144", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.388879", "ticker_sentiment_score": "0.109144", "ticker_sentiment_label": "Neutral"}]}, {"title": "For the First Time, There's a Pill for Postpartum Depression", "url": "https://www.nytimes.com/2023/08/04/health/postpartum-depression-pill-fda.html", "time_published": "20230804T230301", "authors": ["Pam Belluck"], "summary": "Because the pill works faster than other antidepressants and is taken for only two weeks, it may encourage more treatment of the debilitating condition.", "banner_image": "https://static01.nyt.com/images/2023/08/04/multimedia/04Postpartum-01-lqbz/04Postpartum-01-lqbz-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.092527, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.02241", "ticker_sentiment_score": "0.13601", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.000889", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.000889", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Biotech Game Is Changing. Watch for Disruptions, Says RBC.", "url": "https://www.barrons.com/articles/biotech-stocks-changing-regulation-disruption-1b4b3ee", "time_published": "20230804T203300", "authors": ["Bill Alpert"], "summary": "Disruptions in Biotech Could Shake Up the Stocks. Watch Out, Says ...", "banner_image": "https://images.barrons.com/im-830263?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.053357, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.250386", "ticker_sentiment_score": "-0.022243", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.126784", "ticker_sentiment_score": "0.133588", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.063594", "ticker_sentiment_score": "0.146144", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.31006", "ticker_sentiment_score": "-0.034473", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.126784", "ticker_sentiment_score": "0.133588", "ticker_sentiment_label": "Neutral"}]}, {"title": "BIIB: 3 Biotech Stocks Smart Money Is After", "url": "https://stocknews.com/news/biib-cdtx-thtx-3-biotech-stocks-smart-money-is-after/", "time_published": "20230804T194044", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is at the cutting edge of modern healthcare and spearheads it by developing ground-breaking therapies and technologies that cater to underserved or previously unserved markets, thereby increasing the size of the pie for the healthcare industry.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "0.999975"}], "overall_sentiment_score": 0.253225, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDTX", "relevance_score": "0.17715", "ticker_sentiment_score": "0.242702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.076439", "ticker_sentiment_score": "0.163381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.250902", "ticker_sentiment_score": "0.236751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THTX", "relevance_score": "0.226536", "ticker_sentiment_score": "0.389648", "ticker_sentiment_label": "Bullish"}]}, {"title": "Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/bioprocess-validation-market-to-grow-at-a-cagr-of-11-39-from-2022-to-2027increasing-demand-for-biopharmaceuticals-to-boost-market-growth---technavio-301892736.html", "time_published": "20230804T151500", "authors": [], "summary": "Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.244667, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PVARF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHKSF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.031119", "ticker_sentiment_score": "0.104281", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEAGF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.031119", "ticker_sentiment_score": "0.104281", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.031119", "ticker_sentiment_score": "0.113286", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTR", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHHLF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.093168", "ticker_sentiment_score": "0.12168", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLW", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUVPF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.062191", "ticker_sentiment_score": "0.120072", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, DFFN - EQRx  ( NASDAQ:EQRX ) , Diffusion Pharmaceuticals  ( NASDAQ:DFFN ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33542241/shareholder-investigation-halper-sadeh-llc-investigates-reta-eqrx-dffn", "time_published": "20230803T102321", "authors": ["Globe Newswire"], "summary": "NEW YORK, Aug. 03, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.057525, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EQRX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DFFN", "relevance_score": "0.165031", "ticker_sentiment_score": "0.100962", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.165031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.165031", "ticker_sentiment_score": "0.105018", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.165031", "ticker_sentiment_score": "0.105018", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.165031", "ticker_sentiment_score": "0.100962", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Unusual Options Activity For August 02 - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/options/23/08/33530285/biogen-unusual-options-activity-for-august-02", "time_published": "20230802T193126", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen BIIB we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.143473, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MS", "relevance_score": "0.115232", "ticker_sentiment_score": "-0.136083", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.807885", "ticker_sentiment_score": "0.147251", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware partners with AdvanSoft to introduce VIROO in Malaysia", "url": "https://www.globenewswire.com/news-release/2023/08/02/2717130/0/en/Virtualware-partners-with-AdvanSoft-to-introduce-VIROO-in-Malaysia.html", "time_published": "20230802T160000", "authors": ["VIRTUALWARE 2007 SA"], "summary": "Bilbao, Spain, 18 August.- Spanish technology company Virtualware ( EPA: MLVIR ) , one of the European leaders in the virtual reality industry, has signed a partnership agreement with AdvanSoft Sdn Bhd to boost VIROO's presence in Malaysia.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13948b91-ce96-426f-b8a7-b1586665fb52", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.214539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PNAGF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.06577", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTHIF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.045396", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.045396", "ticker_sentiment_score": "0.097424", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.", "url": "https://www.fool.com/investing/2023/08/01/biogens-just-made-its-biggest-acquisition-heres-wh/", "time_published": "20230801T094500", "authors": ["Adria Cimino"], "summary": "Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998663"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.278362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.054114", "ticker_sentiment_score": "0.053945", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.054114", "ticker_sentiment_score": "0.193835", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.58463", "ticker_sentiment_score": "0.464328", "ticker_sentiment_label": "Bullish"}]}, {"title": "ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMNB, RETA, PACW, INPX", "url": "https://www.benzinga.com/pressreleases/23/07/g33481779/alert-the-m-a-class-action-firm-continues-investigating-the-merger-amnb-reta-pacw-inpx", "time_published": "20230731T214130", "authors": ["Globe Newswire"], "summary": "NEW YORK, July 31, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.344705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.272788", "ticker_sentiment_score": "0.319454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKSH", "relevance_score": "0.138464", "ticker_sentiment_score": "0.199482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.272788", "ticker_sentiment_score": "0.242042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.161798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BANC", "relevance_score": "0.138464", "ticker_sentiment_score": "0.199482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMNB", "relevance_score": "0.272788", "ticker_sentiment_score": "0.319454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.161798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.121224", "ticker_sentiment_label": "Neutral"}, {"ticker": "INPX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.162347", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33480589/heres-how-much-you-would-have-made-owning-biogen-stock-in-the-last-15-years", "time_published": "20230731T210041", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 3.6% on an annualized basis producing an average annual return of 12.44%. Currently, Biogen has a market capitalization of $39.13 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer's disease", "url": "https://www.marketwatch.com/story/quest-diagnostics-launches-first-at-home-blood-test-to-assess-risk-of-developing-alzheimers-disease-20cd3639", "time_published": "20230731T152700", "authors": ["Ciara Linnane"], "summary": "A simple test can detect the brain protein beta amyloid that is linked to the progression of Alzheimer's disease.", "banner_image": "https://images.mktw.net/im-696087/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.030889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.191929", "ticker_sentiment_score": "0.08982", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.191929", "ticker_sentiment_score": "0.010881", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.191929", "ticker_sentiment_score": "0.191759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.191929", "ticker_sentiment_score": "0.191759", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Rising Stars, Falling Trends: July's Industry ETF Winners and Losers - Invesco Solar ETF  ( ARCA:TAN ) , Deere  ( NYSE:DE ) , SLB  ( NYSE:SLB ) , Archer-Daniels Midland  ( NYSE:ADM ) , Mueller Industries  ( NYSE:MLI ) , Amgen  ( NASDAQ:AMGN ) , Ferguson  ( NYSE:FERG ) , Vanguard Real Estate ETF  ( ARCA:VNQ ) , VanEck Gold Miners ETF  ( ARCA:GDX ) , SPDR S&P 500  ( ARCA:SPY ) , American Tower  ( NYSE:AMT ) , SMA Solar Tech  ( OTC:SMTGF ) , VanEck Oil Services ETF  ( ARCA:OIH ) , VanEck Semiconductor ETF  ( NASDAQ:SMH ) , Taiwan Semiconductor  ( NYSE:TSM ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Antero Resources  ( NYSE:AR ) , First Solar  ( NASDAQ:FSLR ) , SPDR S&P Oil & Gas Explor & Product  ( ARCA:XOP ) , Biogen  ( NASDAQ:BIIB ) , SPDR S&P Regional Banking ETF  ( ARCA:KRE ) , Enphase Energy  ( NASDAQ:ENPH ) , Broadcom  ( NASDAQ:AVGO ) , Western Alliance  ( NYSE:WAL ) , CoStar Gr  ( NASDAQ:CSGP ) , iShares Biotechnology ETF  ( NASDAQ:IBB ) , Prologis  ( NYSE:PLD ) , Waters  ( NYSE:WAT ) , Ovintiv  ( NYSE:OVV ) , Danaher  ( NYSE:DHR ) , Invesco Water Resources ETF  ( NASDAQ:PHO ) , U.S. Global Jets ETF  ( ARCA:JETS ) , Lam Research  ( NASDAQ:LRCX ) , Zoetis  ( NYSE:ZTS ) , SM Energy  ( NYSE:SM ) , SPDR Dow Jones Industrial Average ETF  ( ARCA:DIA ) , iShares Russell 2000 ETF  ( ARCA:IWM ) , NVIDIA  ( NASDAQ:NVDA ) , Zions Bancorp  ( NASDAQ:ZION ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) , Crown Castle  ( NYSE:CCI ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , Southwest Airlines  ( NYSE:LUV ) , VanEck Agribusiness ETF  ( ARCA:MOO ) , Pinnacle Finl Partners  ( NASDAQ:PNFP ) , Delta Air Lines  ( NYSE:DAL ) , Ecolab  ( NYSE:ECL ) , APA  ( NASDAQ:APA ) , Halliburton  ( NYSE:HAL ) , SolarEdge Technologies  ( NASDAQ:SEDG ) , Valmont Industries  ( NYSE:VMI ) , Intel  ( NASDAQ:INTC ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33471902/rising-stars-falling-trends-julys-industry-etf-winners-and-losers", "time_published": "20230731T145922", "authors": ["Piero Cingari"], "summary": "As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month. Among the largest ETFs that represent major U.S. stock indices, the SPDR S&P 500 ETF Trust SPY returned 3.1% in July, marking its fifth consecutive month of gains.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Spanish,Bull,Running,In,The,Bullring,With,Big,Horns,On_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.166243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.056323", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSGP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLD", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.164656", "ticker_sentiment_score": "0.180471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "OVV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "FERG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.164656", "ticker_sentiment_score": "0.061707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.031505", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIONL", "relevance_score": "0.055236", "ticker_sentiment_score": "0.041883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.054977", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMTGF", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNFP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.045851", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "AR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.057668", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More", "url": "https://www.zacks.com/stock/news/2129900/drug-biotech-stocks-q2-earnings-due-on-aug-1-pfe-mrk-more", "time_published": "20230731T135800", "authors": ["Ahan Chakraborty"], "summary": "Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.160061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.043658", "ticker_sentiment_score": "0.134273", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.215702", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.415927", "ticker_sentiment_score": "0.104372", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.377776", "ticker_sentiment_score": "0.007815", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.087185", "ticker_sentiment_score": "0.141037", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.298437", "ticker_sentiment_score": "0.100076", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.087185", "ticker_sentiment_score": "0.141037", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen", "url": "https://www.fool.com/investing/2023/07/31/better-alzheimers-drug-stock-eli-lilly-vs-biogen/", "time_published": "20230731T114500", "authors": ["Alex Carchidi"], "summary": "By 2024, their medicines will likely be competing on the market, and one might win.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740806%2Fworkers-plants-crops.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.163219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.478692", "ticker_sentiment_score": "0.189427", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.431371", "ticker_sentiment_score": "0.20737", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Quest Diagnostics launches Alzheimer's blood test for consumers", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/quest-diagnostics-launches-alzheimers-blood-test-consumers-2023-07-31/", "time_published": "20230731T111000", "authors": ["Julie Steenhuysen"], "summary": "CHICAGO, July 31 ( Reuters ) - Quest Diagnostics ( DGX.N ) on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/K6ZXQDLC3FJSJI4AIU3XXNYONM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DGX", "relevance_score": "0.127456", "ticker_sentiment_score": "-0.114349", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.127456", "ticker_sentiment_score": "0.030949", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.127456", "ticker_sentiment_score": "0.030949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's New Boss Is Delivering, but Stock Isn't Pricing It in Yet", "url": "https://www.wsj.com/articles/biogens-new-boss-is-delivering-but-stock-isnt-pricing-it-in-yet-2ad9ceb6", "time_published": "20230731T110000", "authors": ["David Wainer"], "summary": "The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street's skepticism presents an opportunity.", "banner_image": "https://images.wsj.net/im-826055?width=700&height=466", "source": "Wall Street Journal", "category_within_source": "Markets", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028331, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.922387", "ticker_sentiment_score": "0.050543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could This Stock Be the Next Biotech Buyout?", "url": "https://www.fool.com/investing/2023/07/31/a-buyout-deal-pushed-reata-higher-could-these-be-n/", "time_published": "20230731T101300", "authors": ["Cory Renauer"], "summary": "A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741915%2Fman-bun-investor-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.214657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.175009", "ticker_sentiment_score": "0.132435", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.231884", "ticker_sentiment_score": "0.082913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Robert W. Baird Remains a Hold on Gilead Sciences  ( GILD ) ", "url": "https://markets.businessinsider.com/news/stocks/robert-w-baird-remains-a-hold-on-gilead-sciences-gild-1032494585", "time_published": "20230731T094515", "authors": ["Tipranks"], "summary": "Robert W. Baird Remains a Hold on Gilead Sciences (GILD) - Markets Insider ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.067803, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.651499", "ticker_sentiment_score": "-0.043652", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.148731", "ticker_sentiment_score": "0.056613", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.135159", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.148731", "ticker_sentiment_score": "0.135159", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/promising-new-alzheimers-drugs-may-benefit-whites-more-than-blacks-2023-07-31/", "time_published": "20230731T090400", "authors": ["Julie Steenhuysen"], "summary": "[1/5] Barrington and Vickie Riley pose at the Emory University Brain Health Center in Atlanta, Georgia, U.S., July 12, 2023. The Riley's, who have been married more than 35 years, participated in the Charlie and Harriet Shaffer Cognitive Empowerment Program. Barrington Riley has mild cognitive...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/V6T2WJ2LYROITJY47OYBRI4ZKI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.021407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.049784", "ticker_sentiment_score": "-0.039896", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Double Whammy That Could Reduce Your Social Security Increase in 2024", "url": "https://www.fool.com/retirement/2023/07/30/a-double-whammy-that-could-reduce-your-social-secu/", "time_published": "20230730T110000", "authors": ["Keith Speights"], "summary": "There's also a third potential whammy to consider.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741381%2Folder-couple-looking-out-window.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.983605"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.031751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.067919", "ticker_sentiment_score": "-0.061138", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.067919", "ticker_sentiment_score": "-0.061138", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street ends week higher on US soft landing hopes", "url": "https://www.moneycontrol.com/news/business/markets/wall-street-ends-week-higher-on-us-soft-landing-hopes-11055541.html", "time_published": "20230729T032736", "authors": [], "summary": "The Dow Jones Industrial Average rose 176.37 points, or 0.5%, to 35,459.09, the SP 500 gained 44.76 points, or 0.99%, to 4,582.17 and the Nasdaq Composite added 266.55 points, or 1.9%, to 14,316.66.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/03/Wall-Street.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.143501, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.055751", "ticker_sentiment_score": "-0.254994", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVDA", "relevance_score": "0.055751", "ticker_sentiment_score": "0.385068", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.055751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNPR", "relevance_score": "0.055751", "ticker_sentiment_score": "-0.254994", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "F", "relevance_score": "0.055751", "ticker_sentiment_score": "-0.082876", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.055751", "ticker_sentiment_score": "0.122889", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.055751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.055751", "ticker_sentiment_score": "-0.134237", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055751", "ticker_sentiment_score": "0.122889", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.055751", "ticker_sentiment_score": "0.385068", "ticker_sentiment_label": "Bullish"}]}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SURF, RETA, INPX", "url": "https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-surf-reta-inpx-301888529.html", "time_published": "20230728T204600", "authors": ["Halper Sadeh LLP"], "summary": "NEW YORK, July 28, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Coherus BioSciences, Inc.", "banner_image": "https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.134147, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "0.175859", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.175859", "ticker_sentiment_score": "0.118146", "ticker_sentiment_label": "Neutral"}, {"ticker": "INPX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc.  ( Nasdaq - RETA ) , Talaris Therapeutics, Inc.  ( Nasdaq - TALS ) , Inpixon\u00ae  ( Nasdaq - INPX ) , Amedisys, Inc.  ( Nasdaq - AMED ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33448233/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-reata-pharmac", "time_published": "20230728T182102", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., July 28, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.77141"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.104491, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TALS", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMED", "relevance_score": "0.310843", "ticker_sentiment_score": "0.144659", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.235823", "ticker_sentiment_score": "0.069408", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.079656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.235823", "ticker_sentiment_score": "0.210602", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INPX", "relevance_score": "0.310843", "ticker_sentiment_score": "0.006831", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering", "url": "https://www.marketwatch.com/story/biogen-agrees-to-acquire-reata-pharmaceuticals-for-7-3-billion-in-cash-e0a6135", "time_published": "20230728T181200", "authors": ["Ciara Linnane"], "summary": "Biogen's all-cash deal is a rare-disease play.", "banner_image": "https://images.mktw.net/im-705451/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.061302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.240489", "ticker_sentiment_score": "0.144419", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.779232", "ticker_sentiment_score": "0.381337", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Market Rallies Amid Earnings Wave, Fed Hike: Weekly Review", "url": "https://www.investors.com/news/stock-market-rallies-amid-huge-earnings-fed-rate-hike-inflation-data-weekly-review/", "time_published": "20230728T180600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally advanced amid a massive wave of earnings reports, a new Fed rate hike and tame inflation data, though the Dow Jones ended a long winning streak. Microsoft ( MSFT ) guidance disappointed, hitting many related stocks.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/11/SSA_runners_111716_adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.998626"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.046839, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.028023", "ticker_sentiment_score": "0.085676", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEDP", "relevance_score": "0.042024", "ticker_sentiment_score": "0.023927", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXL", "relevance_score": "0.042024", "ticker_sentiment_score": "0.080984", "ticker_sentiment_label": "Neutral"}, {"ticker": "XPEV", "relevance_score": "0.056011", "ticker_sentiment_score": "0.075891", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.028023", "ticker_sentiment_score": "0.000969", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.03692", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.028023", "ticker_sentiment_score": "0.022458", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMHC", "relevance_score": "0.042024", "ticker_sentiment_score": "0.040814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.042024", "ticker_sentiment_score": "0.067579", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.014014", "ticker_sentiment_score": "0.125985", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.056011", "ticker_sentiment_score": "0.001005", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.028023", "ticker_sentiment_score": "0.045804", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.125606", "ticker_sentiment_score": "0.003689", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.042024", "ticker_sentiment_score": "0.023684", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELL", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.183394", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DMPZF", "relevance_score": "0.014014", "ticker_sentiment_score": "0.000903", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.028023", "ticker_sentiment_score": "0.082349", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.00188", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.045613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.042024", "ticker_sentiment_score": "0.088612", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.097854", "ticker_sentiment_score": "0.057951", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028023", "ticker_sentiment_score": "0.19241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.028023", "ticker_sentiment_score": "0.082349", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.045613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.042024", "ticker_sentiment_score": "0.20082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRGRF", "relevance_score": "0.014014", "ticker_sentiment_score": "0.077924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPH", "relevance_score": "0.042024", "ticker_sentiment_score": "0.040814", "ticker_sentiment_label": "Neutral"}, {"ticker": "URI", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARCB", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.188433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DPZ", "relevance_score": "0.028023", "ticker_sentiment_score": "0.000969", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.125606", "ticker_sentiment_score": "0.044225", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.042024", "ticker_sentiment_score": "0.088612", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.183394", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "V", "relevance_score": "0.028023", "ticker_sentiment_score": "0.135277", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTX", "relevance_score": "0.069982", "ticker_sentiment_score": "-0.057853", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "X", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.037481", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.028023", "ticker_sentiment_score": "0.068047", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.069982", "ticker_sentiment_score": "0.163632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUE", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.038835", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.069982", "ticker_sentiment_score": "0.021478", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.083931", "ticker_sentiment_score": "0.056588", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.028023", "ticker_sentiment_score": "0.085676", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCS", "relevance_score": "0.028023", "ticker_sentiment_score": "0.03937", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.028023", "ticker_sentiment_score": "0.069735", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "PI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIO", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.037481", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLF", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.038835", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.069735", "ticker_sentiment_label": "Neutral"}, {"ticker": "ODFL", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.188433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:NXT", "relevance_score": "0.028023", "ticker_sentiment_score": "0.045804", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Finishing Week On Strong Note; Chip Stock Leads The Dow", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-finishing-week-on-strong-note-intel-leads-dow/", "time_published": "20230728T175000", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Finishing Week On Strong Note. Chip Stock Leads The Dow Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-Intel-emeraldrapidchip-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.184051, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.136888", "ticker_sentiment_score": "0.007827", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.002455", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.008723", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.204072", "ticker_sentiment_score": "0.076448", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.136888", "ticker_sentiment_score": "0.311896", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.133889", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAH", "relevance_score": "0.136888", "ticker_sentiment_score": "0.397621", "ticker_sentiment_label": "Bullish"}, {"ticker": "HURN", "relevance_score": "0.136888", "ticker_sentiment_score": "0.121839", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.204072", "ticker_sentiment_score": "0.397128", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm - Denbury  ( NYSE:DEN ) , Inpixon  ( NASDAQ:INPX ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33446821/moore-kuehn-encourages-reta-tals-inpx-and-den-investors-to-contact-law-firm", "time_published": "20230728T165712", "authors": ["Globe Newswire"], "summary": "NEW YORK, July 28, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.158704, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.026382", "ticker_sentiment_label": "Neutral"}, {"ticker": "TALS", "relevance_score": "0.110462", "ticker_sentiment_score": "0.092032", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.110462", "ticker_sentiment_score": "0.212618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.110462", "ticker_sentiment_score": "0.212618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INPX", "relevance_score": "0.218817", "ticker_sentiment_score": "0.132558", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.218817", "ticker_sentiment_score": "0.426899", "ticker_sentiment_label": "Bullish"}]}, {"title": "Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-", "time_published": "20230728T155617", "authors": ["Vandana Singh"], "summary": "Earlier today, Biogen Inc BIIB agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/28/aapharma_5.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.162687, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SLDB", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.280615", "ticker_sentiment_score": "0.481365", "ticker_sentiment_label": "Bullish"}, {"ticker": "LRMR", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.718897", "ticker_sentiment_score": "0.314394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/m-a/23/07/33444844/health-care-company-biogen-announces-acquisition-of-reata-pharmaceuticals", "time_published": "20230728T151007", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has announced an acquisition of Reata Pharmaceuticals RETA that is expected to be completed in Q4 of 2023. Under the terms of the agreement, Biogen has agreed to give Reata Pharmaceuticals $7.30 billion in cash in exchange for RETA stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.063859, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.642555", "ticker_sentiment_score": "0.113562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.538389", "ticker_sentiment_score": "0.036618", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies", "url": "https://www.marketwatch.com/story/astrazeneca-strikes-1-billion-deal-for-pfizer-rare-disease-gene-therapies-705d2fc5", "time_published": "20230728T150000", "authors": ["Eleanor Laise"], "summary": "Stock gains 5% after AstraZeneca's second-quarter results top analyst expectations.", "banner_image": "https://images.mktw.net/im-279157/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.622414", "ticker_sentiment_score": "-0.145221", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.199037", "ticker_sentiment_score": "-0.113923", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.199037", "ticker_sentiment_score": "0.167833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.199037", "ticker_sentiment_score": "0.167833", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Rally Sparked By Surging Intel Stock; Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rally-sparked-by-surging-intel-stock-nasdaq-100-leaders-tesla-tsla-dexcom-dxcm-klacs/", "time_published": "20230728T145000", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Rally Sparked By Surging Intel Stock. Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999986"}], "overall_sentiment_score": 0.32493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.156461", "ticker_sentiment_score": "0.336563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.156461", "ticker_sentiment_score": "-0.164017", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVX", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.225203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RETA", "relevance_score": "0.104683", "ticker_sentiment_score": "0.15005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HURN", "relevance_score": "0.104683", "ticker_sentiment_score": "0.248102", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.052455", "ticker_sentiment_score": "0.414996", "ticker_sentiment_label": "Bullish"}, {"ticker": "FUTU", "relevance_score": "0.156461", "ticker_sentiment_score": "0.152466", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.104683", "ticker_sentiment_score": "0.128486", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.104683", "ticker_sentiment_score": "0.300492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.156461", "ticker_sentiment_score": "0.375556", "ticker_sentiment_label": "Bullish"}, {"ticker": "PG", "relevance_score": "0.104683", "ticker_sentiment_score": "0.267759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.225203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LI", "relevance_score": "0.104683", "ticker_sentiment_score": "0.126157", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.104683", "ticker_sentiment_score": "0.450224", "ticker_sentiment_label": "Bullish"}, {"ticker": "SAM", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.099024", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.104683", "ticker_sentiment_score": "0.15005", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition", "url": "https://www.forbes.com/sites/maryroeloffs/2023/07/28/biogen-looks-to-bulk-up-rare-disease-portfolio-with-73-billion-acquisition/", "time_published": "20230728T134522", "authors": ["Mary Whitfill Roeloffs"], "summary": "Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64c3c27406d388280116a7fe/0x0.jpg?format=jpg&crop=4306,2424,x0,y222,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.070332, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.163354", "ticker_sentiment_score": "0.149334", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.082111", "ticker_sentiment_score": "0.207875", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.783955", "ticker_sentiment_score": "0.191166", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals", "url": "https://www.investors.com/news/technology/biogen-stock-biogen-announces-7-3-billion-acquisition-of-reata-pharmaceuticals/", "time_published": "20230728T133400", "authors": ["Investor's Business Daily", "KIT NORTON"], "summary": "Biogen ( BIIB ) announced Friday it has agreed to acquire Reata Pharmaceuticals ( RETA ) for about $7.3 billion, boosting the biopharmaceutical company's drug offerings for serious neurological diseases. Reata stock surged early as Biogen stock slid Friday.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/07/Stock-biogen-10-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.208686, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SBUX", "relevance_score": "0.195814", "ticker_sentiment_score": "0.265237", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.543004", "ticker_sentiment_score": "0.174611", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.917354", "ticker_sentiment_score": "0.299614", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Investing Club's top 10 things to watch in the stock market Friday", "url": "https://www.cnbc.com/2023/07/28/the-investing-clubs-top-10-things-to-watch-in-the-stock-market-friday.html", "time_published": "20230728T132756", "authors": ["Jeff Marks"], "summary": "We're watching the bond market Friday after Thursday's spike in yields triggered a late-day reversal for equities.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107032647-1647599094433-gettyimages-1287485030-dscf0116_2020112423848236.jpeg?v=1690550991&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.124394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LIN", "relevance_score": "0.187705", "ticker_sentiment_score": "0.098033", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.063091", "ticker_sentiment_score": "0.065138", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.063091", "ticker_sentiment_score": "-0.117068", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.063091", "ticker_sentiment_score": "0.065138", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.063091", "ticker_sentiment_score": "0.065138", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.125789", "ticker_sentiment_score": "0.219384", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.125789", "ticker_sentiment_score": "0.085162", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.125789", "ticker_sentiment_score": "0.090321", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.125789", "ticker_sentiment_score": "-0.135407", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.125789", "ticker_sentiment_score": "0.219384", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Reata Pharmaceuticals  ( RETA )  Stock Is Trading Higher Premarket Today - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-", "time_published": "20230728T130749", "authors": ["Vandana Singh"], "summary": "Biogen Inc BIIB has agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/28/reta.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.27017, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.410059", "ticker_sentiment_score": "0.432901", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.849318", "ticker_sentiment_score": "0.587963", "ticker_sentiment_label": "Bullish"}]}, {"title": "Market Rebounds With Inflation Data Due; 5 Earnings Winners", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-rebounds-inflation-data-5-earnings-winners/", "time_published": "20230728T120900", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: Market Rally Set To Rebound With Inflation Data Due. 5 Earnings Winners Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/KPBLOG01-022916-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.997902"}], "overall_sentiment_score": 0.174092, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.17484", "ticker_sentiment_score": "0.356094", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOOG", "relevance_score": "0.070414", "ticker_sentiment_score": "0.240804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.17484", "ticker_sentiment_score": "0.182407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.14028", "ticker_sentiment_score": "0.181152", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROKU", "relevance_score": "0.14028", "ticker_sentiment_score": "0.209496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.17484", "ticker_sentiment_score": "0.029781", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.17484", "ticker_sentiment_score": "0.271358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.105449", "ticker_sentiment_score": "0.053918", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.24289", "ticker_sentiment_score": "0.133391", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.14028", "ticker_sentiment_score": "0.264604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.24289", "ticker_sentiment_score": "0.20334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.17484", "ticker_sentiment_score": "0.394719", "ticker_sentiment_label": "Bullish"}, {"ticker": "NOW", "relevance_score": "0.035241", "ticker_sentiment_score": "0.142231", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.14028", "ticker_sentiment_score": "0.184321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LRCX", "relevance_score": "0.070414", "ticker_sentiment_score": "0.188193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.070414", "ticker_sentiment_score": "0.185183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.105449", "ticker_sentiment_score": "0.26509", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.105449", "ticker_sentiment_score": "0.053918", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to bulk up rare disease treatments with $7 billion Reata acquisition", "url": "https://apnews.com/article/biogen-reata-acquisition-98308231d2e704171ea44ac6a32637c6", "time_published": "20230728T120700", "authors": ["TOM MURPHY"], "summary": "Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer's treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.", "banner_image": "https://dims.apnews.com/dims4/default/8f694ce/2147483647/strip/true/crop/5472x3642+0+3/resize/320x213!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fa3%2F62%2F6bda062e605c9590dff2b8d69d01%2F3a04cd14bc194edeb3124d25e8cc958e", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.119848, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.105604", "ticker_sentiment_score": "0.003306", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.209365", "ticker_sentiment_score": "0.185555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.647216", "ticker_sentiment_score": "0.295113", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal", "url": "https://www.wsj.com/articles/biogen-to-buy-reata-pharmaceuticals-in-7-3-billion-deal-512adde2", "time_published": "20230728T120300", "authors": ["Colin Kellaher"], "summary": "The deal would bolster the biotech company's portfolio of treatments for neuromuscular and rare diseases.", "banner_image": "https://images.wsj.net/im-825624?width=700&height=466", "source": "Wall Street Journal", "category_within_source": "Business", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14238, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.716023", "ticker_sentiment_score": "0.28346", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.967875", "ticker_sentiment_score": "0.252802", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more", "url": "https://www.cnbc.com/2023/07/28/stocks-making-the-biggest-moves-premarket-intc-roku-pg-.html", "time_published": "20230728T115616", "authors": ["Samantha Subin"], "summary": "These are the stocks posting the largest moves in premarket trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107186186-1675118079202-gettyimages-1246677801-INTEL_EARNS.jpeg?v=1690545376&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.109911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.015941", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.098456", "ticker_sentiment_score": "0.11968", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNPR", "relevance_score": "0.049322", "ticker_sentiment_score": "0.108819", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.049322", "ticker_sentiment_score": "0.066943", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.049322", "ticker_sentiment_score": "0.174882", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NYCB", "relevance_score": "0.098456", "ticker_sentiment_score": "0.072617", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.049322", "ticker_sentiment_score": "0.062355", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.049322", "ticker_sentiment_score": "0.136082", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.098456", "ticker_sentiment_score": "0.066545", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.015941", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.050875", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.049322", "ticker_sentiment_score": "-0.010999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.098456", "ticker_sentiment_score": "0.189304", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio", "url": "https://www.reuters.com/markets/deals/biogen-buy-reata-65-bln-bulk-up-rare-disease-portfolio-2023-07-28/", "time_published": "20230728T112140", "authors": ["Reuters"], "summary": "July 28 ( Reuters ) - Biogen ( BIIB.O ) said it would buy biotech firm Reata Pharmaceuticals ( RETA.O ) for roughly $6.5 billion to expand its presence in the rare disease drugs market. Biogen will pay $172.50 per share in cash, which represents a 58.9% premium to Reata's last closing price.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/YYQ3KYBNSNLEZDYU4ZVIFPQGNE.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.072019, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RETA", "relevance_score": "0.382925", "ticker_sentiment_score": "0.215274", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.9545", "ticker_sentiment_score": "0.141564", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to Acquire Reata Pharmaceuticals - Reata Pharmaceuticals  ( NASDAQ:RETA ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33439516/biogen-to-acquire-reata-pharmaceuticals", "time_published": "20230728T110544", "authors": ["Globe Newswire"], "summary": "SKYCLARYS\u00ae recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.141994, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.020704", "ticker_sentiment_score": "0.061299", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.020704", "ticker_sentiment_score": "0.061299", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.020704", "ticker_sentiment_score": "0.071195", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.062056", "ticker_sentiment_score": "0.146067", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.359592", "ticker_sentiment_score": "0.207274", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen to Acquire Reata Pharmaceuticals", "url": "https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html", "time_published": "20230728T110500", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) and Reata Pharmaceuticals, Inc. ( Nasdaq: RETA ) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.144426, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.02065", "ticker_sentiment_score": "0.061277", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.02065", "ticker_sentiment_score": "0.061277", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.02065", "ticker_sentiment_score": "0.071169", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.061896", "ticker_sentiment_score": "0.154071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.395324", "ticker_sentiment_score": "0.252143", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Virtualware  ( MLVIR )  launches VIROO 2.4, the new version of its Virtual Reality as a service  ( VRaaS )  platform", "url": "https://www.globenewswire.com/news-release/2023/07/28/2712895/0/en/Virtualware-MLVIR-launches-VIROO-2-4-the-new-version-of-its-Virtual-Reality-as-a-service-VRaaS-platform.html", "time_published": "20230728T063800", "authors": ["VIRTUALWARE 2007 SA"], "summary": "BILBAO, July 28, 2023 - Spanish publicly traded company, Virtualware ( EPA:MLVIR ) , one of the leaders in virtual reality, announced today the release of the new version 2.4 of its VRaaS platfom, VIROO, which incorporates, among other capabilities, Mixed Reality ( MR ) and VR CAVEs integration ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.337705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.076847", "ticker_sentiment_score": "0.100195", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.076847", "ticker_sentiment_score": "0.100195", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.076847", "ticker_sentiment_score": "0.100195", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.076847", "ticker_sentiment_score": "0.100195", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.076847", "ticker_sentiment_score": "0.100195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( NASDAQ:BIIB )  Rating Lowered to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/07/28/biogen-nasdaqbiib-rating-lowered-to-buy-at-stocknews-com.html", "time_published": "20230728T050251", "authors": ["Defense World Staff"], "summary": "Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Wednesday. Other equities analysts have also issued research reports about the stock.", "banner_image": "https://www.marketbeat.com/logos/biogen-inc-logo.jpg?v=20221024141534", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.233458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.063933", "ticker_sentiment_score": "-0.026007", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.063933", "ticker_sentiment_score": "0.074041", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.827318", "ticker_sentiment_score": "0.387918", "ticker_sentiment_label": "Bullish"}]}, {"title": "Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche, Atara, Immunic, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Genzyme, ImStem, Rho, Bristol-Myers Squibb", "url": "https://www.prnewswire.com/news-releases/multiple-sclerosis-market-size-and-share-to-grow-significantly-assesses-delveinsight--leading-companies---roche-atara-immunic-celgene-anokion-sa-sanofi-actelion-biogen-genzyme-imstem-rho-bristol-myers-squibb-301887032.html", "time_published": "20230727T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.161247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZVSA", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMUX", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.06623", "ticker_sentiment_score": "0.080288", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUPN", "relevance_score": "0.022099", "ticker_sentiment_score": "0.090639", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOSS", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASLN", "relevance_score": "0.06623", "ticker_sentiment_score": "0.091219", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHJF", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.022099", "ticker_sentiment_score": "0.122644", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEARQ", "relevance_score": "0.06623", "ticker_sentiment_score": "0.080288", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDHL", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.06623", "ticker_sentiment_score": "0.087201", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.06623", "ticker_sentiment_score": "0.096236", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044182", "ticker_sentiment_score": "0.088537", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.088228", "ticker_sentiment_score": "0.095195", "ticker_sentiment_label": "Neutral"}]}, {"title": "I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO", "url": "https://www.fool.com/investing/2023/07/27/biogen-11-words-from-ceo/", "time_published": "20230727T100000", "authors": ["Adria Cimino"], "summary": "Biogen shares have stagnated in recent years, but the company has a plan to change that.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.197398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.023812", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.09239", "ticker_sentiment_score": "0.057342", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.583426", "ticker_sentiment_score": "0.268134", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon", "url": "https://www.prnewswire.com/news-releases/dementia-market-to-grow-rapidly-estimates-delveinsight--key-companies-active-in-the-market---pfizer-eli-lilly-and-company-janssen-merck-biovie-biogen-vivoryon-sage-alnylam-bioxcel-eip-otsuka-alector-transposon-301885979.html", "time_published": "20230726T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.228916, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNPX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.047607", "ticker_sentiment_score": "0.091165", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.047607", "ticker_sentiment_score": "0.083205", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.071357", "ticker_sentiment_score": "0.095722", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047607", "ticker_sentiment_score": "0.083205", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.023814", "ticker_sentiment_score": "0.071712", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "PASG", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.071357", "ticker_sentiment_score": "0.077488", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTAI", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.031839", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.038114", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVPI", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHA", "relevance_score": "0.071357", "ticker_sentiment_score": "0.079506", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.047607", "ticker_sentiment_score": "0.057191", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.023814", "ticker_sentiment_score": "0.031839", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORYZF", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.071357", "ticker_sentiment_score": "0.077488", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fed Staff No Longer Predict Recession As Inflation Cools", "url": "https://www.forbes.com/sites/brianbushard/2023/07/26/fed-staff-no-longer-predict-recession-as-inflation-cools/", "time_published": "20230726T195958", "authors": ["Brian Bushard"], "summary": "Federal Reserve Chair Jerome Powell said the \"resiliency\" of the economy prompted the Fed to no longer forecast a looming recession.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64c176f9718dd4815716a7fe/0x0.jpg?format=jpg&crop=3000,1688,x0,y9,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.9973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.219482, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.080728", "ticker_sentiment_score": "-0.066322", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Sage Therapeutics Stock Is Tumbling Today", "url": "https://www.fool.com/investing/2023/07/26/why-sage-therapeutics-stock-is-tumbling-today/", "time_published": "20230726T194600", "authors": ["George Budwell"], "summary": "A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.166784, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.229149", "ticker_sentiment_score": "0.035384", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.337811", "ticker_sentiment_score": "-0.325964", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More", "url": "https://www.zacks.com/stock/news/2128013/biotech-stock-roundup-biib-gsks-q2-earnings-kod-faces-setback-more", "time_published": "20230726T140800", "authors": ["Zacks Equity Research"], "summary": "Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.151902, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.038969", "ticker_sentiment_score": "0.014869", "ticker_sentiment_label": "Neutral"}, {"ticker": "KOD", "relevance_score": "0.116536", "ticker_sentiment_score": "0.112892", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.077845", "ticker_sentiment_score": "0.122632", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.193001", "ticker_sentiment_score": "0.117207", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116536", "ticker_sentiment_score": "0.027736", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It - Could This Rising Company Have The Answer? - Tiziana Life Sciences  ( NASDAQ:TLSA ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33390126/neuroinflammation-a-key-indicator-for-alzheimers-but-current-treatments-show-little-success-in-re", "time_published": "20230726T120546", "authors": ["David Willey"], "summary": "There have been several accelerated approvals granted to treatments for patients with Alzheimer's disease ( AD ) by the Food and Drug Administration ( FDA ) in recent months, and there are several treatments also in development.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/26/screenshot_2023-07-26_at_5.30.02_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.129755, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TLSA", "relevance_score": "0.157483", "ticker_sentiment_score": "0.128133", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABOS", "relevance_score": "0.157483", "ticker_sentiment_score": "0.076963", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.095537", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.234307", "ticker_sentiment_score": "-0.170296", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33389178/monte-rosa-therapeutics-appoints-dr-anthony-m-manning-to-board-of-directors", "time_published": "20230726T113000", "authors": ["Globe Newswire"], "summary": "BOSTON, July 26, 2023 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLUE", "relevance_score": "0.272788", "ticker_sentiment_score": "0.069074", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.074263", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.069495", "ticker_sentiment_score": "0.074263", "ticker_sentiment_label": "Neutral"}]}, {"title": "Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/07/26/2711202/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Anthony-M-Manning-to-Board-of-Directors.html", "time_published": "20230726T113000", "authors": ["Inc.", "Monte Rosa Therapeutics"], "summary": "BOSTON, July 26, 2023 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( NASDAQ: GLUE ) , a clinical stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.", "banner_image": "https://ml.globenewswire.com/Resource/Download/20ed9999-454a-4e2a-aabc-217270a87d2d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.060082, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLUE", "relevance_score": "0.182506", "ticker_sentiment_score": "-0.029393", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046006", "ticker_sentiment_score": "0.072788", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.046006", "ticker_sentiment_score": "0.072788", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines", "url": "https://www.investors.com/news/technology/gsk-stock-vaccine-sales-drive-q2-beat/", "time_published": "20230726T110200", "authors": ["Investor's Business Daily", "PATRICK SEITZ"], "summary": "GSK Stock: Vaccine Sales Drive Q2 Beat Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-GSK-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.243695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.102888", "ticker_sentiment_score": "0.027642", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.102888", "ticker_sentiment_score": "0.08308", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes plc Reports Second Quarter 2023 Financial Results", "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-second-quarter-2023-financial-results-301885734.html", "time_published": "20230726T110000", "authors": ["Alkermes plc"], "summary": "- Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA\u00ae Product Royalties - - Net Sales of Proprietary Products Increased Approximately 21% Year-Over-Year - - Prevailed in Janssen Arbitration.", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.141698, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.459055", "ticker_sentiment_score": "0.139314", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.01682", "ticker_sentiment_score": "-0.035366", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.033632", "ticker_sentiment_score": "0.017988", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Biogen Stock Got Sick Today", "url": "https://www.fool.com/investing/2023/07/25/why-biogen-stock-got-sick-today/", "time_published": "20230725T220946", "authors": ["Eric Volkman"], "summary": "While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740538%2Fvisulization-chart-of-tesla-q2-2023-earnings.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.168551, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.605266", "ticker_sentiment_score": "0.241668", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen  ( BIIB )  Q2 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/07/25/biogen-biib-q2-2023-earnings-call-transcript/", "time_published": "20230725T193045", "authors": ["Motley Fool Transcribing"], "summary": "BIIB earnings call for the period ending June 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.196053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.003968", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.003968", "ticker_sentiment_score": "0.045247", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.003968", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.003968", "ticker_sentiment_score": "0.046499", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.003968", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035702", "ticker_sentiment_score": "0.072198", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.071333", "ticker_sentiment_score": "0.102025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: Spotify, RTX, General Electric and more", "url": "https://www.cnbc.com/2023/07/25/stocks-making-the-biggest-moves-midday-spot-rtx-ge.html", "time_published": "20230725T161651", "authors": ["Hakyung Kim"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107136597-16661100832022-10-18t155337z_1301159980_rc2q3x9bjhuj_rtrmadp_0_colgate-third-point.jpeg?v=1675078627", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.224607, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.070105", "ticker_sentiment_score": "0.154851", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EADSF", "relevance_score": "0.035086", "ticker_sentiment_score": "0.101377", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHW", "relevance_score": "0.035086", "ticker_sentiment_score": "0.133273", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.070105", "ticker_sentiment_score": "0.152834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.035086", "ticker_sentiment_score": "-0.182677", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NXPI", "relevance_score": "0.035086", "ticker_sentiment_score": "0.117654", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.035086", "ticker_sentiment_score": "0.119801", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.035086", "ticker_sentiment_score": "0.157402", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PKG", "relevance_score": "0.035086", "ticker_sentiment_score": "0.044211", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.104988", "ticker_sentiment_score": "0.240216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.070105", "ticker_sentiment_score": "-0.007099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch", "url": "https://www.foxbusiness.com/economy/biogen-cut-1000-jobs-focus-turns-alzheimers-drug-leqembi-launch", "time_published": "20230725T155817", "authors": ["Joe Toppe"], "summary": "Biogen said it expects to eliminate roughly 1,000 positions to save money ahead of launching a new drug to treat Alzheimer's disease.", "banner_image": "https://static.foxbusiness.com/foxbusiness.com/content/uploads/2023/07/BIO-1.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.161334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.146916", "ticker_sentiment_score": "0.212337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.733479", "ticker_sentiment_score": "0.436648", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen  ( BIIB )  Beats on Q2 Earnings & Sales, Announces Job Cuts", "url": "https://www.zacks.com/stock/news/2127098/biogen-biib-beats-on-q2-earnings-sales-announces-job-cuts", "time_published": "20230725T152100", "authors": ["Zacks Equity Research"], "summary": "Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.021731, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.228073", "ticker_sentiment_score": "0.028693", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.264761", "ticker_sentiment_score": "0.169739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.03853", "ticker_sentiment_score": "0.077855", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.228073", "ticker_sentiment_score": "-0.05759", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to slash 1,000 jobs as it looks to save $700 million", "url": "https://www.marketwatch.com/story/biogen-tops-earnings-estimates-and-says-it-will-shift-resources-to-higher-value-areas-8d6f9f2d", "time_published": "20230725T144400", "authors": ["", "Eleanor Laise", "Ciara Linnane"], "summary": "Biotech giant's cost-cutting effort comes amid the launch of its Alzheimer's treatment, Leqembi.", "banner_image": "https://images.mktw.net/im-536766/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.262557, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.204072", "ticker_sentiment_score": "0.079963", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.136888", "ticker_sentiment_score": "0.053347", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.136888", "ticker_sentiment_score": "0.120547", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.56217", "ticker_sentiment_score": "0.357617", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top Stories Tuesday, July 25: Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years - Apple  ( NASDAQ:AAPL ) , American Airlines Group  ( NASDAQ:AAL ) ", "url": "https://www.benzinga.com/news/23/07/33370617/ron-desantis-escapes-car-accident-unhurt-en-route-to-campaign-event-tiktok-takes-on-twitter-analysts", "time_published": "20230725T142624", "authors": ["Vandana Singh"], "summary": "The campaign for Republican presidential contender and Florida Gov. Ron DeSantis said the candidate and a few of his team members were involved in a vehicular accident on their way to a campaign event on Tuesday. DeSantis and his staff emerged unscathed from the incident.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/25/ron_desantis_51326400547.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": -0.007218, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.150592", "ticker_sentiment_score": "0.126088", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.180236", "ticker_sentiment_score": "-0.014992", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMRZF", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.319385", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPOT", "relevance_score": "0.060541", "ticker_sentiment_score": "0.004021", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.090702", "ticker_sentiment_score": "0.073612", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.090702", "ticker_sentiment_score": "0.042548", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOV", "relevance_score": "0.090702", "ticker_sentiment_score": "-0.046233", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.029463", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.060541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.060541", "ticker_sentiment_score": "0.065", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.060541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.090702", "ticker_sentiment_score": "0.088883", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.120733", "ticker_sentiment_score": "-0.158721", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GE", "relevance_score": "0.090702", "ticker_sentiment_score": "-0.005392", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.088001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.107004", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRX", "relevance_score": "0.060541", "ticker_sentiment_score": "0.023058", "ticker_sentiment_label": "Neutral"}]}, {"title": "2023 Layoff Tracker: Biogen Cuts 1,000 Employees", "url": "https://www.forbes.com/sites/brianbushard/2023/07/25/2023-layoff-tracker-biogen-cuts-1000-employees/", "time_published": "20230725T141907", "authors": ["Brian Bushard"], "summary": "Second quarter layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/62f3a6cba3427f0e56fe6374/0x0.jpg?format=jpg&crop=3205,1804,x0,y0,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.141228, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.482704", "ticker_sentiment_label": "Bearish"}]}, {"title": "Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs", "url": "https://www.wsj.com/articles/biogen-to-cut-roughly-11-of-workforce-to-focus-on-big-return-drugs-145b3f23", "time_published": "20230725T132600", "authors": ["Peter Loftus"], "summary": "The biotech cited the launch of Alzheimer's drug Leqembi as part of its new focus.", "banner_image": "https://images.wsj.net/im-823166?width=700&height=466", "source": "Wall Street Journal", "category_within_source": "Business", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.110362, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.947069", "ticker_sentiment_score": "-0.196935", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable", "url": "https://www.investors.com/news/technology/biogen-stock-alzheimers-drug-not-yet-profitable-as-company-tops-earnings-views/", "time_published": "20230725T132400", "authors": ["Investor's Business Daily", "KIT NORTON"], "summary": "Biogen Stock: Alzheimer's Drug Not Yet Profitable As Company Tops Earnings Views Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-biogen-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.999346"}], "overall_sentiment_score": 0.081645, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.097457", "ticker_sentiment_score": "0.189652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.04882", "ticker_sentiment_score": "0.173971", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.14573", "ticker_sentiment_score": "0.011796", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.729556", "ticker_sentiment_score": "0.066848", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch", "url": "https://www.cnbc.com/2023/07/25/biogen-to-cut-1000-jobs-as-company-prepares-for-leqembi-launch-.html", "time_published": "20230725T123948", "authors": ["Annika Kim Constantino"], "summary": "Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107275518-1690206948460-gettyimages-1414568582-kob00117.jpeg?v=1690209446", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185872, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WFC", "relevance_score": "0.129516", "ticker_sentiment_score": "0.13374", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.585052", "ticker_sentiment_score": "0.255851", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area ( s ) , Layoff 1K Staff - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33365698/biogen-q2-earnings-tops-expectations-shift-resources-to-higher-value-area-s-layoff-1k-staff", "time_published": "20230725T123640", "authors": ["Vandana Singh"], "summary": "Biogen Inc BIIB posted Q2 FY23 sales of $2.46 billion, beating the consensus of $2.37 billion, down 5% Y/Y and 3% at constant currency ( CC ) . Multiple sclerosis revenue of $1.21 billion decreased by 15% ( down 14% CC ) . Multiple sclerosis drug Tysabri sales are down to $483.1 million from ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/25/biib.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.033191, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.628066", "ticker_sentiment_score": "-0.090416", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Tops Q2 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2126717/biogen-inc-biib-tops-q2-earnings-and-revenue-estimates", "time_published": "20230725T122507", "authors": ["Zacks Equity Research"], "summary": "Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default66.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.161878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.405651", "ticker_sentiment_score": "0.175573", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GERN", "relevance_score": "0.140896", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' - Alaska Air Gr  ( NYSE:ALK ) , Alphabet  ( NASDAQ:GOOG ) , Alphabet  ( NASDAQ:GOOGL ) , Kimberly-Clark  ( NYSE:KMB ) , Teladoc Health  ( NYSE:TDOC ) , Spotify Technology  ( NYSE:SPOT ) , Verizon Communications  ( NYSE:VZ ) , General Motors  ( NYSE:GM ) , 3M  ( NYSE:MMM ) , Snap  ( NYSE:SNAP ) , Dow  ( NYSE:DOW ) , F5  ( NASDAQ:FFIV ) , Microsoft  ( NASDAQ:MSFT ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Visa  ( NYSE:V ) , SPDR S&P 500  ( ARCA:SPY ) , General Electric  ( NYSE:GE ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33365504/nasdaq-futures-rise-ahead-of-microsoft-alphabet-earnings-analyst-warns-of-volatility-from-feds-mess", "time_published": "20230725T114100", "authors": ["Shanthi Rexaline"], "summary": "Stock futures indicate a positive start on Tuesday, driven by strong earnings momentum. However, concerns loom over overbought small-cap stocks. Investors are keeping an eye on the Federal Reserve's two-day rate-setting meeting, which begins today.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/nasdaq_shutter_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.059328, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.235247", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VZ", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.05339", "ticker_sentiment_score": "0.219805", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.235247", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNAP", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOW", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIV", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.235247", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-cut-1000-jobs-save-costs-alzheimers-drug-launch-gathers-pace-2023-07-25/", "time_published": "20230725T110700", "authors": ["Reuters"], "summary": "Biogen to cut 1000 jobs to save costs as Alzheimer's drug launch gathers pace ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/YYQ3KYBNSNLEZDYU4ZVIFPQGNE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.128822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.116914", "ticker_sentiment_score": "0.19681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.443626", "ticker_sentiment_score": "0.209619", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow futures lackluster after scorching rally; Big Tech earnings in focus", "url": "https://www.reuters.com/markets/us/dow-futures-lackluster-after-scorching-rally-big-tech-earnings-focus-2023-07-25/", "time_published": "20230725T095700", "authors": ["Reuters"], "summary": "Dow futures lackluster after scorching rally. Big Tech earnings in focus ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/F4EO62IRNRIWRF4RAFXMFM37EA.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.244201, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.118647", "ticker_sentiment_score": "0.319695", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.077614", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.077614", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BILI", "relevance_score": "0.118647", "ticker_sentiment_score": "0.319695", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXN", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "All Eyes On Biogen's Alzheimer's Drug, Big Potential Payday, Ahead Of Earnings", "url": "https://www.investors.com/news/technology/biogen-stock-all-eyes-are-on-alzheimers-drug-big-potential-payday-ahead-of-earnings/", "time_published": "20230724T214600", "authors": ["KIT NORTON", "Investor's Business Daily"], "summary": "Biogen ( BIIB ) reports second-quarter financials Tuesday, with analysts expecting both profit and revenue to fall as all eyes are on the company's recently fully approved Alzheimer's drug, Leqembi.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-biogen-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.139753, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.121343", "ticker_sentiment_score": "0.201001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.060848", "ticker_sentiment_score": "0.175054", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.181137", "ticker_sentiment_score": "0.00891", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.778056", "ticker_sentiment_score": "0.193697", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Top ETFs to Buy Right Now", "url": "https://www.fool.com/investing/2023/07/24/3-top-etfs-to-buy-right-now/", "time_published": "20230724T214500", "authors": ["George Budwell"], "summary": "These three exchange-traded funds could be winning plays for patient investors.", "banner_image": "https://media.ycharts.com/charts/10c809fadfdf2cfdadbb0f05f36f42c8.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.857896"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.280327, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}]}, {"title": "Brace For Action: Big Week Ahead Includes Fed Meeting, Heavy Earnings And Data Calendar - Apple  ( NASDAQ:AAPL ) , FedEx  ( NYSE:FDX ) ", "url": "https://www.benzinga.com/markets/23/07/33349594/brace-for-action-big-week-ahead-includes-fed-meeting-heavy-earnings-and-data-calendar", "time_published": "20230724T160703", "authors": ["Alex Coffey"], "summary": "( Monday market open ) The week ahead has something for everyone, including a Federal Reserve meeting and reports from roughly 30% of all S&P 500\u00ae companies. Most of the action starts tomorrow, and trading was subdued in premarket hours Monday as investors awaited the excitement to come.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/24/shutterstock_1055599112_18.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Economy - Fiscal", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.995015"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.030954, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.042011", "ticker_sentiment_score": "-0.021619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.042011", "ticker_sentiment_score": "0.015804", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.042011", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.083906", "ticker_sentiment_score": "0.054939", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "THC", "relevance_score": "0.042011", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.207749", "ticker_sentiment_score": "0.048988", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.042011", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPS", "relevance_score": "0.083906", "ticker_sentiment_score": "-0.052856", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.042011", "ticker_sentiment_score": "-0.050348", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.042011", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "AON", "relevance_score": "0.042011", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.083906", "ticker_sentiment_score": "-0.00923", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.042011", "ticker_sentiment_score": "0.015804", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.083906", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.042011", "ticker_sentiment_score": "-0.021619", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.083906", "ticker_sentiment_score": "-0.036756", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.042011", "ticker_sentiment_score": "-0.021619", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.083906", "ticker_sentiment_score": "0.050338", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNA", "relevance_score": "0.042011", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.042011", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.042011", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.042011", "ticker_sentiment_score": "-0.021619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.042011", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042011", "ticker_sentiment_score": "0.072014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Big Biotech Buy: Vertex vs. Biogen", "url": "https://www.fool.com/investing/2023/07/24/better-big-biotech-buy-vertex-vs-biogen/", "time_published": "20230724T140927", "authors": ["Adria Cimino"], "summary": "These companies have a track record of billion-dollar earnings.", "banner_image": "https://media.ycharts.com/charts/e32e197244130a4e5abf93d4d9463607.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.244412, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.109705", "ticker_sentiment_score": "0.077802", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.109705", "ticker_sentiment_score": "0.255323", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.018064", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.054983", "ticker_sentiment_score": "0.242959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.592095", "ticker_sentiment_score": "0.391347", "ticker_sentiment_label": "Bullish"}]}, {"title": "Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/07/24/2709506/0/en/Capricor-Therapeutics-Announces-Appointment-of-Philip-J-Gotwals-Ph-D-to-its-Board-of-Directors.html", "time_published": "20230724T123000", "authors": ["Capricor Therapeutics"], "summary": "SAN DIEGO, July 24, 2023 ( GLOBE NEWSWIRE ) -- Capricor Therapeutics ( NASDAQ: CAPR ) , a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/16ce4387-5b8f-447c-96b8-7c453633f9bf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.232876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.03878", "ticker_sentiment_score": "0.150709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.03878", "ticker_sentiment_score": "0.029033", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPR", "relevance_score": "0.154207", "ticker_sentiment_score": "0.177146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NPNKF", "relevance_score": "0.03878", "ticker_sentiment_score": "0.150709", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech wins fail to move stock indicators ahead of earnings", "url": "https://www.financialexpress.com/healthcare/news-healthcare/biotech-wins-fail-to-move-stock-indicators-ahead-of-earnings/3184760/", "time_published": "20230724T103525", "authors": ["Bloomberg"], "summary": "Biotech has had a pretty good year between a flurry of deals and approvals of new drugs for vexing diseases such as Alzheimer's. Yet that isn't showing up in stock performance. Two closely watched indicators lag far behind the overall market.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/pathology-rp.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.114137", "ticker_sentiment_score": "0.0994", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRPH", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOSS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.085371", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVRO", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.144975", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly Joins Biogen as Alzheimer's Drugs Finally Emerge", "url": "https://www.barrons.com/articles/lilly-joins-biogen-as-alzheimers-drugs-finally-emerge-c5a3235f", "time_published": "20230722T000300", "authors": ["Josh Nathan-Kazis", "Bill Alpert"], "summary": "After years of false starts and regulatory stumbles, Alzheimer's therapies have suddenly emerged. Earlier this month, Biogen and Japanese partner Eisai received full approval for Leqembi, which, significantly, Medicare will pay for.", "banner_image": "https://images.barrons.com/im-821055?width=620&height=413", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031495, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.546745", "ticker_sentiment_score": "0.044252", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.546745", "ticker_sentiment_score": "0.044252", "ticker_sentiment_label": "Neutral"}]}, {"title": "Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' - Goldman Sachs Gr  ( NYSE:GS ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33318021/goldman-sachs-charles-schwab-and-this-healthcare-stock-on-cnbcs-final-trades", "time_published": "20230721T133423", "authors": ["Lisa Levin"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management named Biogen Inc. BIIB as the 4th cheapest stock in the whole Health Care Select Sector SPDR Fund XLV. The company is scheduled to report quarterly earnings next week.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/21/trader_shutter2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.213356, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.633079", "ticker_sentiment_score": "-0.022435", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.633079", "ticker_sentiment_score": "0.618071", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.501398", "ticker_sentiment_score": "0.503842", "ticker_sentiment_label": "Bullish"}]}, {"title": "Treatments for Alzheimer's, finally", "url": "https://www.ft.com/content/49ab3e87-aefd-43bf-9e64-dc34daffa559", "time_published": "20230721T040038", "authors": [], "summary": "This is an audio transcript of the FT News Briefing podcast episode: 'Treatments for Alzheimer's, finally' Good morning from the Financial Times. Today is Friday, July 21st. And this is your FT News Briefing.", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Fffeb5fec-4d38-4382-b9e6-2cffd1dfc473.jpg?fit=scale-down&source=next&width=700", "source": "Financial Times", "category_within_source": "GoogleRSS", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.142451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.033703", "ticker_sentiment_score": "-0.071663", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.075336", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.075336", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.033703", "ticker_sentiment_score": "0.135516", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.033703", "ticker_sentiment_score": "0.135516", "ticker_sentiment_label": "Neutral"}]}, {"title": "Win Streak Threatened: Tesla, Netflix Results Bring Pressure as Housing, Leading Indicators Data Awaited - American Express  ( NYSE:AXP ) , American Airlines Group  ( NASDAQ:AAL ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33307492/win-streak-threatened-tesla-netflix-results-bring-pressure-as-housing-leading-indicators-data-await", "time_published": "20230720T155129", "authors": ["Alex Coffey"], "summary": "( Thursday market open ) Pressure surfaced early Thursday as investors assessed yesterday's results from Tesla TSLA and Netflix NFLX. The Nasdaq ( COMP ) fell sharply in premarket trading, but the Dow Jones Industrial Average ( $DJI ) and its eight-session winning streak remained in the green.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/20/shutterstock_534464629.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.972193"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.004848, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.040899", "ticker_sentiment_score": "-0.023524", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.040899", "ticker_sentiment_score": "0.22929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.020456", "ticker_sentiment_score": "-0.021389", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.040899", "ticker_sentiment_score": "-0.12677", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.040899", "ticker_sentiment_score": "0.22929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DPZ", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.142445", "ticker_sentiment_score": "-0.002587", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHR", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.040899", "ticker_sentiment_score": "-0.023524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.040899", "ticker_sentiment_score": "-0.023524", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.040899", "ticker_sentiment_score": "0.22929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AN", "relevance_score": "0.020456", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.020456", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RF", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.020456", "ticker_sentiment_score": "0.000897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.102013", "ticker_sentiment_score": "0.148879", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.040899", "ticker_sentiment_score": "-0.023524", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040899", "ticker_sentiment_score": "0.071765", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.020456", "ticker_sentiment_score": "0.053709", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.061315", "ticker_sentiment_score": "0.058338", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/07/33305393/biib-analyzing-biogens-short-interest", "time_published": "20230720T143023", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has fallen 6.9% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.03 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference  ( AAIC )  2023", "url": "https://markets.businessinsider.com/news/stocks/eisai-presents-latest-analysis-of-lecanemab-s-effect-on-biomarker-changes-and-subcutaneous-dosing-at-the-alzheimer-s-association-international-conference-aaic-2023-1032460519", "time_published": "20230719T233000", "authors": [], "summary": "Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference ...", "banner_image": "https://mma.prnewswire.com/media/723010/Eisai_Logo_and_Biogen_Logo.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.030968, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012344", "ticker_sentiment_score": "0.054989", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.024686", "ticker_sentiment_score": "0.073936", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.012344", "ticker_sentiment_score": "0.067281", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.254751", "ticker_sentiment_score": "0.143528", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.171485", "ticker_sentiment_score": "0.038924", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference  ( AAIC )  2023", "url": "https://www.globenewswire.com/news-release/2023/07/19/2707815/0/en/Eisai-Presents-Latest-Analysis-of-Lecanemab-s-Effect-on-Biomarker-Changes-and-Subcutaneous-Dosing-at-The-Alzheimer-s-Association-International-Conference-AAIC-2023.html", "time_published": "20230719T233000", "authors": ["Biogen Inc."], "summary": "Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.03821, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012766", "ticker_sentiment_score": "0.055183", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.025528", "ticker_sentiment_score": "0.076158", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.012766", "ticker_sentiment_score": "0.080635", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.238872", "ticker_sentiment_score": "0.145684", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.152258", "ticker_sentiment_score": "0.046701", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Is the Nasdaq?", "url": "https://www.kiplinger.com/investing/stocks/what-is-the-nasdaq", "time_published": "20230719T202804", "authors": ["Tom Taulli"], "summary": "\"The Nasdaq\" is a term market participants hear several times a day, but what exactly is \"the Nasdaq\"? Typically, when an investor says \"the Nasdaq,\" they're referring to the Nasdaq Composite, or IXIC. This is an index that tracks the performance of the Nasdaq Stock Market, an electronic platform ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/V5bwoDADBb3z3nyMfkHFef-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.213677, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.134339", "ticker_sentiment_score": "0.100175", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.178459", "ticker_sentiment_score": "0.086592", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.089797", "ticker_sentiment_score": "0.028913", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.04497", "ticker_sentiment_score": "0.269086", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tesla On Tap: \"Mega-cap\" Reporting Season Gets Underway After Close With EV Giant's Earnings - Apple  ( NASDAQ:AAPL ) , Albertsons Companies  ( NYSE:ACI ) ", "url": "https://www.benzinga.com/markets/23/07/33291567/tesla-on-tap-mega-cap-reporting-season-gets-underway-after-close-with-ev-giants-earnings", "time_published": "20230719T193645", "authors": ["Alex Coffey"], "summary": "( Wednesday market open ) Major indexes ride into Tesla's TSLA earnings later today on a long winning streak that carried stocks to new 15-month highs yesterday. Hopes for an economic \"soft landing\" based on recent positive data drove gains. Investors appear to expect more positive news after ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064807, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.038811", "ticker_sentiment_score": "0.066517", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.038811", "ticker_sentiment_score": "0.043159", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHN", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.096827", "ticker_sentiment_score": "0.052368", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.192234", "ticker_sentiment_score": "0.087496", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.019411", "ticker_sentiment_score": "0.027711", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.077531", "ticker_sentiment_score": "0.103215", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHR", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.077531", "ticker_sentiment_score": "0.060153", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.058188", "ticker_sentiment_score": "0.031019", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.019411", "ticker_sentiment_score": "0.027711", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.038811", "ticker_sentiment_score": "0.043159", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.058188", "ticker_sentiment_score": "-0.046124", "ticker_sentiment_label": "Neutral"}, {"ticker": "AN", "relevance_score": "0.019411", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.019411", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RF", "relevance_score": "0.077531", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.038811", "ticker_sentiment_score": "0.030334", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.038811", "ticker_sentiment_score": "0.030334", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.038811", "ticker_sentiment_score": "0.043159", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.038811", "ticker_sentiment_score": "0.041829", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.038811", "ticker_sentiment_score": "0.043159", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.038811", "ticker_sentiment_score": "0.066517", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.038811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.038811", "ticker_sentiment_score": "0.071259", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.019411", "ticker_sentiment_score": "0.191482", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen  ( BIIB )  to Report Q2 Earnings: Here's What to Expect", "url": "https://www.zacks.com/stock/news/2123856/biogen-biib-to-report-q2-earnings-heres-what-to-expect", "time_published": "20230719T145600", "authors": ["Zacks Investment Research"], "summary": "Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.149482, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.167322", "ticker_sentiment_score": "-0.062294", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.208285", "ticker_sentiment_score": "-0.019451", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.042122", "ticker_sentiment_score": "0.074982", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.327366", "ticker_sentiment_score": "0.280062", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GSK  ( GSK )  Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release", "url": "https://www.zacks.com/stock/news/2123708/gsk-gsk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q2-release", "time_published": "20230719T140146", "authors": ["Zacks Investment Research"], "summary": "Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.156453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.176502", "ticker_sentiment_score": "-0.001433", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Biogen Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/07/19/is-biogen-stock-a-buy-now/", "time_published": "20230719T123000", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech hasn't been the best investment recently.", "banner_image": "https://media.ycharts.com/charts/43bae851cd924ef39cb178c60c8529d6.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.205568, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.499254", "ticker_sentiment_score": "0.275555", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences' Advisory Board", "url": "https://www.benzinga.com/pressreleases/23/07/g33281046/biotech-and-biopharma-executive-eliana-clark-joins-culture-biosciences-advisory-board", "time_published": "20230719T103941", "authors": ["Globe Newswire"], "summary": "SAN FRANCISCO, July 19, 2023 ( GLOBE NEWSWIRE ) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company's Advisory Board.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.229828, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.05833", "ticker_sentiment_score": "0.028026", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.116348", "ticker_sentiment_score": "0.193623", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.05833", "ticker_sentiment_score": "0.028026", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030", "url": "https://www.fool.com/investing/2023/07/19/prediction-company-will-be-a-biotech-giant-by-2030/", "time_published": "20230719T093000", "authors": ["Adria Cimino"], "summary": "You might want to get in on this story right now.", "banner_image": "https://media.ycharts.com/charts/28ad1fa3d8b7dfd1b9bde13c28133443.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99676"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.164703, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.732373", "ticker_sentiment_score": "0.240239", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.164656", "ticker_sentiment_score": "0.160826", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2123266/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230718T215020", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default48.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.193142, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.624172", "ticker_sentiment_score": "0.310732", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too.", "url": "https://www.barrons.com/articles/alzheimer-prothea-plaque-tau-tangles-1ab2626a", "time_published": "20230718T213600", "authors": ["Bill Alpert"], "summary": "Keep your eyes on tau, not just amyloid-beta, as the world of medical research takes on Alzheimer's disease. A rivalry between Eli Lilly and the team of Biogen and Eisai Pharmaceuticals was the main event at this week's international conference of the Alzheimer's Association in Amsterdam.", "banner_image": "https://images.barrons.com/im-819218?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.073064, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.016106", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.540042", "ticker_sentiment_score": "0.192684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.342487", "ticker_sentiment_score": "0.146875", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.445569", "ticker_sentiment_score": "0.174965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.058903", "ticker_sentiment_score": "0.079989", "ticker_sentiment_label": "Neutral"}]}, {"title": "A new treatment for Alzheimer's offers hope-but raises questions, too", "url": "https://www.economist.com/science-and-technology/2023/07/18/a-new-treatment-for-alzheimers-offers-hope-but-raises-questions-too", "time_published": "20230718T183544", "authors": [], "summary": "F the search for a drug to treat Alzheimer's disease had seemed a costly wild-goose chase. Then, in 2021, a drug called aducanumab received regulatory approval in America. A second, lecanemab, got the nod in January this year.", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20230722_STP501.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009684, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.005879", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off.", "url": "https://www.barrons.com/articles/alzheimers-drugs-competition-lilly-biogen-4cdc6c6", "time_published": "20230718T181300", "authors": ["Josh Nathan-Kazis"], "summary": "After two years of false starts and regulatory stumbles, two huge biopharma companies are getting ready for a showdown over the market for new Alzheimer's disease therapies. Billions of dollars in sales hang in the balance.", "banner_image": "https://images.barrons.com/im-819219?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.050493, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.288327", "ticker_sentiment_score": "-0.040484", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.098054", "ticker_sentiment_score": "0.029485", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.146618", "ticker_sentiment_score": "0.079058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.241924", "ticker_sentiment_score": "0.22259", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Subdued Tone: Major Indexes Waver Despite Earnings Beats by Bank of America, Morgan Stanley - American Express  ( NYSE:AXP ) , American Airlines Group  ( NASDAQ:AAL ) ", "url": "https://www.benzinga.com/markets/23/07/33272167/subdued-tone-major-indexes-waver-despite-earnings-beats-by-bank-of-america-morgan-stanley", "time_published": "20230718T175732", "authors": ["Alex Coffey"], "summary": "( Tuesday market open ) The morning kicks off with more big banks beating analysts' earnings expectations, but major indexes were barely changed in premarket trading. Retail Sales-an important barometer of consumer health-rose less than expected in June.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/18/shutterstock_1850586967_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.065073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.079788", "ticker_sentiment_score": "0.029409", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHN", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.13915", "ticker_sentiment_score": "0.015283", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.079788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHR", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.099642", "ticker_sentiment_score": "0.144466", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.099642", "ticker_sentiment_score": "0.089705", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.079788", "ticker_sentiment_score": "0.029409", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AN", "relevance_score": "0.019978", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.019978", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.039944", "ticker_sentiment_score": "0.236864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RF", "relevance_score": "0.039944", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.079788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.039944", "ticker_sentiment_score": "0.043342", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.079788", "ticker_sentiment_score": "0.029409", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.039944", "ticker_sentiment_score": "0.07154", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.039944", "ticker_sentiment_score": "0.043631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly's  ( LLY )  Donanemab Slows Alzheimer's Disease Progression", "url": "https://www.zacks.com/stock/news/2123179/lillys-lly-donanemab-slows-alzheimers-disease-progression", "time_published": "20230718T153000", "authors": ["Zacks Investment Research"], "summary": "Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.454714", "ticker_sentiment_score": "0.179456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRTA", "relevance_score": "0.283323", "ticker_sentiment_score": "0.022972", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.143987", "ticker_sentiment_score": "0.164116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Earnings Preview: Biogen Inc.  ( BIIB )  Q2 Earnings Expected to Decline", "url": "https://www.zacks.com/stock/news/2122901/earnings-preview-biogen-inc-biib-q2-earnings-expected-to-decline", "time_published": "20230718T140122", "authors": ["Zacks Investment Research"], "summary": "Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default66.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.129175, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.299478", "ticker_sentiment_score": "-0.024572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware  ( EPA:MLVIR )  Announces record-breaking First-Half 2023 Results: VR SaaS Business Line Records Steady 208% Growth", "url": "https://www.globenewswire.com/news-release/2023/07/18/2706087/0/en/Virtualware-EPA-MLVIR-Announces-record-breaking-First-Half-2023-Results-VR-SaaS-Business-Line-Records-Steady-208-Growth.html", "time_published": "20230718T055700", "authors": ["Virtualware"], "summary": "BILBAO, Spain, July 18, 2023 ( GLOBE NEWSWIRE ) -- Virtualware ( EPA:MLVIR ) , a pioneering VR company employing a SaaS business model, today announced record-breaking H1 2023 financial results, just three months after it went public in Euronext Access Paris.", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.199388, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.098632", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.098632", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.052801", "ticker_sentiment_score": "0.098632", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052801", "ticker_sentiment_score": "0.098632", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.052801", "ticker_sentiment_score": "0.098632", "ticker_sentiment_label": "Neutral"}]}, {"title": "Treating Alzheimer's Very Early Offers Better Hope of Slowing Decline, Study Finds", "url": "https://www.nytimes.com/2023/07/17/health/alzheimers-drug-donanemab.html", "time_published": "20230717T141851", "authors": [], "summary": "A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.", "banner_image": "https://static01.nyt.com/images/2023/07/17/multimedia/17Alzheimers-phlc/17Alzheimers-phlc-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.161513, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.027828", "ticker_sentiment_score": "-0.18346", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.027828", "ticker_sentiment_score": "-0.18346", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Second Alzheimer's drug to slow disease's progression may be approved in the US this year", "url": "https://www.cnn.com/2023/07/17/health/second-alzheimers-drug-to-slow-disease-may-be-approved-this-year/index.html", "time_published": "20230717T141500", "authors": ["Meg Tirrell"], "summary": "The full approval this month of the Alzheimer's drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have a medicine to prescribe that has been proven to slow the loss of memory and ability to do daily tasks that Alzheimer's brings.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230502211746-eli-lilly-company-office-2020.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.102491, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.065327", "ticker_sentiment_score": "-0.031083", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.043579", "ticker_sentiment_score": "0.057612", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.043579", "ticker_sentiment_score": "0.057612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Buy the Dip With Biogen Stock Right Now?", "url": "https://www.fool.com/investing/2023/07/17/should-you-buy-the-dip-with-biogen-stock-right-now/", "time_published": "20230717T134500", "authors": ["Alex Carchidi"], "summary": "It's expected to grow, but things might not work out precisely as planned.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.070358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.054114", "ticker_sentiment_score": "0.034853", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.213988", "ticker_sentiment_score": "0.079119", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Numbers Should Scare Every Biogen Shareholder", "url": "https://www.fool.com/investing/2023/07/16/numbers-should-scare-every-biogen-shareholder/", "time_published": "20230716T111500", "authors": ["Alex Carchidi"], "summary": "There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.", "banner_image": "https://media.ycharts.com/charts/9b620ff8aa5bd98c2bdaba7734389acc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.043812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.222327", "ticker_sentiment_score": "0.152752", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Acumen's Alzheimer's drug passes initial safety test", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/acumens-alzheimers-drug-passes-initial-safety-test-2023-07-16/", "time_published": "20230716T060413", "authors": ["Julie Steenhuysen"], "summary": "CHICAGO, July 16 ( Reuters ) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals ( ABOS.O ) targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=148", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01917, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABOS", "relevance_score": "0.126119", "ticker_sentiment_score": "0.027769", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.126119", "ticker_sentiment_score": "0.017125", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novartis  ( NVS )  to Report Q2 Earnings: Is a Beat in Store?", "url": "https://www.zacks.com/stock/news/2121531/novartis-nvs-to-report-q2-earnings-is-a-beat-in-store", "time_published": "20230714T152900", "authors": ["Zacks Investment Research"], "summary": "When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.161914, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.273297", "ticker_sentiment_score": "0.205349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.13873", "ticker_sentiment_score": "0.069003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.13873", "ticker_sentiment_score": "0.072651", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.046452", "ticker_sentiment_score": "0.046183", "ticker_sentiment_label": "Neutral"}]}, {"title": "Puzzles And Games Cut Dementia Risk-But Socializing With Friends And Family Barely Helps, Study Finds", "url": "https://www.forbes.com/sites/maryroeloffs/2023/07/14/puzzles-and-games-cut-dementia-risk-but-socializing-with-friends-and-family-barely-helps-study-finds/", "time_published": "20230714T150118", "authors": ["Mary Whitfill Roeloffs"], "summary": "A new study says activities that involve competition, require problem solving or learning a new skill can stave off dementia in older adults, a new study says.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64b1608b6a1ad40e6ee9bcfd/0x0.jpg?format=jpg&crop=3630,2041,x0,y164,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.072324, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.141254", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.141254", "ticker_sentiment_label": "Neutral"}]}, {"title": "Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period  ( 2019-2032 ) , Assesses DelveInsight", "url": "https://www.prnewswire.com/news-releases/progressive-supranuclear-palsy-market-growing-at-a-cagr-of-27-7-during-the-study-period-20192032-assesses-delveinsight-301876550.html", "time_published": "20230713T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187294, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AHKSF", "relevance_score": "0.055428", "ticker_sentiment_score": "0.178918", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIVI", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.027731", "ticker_sentiment_score": "0.073361", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHHLF", "relevance_score": "0.055428", "ticker_sentiment_score": "0.178918", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IKT", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.027731", "ticker_sentiment_score": "0.073361", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.027731", "ticker_sentiment_score": "0.10444", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYPHF", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.027731", "ticker_sentiment_score": "0.073361", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027731", "ticker_sentiment_score": "0.096866", "ticker_sentiment_label": "Neutral"}]}, {"title": "Column: New Alzheimer's drug holds promise but adds cost pressures for Medicare", "url": "https://www.reuters.com/markets/europe/new-alzheimers-drug-holds-promise-adds-cost-pressures-medicare-2023-07-13/", "time_published": "20230713T154100", "authors": ["Mark Miller"], "summary": "July 13 ( Reuters ) - Federal officials made a splash last week by giving the green light to an expensive new drug that holds promise of slowing the advance of Alzheimer's disease. If this sounds like deja vu, you are not wrong.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EJ2S7AJUQBPDNPUERPIJRVWC2U.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.041133, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.045816", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.039614", "ticker_sentiment_score": "0.023982", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.045816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment", "url": "https://www.zacks.com/stock/news/2120702/biotech-stock-roundup-biib-eisais-drug-update-nvax-gains-on-deal-amendment", "time_published": "20230713T132200", "authors": ["Zacks Investment Research"], "summary": "Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.266448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRTA", "relevance_score": "0.19117", "ticker_sentiment_score": "0.079032", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.301315", "ticker_sentiment_score": "0.257756", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.077094", "ticker_sentiment_score": "0.127616", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.077094", "ticker_sentiment_score": "0.151068", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.038592", "ticker_sentiment_score": "0.261198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.15347", "ticker_sentiment_score": "0.153248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.115416", "ticker_sentiment_score": "0.228499", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.19117", "ticker_sentiment_score": "0.079032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Isn't Biogen Stock Soaring After This Major FDA Approval?", "url": "https://www.fool.com/investing/2023/07/13/why-isnt-biogen-stock-soaring-after-this-major-fda/", "time_published": "20230713T121500", "authors": ["David Jagielski"], "summary": "Is the stock a good contrarian buy?", "banner_image": "https://media.ycharts.com/charts/63cdcbb47f048e1cdbcc7d5648f53742.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.139212, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.062926", "ticker_sentiment_score": "0.073235", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.062926", "ticker_sentiment_score": "0.107702", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.364275", "ticker_sentiment_score": "0.092217", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2120242/biogen-inc-biib-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230712T215018", "authors": ["Zacks Investment Research"], "summary": "Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.150774, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.663374", "ticker_sentiment_score": "0.277382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BIIB: 3 Biotech Stocks to Acquire in July", "url": "https://stocknews.com/news/biib-alks-thtx-3-biotech-stocks-to-acquire-in-july/", "time_published": "20230712T182740", "authors": [], "summary": "The biotech industry is poised for substantial expansion due to growing new drug formulations, the rising prevalence of personalized medicine, and several government initiatives and funding in the space.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997405"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.335357, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.304886", "ticker_sentiment_score": "0.297469", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.028422", "ticker_sentiment_score": "0.194681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.27838", "ticker_sentiment_score": "0.342506", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THTX", "relevance_score": "0.251536", "ticker_sentiment_score": "0.385358", "ticker_sentiment_label": "Bullish"}]}, {"title": "P/E Ratio Insights for Biogen - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/07/33201740/pe-ratio-insights-for-biogen", "time_published": "20230712T161605", "authors": ["Benzinga Insights"], "summary": "In the current market session, Biogen Inc. BIIB share price is at $280.50, after a 0.24% increase. Moreover, over the past month, the stock fell by 6.52%, but in the past year, spiked by 30.88%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.090836, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.405651", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Biogen Inc.  ( BIIB )  is Poised to Beat Earnings Estimates Again", "url": "https://www.zacks.com/stock/news/2120090/why-biogen-inc-biib-is-poised-to-beat-earnings-estimates-again", "time_published": "20230712T161012", "authors": ["Zacks Investment Research"], "summary": "Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.308262, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.410505", "ticker_sentiment_score": "0.414748", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy", "url": "https://www.globenewswire.com/news-release/2023/07/12/2703461/20739/en/Ultragenyx-Appoints-Howard-Horn-as-Chief-Financial-Officer-and-Executive-Vice-President-Corporate-Strategy.html", "time_published": "20230712T120000", "authors": ["Ultragenyx Pharmaceutical Inc."], "summary": "NOVATO, Calif., July 12, 2023 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/8477da18-8d4c-4daf-a8d8-b429810f7ff3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.281215, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.154455", "ticker_sentiment_score": "0.16872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIR", "relevance_score": "0.077593", "ticker_sentiment_score": "0.047914", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.077593", "ticker_sentiment_score": "0.047914", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBS", "relevance_score": "0.077593", "ticker_sentiment_score": "0.047914", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should iShares Morningstar Mid-Cap Value ETF  ( IMCV )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2119612/should-ishares-morningstar-mid-cap-value-etf-imcv-be-on-your-investing-radar", "time_published": "20230712T102007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default119.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.304007, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061949", "ticker_sentiment_score": "0.11403", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.184363", "ticker_sentiment_score": "0.209578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOW", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEM", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NEM", "relevance_score": "0.061949", "ticker_sentiment_score": "0.060004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Posts Encouraging Data From Amyloidosis Drug Study", "url": "https://www.zacks.com/stock/news/2119263/ionis-ions-posts-encouraging-data-from-amyloidosis-drug-study", "time_published": "20230711T134000", "authors": ["Zacks Investment Research"], "summary": "Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.542539", "ticker_sentiment_score": "0.271969", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONS", "relevance_score": "0.289748", "ticker_sentiment_score": "0.135037", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.422661", "ticker_sentiment_score": "0.227425", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Prothena  ( PRTA )  Alzheimer's Disease Drug Licensed by BMY", "url": "https://www.zacks.com/stock/news/2119204/prothena-prta-alzheimers-disease-drug-licensed-by-bmy", "time_published": "20230711T125900", "authors": ["Zacks Investment Research"], "summary": "Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.159244, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.28387", "ticker_sentiment_score": "0.114183", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.350564", "ticker_sentiment_score": "0.073664", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.144275", "ticker_sentiment_score": "0.355965", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.414559", "ticker_sentiment_score": "0.163005", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eisai exec who helped steer Alzheimer's drug approval to retire in July", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-exec-who-helped-steer-alzheimers-drug-approval-retire-july-2023-07-11/", "time_published": "20230711T071500", "authors": ["Reuters"], "summary": "[1/2] A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of Readaptation and Geriatrics of the University Hospital ( HUG ) , in Geneva, Switzerland, June 6, 2023.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/NLM7HXIFFNKK5PAKBNVNDHZ53Y.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.166629, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.685927", "ticker_sentiment_score": "0.358774", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.159569", "ticker_sentiment_score": "0.020879", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB )  Stock Down Despite FDA Nod to Alzheimer's Drug", "url": "https://www.zacks.com/stock/news/2118733/biogen-biib-stock-down-despite-fda-nod-to-alzheimers-drug", "time_published": "20230710T152200", "authors": ["Zacks Investment Research"], "summary": "Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.071772, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.219312", "ticker_sentiment_score": "0.025772", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.165409", "ticker_sentiment_score": "0.029056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.219312", "ticker_sentiment_score": "0.133484", "ticker_sentiment_label": "Neutral"}]}, {"title": "Icahn Enterprises shares jump on loan agreement and other stocks on the move", "url": "https://www.marketwatch.com/story/icahn-enterprises-shares-jump-on-report-of-loan-agreement-and-other-stocks-on-the-move-ae6968af", "time_published": "20230710T140700", "authors": ["MarketWatch"], "summary": "Icahn Enterprises, Alibaba and Northern Trust are stocks on the move.", "banner_image": "https://images.mktw.net/im-280130/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": -0.038255, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.190417", "ticker_sentiment_score": "0.115057", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.282234", "ticker_sentiment_score": "-0.168576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "C", "relevance_score": "0.282234", "ticker_sentiment_score": "0.154464", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTRS", "relevance_score": "0.282234", "ticker_sentiment_score": "-0.229807", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FSR", "relevance_score": "0.190417", "ticker_sentiment_score": "-0.11318", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.039819", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.190417", "ticker_sentiment_score": "0.196592", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides", "url": "https://www.forbes.com/sites/qai/2023/07/10/fda-approves-new-alzheimers-drug-but-creators-biogen-and-eisai-stock-slides/", "time_published": "20230710T120000", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64aafea2f0463b467e534a09/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.13425, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.141935", "ticker_sentiment_score": "0.085657", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.141935", "ticker_sentiment_score": "0.085657", "ticker_sentiment_label": "Neutral"}]}, {"title": "Newly approved Alzheimer's drug may not work as well on women", "url": "https://www.axios.com/2023/07/11/leqembi-azheimers-drug-women-men-efficacy", "time_published": "20230710T103755", "authors": ["https://www.axios.com/authors/ogonzalez", "Caitlin Owens", "Oriana Gonz\u00e1lez", "https://www.axios.com/authors/caitlin"], "summary": "Some experts are questioning whether a newly approved Alzheimer's drug was shown in clinical trials to be less effective on women - even though the FDA didn't flag any such concerns when it was authorized last week.", "banner_image": "https://images.axios.com/sFze1nCYd4giqAeVct_8ZAgi2t8=/1920x1080/smart/2023/07/10/1689024987428.jpg?w=1920", "source": "Axios", "category_within_source": "Economy", "source_domain": "www.axios.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.088475, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.129983", "ticker_sentiment_score": "0.188047", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.043499", "ticker_sentiment_score": "0.142862", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biden's inside voice", "url": "https://www.axios.com/2023/07/10/bidens-inside-voice", "time_published": "20230710T094500", "authors": ["https://www.axios.com/authors/nboodhoo", "Niala Boodhoo"], "summary": "Maybe you've noticed President Biden sometimes whispering in public settings - especially when answering questions from reporters. But behind closed doors, he's been known to take the volume up a notch. \u2022 And, CVS and Walgreens get into the clinical trials business.", "banner_image": "https://images.axios.com/xdkToNLw1Dvmhkzwa41XJSVY8Vo=/0x0:1920x1080/1366x768/2023/07/09/1688939482160.png", "source": "Axios", "category_within_source": "Markets", "source_domain": "www.axios.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.066555, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.023464", "ticker_sentiment_score": "-0.132087", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.093653", "ticker_sentiment_score": "0.031396", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023464", "ticker_sentiment_score": "0.070641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.023464", "ticker_sentiment_score": "0.070641", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.046907", "ticker_sentiment_score": "0.034852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?", "url": "https://www.fool.com/investing/2023/07/09/biogen-just-milestone-why-isnt-stock-rising/", "time_published": "20230709T100000", "authors": ["Adria Cimino"], "summary": "Biogen shares are little changed year to date.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738839%2Fusing-a-tablet-with-a-dog.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.260706, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.051003", "ticker_sentiment_score": "0.282638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.152178", "ticker_sentiment_score": "0.247104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.693907", "ticker_sentiment_score": "0.3581", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know", "url": "https://www.cnbc.com/2023/07/08/leqembi-and-medicare-what-patients-and-doctors-should-know.html", "time_published": "20230708T110001", "authors": ["Spencer Kimball"], "summary": "Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107198790-16771574832023-02-23t020744z_307853963_rc2f2w9v65fn_rtrmadp_0_health-alzheimers-medicare.jpeg?v=1688814001&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.118847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.091509", "ticker_sentiment_score": "0.107776", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.04583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stocks Dip After Mixed Jobs Data", "url": "https://www.barrons.com/news/us-stocks-dip-after-mixed-jobs-data-da0d5c5b", "time_published": "20230707T203544", "authors": ["AFP - Agence France Presse"], "summary": "Wall Street stocks dipped Friday following data that showed slower hiring in the United States but which was seen as keeping the Federal Reserve on track to raise interest rates.", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.034599, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COST", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPLA", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets - BlackRock  ( NYSE:BLK ) , Citigroup  ( NYSE:C ) , JPMorgan Chase  ( NYSE:JPM ) , HDFC Bank  ( NYSE:HDB ) , America Movil  ( NYSE:AMX ) , Delta Air Lines  ( NYSE:DAL ) , UnitedHealth Group  ( NYSE:UNH ) , Microsoft  ( NASDAQ:MSFT ) , Tesla  ( NASDAQ:TSLA ) , Wells Fargo  ( NYSE:WFC ) , United Parcel Service  ( NYSE:UPS ) , Progressive  ( NYSE:PGR ) , Fastenal  ( NASDAQ:FAST ) , Amazon.com  ( NASDAQ:AMZN ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/asia/23/07/33152597/mixed-jobs-data-fed-governors-want-more-interest-rate-hikes-us-china-spat-rattles-semiconductor-sect", "time_published": "20230707T195250", "authors": ["Natan Ponieman"], "summary": "The June jobs report released Friday showcased mixed data on the economy. The unemployment rate dropped from 3.7% to 3.6%, but job additions came in at 209,000, below economist expectations of 225,000. The figure is a sharp decline from May's 306,000 increase.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Wall_Street_US_Stocks_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.00962, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "HDB", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.12013", "ticker_sentiment_score": "-0.08039", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.12013", "ticker_sentiment_score": "-0.001144", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPS", "relevance_score": "0.179343", "ticker_sentiment_score": "-0.116326", "ticker_sentiment_label": "Neutral"}, {"ticker": "CME", "relevance_score": "0.060236", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGR", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088247", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAST", "relevance_score": "0.12013", "ticker_sentiment_score": "0.068932", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.12013", "ticker_sentiment_score": "-0.08039", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.060236", "ticker_sentiment_score": "0.074571", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.12013", "ticker_sentiment_score": "0.088734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Factbox: Companies in Alzheimer's race after US nod for Eisai/Biogen drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/companies-alzheimers-race-after-us-nod-eisaibiogen-drug-2023-07-07/", "time_published": "20230707T182800", "authors": ["Reuters"], "summary": "July 7 ( Reuters ) - Eisai Co Ltd ( 4523.T ) and Biogen Inc's ( BIIB.O ) Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EJ2S7AJUQBPDNPUERPIJRVWC2U.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.443626", "ticker_sentiment_score": "0.225038", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.443626", "ticker_sentiment_score": "0.225038", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33151400/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-4-900-today", "time_published": "20230707T180029", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 2.33% on an annualized basis producing an average annual return of 11.25%. Currently, Biogen has a market capitalization of $40.28 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sales of Alzheimer's drug Leqembi may be slow initially but could pick up in 2024", "url": "https://www.cnbc.com/2023/07/07/alzheimers-drug-leqembi-sales-may-be-slow-at-first-analysts.html", "time_published": "20230707T175937", "authors": ["Annika Kim Constantino"], "summary": "Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107268376-1688751190899-gettyimages-1421992292-ALZHEIMERSDRUG.jpeg?v=1688752777&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.057347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.03343", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.0699", "ticker_sentiment_score": "0.03343", "ticker_sentiment_label": "Neutral"}]}, {"title": "Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33148410/expanded-medicare-coverage-for-biogen-eisais-leqembi-signals-a-turning-point-in-alz", "time_published": "20230707T172503", "authors": ["Vandana Singh"], "summary": "The FDA approved a supplemental marketing application for Biogen Inc BIIB-Eisai Co Ltd ESALY supporting the traditional approval of Leqembi ( lecanemab-irmb ) , making it the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/biib.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.204541, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.117486", "ticker_sentiment_score": "0.13058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.540042", "ticker_sentiment_score": "0.285406", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/more-eisaibiogen-alzheimers-drug-approvals-seen-likely-despite-safety-warning-2023-07-07/", "time_published": "20230707T170600", "authors": ["Bhanvi Satija"], "summary": "July 7 ( Reuters ) - With U.S. approval of Eisai's ( 4523.T ) and Biogen's ( BIIB.O ) Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/24e53264-190b-4097-835a-edeca236a9f4.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.024478, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.076115", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.2256", "ticker_sentiment_score": "0.015013", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.151539", "ticker_sentiment_score": "0.085725", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more", "url": "https://www.cnbc.com/2023/07/07/stocks-making-the-biggest-moves-midday-rivian-levi-strauss-biogen-first-solar-and-more.html", "time_published": "20230707T165242", "authors": ["Brian Evans"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107164505-1670837928683-gettyimages-1242039491-RIVIAN_AMAZON.jpeg?v=1688748762&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.208276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.258351", "ticker_sentiment_score": "0.047615", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.258351", "ticker_sentiment_score": "-0.106066", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.258351", "ticker_sentiment_score": "0.432356", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.130926", "ticker_sentiment_score": "0.28044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIVN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.214035", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.130926", "ticker_sentiment_score": "0.28044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.130926", "ticker_sentiment_score": "0.236595", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.130926", "ticker_sentiment_score": "0.236595", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline - Eli Lilly  ( NYSE:LLY ) , Biogen  ( NASDAQ:BIIB ) , Cassava Sciences  ( NASDAQ:SAVA ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33149295/fda-approves-biogens-alzheimers-drug-here-are-other-companies-with-treatments-in-the-pipeline", "time_published": "20230707T161621", "authors": ["Aaron Bry"], "summary": "The FDA fully approved Biogen Inc.'s BIIB Alzheimer's treatment Leqembi on Thursday, becoming the first Alzheimer's antibody treatment to reach full approval. Alzheimer's disease is a brain disease that leads to cognitive decline, impacting more than six million Americans according to the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/lab.julia-koblitz-rloawxt2fea-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.168489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.597963", "ticker_sentiment_score": "0.376528", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALZN", "relevance_score": "0.38489", "ticker_sentiment_score": "0.307159", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.497391", "ticker_sentiment_score": "0.094059", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.262522", "ticker_sentiment_score": "0.160978", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Pull Back As Yields Jump; Tesla, Meta In Focus: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-pulls-back-as-yields-jump-tesla-meta-in-focus/", "time_published": "20230707T153600", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Stocks Pull Back As Yields Jump. Tesla, Meta In Focus: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-teslafrontnose-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.135124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.070935", "ticker_sentiment_score": "0.14993", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.14131", "ticker_sentiment_score": "0.024586", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.070935", "ticker_sentiment_score": "0.067004", "ticker_sentiment_label": "Neutral"}, {"ticker": "MP", "relevance_score": "0.070935", "ticker_sentiment_score": "0.067004", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.070935", "ticker_sentiment_score": "0.044457", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.244635", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.035502", "ticker_sentiment_score": "-0.104154", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.035502", "ticker_sentiment_score": "-0.104154", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.278222", "ticker_sentiment_score": "0.106716", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.070935", "ticker_sentiment_score": "-0.107952", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.106227", "ticker_sentiment_score": "0.161676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QRVO", "relevance_score": "0.070935", "ticker_sentiment_score": "0.067004", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.070935", "ticker_sentiment_score": "0.14993", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.070935", "ticker_sentiment_score": "0.14993", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.070935", "ticker_sentiment_score": "0.14892", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout", "url": "https://www.marketwatch.com/story/biogens-big-alzheimers-drug-win-fails-to-boost-the-stock-as-analysts-see-slow-leqembi-rollout-1e94302c", "time_published": "20230707T144900", "authors": ["Eleanor Laise"], "summary": "Milestone Leqembi approval is \"a mixed bag,\" analysts say, given drug label's risk warnings and infusion-center bottlenecks.", "banner_image": "https://images.mktw.net/im-448250/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.116702, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.107978", "ticker_sentiment_score": "0.116464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.213988", "ticker_sentiment_score": "0.047382", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.458708", "ticker_sentiment_score": "0.129832", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Dips After Lukewarm Jobs Report; 2 Software Stocks Make Bullish Moves", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-dips-lukewarm-jobs-report-software-leaders-dynatrace-datadog-make-bullish-moves/", "time_published": "20230707T144800", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Dips After Lukewarm Jobs Report. 2 Software Stocks Make Bullish Moves Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/Stock-NYSE-09-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.140138, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.166935", "ticker_sentiment_score": "-0.006946", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.111747", "ticker_sentiment_score": "0.187886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKNG", "relevance_score": "0.166935", "ticker_sentiment_score": "0.139894", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.059943", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.04469", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.111747", "ticker_sentiment_score": "0.187886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.166935", "ticker_sentiment_score": "0.230955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMCI", "relevance_score": "0.111747", "ticker_sentiment_score": "0.196793", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DDOG", "relevance_score": "0.111747", "ticker_sentiment_score": "0.256955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIVN", "relevance_score": "0.111747", "ticker_sentiment_score": "0.177868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DT", "relevance_score": "0.111747", "ticker_sentiment_score": "0.256955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.198347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FSLR", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.059943", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRA", "relevance_score": "0.111747", "ticker_sentiment_score": "0.196793", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.111747", "ticker_sentiment_score": "0.187886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.111747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.221313", "ticker_sentiment_score": "0.121044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.111747", "ticker_sentiment_score": "0.252498", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen  ( BIIB ) , Eisai Get Full FDA Nod for Leqembi in Alzheimer's", "url": "https://www.zacks.com/stock/news/2118140/biogen-biib-eisai-get-full-fda-nod-for-leqembi-in-alzheimers", "time_published": "20230707T135100", "authors": ["Zacks Investment Research"], "summary": "Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104717, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.299478", "ticker_sentiment_score": "-0.028304", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.355588", "ticker_sentiment_score": "-0.061586", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.182506", "ticker_sentiment_score": "0.128405", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.241684", "ticker_sentiment_score": "0.167178", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top 10 things to watch in the stock market Friday including a jobs shocker", "url": "https://www.cnbc.com/2023/07/07/top-10-things-to-watch-in-the-stock-market-friday-including-a-jobs-shocker.html", "time_published": "20230707T131534", "authors": ["Jeff Marks"], "summary": "Surprising jobs miss in June after Thursday's blowout ADP hiring number.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107264533-1688040218973-gettyimages-1503701959-_53a3781.jpeg?v=1688735810&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.110613, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.184246", "ticker_sentiment_score": "-0.044079", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.092748", "ticker_sentiment_score": "-0.188431", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COST", "relevance_score": "0.13873", "ticker_sentiment_score": "0.157044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MA", "relevance_score": "0.046452", "ticker_sentiment_score": "0.086734", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.273297", "ticker_sentiment_score": "0.125334", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.046452", "ticker_sentiment_score": "-0.014818", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.229149", "ticker_sentiment_score": "0.096492", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.13873", "ticker_sentiment_score": "0.099888", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.092748", "ticker_sentiment_score": "0.091745", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.092748", "ticker_sentiment_score": "0.23397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.092748", "ticker_sentiment_score": "-0.030494", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.092748", "ticker_sentiment_score": "0.23397", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more", "url": "https://www.cnbc.com/2023/07/07/stocks-making-the-biggest-premarket-moves-.html", "time_published": "20230707T122233", "authors": ["Michelle Fox"], "summary": "These are the stocks posting the largest moves in the premarket.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107221641-16807836042023-04-06t120233z_618975994_rc2hks9w7bbp_rtrmadp_0_levi-strauss-results.jpeg?v=1688732553&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.226595, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.207571", "ticker_sentiment_score": "0.270532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.078625", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.207571", "ticker_sentiment_score": "0.082619", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.104683", "ticker_sentiment_score": "0.435147", "ticker_sentiment_label": "Bullish"}, {"ticker": "BE", "relevance_score": "0.207571", "ticker_sentiment_score": "0.269088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.104683", "ticker_sentiment_score": "0.435147", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.207571", "ticker_sentiment_score": "0.162165", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: Jobs Data Looms; 7 Resilient Stocks", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-on-tap-meta-leads-resilient-stocks-as-threads-signups-soar/", "time_published": "20230707T120100", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: Jobs Report Looms Large As Yields Soar. Meta Leads 7 Resilient Stocks | Investor's Business Daily Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-threadsmeta-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.03149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.093289", "ticker_sentiment_score": "0.017315", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.162489", "ticker_sentiment_score": "0.012497", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.023372", "ticker_sentiment_score": "0.025513", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023372", "ticker_sentiment_score": "0.088997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIU", "relevance_score": "0.023372", "ticker_sentiment_score": "0.047218", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.139534", "ticker_sentiment_score": "-0.065431", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.070036", "ticker_sentiment_score": "0.013407", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.046724", "ticker_sentiment_score": "0.042268", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.116461", "ticker_sentiment_score": "0.079599", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.046724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.070036", "ticker_sentiment_score": "0.062235", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.185306", "ticker_sentiment_score": "0.11497", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.093289", "ticker_sentiment_score": "0.102104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023372", "ticker_sentiment_score": "0.352308", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.070036", "ticker_sentiment_score": "0.229579", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The daily business briefing: July 7, 2023", "url": "https://theweek.com/briefing/business-briefing/1024836/the-daily-business-briefing-july-7-2023", "time_published": "20230707T111943", "authors": ["The Week Staff"], "summary": "MARK SCHIEFELBEIN / POOL / AFP via Getty Images The Food and Drug Administration on Thursday gave full approval to Leqembi, a drug that can slow the progression of Alzheimer's disease.", "banner_image": "https://mediacloud.theweek.com/image/upload/f_auto,t_primary-image-mobile@1/v1688728701/GettyImages-1512317655.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.007287, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.107978", "ticker_sentiment_score": "0.047578", "ticker_sentiment_label": "Neutral"}, {"ticker": "GETY", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.008007", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.008007", "ticker_sentiment_label": "Neutral"}]}, {"title": "10 things you need to know today: July 7, 2023", "url": "https://theweek.com/briefing/daily-briefing/1024837/10-things-you-need-to-know-today-july-7-2023", "time_published": "20230707T105509", "authors": ["The Week Staff"], "summary": "The feud between Mark Zuckerberg and Elon Musk continues to escalate With Ukraine low on ammunition, the Biden administration is expected to announce on Friday that it will send the country cluster munitions as part of a weapons package worth $800 million, U.S. officials told CBS News on Thursday.", "banner_image": "https://mediacloud.theweek.com/image/upload/f_auto,t_primary-image-mobile@1/v1688727221/GettyImages-1516022715.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.038712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.101869", "ticker_sentiment_score": "0.006645", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.068016", "ticker_sentiment_score": "-0.152408", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ESALF", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.00782", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.00782", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why US Stock Futures Signal Weak Open On Friday - Eisai Co  ( OTC:ESAIY ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Costco Wholesale  ( NASDAQ:COST ) , SPDR S&P 500  ( ARCA:SPY ) , Biogen  ( NASDAQ:BIIB ) , Levi Strauss  ( NYSE:LEVI ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33145327/stock-futures-dip-as-traders-eye-friday-jobs-report-analyst-says-q3-returns-hinge-more-on-this-cata", "time_published": "20230707T105256", "authors": ["Shanthi Rexaline"], "summary": "The market continues to be influenced by negative sentiment, as reflected in slightly lower stock futures early Friday. The June non-farm payrolls report, set to be released before the market opens, is expected to be a determining factor for today's trading direction.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Forex,Chart,On,Cityscape,With,Tall,Buildings,Background,Multi,Exposure._3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.009709, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COST", "relevance_score": "0.142989", "ticker_sentiment_score": "-0.433507", "ticker_sentiment_label": "Bearish"}, {"ticker": "IVZ", "relevance_score": "0.071784", "ticker_sentiment_score": "0.063249", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.071784", "ticker_sentiment_score": "0.213804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.142989", "ticker_sentiment_score": "0.262381", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug", "url": "https://www.cnbc.com/2023/07/07/eisai-shares-tumble-despite-receiving-fda-greenlight.html", "time_published": "20230707T100007", "authors": ["Anmar Frangoul", "Jihye Lee"], "summary": "Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107268019-1688712816812-gettyimages-1246775562-JAPAN_EISAI.jpeg?v=1688724007&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.233192, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSBHF", "relevance_score": "0.089797", "ticker_sentiment_score": "0.262633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.348103", "ticker_sentiment_score": "0.061466", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.089797", "ticker_sentiment_score": "0.262633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.089797", "ticker_sentiment_score": "-0.007584", "ticker_sentiment_label": "Neutral"}]}, {"title": "PWM, RIVN, META, TSLA, BIIB: Top 5 Trending Stocks - Meta Platforms  ( NASDAQ:META ) , Tesla  ( NASDAQ:TSLA ) , Prestige Wealth  ( NASDAQ:PWM ) , Rivian Automotive  ( NASDAQ:RIVN ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33142132/top-5-trending-stocks-prestige-wealths-ipo-rivians-lawsuit-metas-new-platform-teslas-dip-and-bio", "time_published": "20230707T002734", "authors": ["Benzinga Newsbot"], "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. The Dow traded down 1.07 to 33,922.26 while the NASDAQ fell 0.82% to 13,679.04. The S&P 500 also fell, dropping 0.79% to 4,411.59.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.803643"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.111775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.09018", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.188632", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ESALF", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.020156", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.107978", "ticker_sentiment_score": "-0.020156", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tokyo Stocks Open Lower", "url": "https://www.barrons.com/news/tokyo-stocks-open-lower-41609f92", "time_published": "20230707T001651", "authors": ["AFP - Agence France Presse"], "summary": "Tokyo stocks opened lower on Friday after falls on Wall Street as investors fretted over the prospect of more US interest rate hikes and the risk of recession. The benchmark Nikkei 225 index was down 0.88 percent, or 289.28 points, at 32,483.74 in early trade, while the broader Topix index ...", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.081182, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNEJF", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOELF", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.110462", "ticker_sentiment_score": "0.067461", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTTF", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.110462", "ticker_sentiment_score": "0.067461", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.7887", "ticker_sentiment_score": "0.079281", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Grants Traditional Approval for LEQEMBI\u00ae  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease", "url": "https://www.globenewswire.com/news-release/2023/07/07/2700886/0/en/FDA-Grants-Traditional-Approval-for-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzheimer-s-Disease.html", "time_published": "20230707T000000", "authors": ["Biogen Inc."], "summary": "The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.111901, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.01101", "ticker_sentiment_score": "0.054369", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.01101", "ticker_sentiment_score": "0.054369", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.01101", "ticker_sentiment_score": "0.079868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.269895", "ticker_sentiment_score": "0.248287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.142371", "ticker_sentiment_score": "0.062395", "ticker_sentiment_label": "Neutral"}]}, {"title": "US government approves Alzheimer's drug to slow cognitive decline", "url": "https://www.aljazeera.com/news/2023/7/6/us-government-approves-alzheimers-drug-to-slow-cognitive-decline", "time_published": "20230706T233427", "authors": [], "summary": "Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/07/2023-07-06T174337Z_1961982450_RC2F2W9K01GK_RTRMADP_3_EISAI-BIOGEN-ALZHEIMERS-1688685588.jpg?w=770&resize=770%2C552", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.081435, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.21686", "ticker_sentiment_score": "0.008606", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.054857", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves Alzheimer's treatment Leqembi, clearing the way for Medicare coverage", "url": "https://www.marketwatch.com/story/fda-approves-biogen-and-eisai-alzheimers-treatment-leqembi-56e3acd7", "time_published": "20230706T215100", "authors": ["Eleanor Laise"], "summary": "Despite Medicare coverage, drug may remain out of reach for many patients, policy experts say ...", "banner_image": "https://images.mktw.net/im-707210/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.7887", "ticker_sentiment_score": "0.456167", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.7887", "ticker_sentiment_score": "0.456167", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA Grants Full Approval For Alzheimer's Drug, Despite Concerns", "url": "https://www.forbes.com/sites/brianbushard/2023/07/06/fda-grants-full-approval-for-alzheimers-drug-despite-concerns/", "time_published": "20230706T213031", "authors": ["Brian Bushard"], "summary": "Leqembi costs $26,000 per year before insurance.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64a730d567c2f785098aa508/0x0.jpg?format=jpg&crop=5671,3192,x0,y332,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031815, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.166743", "ticker_sentiment_score": "0.013191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.166743", "ticker_sentiment_score": "0.020737", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Has Approved The Anti-Alzheimer's Drug Leqembi. What You Need To Know", "url": "https://www.forbes.com/sites/howardgleckman/2023/07/06/fda-has-approved-the-anti-alzheimers-drug-leqembi-what-you-need-to-know/", "time_published": "20230706T212520", "authors": ["Howard Gleckman"], "summary": "What You Need To Know The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer's drug lecanamab, marked as Leqembi by drugmakers Eisai a...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64a73072d2d294ea0eb4ddd4/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009589, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.045396", "ticker_sentiment_score": "0.152111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.045396", "ticker_sentiment_score": "0.152111", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: Jobs Data Due; Elon Musk Rips 'Cheating' Threads", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-with-jobs-report-due-meta-threads-has-record-launch-elon-musk-decries-cheating/", "time_published": "20230706T211600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Falls With Jobs Report Due. Meta's Threads Has Record Launch As Elon Musk Decries 'Cheating ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-threadsmeta-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.033961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.099683", "ticker_sentiment_score": "0.01996", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.173511", "ticker_sentiment_score": "0.013077", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.024982", "ticker_sentiment_score": "0.025792", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.024982", "ticker_sentiment_score": "0.089839", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.149038", "ticker_sentiment_score": "-0.067984", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.074848", "ticker_sentiment_score": "0.014671", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.049939", "ticker_sentiment_score": "0.042561", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.124421", "ticker_sentiment_score": "0.081884", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.049939", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.049939", "ticker_sentiment_score": "0.077345", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.197816", "ticker_sentiment_score": "0.120699", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.099683", "ticker_sentiment_score": "0.104064", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.024982", "ticker_sentiment_score": "0.35403", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.074848", "ticker_sentiment_score": "0.254359", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Going On With Biogen  ( BIIB )  Stock After Hours - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33140561/whats-going-on-with-biogen-stock-thursday", "time_published": "20230706T210822", "authors": ["Henry Khederian"], "summary": "Biogen Inc BIIB shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during regular trading. The U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/06/doctor-2568481.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.108332, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.669956", "ticker_sentiment_score": "0.445371", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.669956", "ticker_sentiment_score": "0.162442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US FDA grants standard approval of Eisai/Biogen Alzheimer's drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-standard-approval-eisaibiogen-alzheimers-drug-2023-07-06/", "time_published": "20230706T210300", "authors": ["Julie Steenhuysen", "Deena Beasley"], "summary": "LOS ANGELES, July 6 ( Reuters ) - The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai ( 4523.T ) and Biogen's ( BIIB.O ) Leqembi for patients with Alzheimer's disease, clearing the way for wider insurance coverage of the drug.", "banner_image": "https://graphics.reuters.com/EISAI-BIOGEN/ALZHEIMERS/klvygxnwyvg/BIIBeisaistock.PNG", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.058472", "ticker_sentiment_score": "-0.224018", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Alzheimer's drug Leqembi has full FDA approval now and that means Medicare will pay for it", "url": "https://apnews.com/article/alzheimers-drug-fda-approval-medicare-leqembi-a9c8b770aa1868a59889143c3bc9d127", "time_published": "20230706T205000", "authors": [], "summary": "WASHINGTON ( AP ) - U.S. officials granted full approval to a on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.", "banner_image": "https://dims.apnews.com/dims4/default/ea67a02/2147483647/strip/true/crop/3159x1775+0+1/resize/500x281!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc8%2Fd2%2Fdf9ec7711add405008b68fb801c9%2F9e395c81b3dd4640b1af37ed5c24858a", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.095723, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.236396", "ticker_sentiment_score": "-0.054659", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHC", "relevance_score": "0.059935", "ticker_sentiment_score": "0.167019", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.059935", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Federal Decisions Make Alzheimer's Drug Leqembi Widely Accessible", "url": "https://www.nytimes.com/2023/07/06/health/alzheimers-leqembi-medicare.html", "time_published": "20230706T204830", "authors": [], "summary": "The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.", "banner_image": "https://static01.nyt.com/images/2023/07/06/multimedia/06Alzheimers-leqembi-tqkb/06Alzheimers-leqembi-tqkb-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.051001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.090389", "ticker_sentiment_score": "-0.063381", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.022643", "ticker_sentiment_score": "0.023273", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage", "url": "https://www.cnbc.com/2023/07/06/fda-approves-alzheimers-drug-leqembi-from-eisai-biogen.html", "time_published": "20230706T204419", "authors": ["Spencer Kimball"], "summary": "Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1688676259&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.046006, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.135043", "ticker_sentiment_score": "0.078771", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027134", "ticker_sentiment_score": "0.136509", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.081276", "ticker_sentiment_score": "0.100389", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen's Make-Or-Break Moment In Alzheimer's Treatment Is Here", "url": "https://www.investors.com/news/technology/biogen-stock-faces-a-pivotal-test-as-fda-mulls-alzheimers-treatment/", "time_published": "20230706T142700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biogen Stock Faces A Pivotal Test As FDA Mulls Alzheimer's Treatment | Investor's Business Daily Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/07/Stock-biogen-04-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.26456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.091162", "ticker_sentiment_score": "0.143617", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.747807", "ticker_sentiment_score": "0.394391", "ticker_sentiment_label": "Bullish"}, {"ticker": "KDNY", "relevance_score": "0.091162", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "NeuroSense CEO Provides Q2 2023 Update", "url": "https://www.prnewswire.com/news-releases/neurosense-ceo-provides-q2-2023-update-301871106.html", "time_published": "20230706T123000", "authors": ["NeuroSense"], "summary": "CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( \"NeuroSense\" ) , a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments ...", "banner_image": "https://i.ytimg.com/vi/evUqaSOABRU/hqdefault.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.028734, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.115787", "ticker_sentiment_score": "0.068844", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.2842", "ticker_sentiment_score": "-0.038396", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biosimilar BYOOVIZ\u2122 now reimbursed in Quebec to treat serious retinal disorders", "url": "https://www.newswire.ca/news-releases/biosimilar-byooviz-tm-now-reimbursed-in-quebec-to-treat-serious-retinal-disorders-808170767.html", "time_published": "20230706T110000", "authors": ["Biogen Canada"], "summary": "\u2022 First provincial listing of anti-VEGF ranibizumab biosimilar brings cost-effective new option to patients and helps support healthcare system sustainability", "banner_image": "https://mma.prnewswire.com/media/2147755/Biogen_Canada_Biosimilar_BYOOVIZ__now_reimbursed_in_Quebec_to_tr.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.302543, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.382925", "ticker_sentiment_score": "0.461703", "ticker_sentiment_label": "Bullish"}]}, {"title": "First Alzheimer's drug to slow disease progression expected to get full FDA approval", "url": "https://www.cnn.com/2023/07/06/health/leqembi-alzheimers-fda-approval-medicare/index.html", "time_published": "20230706T104700", "authors": ["Meg Tirrell", "Tami Luhby", "Nadia Kounang"], "summary": "The US Food and Drug Administration is expected to decide on Thursday whether to grant traditional approval to the Alzheimer's drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230107165525-lecanemab-vpx.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.15112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.035293", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.140485", "ticker_sentiment_score": "0.071022", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.035293", "ticker_sentiment_score": "0.064528", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA weighs first full approval for experimental Alzheimer's drug", "url": "https://www.axios.com/2023/07/06/leqembi-fda-expected-approval-alzheimers", "time_published": "20230706T033805", "authors": ["Oriana Gonz\u00e1lez", "https://www.axios.com/authors/ogonzalez"], "summary": "The Food and Drug Administration is set to decide today whether to make a drug shown to have modest success delaying Alzheimer's disease widely available to the public - or whether cost and safety concerns justify limiting its availability.", "banner_image": "https://images.axios.com/5yvcTYgDtKxYTZZeB16TDTaojq4=/0x0:1920x1080/1920x1080/2023/07/05/1688593731635.jpg?w=1920", "source": "Axios", "category_within_source": "Markets", "source_domain": "www.axios.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.179512, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.044634", "ticker_sentiment_score": "0.143294", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.089129", "ticker_sentiment_score": "0.082905", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight", "url": "https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html", "time_published": "20230703T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.081483", "ticker_sentiment_score": "0.144952", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBPH", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRIS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.040795", "ticker_sentiment_score": "0.06675", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.020404", "ticker_sentiment_score": "0.003677", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELDN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.020404", "ticker_sentiment_score": "0.130751", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.081483", "ticker_sentiment_score": "0.105903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABUS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.040795", "ticker_sentiment_score": "0.032589", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.061159", "ticker_sentiment_score": "0.058024", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMMT", "relevance_score": "0.020404", "ticker_sentiment_score": "0.167562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCUS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCON", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.040795", "ticker_sentiment_score": "0.126795", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASCLF", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.020404", "ticker_sentiment_score": "0.202125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHIO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.081483", "ticker_sentiment_score": "0.048837", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040795", "ticker_sentiment_score": "0.143852", "ticker_sentiment_label": "Neutral"}]}, {"title": "COREVITAS\u00ae VANTAGE\u00ae SIMULATIONS WINS AWARD FOR BEST USE OF INNOVATION", "url": "https://www.prnewswire.com/news-releases/corevitas-vantage-simulations-wins-award-for-best-use-of-innovation-301869174.html", "time_published": "20230703T180000", "authors": ["CorEvitas", "LLC"], "summary": "WALTHAM, Mass., July 3, 2023 /PRNewswire/ -- CorEvitas, LLC, the gold-standard provider of real-world evidence solutions for the life sciences industry, today announced that it has received the 2023 BOBI ( Best of Business Intelligence ) Award for Best Use of Innovation from the British ...", "banner_image": "https://mma.prnewswire.com/media/1451011/CorEvitas_gradient_full_color_RGB_black_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.478016, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.230782", "ticker_sentiment_score": "0.46967", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33094946/biogen-reports-new-spinraza-data-in-atrophy-patients-after-incomplete-response-to-n", "time_published": "20230703T123609", "authors": ["Vandana Singh"], "summary": "Biogen Inc BIIB announced new Spinraza ( nusinersen ) data that were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/03/biib.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.227427, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.265378", "ticker_sentiment_score": "0.318083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.502207", "ticker_sentiment_score": "0.470579", "ticker_sentiment_label": "Bullish"}]}, {"title": "Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth", "url": "https://www.globenewswire.com/news-release/2023/07/03/2698382/0/en/Bionomics-Announces-Key-Leadership-Updates-to-Drive-U-S-Focused-Transformation-and-Next-Stage-of-Strategic-Growth.html", "time_published": "20230703T100000", "authors": ["Bionomics Ltd"], "summary": "ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 ( GLOBE NEWSWIRE ) -- Bionomics Limited ( Nasdaq: BNOX | ASX: BNO ) ( Bionomics or Company ) , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/822aaa99-a2bd-4905-ab9c-07869668b7f7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.184747, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNOX", "relevance_score": "0.4209", "ticker_sentiment_score": "0.350257", "ticker_sentiment_label": "Bullish"}, {"ticker": "AVRO", "relevance_score": "0.036869", "ticker_sentiment_score": "0.086244", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.036869", "ticker_sentiment_score": "0.086244", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.036869", "ticker_sentiment_score": "0.086244", "ticker_sentiment_label": "Neutral"}, {"ticker": "WVE", "relevance_score": "0.036869", "ticker_sentiment_score": "0.086244", "ticker_sentiment_label": "Neutral"}]}, {"title": "New data highlight potential benefit of SPINRAZA\u00ae  ( nusinersen )  in infants and toddlers with unmet medical needs after gene therapy", "url": "https://www.prnewswire.com/news-releases/new-data-highlight-potential-benefit-of-spinraza-nusinersen-in-infants-and-toddlers-with-unmet-medical-needs-after-gene-therapy-301868324.html", "time_published": "20230630T200800", "authors": ["Ionis Pharmaceuticals", "Inc."], "summary": "New data highlight potential benefit of SPINRAZA\u00ae ( nusinersen ) in infants and toddlers with unmet medical needs after ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2144844/Ionis_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.158048, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASOMF", "relevance_score": "0.034136", "ticker_sentiment_score": "-0.029618", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.135921", "ticker_sentiment_score": "0.092037", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.135921", "ticker_sentiment_score": "0.147846", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Data at Cure SMA Highlight Potential Benefit of SPINRAZA\u00ae  ( nusinersen )  in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy - Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33084807/new-data-at-cure-sma-highlight-potential-benefit-of-spinraza-nusinersen-in-infants-and-toddlers-wi", "time_published": "20230630T200600", "authors": ["Globe Newswire"], "summary": "Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma\u00ae ( onasemnogene abeparvovec ) Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.175523, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.027603", "ticker_sentiment_score": "0.063985", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.055173", "ticker_sentiment_score": "0.226953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.027603", "ticker_sentiment_score": "0.063985", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASOMF", "relevance_score": "0.027603", "ticker_sentiment_score": "-0.006819", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.244518", "ticker_sentiment_score": "0.271476", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New Data at Cure SMA Highlight Potential Benefit of SPINRAZA\u00ae  ( nusinersen )  in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy", "url": "https://www.globenewswire.com/news-release/2023/06/30/2698081/0/en/New-Data-at-Cure-SMA-Highlight-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-After-Gene-Therapy.html", "time_published": "20230630T200600", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., June 30, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced new SPINRAZA\u00ae ( nusinersen ) data aimed at answering critical questions for the spinal muscular atrophy ( SMA ) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.187301, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASOMF", "relevance_score": "0.029728", "ticker_sentiment_score": "-0.029278", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.059415", "ticker_sentiment_score": "0.227055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.234401", "ticker_sentiment_score": "0.295735", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Is The Market Feeling About Biogen? - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/06/33059937/how-is-the-market-feeling-about-biogen", "time_published": "20230629T140044", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has fallen 24.68% since its last report. The company recently reported that it has 2.23 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can A Woman Be Respected If She's In The Same Industry As Her Boyfriend? We May Soon Find Out", "url": "https://www.forbes.com/sites/ikebrannon/2023/06/28/can-a-woman-be-respected-if-shes-in-the-same-industry-as-her-boyfriend-we-may-soon-find-out/", "time_published": "20230628T162135", "authors": ["Ike Brannon"], "summary": "Sarissa Capital recently acquired a nine percent stake in another biotech company called Alkermes, which-like Biogen-has a focus on neuroscience, and partners with Bio...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/649c5df9ef284e36e50b96cb/0x0.jpg?format=jpg&crop=1909,1073,x0,y120,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.182361, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.03321", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.420316", "ticker_sentiment_score": "0.193281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A Look Into Biogen Inc's Price Over Earnings - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/06/33031168/a-look-into-biogen-incs-price-over-earnings", "time_published": "20230627T180202", "authors": ["Benzinga Insights"], "summary": "In the current market session, Biogen Inc. BIIB share price is at $281.65, after a 0.03% increase. Moreover, over the past month, the stock fell by 5.68%, but in the past year, spiked by 37.28%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.163209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.344074", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BIIB: 3 Stocks to Own as Alzheimer's Drugs Bring Relief", "url": "https://stocknews.com/news/biib-esaly-lly-3-stocks-to-own-as-alzheimers-drugs-bring-relief/", "time_published": "20230627T170416", "authors": [], "summary": "Rapidly aging populations pose a huge challenge to society, governments and public services. Older populations put an immense strain on healthcare expenditure, and the financial costs of dementia are large and growing.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/07/shutterstock_1006149949-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.159635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.372077", "ticker_sentiment_score": "0.296096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.077218", "ticker_sentiment_score": "-0.01942", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.439153", "ticker_sentiment_score": "0.257919", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BNGO: Should You Watch Bionano Genomics  ( BNGO )  this Week?", "url": "https://stocknews.com/news/bngo-alks-gild-biib-should-you-watch-bionano-genomics-bngo-this-week/", "time_published": "20230627T162238", "authors": [], "summary": "Genomic testing equipment manufacturer Bionano Genomics, Inc. ( BNGO ) is gaining traction with its third-generation optical mapping solution, Saphyr, which offers advanced capabilities crucial for genome research.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_757996678-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.158957, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.68781", "ticker_sentiment_score": "0.303132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALKS", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 3 Biotech Stocks With Some Major Value in Them", "url": "https://stocknews.com/news/gild-biib-alks-rcus-dnli-3-biotech-stocks-with-some-major-value-in-them/", "time_published": "20230627T121456", "authors": [], "summary": "The biotech sector assumes a crucial role in propelling the advancement of healthcare by spearheading the creation of innovative therapies and technologies aimed at addressing unmet medical requirements.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.1752, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.070128", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.288214", "ticker_sentiment_score": "-0.032922", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.260498", "ticker_sentiment_score": "0.178042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.232439", "ticker_sentiment_score": "0.087244", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.058903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report", "url": "https://www.benzinga.com/pressreleases/23/06/g33011292/amyotrophic-lateral-sclerosis-treatment-market-to-reach-us-594-1-million-in-2031-expanding-at-a-ca", "time_published": "20230626T173000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, June 26, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - In 2022, the global industry was estimated to be worth $594.1 million. It is expected to increase at a 5.5% CAGR from 2023 to 2031, reaching more than US$ 958.2 million by the end of 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.210071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCLI", "relevance_score": "0.042271", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.042271", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042271", "ticker_sentiment_score": "0.074033", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen shareholders back Susan Langer as director", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-shareholders-back-susan-langer-director-2023-06-26/", "time_published": "20230626T170700", "authors": ["Reuters"], "summary": "June 26 ( Reuters ) - Biogen ( BIIB.O ) shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him. Langer, 32, had served in various roles at the biotech ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/2W4SPW6CIVOW5AFGYQ7YQD4LAM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009336, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.213048", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.213048", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.720339", "ticker_sentiment_score": "0.026645", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?", "url": "https://www.fool.com/investing/2023/06/23/is-this-a-sign-that-biogens-leqembi-could-obtain/", "time_published": "20230623T113000", "authors": ["David Jagielski"], "summary": "The catalyst many Biogen investors have been waiting for may soon arrive.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736790%2Fbuffett11-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.22479, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.128822", "ticker_sentiment_score": "0.097448", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.627549", "ticker_sentiment_score": "0.300025", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medicare offers details on reimbursement for new Alzheimer's drugs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/medicare-offers-details-reimbursement-new-alzheimers-drugs-2023-06-22/", "time_published": "20230622T203900", "authors": ["Julie Steenhuysen"], "summary": "CHICAGO, June 22 ( Reuters ) - The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd ( 4523.T ) and Biogen Inc's ( BIIB.O ) new Alzheimer's drug Leqembi, should it win traditional U.S. approval as expected by ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/6DKBTCGDCJPAPDY5OEFS57TV2U.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187889, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.072655", "ticker_sentiment_score": "0.188676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.072655", "ticker_sentiment_score": "0.188676", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alleged Industrial Espionage Makes an Interesting Story", "url": "https://www.fool.com/investing/2023/06/21/alleged-industrial-espionage-makes-an-interesting/", "time_published": "20230622T010900", "authors": ["Motley Fool Staff"], "summary": "We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736716%2Fa-person-riding-in-a-futuristic-self-driving-robotaxi.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.083512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.02979", "ticker_sentiment_score": "-0.034297", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118744", "ticker_sentiment_score": "0.033705", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.009932", "ticker_sentiment_score": "-0.012494", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.049629", "ticker_sentiment_score": "-0.017001", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.049629", "ticker_sentiment_score": "0.067792", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.009932", "ticker_sentiment_score": "0.00082", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02979", "ticker_sentiment_score": "0.102635", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.009932", "ticker_sentiment_score": "0.057189", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Biotech Stocks Every Investor Wants", "url": "https://stocknews.com/news/gild-biib-alks-3-biotech-stocks-every-investor-wants/", "time_published": "20230621T161943", "authors": [], "summary": "The biotech sector is expanding due to innovations and robust demand. Furthermore, the biotech sector enjoys inelastic demand for its products and services and is relatively stable in the face of economic uncertainty.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.208038, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.368773", "ticker_sentiment_score": "0.19747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.152258", "ticker_sentiment_score": "0.083183", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.299022", "ticker_sentiment_score": "0.27677", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote \"FOR\" All Seven of the Company's Highly Qualified Director Nominees - Alkermes  ( NASDAQ:ALKS ) ", "url": "https://www.benzinga.com/pressreleases/23/06/n32943919/independent-proxy-advisory-firm-glass-lewis-recommends-alkermes-shareholders-vote-for-all-seven-of", "time_published": "20230621T120000", "authors": ["PRNewswire"], "summary": "Supports Alkermes' Existing Board and Notes Strong Positive Momentum Shares Board's Belief that Sarissa's Nominees Would Not Be Additive to the Board Notes Alkermes Board is \"sufficiently independent, qualified and capable to oversee the Company\"", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.140682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.413992", "ticker_sentiment_score": "0.191385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.0362", "ticker_sentiment_score": "-0.011842", "ticker_sentiment_label": "Neutral"}]}, {"title": "Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote \"FOR\" All Seven of the Company's Highly Qualified Director Nominees", "url": "https://www.prnewswire.com/news-releases/independent-proxy-advisory-firm-glass-lewis-recommends-alkermes-shareholders-vote-for-all-seven-of-the-companys-highly-qualified-director-nominees-301856284.html", "time_published": "20230621T120000", "authors": ["Alkermes plc"], "summary": "Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote \"FOR\" All Seven of the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.107044, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.310131", "ticker_sentiment_score": "0.112798", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028937", "ticker_sentiment_score": "0.065277", "ticker_sentiment_label": "Neutral"}]}, {"title": "ISS recommends one of Sarissa's three nominees for Alkermes board", "url": "https://www.reuters.com/business/iss-recommends-one-sarissas-three-nominees-alkermes-board-2023-06-20/", "time_published": "20230620T133200", "authors": ["Svea Herbst-Bayliss"], "summary": "NEW YORK, June 20 ( Reuters ) - Proxy advisory firm Institutional Investor Services urged Alkermes ( ALKS.O ) shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=144", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.036352, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.595343", "ticker_sentiment_score": "0.095474", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.014567", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board", "url": "https://www.prnewswire.com/news-releases/independent-proxy-advisory-firm-iss-recommends-alkermes-shareholders-vote-against-sarissa-employees-election-to-alkermes-board-301854859.html", "time_published": "20230620T110000", "authors": ["Alkermes plc"], "summary": "Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election ... PR ...", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.116946, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INVA", "relevance_score": "0.038561", "ticker_sentiment_score": "-0.004865", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.45439", "ticker_sentiment_score": "0.164265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.077032", "ticker_sentiment_score": "-0.011346", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.019286", "ticker_sentiment_score": "0.020296", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.019286", "ticker_sentiment_score": "-0.009931", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does This Signal Trouble for Biogen's New Alzheimer's Drug?", "url": "https://www.fool.com/investing/2023/06/19/does-this-signal-trouble-for-biogens-new-alzheimer/", "time_published": "20230619T093000", "authors": ["Adria Cimino"], "summary": "Biogen is counting on Leqembi to boost its revenue growth.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F735386%2Fcounting-money-dollar-bills-1.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.15059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.109705", "ticker_sentiment_score": "0.119828", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.054983", "ticker_sentiment_score": "0.049018", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.370733", "ticker_sentiment_score": "0.266196", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Market-Beating Stocks With Major Catalysts on the Way", "url": "https://www.fool.com/investing/2023/06/17/2-market-beating-stocks-with-major-catalysts-on/", "time_published": "20230617T140700", "authors": ["Prosper Junior Bakiny"], "summary": "Can these companies keep climbing?", "banner_image": "https://media.ycharts.com/charts/58d9c6a1c57d29095bb29106d93ccecf.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.215292, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.190793", "ticker_sentiment_score": "0.229458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.048133", "ticker_sentiment_score": "0.123661", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.327366", "ticker_sentiment_score": "0.260878", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BNGO: Is Bionano Genomics  ( BNGO )  a Buy or Sell this Week?", "url": "https://stocknews.com/news/bngo-alks-smlr-biib-is-bionano-genomics-bngo-a-buy-or-sell-this-week/", "time_published": "20230616T185036", "authors": [], "summary": "Bionano Genomics, Inc. ( BNGO ) has garnered attention with its Saphyr system, a third-generation optical mapping solution offering quick, high-throughput, long-range genome mapping and structural variation detection capabilities critical for genomic research.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.086258, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.442767", "ticker_sentiment_score": "0.149478", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.103778", "ticker_sentiment_score": "0.193065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMLR", "relevance_score": "0.103778", "ticker_sentiment_score": "0.193065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.103778", "ticker_sentiment_score": "0.193065", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.", "url": "https://www.fool.com/investing/2023/06/16/this-stock-crushed-the-market-last-year-heres-why/", "time_published": "20230616T180000", "authors": ["Adria Cimino"], "summary": "This small biotech could become much bigger in just a few years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736252%2Fhealthcare-gettyimages-660133306.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.212846, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JAZZ", "relevance_score": "0.057079", "ticker_sentiment_score": "0.238395", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.113866", "ticker_sentiment_score": "-0.160607", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.057079", "ticker_sentiment_score": "0.123958", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie's  ( ABBV )  Skyrizi Meets Ulcerative Colitis Study Goals", "url": "https://www.zacks.com/stock/news/2109293/abbvies-abbv-skyrizi-meets-ulcerative-colitis-study-goals", "time_published": "20230616T114500", "authors": ["Zacks Investment Research"], "summary": "AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.192402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.489394", "ticker_sentiment_score": "0.261914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.101135", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052455", "ticker_sentiment_score": "0.10259", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.156461", "ticker_sentiment_score": "0.060314", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.104683", "ticker_sentiment_score": "0.072563", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clene's ALS drug shows reduction in disease indicator levels in trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/clenes-als-drug-shows-reduction-disease-indicator-levels-trial-2023-06-15/", "time_published": "20230615T225500", "authors": ["Reuters"], "summary": "June 15 ( Reuters ) - Clene ( CLNN.O ) said on Thursday its experimental amyotrophic lateral sclerosis ( ALS ) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=144", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.06728, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLNN", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.167322", "ticker_sentiment_score": "0.315938", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ISS backs election of Langer to replace former Biogen director Denner", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/iss-backs-election-langer-replace-former-biogen-director-denner-2023-06-15/", "time_published": "20230615T183200", "authors": ["Svea Herbst-Bayliss"], "summary": "[1/2] Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/55H44PU3TBL3TI5DOA2Z6ZWB74.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.155451", "ticker_sentiment_score": "0.089337", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.673107", "ticker_sentiment_score": "-0.022353", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More", "url": "https://www.zacks.com/stock/news/2108932/biotech-stock-roundup-kdny-up-on-nvs-buyout-biib-eisais-ad-drug-update-more", "time_published": "20230615T142100", "authors": ["Zacks Investment Research"], "summary": "Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.10433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSVT", "relevance_score": "0.117104", "ticker_sentiment_score": "-0.016054", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.078226", "ticker_sentiment_score": "0.004104", "ticker_sentiment_label": "Neutral"}, {"ticker": "DERM", "relevance_score": "0.117104", "ticker_sentiment_score": "0.212802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.03916", "ticker_sentiment_score": "0.111448", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.2317", "ticker_sentiment_score": "0.142861", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.078226", "ticker_sentiment_score": "0.116672", "ticker_sentiment_label": "Neutral"}]}, {"title": "Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32859749/senator-bernie-sanders-puts-brakes-on-health-agency-nominees-until-drug-pricing-issue-is-addresse", "time_published": "20230614T175239", "authors": ["Vandana Singh"], "summary": "Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health until the administration delivers a plan to lower prescription drug prices.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/14/bernie_sanders_16603911783.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.105581, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.127456", "ticker_sentiment_score": "-0.1058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.25168", "ticker_sentiment_score": "-0.1685", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "The Biggest Barrier To New Anti-Alzheimer's Drugs May Be Cost, Not Medicare Rules", "url": "https://www.forbes.com/sites/howardgleckman/2023/06/14/the-biggest-barrier-to-new-anti-alzheimers-drugs-may-be-cost-not-medicare-rules/", "time_published": "20230614T161158", "authors": ["Howard Gleckman"], "summary": "CMS says the record-keeping will help provide important, real-world information about the benefits and risks of these new drugs.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6489e49796e652d07075c365/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.094576", "ticker_sentiment_score": "0.066113", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.094576", "ticker_sentiment_score": "0.066113", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Happening With Biogen Stock?", "url": "https://www.forbes.com/sites/greatspeculations/2023/06/14/whats-happening-with-biogen-stock/", "time_published": "20230614T120046", "authors": ["Trefis Team"], "summary": "After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/648958292db8a2e5087d5722/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.188789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.095138", "ticker_sentiment_score": "0.042588", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.879764", "ticker_sentiment_score": "0.299281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BUSINESS LOCATION SWITZERLAND - A THRIVING HUB FOR HEALTH TECH", "url": "https://www.prnewswire.com/news-releases/business-location-switzerland--a-thriving-hub-for-health-tech-301850632.html", "time_published": "20230614T120000", "authors": ["Business Location Switzerland"], "summary": "ZURICH, June 14, 2023 /PRNewswire/ -- Switzerland is home to a globally unique life science cluster.", "banner_image": "https://mma.prnewswire.com/media/2100723/Business_Locations_Switzerland_logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.376959, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.024648", "ticker_sentiment_score": "0.283278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNEJF", "relevance_score": "0.024648", "ticker_sentiment_score": "0.283278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.024648", "ticker_sentiment_score": "0.283278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOPH", "relevance_score": "0.024648", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.024648", "ticker_sentiment_score": "0.127229", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.024648", "ticker_sentiment_score": "0.079462", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.024648", "ticker_sentiment_score": "0.127229", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Well-Known Stocks Hit 52-Week Lows Monday While The Overall Market Surged Higher - SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/23/06/32841170/3-well-known-stocks-hit-52-week-lows-monday-while-the-overall-market-surged-higher", "time_published": "20230613T182547", "authors": ["Chris Katje"], "summary": "The stock market ended Monday with the S&P 500 continuing to hit new 52-week highs. While many stocks have hit new 52-week highs in recent weeks, three well-known companies found themselves hitting new 52-week lows:", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/13/stock_chart_image.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.103651, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.252987", "ticker_sentiment_score": "0.100791", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.064276", "ticker_sentiment_score": "0.069043", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.064276", "ticker_sentiment_score": "-0.039418", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.152407", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ULTA", "relevance_score": "0.128135", "ticker_sentiment_score": "0.415741", "ticker_sentiment_label": "Bullish"}, {"ticker": "DLTR", "relevance_score": "0.19117", "ticker_sentiment_score": "0.003251", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.064276", "ticker_sentiment_score": "0.069043", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVE", "relevance_score": "0.128135", "ticker_sentiment_score": "0.002502", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.064276", "ticker_sentiment_score": "0.069043", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.128135", "ticker_sentiment_score": "0.415741", "ticker_sentiment_label": "Bullish"}, {"ticker": "DRI", "relevance_score": "0.064276", "ticker_sentiment_score": "0.064038", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.064276", "ticker_sentiment_score": "0.064038", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.064276", "ticker_sentiment_score": "0.064038", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.128135", "ticker_sentiment_score": "0.283384", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sarissas-denner-quits-biogen-board-firm-seeks-seats-alkermes-2023-06-13/", "time_published": "20230613T175200", "authors": ["Svea Herbst-Bayliss"], "summary": "NEW YORK, June 13 ( Reuters ) - Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes ( ALKS.O ) when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4EYDESMEHJJHBAINR4RJIDJTJA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.031333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.827318", "ticker_sentiment_score": "-0.06987", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.265805", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stocks making the biggest moves midday: JD.com, Biogen, Oracle and more", "url": "https://www.cnbc.com/2023/06/13/stocks-making-the-biggest-moves-midday-jdcom-biogen-oracle-and-more.html", "time_published": "20230613T163801", "authors": ["Hakyung Kim"], "summary": "These are some of the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106993115-1640239227235-gettyimages-541117216-000096738405_Unapproved.jpeg?v=1686674703&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.248907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.088472", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.088472", "ticker_sentiment_score": "0.176572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NCLH", "relevance_score": "0.175859", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.088472", "ticker_sentiment_score": "0.025979", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIONL", "relevance_score": "0.088472", "ticker_sentiment_score": "0.068293", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.088472", "ticker_sentiment_score": "0.176572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.175859", "ticker_sentiment_score": "0.33022", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVN", "relevance_score": "0.088472", "ticker_sentiment_score": "0.380284", "ticker_sentiment_label": "Bullish"}, {"ticker": "URBN", "relevance_score": "0.175859", "ticker_sentiment_score": "0.036967", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.261117", "ticker_sentiment_score": "0.09744", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLD", "relevance_score": "0.088472", "ticker_sentiment_score": "0.176572", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A 53-year-old biotech investor is set to be replaced by a 32-year-old exec on Biogen's board. No one disclosed that the new board member is his girlfriend and the mother of his child.", "url": "https://www.businessinsider.com/biogen-board-susan-langer-alex-denner-2023-6", "time_published": "20230613T161300", "authors": ["Zachary Tracer"], "summary": "Biogen board: Susan Langer joining as partner Alex Denner departs - Business Insider ...", "banner_image": "https://i.insider.com/64886fb743c1740019300bb6?width=1200&format=jpeg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.16253, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.13459", "ticker_sentiment_score": "0.117086", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.824879", "ticker_sentiment_score": "0.274152", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday - Beneficient  ( NASDAQ:BENF ) , AvePoint  ( NASDAQ:AVPT ) ", "url": "https://www.benzinga.com/news/23/06/32837210/methode-electronics-brookfield-renewable-partners-and-other-big-stocks-moving-lower-on-tuesday", "time_published": "20230613T143627", "authors": ["Lisa Levin"], "summary": "Methode Electronics, Inc. MEI shares dipped 15.7% to $37.98 after the company reported worse-than-expected preliminary fourth-quarter results. The company's outlook for FY24 lagged consensus. Cibus, Inc. CBUS declined 10.6% to $20.74. Chijet Motor Company, Inc. CJET fell 9.4% to $3.5880.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/13/methode_electronics_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.088037, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COMP", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSEA", "relevance_score": "0.47672", "ticker_sentiment_score": "0.441585", "ticker_sentiment_label": "Bullish"}, {"ticker": "MEI", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPGF", "relevance_score": "0.16849", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.329551", "ticker_sentiment_score": "-0.201863", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DUK", "relevance_score": "0.16849", "ticker_sentiment_score": "0.137739", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEP", "relevance_score": "0.605266", "ticker_sentiment_score": "0.332244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUBS", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.25219", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.47672", "ticker_sentiment_score": "-0.508105", "ticker_sentiment_label": "Bearish"}]}, {"title": "Top Stories Tuesday, June 13: FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business - Apple  ( NASDAQ:AAPL ) , Activision Blizzard  ( NASDAQ:ATVI ) ", "url": "https://www.benzinga.com/news/23/06/32835975/ftc-sues-to-block-microsoft-activision-blizzard-deal-netflixs-first-sports-streaming-debut-european", "time_published": "20230613T140210", "authors": ["Vandana Singh"], "summary": "The U.S. Federal Trade Commission ( FTC ) has sued to block Microsoft Inc's MSFT acquisition of video game maker Activision Blizzard ATVI, stating that the deal will hurt consumer choice and competition. The FTC complaint comes when Microsoft has appealed the U.K.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/13/msft-atvi.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.007175, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NEX", "relevance_score": "0.079392", "ticker_sentiment_score": "0.177175", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NFLX", "relevance_score": "0.079392", "ticker_sentiment_score": "-0.069007", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.050606", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.118842", "ticker_sentiment_score": "0.071999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.031385", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.118842", "ticker_sentiment_score": "0.151424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "F", "relevance_score": "0.079392", "ticker_sentiment_score": "-0.075111", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.083323", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTEN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.177175", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BEP", "relevance_score": "0.079392", "ticker_sentiment_score": "0.255133", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.158", "ticker_sentiment_score": "-0.205377", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.047182", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.017482", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.118842", "ticker_sentiment_score": "-0.201535", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TM", "relevance_score": "0.079392", "ticker_sentiment_score": "0.155689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DUK", "relevance_score": "0.079392", "ticker_sentiment_score": "0.255133", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.039745", "ticker_sentiment_score": "-0.143039", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079392", "ticker_sentiment_score": "-0.149065", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32830662/alzheimers-drug-leqembi-faces-hurdles-in-europe-concerns-over-health-risks-and-healthcare-resourc", "time_published": "20230613T123017", "authors": ["Vandana Singh"], "summary": "Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd ESALY and Biogen Inc BIIB say Leqembi ( lecanemab ) 's ability to slow cognitive decline may not outweigh its health risks or justify the strain it would place on limited healthcare ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/13/dementia-3051832_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.045589, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.116914", "ticker_sentiment_score": "-0.166535", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.116914", "ticker_sentiment_score": "0.154942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.340915", "ticker_sentiment_score": "-0.19526", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Virtualware's VIROO set to support Mixed Reality capabilities upon its new release", "url": "https://www.benzinga.com/pressreleases/23/06/g32832191/virtualwares-viroo-set-to-support-mixed-reality-capabilities-upon-its-new-release", "time_published": "20230613T113850", "authors": ["Globe Newswire"], "summary": "BILBAO, Spain, June 13, 2023 ( GLOBE NEWSWIRE ) -- Spanish listed company Virtualware MLVIR, a global leader in immersive technology solutions, today announced its readiness to support mixed reality ( MR ) capabilities on its VIROO 2.4 release coming in July.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.393262, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.103331", "ticker_sentiment_score": "0.128897", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.103331", "ticker_sentiment_score": "0.128897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.103331", "ticker_sentiment_score": "0.128897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.103331", "ticker_sentiment_score": "0.128897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.103331", "ticker_sentiment_score": "0.128897", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware's VIROO set to support Mixed Reality capabilities upon its new release", "url": "https://www.globenewswire.com/news-release/2023/06/13/2687037/0/en/Virtualware-s-VIROO-set-to-support-Mixed-Reality-capabilities-upon-its-new-release.html", "time_published": "20230613T113800", "authors": ["Virtualware"], "summary": "BILBAO, Spain, June 13, 2023 ( GLOBE NEWSWIRE ) -- Spanish listed company Virtualware ( EPA:MLVIR ) , a global leader in immersive technology solutions, today announced its readiness to support mixed reality ( MR ) capabilities on its VIROO 2.4 release coming in July.", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.411558, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.107495", "ticker_sentiment_score": "0.130525", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.107495", "ticker_sentiment_score": "0.130525", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.107495", "ticker_sentiment_score": "0.130525", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.107495", "ticker_sentiment_score": "0.130525", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.107495", "ticker_sentiment_score": "0.130525", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ", "url": "https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di", "time_published": "20230613T110000", "authors": ["PRNewswire"], "summary": "Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote \"FOR\" Alkermes' Director Nominees on Company's WHITE Proxy Card", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.165805, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRM", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.122763", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.028649", "ticker_sentiment_score": "0.027306", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.177696", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PRTA", "relevance_score": "0.009551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDPQ", "relevance_score": "0.009551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.350825", "ticker_sentiment_score": "0.247017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.047079", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRWD", "relevance_score": "0.028649", "ticker_sentiment_score": "-0.042413", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDXG", "relevance_score": "0.009551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.048746", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPTX", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.177696", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMRX", "relevance_score": "0.009551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXLA", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.048746", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.019102", "ticker_sentiment_score": "-0.112723", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLAB", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.177696", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXEL", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.122763", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.019102", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCN", "relevance_score": "0.009551", "ticker_sentiment_score": "-0.048746", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.009551", "ticker_sentiment_score": "0.062837", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors", "url": "https://www.prnewswire.com/news-releases/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-directors-301848944.html", "time_published": "20230613T110000", "authors": ["Alkermes plc"], "summary": "Sarissa's Proposed Candidates Would Not Bring New Skills to the Board DUBLIN, June 13, 2023 /PRNewswire/ -- Alkermes plc ( Nasdaq: ALKS ) ( the Company ) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders ( the Annual ...", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.216916, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.448266", "ticker_sentiment_score": "0.344799", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.014839", "ticker_sentiment_score": "0.143356", "ticker_sentiment_label": "Neutral"}]}, {"title": "European Alzheimer's experts unconvinced by new Eisai, Biogen drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/european-alzheimers-experts-unconvinced-by-new-eisai-biogen-drug-2023-06-13/", "time_published": "20230613T071600", "authors": ["Natalie Grover"], "summary": "[1/5] A scientist looks at scans of grains at the Memory Centre at the Department of Readaptation and Geriatrics of the University Hospital ( HUG ) in Geneva, Switzerland, June 6, 2023. REUTERS/Denis Balibouse", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XUQO6TYYOVNOJAHOWG7KOXWRFE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.028718, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.124593", "ticker_sentiment_score": "-0.010945", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.041682", "ticker_sentiment_score": "0.072922", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.041682", "ticker_sentiment_score": "-0.152658", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "S&P 500 and Nasdaq close at highest since April 2022", "url": "https://www.moneycontrol.com/news/business/markets/sp-500-and-nasdaq-close-at-highest-since-april-2022-10785741.html", "time_published": "20230613T003855", "authors": [], "summary": "Lifted by gains in market heavyweights Amazon ( AMZN.O ) , Apple ( AAPL.O ) and Tesla ( TSLA.O ) , the SP 500 has now recovered 21% from its October 2022 lows. Some investors say Wall Street is the midst of a bull market.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/03/wall-street-bbo.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.156966, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.060085", "ticker_sentiment_score": "0.341409", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VMW", "relevance_score": "0.060085", "ticker_sentiment_score": "0.165327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.060085", "ticker_sentiment_score": "0.165327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.11983", "ticker_sentiment_score": "0.15441", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.060085", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.060085", "ticker_sentiment_score": "0.124447", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Announces Changes to Its Board of Directors - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g32825498/biogen-announces-changes-to-its-board-of-directors", "time_published": "20230612T211401", "authors": ["Globe Newswire"], "summary": "Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB announced several changes to its Board of Directors today.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.132459, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.031696", "ticker_sentiment_score": "-0.017757", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.031696", "ticker_sentiment_score": "0.165842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.031696", "ticker_sentiment_score": "0.165842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.279369", "ticker_sentiment_score": "0.149238", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Announces Changes to Its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/06/12/2686722/0/en/Biogen-Announces-Changes-to-Its-Board-of-Directors.html", "time_published": "20230612T211400", "authors": ["Biogen Inc."], "summary": "CAMBRIDGE, Mass., June 12, 2023 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board's continual interaction with company stockholders to solicit their perspective ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.134926, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.032164", "ticker_sentiment_score": "-0.017776", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.032164", "ticker_sentiment_score": "0.065518", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.032164", "ticker_sentiment_score": "0.065518", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.252987", "ticker_sentiment_score": "0.187488", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasdaq Jumps More Than 1%; Musk Mocks Short Sale", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-up-as-oracle-earnings-stock-pops-on-upgrade-elon-musk-mocks-short-call-tesla-stock-gains/", "time_published": "20230612T190800", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Up As Oracle Pops On Upgrade. Elon Musk Mocks Short ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/07/Stock-elonmusk-03-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.245442, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INTA", "relevance_score": "0.170878", "ticker_sentiment_score": "0.219414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.170878", "ticker_sentiment_score": "0.065576", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.085936", "ticker_sentiment_score": "0.20009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.085936", "ticker_sentiment_score": "0.281244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.253866", "ticker_sentiment_score": "0.137398", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.085936", "ticker_sentiment_score": "0.175185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.04303", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.093487", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.410505", "ticker_sentiment_score": "0.439344", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABNB", "relevance_score": "0.085936", "ticker_sentiment_score": "0.281244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.128592", "ticker_sentiment_score": "0.146227", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.128592", "ticker_sentiment_score": "0.069706", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32818719/prospects-for-full-approval-of-eisai-and-biogens-leqembi-shine-brighter-after-fda-c", "time_published": "20230612T180111", "authors": ["Vandana Singh"], "summary": "Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd ESALY and Biogen Inc BIIB Phase 3 Clarity AD trial confirms the clinical benefit of Leqembi ( lecanemab ) for Alzheimer's disease.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/12/biib.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221026, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.163909", "ticker_sentiment_score": "0.113581", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.465196", "ticker_sentiment_score": "0.289262", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "TriNet, Nasdaq fall; Ballard Power, Chinook Therapeutics rise, Monday, 6/12/2023", "url": "https://apnews.com/article/financial-markets-stocks-wall-street-58a2518c3cc898958159a59e72f05038", "time_published": "20230612T161913", "authors": [], "summary": "TriNet, Nasdaq fall. Ballard Power, Chinook Therapeutics rise ... The Associated Press ...", "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.079665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLDP", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNET", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.443626", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Upbeat On Monday; IPO Stock Breaks Out", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-upbeat-ahead-of-cpi-fed-decision-ipo-stock-breaks-out/", "time_published": "20230612T145800", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Upbeat On Monday. IPO Stock Breaks Out Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-intapp-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.142035, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INTA", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.006507", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.099476", "ticker_sentiment_score": "0.220775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.049835", "ticker_sentiment_score": "0.054912", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.049835", "ticker_sentiment_score": "-0.21425", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KDNY", "relevance_score": "0.099476", "ticker_sentiment_score": "0.12215", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.148731", "ticker_sentiment_score": "0.264395", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.112538", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.099476", "ticker_sentiment_score": "0.006479", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.049835", "ticker_sentiment_score": "0.224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.017503", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.099476", "ticker_sentiment_score": "0.07098", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.049835", "ticker_sentiment_score": "-0.015998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Launches Almost 60% On Novartis Takeover", "url": "https://www.investors.com/news/technology/biotech-stock-chinook-skyrockets-on-novartis-takeover/", "time_published": "20230612T140900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stock Chinook Skyrockets On $3.5 Billion Novartis Takeover ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/STOCK-Novartis-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.387105, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.295867", "ticker_sentiment_score": "0.639223", "ticker_sentiment_label": "Bullish"}, {"ticker": "KDNY", "relevance_score": "0.552443", "ticker_sentiment_score": "-0.211999", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Questex's Fierce Biotech Summit Returns to Boston in October, Gathering the Industry's Most Influential Leaders to Discuss the Future of Biotech", "url": "https://www.benzinga.com/pressreleases/23/06/g32816429/questexs-fierce-biotech-summit-returns-to-boston-in-october-gathering-the-industrys-most-influenti", "time_published": "20230612T140000", "authors": ["Globe Newswire"], "summary": "NEW YORK, June 12, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Biotech, today announces the Fierce Biotech Summit, the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials, will take place October 16-18 in Boston. Register here.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.156545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.040145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEM", "relevance_score": "0.040145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.040145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.040145", "ticker_sentiment_score": "-0.035093", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADPT", "relevance_score": "0.080188", "ticker_sentiment_score": "0.12682", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.040145", "ticker_sentiment_score": "0.06694", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.040145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.040145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040145", "ticker_sentiment_score": "-0.226958", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Did This CRISPR Company Just Cure A Rare Swelling Disease?", "url": "https://www.investors.com/news/technology/ntla-stock-surges-why-its-crispr-drug-could-cure-a-rare-swelling-disease/", "time_published": "20230612T133800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "NTLA Stock Surges. Why Its CRISPR Drug Could Cure A Rare ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/Stock-Biotech-11-Adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.012268, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.072655", "ticker_sentiment_score": "0.185636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.638154", "ticker_sentiment_score": "0.007444", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB ) , Eisai Alzheimer Drug Gets FDA Panel Endorsement", "url": "https://www.zacks.com/stock/news/2107073/biogen-biib-eisai-alzheimer-drug-gets-fda-panel-endorsement", "time_published": "20230612T132500", "authors": ["Zacks Investment Research"], "summary": "An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.089805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.279015", "ticker_sentiment_score": "-0.026746", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.331765", "ticker_sentiment_score": "-0.058378", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.169676", "ticker_sentiment_score": "0.149696", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.279015", "ticker_sentiment_score": "0.292392", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Monday", "url": "https://www.cnbc.com/2023/06/12/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html", "time_published": "20230612T130825", "authors": ["Jim Cramer"], "summary": "The Magnificent Seven keep rolling, the cruise lines catch price target boosts and consumers stay strong.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107190373-1675796003229-gettyimages-1463870138-029a6771_ba1de0b3-c2ff-44a3-bf63-256169e7b95c.jpeg?v=1686575305&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.153421, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.059785", "ticker_sentiment_score": "-0.070027", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.059785", "ticker_sentiment_score": "0.052036", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.119235", "ticker_sentiment_score": "0.031154", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.059785", "ticker_sentiment_score": "-0.027026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.059785", "ticker_sentiment_score": "0.268147", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.119235", "ticker_sentiment_score": "0.031154", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.235823", "ticker_sentiment_score": "0.234535", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NCLH", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.031135", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.178021", "ticker_sentiment_score": "-0.101176", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.119235", "ticker_sentiment_score": "0.103045", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.031135", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.178021", "ticker_sentiment_score": "0.099254", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.119235", "ticker_sentiment_score": "0.102221", "ticker_sentiment_label": "Neutral"}]}, {"title": "Goldman pushes back against bearish Morgan Stanley's Mike Wilson with new 4,500 S&P 500 target", "url": "https://www.marketwatch.com/story/goldman-pushes-back-against-bearish-morgan-stanleys-mike-wilson-with-new-4-500-s-p-500-target-e69059a8", "time_published": "20230612T112300", "authors": ["Barbara Kollmeyer"], "summary": "Resilient economic growth and softening inflation will keep stocks supported, says Goldman Sachs, which has a new bullish S&P 500 target.", "banner_image": "https://images.mktw.net/im-798498?width=700&height=499", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.996675"}], "overall_sentiment_score": -0.017128, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ILMN", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.073701", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.038468", "ticker_sentiment_score": "-0.338995", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.038468", "ticker_sentiment_score": "-0.113143", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.038468", "ticker_sentiment_score": "0.111194", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.076847", "ticker_sentiment_score": "0.275576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.076847", "ticker_sentiment_score": "0.275576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.038468", "ticker_sentiment_score": "0.157493", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Nasdaq, S&P 500 Futures Signal Strong Start To Week - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Illumina  ( NASDAQ:ILMN ) , Chinook Therapeutics  ( NASDAQ:KDNY ) , Oracle  ( NYSE:ORCL ) , Novartis  ( NYSE:NVS ) , SPDR S&P 500  ( ARCA:SPY ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/equities/23/06/32812362/nasdaq-s-amp-p-500-futures-signal-strong-start-to-week-on-hopes-of-fed-pause-why-this-analyst-is", "time_published": "20230612T110046", "authors": ["Shanthi Rexaline"], "summary": "U.S. stocks are set to start the week on an upbeat note, as traders begin to bake in a pause by the Federal Reserve when it meets this week. Technology stocks could large the charge but oil's slide could weigh down on the space.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Created_with_artificial_intelligence_on_MidJourney_6.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.995973"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.057857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ILMN", "relevance_score": "0.113329", "ticker_sentiment_score": "-0.117381", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.113329", "ticker_sentiment_score": "0.109584", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.113329", "ticker_sentiment_score": "0.209008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LPLA", "relevance_score": "0.056808", "ticker_sentiment_score": "-0.093288", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.113329", "ticker_sentiment_score": "0.109584", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.056808", "ticker_sentiment_score": "0.219998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.056808", "ticker_sentiment_score": "-0.050932", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.113329", "ticker_sentiment_score": "-0.056275", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures rise as focus shifts to inflation data, Fed meet", "url": "https://www.reuters.com/markets/us/futures-rise-focus-shifts-inflation-data-fed-meet-2023-06-12/", "time_published": "20230612T102828", "authors": ["Reuters"], "summary": "June 12 ( Reuters ) - U.S. stock index futures rose on Monday ahead of inflation data and the Federal Reserve's interest rate decision this week, while Biogen shares gained in premarket trading after the U.S. FDA panel backed its Alzheimer's drug. Investors are on the watch for the U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/AVH5M4KPL5K67GFCAI5K3W25K4.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.192986, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.192694", "ticker_sentiment_score": "0.287585", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-rises-fda-panel-backs-alzheimers-drug-easing-safety-concerns-2023-06-12/", "time_published": "20230612T102614", "authors": ["Reuters"], "summary": "Biogen rises as FDA panel backs Alzheimer's drug, easing safety ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OI4G2TQGONMKZKDRKMQZ4ANLIQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.253448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.155451", "ticker_sentiment_score": "0.00944", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.155451", "ticker_sentiment_score": "0.201333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.305058", "ticker_sentiment_score": "0.30554", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.155451", "ticker_sentiment_score": "0.00944", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move", "url": "https://www.marketwatch.com/story/biogen-stock-climbs-on-drug-approval-recommendation-oracle-shares-rise-ahead-of-earnings-and-other-stocks-on-the-move-b36703f1", "time_published": "20230612T093800", "authors": ["MarketWatch"], "summary": "Here are some of the biggest movers of Monday.", "banner_image": "https://images.mktw.net/im-705451/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.45622, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.866386", "ticker_sentiment_score": "0.755557", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.975551", "ticker_sentiment_score": "0.771304", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI\u00ae  ( lecanemab-irmb )  for the treatment of early Alzheimer's disease", "url": "https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-unanimously-to-confirm-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-early-alzheimers-disease-301847722.html", "time_published": "20230610T113700", "authors": ["BioArctic"], "summary": "FDA Advisory Committee votes unanimously to confirm clinical ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.064106, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.289405", "ticker_sentiment_score": "0.185999", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.029599", "ticker_sentiment_score": "0.126184", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI\u00ae  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g32805841/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb", "time_published": "20230609T224500", "authors": ["Globe Newswire"], "summary": "Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.064446, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012434", "ticker_sentiment_score": "0.055031", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.012434", "ticker_sentiment_score": "0.055031", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.012434", "ticker_sentiment_score": "0.067317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.232849", "ticker_sentiment_score": "0.146294", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.14835", "ticker_sentiment_score": "0.034087", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI\u00ae  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease", "url": "https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301847597.html", "time_published": "20230609T224500", "authors": ["Eisai Inc."], "summary": "FDA Advisory Committee Votes Unanimously to Confirm the Clinical ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.062015, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012076", "ticker_sentiment_score": "0.054866", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.012076", "ticker_sentiment_score": "0.054866", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.012076", "ticker_sentiment_score": "0.067173", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.226338", "ticker_sentiment_score": "0.144748", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.144131", "ticker_sentiment_score": "0.033499", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI\u00ae  ( lecanemab-irmb )  for the Treatment of Alzheimer's Disease", "url": "https://www.globenewswire.com/news-release/2023/06/09/2685832/0/en/FDA-Advisory-Committee-Votes-Unanimously-to-Confirm-the-Clinical-Benefit-of-LEQEMBI-lecanemab-irmb-for-the-Treatment-of-Alzheimer-s-Disease.html", "time_published": "20230609T224500", "authors": ["Biogen Inc."], "summary": "Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071637, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.012869", "ticker_sentiment_score": "0.05523", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.012869", "ticker_sentiment_score": "0.05523", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.012869", "ticker_sentiment_score": "0.080679", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.228431", "ticker_sentiment_score": "0.148221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.140821", "ticker_sentiment_score": "0.031662", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bullish Market Trend, But Fed Meeting Looms; 7 Stocks To Watch", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-bullish-market-trend-but-fed-meeting-looms-tesla-nvidia-lead-stocks-to-watch/", "time_published": "20230609T211900", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Bullish Market Trend, But Fed Meeting Looms. 7 Stocks To Watch Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-05-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.187346, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.153192", "ticker_sentiment_score": "0.088429", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.044019", "ticker_sentiment_score": "0.139753", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.044019", "ticker_sentiment_score": "0.164645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.131523", "ticker_sentiment_score": "0.007182", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.022018", "ticker_sentiment_score": "0.135632", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.044019", "ticker_sentiment_score": "0.164645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.259497", "ticker_sentiment_score": "0.2165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.131523", "ticker_sentiment_score": "0.009546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.044019", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.044019", "ticker_sentiment_score": "0.115921", "ticker_sentiment_label": "Neutral"}, {"ticker": "PH", "relevance_score": "0.044019", "ticker_sentiment_score": "0.164645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.174745", "ticker_sentiment_score": "0.022478", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.065987", "ticker_sentiment_score": "0.09945", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA advisers vote in favor of Biogen and Eisai's collaborative Alzheimer's treatment", "url": "https://www.marketwatch.com/story/eisai-shares-jump-on-fda-advisers-vote-on-alzheimers-treatment-bed17402", "time_published": "20230609T211200", "authors": ["Eleanor Laise"], "summary": "If granted full FDA approval, which could come in early July, treatment could boost annual Medicare spending by nearly $9 billion, analysis shows.", "banner_image": "https://images.mktw.net/im-696087/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.24293, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.24289", "ticker_sentiment_score": "0.233057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.24289", "ticker_sentiment_score": "0.233057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Experimental Alzheimer's drug endorsed for full approval by FDA advisers", "url": "https://www.axios.com/2023/06/09/alzheimers-drug-leqembi-fda-endorse", "time_published": "20230609T200148", "authors": ["https://www.axios.com/authors/ogonzalez", "Oriana Gonz\u00e1lez"], "summary": "Experimental Alzheimer's drug endorsed for full approval by FDA ... ...", "banner_image": "https://images.axios.com/V5o-pzESDw3WD7AM-h5Q8B-XEdA=/0x0:1920x1080/1920x1080/2023/06/08/1686239539944.jpg?w=1920", "source": "Axios", "category_within_source": "Business", "source_domain": "www.axios.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.194328, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.093289", "ticker_sentiment_score": "0.148823", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046724", "ticker_sentiment_score": "0.191455", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alzheimer's drug gets FDA panel's backing, setting the stage for broader use", "url": "https://apnews.com/article/leqembi-alzheimers-drug-fda-f438cd0d1df98d1df0677a219cee6fa7", "time_published": "20230609T195317", "authors": [], "summary": "Alzheimer's drug gets FDA panel's backing, setting the stage for ... The Associated Press ...", "banner_image": "https://storage.googleapis.com/afs-prod/media/19e57d2e173049c89fe2d1a40bfad90d/3000.jpeg", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.147981, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.088309", "ticker_sentiment_score": "0.09221", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHC", "relevance_score": "0.044222", "ticker_sentiment_score": "0.164712", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.044222", "ticker_sentiment_score": "0.260786", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen Halted As It Faces Make-Or-Break Moment In Alzheimer's", "url": "https://www.investors.com/news/technology/biogen-stock-halted-as-fda-panelists-mull-alzheimers-treatment/", "time_published": "20230609T160800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biogen Stock Halted As FDA Panelists Mull Alzheimer's Treatment ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-biogen-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.325887, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXAS", "relevance_score": "0.08183", "ticker_sentiment_score": "0.236633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESALF", "relevance_score": "0.08183", "ticker_sentiment_score": "-0.13478", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.644856", "ticker_sentiment_score": "0.401051", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval", "url": "https://www.cnbc.com/2023/06/09/fda-advisors-review-alzheimers-drug-leqembi-for-full-approval.html", "time_published": "20230609T140703", "authors": ["Spencer Kimball"], "summary": "Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107198790-16771574832023-02-23t020744z_307853963_rc2f2w9v65fn_rtrmadp_0_health-alzheimers-medicare.jpeg?v=1686319623&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.184071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.067727", "ticker_sentiment_score": "0.364537", "ticker_sentiment_label": "Bullish"}, {"ticker": "ESALF", "relevance_score": "0.329112", "ticker_sentiment_score": "0.190423", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.266101", "ticker_sentiment_score": "0.108745", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.067727", "ticker_sentiment_score": "0.364537", "ticker_sentiment_label": "Bullish"}, {"ticker": "WMT", "relevance_score": "0.067727", "ticker_sentiment_score": "0.426373", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-debate-us-approval-alzheimers-drug-eisai-biogen-2023-06-09/", "time_published": "20230609T110615", "authors": ["Reuters"], "summary": "FDA panel to debate US approval for Alzheimer's drug from Eisai ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5MRPEFS52NLPRC4S5UWMAVPDNQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.091953, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.146916", "ticker_sentiment_score": "0.157478", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.073773", "ticker_sentiment_score": "0.040826", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB ) , Eisai's Alzheimer Drug Likely to Get Full FDA Nod", "url": "https://www.zacks.com/stock/news/2105996/biogen-biib-eisais-alzheimer-drug-likely-to-get-full-fda-nod", "time_published": "20230608T164100", "authors": ["Zacks Investment Research"], "summary": "Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/15392.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.255106", "ticker_sentiment_score": "-0.024869", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.3038", "ticker_sentiment_score": "-0.054454", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.255106", "ticker_sentiment_score": "0.111447", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.3038", "ticker_sentiment_score": "0.200188", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More", "url": "https://www.zacks.com/stock/news/2105968/biotech-stock-roundup-gsk-provides-updates-biogen-to-discontinue-study-more", "time_published": "20230608T163800", "authors": ["Zacks Investment Research"], "summary": "Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.120247, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DAWN", "relevance_score": "0.074809", "ticker_sentiment_score": "0.148566", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.037446", "ticker_sentiment_score": "0.09032", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.074809", "ticker_sentiment_score": "0.066067", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.148961", "ticker_sentiment_score": "-0.025128", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.037446", "ticker_sentiment_score": "-0.027592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32780854/bernie-sanders-takes-on-high-costs-of-alzheimers-treatment-leqembi-calls-price-tag-unconscionable", "time_published": "20230608T152715", "authors": ["Vandana Singh"], "summary": "Senator Bernie Sanders urged the U.S. Department of Health and Human Services ( HHS ) to immediately address the exorbitant cost of Eisai Co Ltd ESALY/Biogen Inc BIIB Alzheimer's treatment Leqembi ( lecanemab ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/08/bernie_sanders_16603911783.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.076593, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.397098", "ticker_sentiment_score": "0.011178", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.512093", "ticker_sentiment_score": "-0.101001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Thursday", "url": "https://www.cnbc.com/2023/06/08/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html", "time_published": "20230608T131038", "authors": ["Jim Cramer"], "summary": "Wall Street little changed heading into the open as the Dow, S&P 500 and Nasdaq track modestly lower for the week.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107251285-1685991400570-NYSE_Traders-OB-20230605-CC-PRESS-10.jpg?v=1686229838&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.164598, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.055236", "ticker_sentiment_score": "0.079999", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.110209", "ticker_sentiment_score": "0.097188", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.164656", "ticker_sentiment_score": "0.030732", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.110209", "ticker_sentiment_score": "0.106579", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.055236", "ticker_sentiment_score": "-0.018067", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.110209", "ticker_sentiment_score": "0.176157", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVNA", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.044585", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.218325", "ticker_sentiment_score": "0.147981", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.026157", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.055236", "ticker_sentiment_score": "0.157032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GME", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.017327", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055236", "ticker_sentiment_score": "0.157032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.164656", "ticker_sentiment_score": "0.120312", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval - Eisai Co  ( OTC:ESALF ) , Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32776205/fda-signals-support-for-eisai-biogen-alzheimers-drug-data-confirms-benefits-for-complete-approval", "time_published": "20230608T123450", "authors": ["Vandana Singh"], "summary": "FDA Peripheral and Central Drugs Advisory Committee is meeting Friday ( June 9 ) to discuss a supplemental marketing application for Leqembi ( lecanemab ) submitted by Eisai Co Ltd ESALY for Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/08/dementia-3051832_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.163293, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.268294", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.392948", "ticker_sentiment_score": "0.237019", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why This Cathie Wood Holding Is On An 8-Month Hot Streak", "url": "https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/", "time_published": "20230608T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "The market for colon cancer screening is massive - and underserved - says Exact Sciences ( EXAS ) Chief Medical Officer Paul Limburg. And that might be why EXAS stock is on an eight-month hot streak. Exact Sciences makes Cologuard, a stool-based detection test for colorectal cancer.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/TECH1_exact_060923_company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.036924, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GH", "relevance_score": "0.044222", "ticker_sentiment_score": "-0.024852", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.654165", "ticker_sentiment_score": "0.063767", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.044222", "ticker_sentiment_score": "0.370369", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.044222", "ticker_sentiment_score": "0.370369", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNTX", "relevance_score": "0.044222", "ticker_sentiment_score": "-0.054001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation", "url": "https://www.prnewswire.com/news-releases/alkermes-publishes-investor-presentation-detailing-companys-transformation-and-value-creation-301846055.html", "time_published": "20230608T110000", "authors": ["Alkermes plc"], "summary": "Alkermes Publishes Investor Presentation Detailing Company's ... PR ...", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.178691, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RARE", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.021778", "ticker_sentiment_score": "0.322255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NBIX", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.277312", "ticker_sentiment_score": "0.20266", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRWD", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.021778", "ticker_sentiment_score": "0.125225", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.043539", "ticker_sentiment_score": "-0.097648", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tokyo Stocks Trade Modestly Higher", "url": "https://www.barrons.com/amp/news/tokyo-stocks-open-modestly-higher-b7777e1", "time_published": "20230608T002138", "authors": ["AFP - Agence France Presse"], "summary": "Tokyo Stocks Open Modestly Higher ...", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.105563, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYCCF", "relevance_score": "0.126119", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITSF", "relevance_score": "0.126119", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCRFF", "relevance_score": "0.126119", "ticker_sentiment_score": "0.057679", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNXBF", "relevance_score": "0.126119", "ticker_sentiment_score": "0.126244", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.249106", "ticker_sentiment_score": "0.172589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FRCOF", "relevance_score": "0.126119", "ticker_sentiment_score": "0.057679", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.126119", "ticker_sentiment_score": "0.108773", "ticker_sentiment_label": "Neutral"}, {"ticker": "NAUBF", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.137903", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.943189", "ticker_sentiment_score": "0.178232", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.126119", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mastering the Double-Bottom Pattern  ( Unveiling 3 Intriguing Setups in Today's Market ) ", "url": "https://www.zacks.com/commentary/2105410/mastering-the-double-bottom-pattern-unveiling-3-intriguing-setups-in-todays-market", "time_published": "20230607T221400", "authors": ["Zacks Investment Research"], "summary": "A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.166655, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VGR", "relevance_score": "0.188193", "ticker_sentiment_score": "0.158743", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.094762", "ticker_sentiment_score": "0.001059", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.094762", "ticker_sentiment_score": "0.063438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.094762", "ticker_sentiment_score": "0.063438", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.188193", "ticker_sentiment_score": "0.117749", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBLY", "relevance_score": "0.188193", "ticker_sentiment_score": "0.117749", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOUG", "relevance_score": "0.047465", "ticker_sentiment_score": "0.105254", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.407844", "ticker_sentiment_score": "0.350821", "ticker_sentiment_label": "Bullish"}]}, {"title": "What To Do Now As Market Rally Turns Upside Down; Two Big Losers Late", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-what-to-do-as-market-rally-turns-upside-down-gamestop-dives-late/", "time_published": "20230607T215600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "What To Do Now As Market Rally Turns Upside Down Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-technologyrace-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.084528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.12455", "ticker_sentiment_score": "-0.075311", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.12455", "ticker_sentiment_score": "-0.194692", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GOOG", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.172213", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVDA", "relevance_score": "0.12455", "ticker_sentiment_score": "0.029895", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.173689", "ticker_sentiment_score": "0.129902", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.015", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.352684", "ticker_sentiment_label": "Bearish"}, {"ticker": "SMAR", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.017241", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.172213", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GME", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.128182", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.12455", "ticker_sentiment_score": "0.154746", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasdaq Skids, But These Stocks Keep Running; What To Do Now", "url": "https://www.investors.com/market-trend/stock-market-today/nasdaq-skids-but-these-areas-run-meme-stock-gamestop-dives-on-miss-ceo-ouster/", "time_published": "20230607T204400", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Nasdaq Skids But These Areas Run. Meme Stock GameStop Dives ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-technologyrace-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.089279, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.12455", "ticker_sentiment_score": "-0.075311", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.12455", "ticker_sentiment_score": "-0.194692", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GOOG", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.172213", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVDA", "relevance_score": "0.12455", "ticker_sentiment_score": "0.029895", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.173689", "ticker_sentiment_score": "0.129902", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.015", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.352684", "ticker_sentiment_label": "Bearish"}, {"ticker": "SMAR", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.017248", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.049991", "ticker_sentiment_score": "-0.172213", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GME", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.130755", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.12455", "ticker_sentiment_score": "0.154746", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action", "url": "https://www.cnbc.com/2023/06/07/sanders-condemns-alzheimers-treatment-price-calls-for-hhs-action.html", "time_published": "20230607T183023", "authors": ["Spencer Kimball"], "summary": "Sen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107250207-1685724860593-gettyimages-1495245678-_m021263_a3lsffup.jpeg?v=1686162623&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048533, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.574972", "ticker_sentiment_label": "Bearish"}, {"ticker": "ESALF", "relevance_score": "0.237668", "ticker_sentiment_score": "-0.003717", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.237668", "ticker_sentiment_score": "0.052195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Is Eyeing A Repeat Alzheimer's Approval, But No Drama", "url": "https://www.investors.com/news/technology/biogen-stock-rises-on-the-fda-uncontroversial-take-on-alzheimers-treatment/", "time_published": "20230607T173700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Biogen Stock Rises On The FDA's Uncontroversial Take On ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/07/Stock-biogen-04-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}], "overall_sentiment_score": 0.127451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FGEN", "relevance_score": "0.055492", "ticker_sentiment_score": "0.209398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVCR", "relevance_score": "0.055492", "ticker_sentiment_score": "-0.28534", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ESALF", "relevance_score": "0.055492", "ticker_sentiment_score": "0.09386", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.46898", "ticker_sentiment_score": "0.194353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2104904/novo-nordisk-and-golden-entertainment-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20230607T113200", "authors": ["Zacks Investment Research"], "summary": "Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.170713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.299113", "ticker_sentiment_score": "0.234831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.327366", "ticker_sentiment_score": "0.076479", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.122114", "ticker_sentiment_score": "0.010266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDEN", "relevance_score": "0.211983", "ticker_sentiment_score": "-0.055608", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck lawsuit opens new effort to cripple drug price negotiations", "url": "https://www.axios.com/2023/06/07/merck-lawsuit-cripple-drug-price-talks", "time_published": "20230607T093000", "authors": ["https://www.axios.com/authors/abettelheim", "Adriel Bettelheim"], "summary": "Merck's lawsuit challenging drug price negotiations established by the Inflation Reduction Act is the likely start of a flurry of litigation to undo Democrats' signature effort to tackle pharmaceutical costs. Why it matters: At a minimum, the IRA's drug pricing provisions probably won't start on ...", "banner_image": "https://images.axios.com/75xL-yF7ue7-nYhKBZ6QFizWquc=/0x0:1920x1080/1920x1080/2023/06/06/1686082069776.jpg?w=1920", "source": "Axios", "category_within_source": "Economy", "source_domain": "www.axios.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.079419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.070655", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( BIIB )  to End One of Two Parkinson's Studies on BIIB122", "url": "https://www.zacks.com/stock/news/2104520/biogen-biib-to-end-one-of-two-parkinsons-studies-on-biib122", "time_published": "20230606T145800", "authors": ["Zacks Investment Research"], "summary": "Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.118383, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.294977", "ticker_sentiment_score": "0.070716", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.656041", "ticker_sentiment_score": "0.112768", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.223522", "ticker_sentiment_score": "-0.036996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32721144/biogen-and-denali-realign-parkinsons-disease-research-priorities-amidst-r-d-restructure", "time_published": "20230605T201515", "authors": ["Vandana Singh"], "summary": "The Phase 2b LUMA study in participants with early-stage Parkinson's disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson's disease related to LRRK2 mutations commenced in September 2022 and was slated for completion in 2031.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/05/aapharma_11.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.524949", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.", "url": "https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3", "time_published": "20230605T190500", "authors": ["Michael Brush"], "summary": "Big pharma will be looking to acquire companies with promsing new medicines.", "banner_image": "https://images.mktw.net/im-273079/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.682689"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.014455, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HZNP", "relevance_score": "0.097193", "ticker_sentiment_score": "0.031463", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.129342", "ticker_sentiment_score": "0.025247", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.064885", "ticker_sentiment_score": "-0.178347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.19295", "ticker_sentiment_score": "0.065446", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064885", "ticker_sentiment_score": "0.058044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32721701/100-invested-in-biogen-15-years-ago-would-be-worth-this-much-today", "time_published": "20230605T180023", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 11.92%. Currently, Biogen has a market capitalization of $43.65 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Autoinjectors Global Market Report 2023: Increasing Prevalence of Chronic Disease Drives Growth", "url": "https://www.prnewswire.com/news-releases/autoinjectors-global-market-report-2023-increasing-prevalence-of-chronic-disease-drives-growth-301841281.html", "time_published": "20230603T010000", "authors": ["Research and Markets"], "summary": "Autoinjectors Global Market Report 2023: Increasing Prevalence of ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.059617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.03853", "ticker_sentiment_score": "0.12297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why The Biotech Buying Bonanza Will Likely Continue", "url": "https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/", "time_published": "20230602T171700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/wJumpB060523.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.962106"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.993781"}], "overall_sentiment_score": 0.055036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.163574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLU", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.031529", "ticker_sentiment_score": "0.161618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110028", "ticker_sentiment_score": "-0.017979", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.001427", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRWD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.117903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTC", "relevance_score": "0.015767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.063008", "ticker_sentiment_score": "0.016034", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.047278", "ticker_sentiment_score": "0.036401", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.047278", "ticker_sentiment_score": "-0.146624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.066264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISEE", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.015767", "ticker_sentiment_score": "0.089075", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.078714", "ticker_sentiment_score": "-0.025629", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012717", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.047297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.032413", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.089095", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.015767", "ticker_sentiment_score": "0.110607", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012628", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.022789", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autoinjectors Market worth $1.7 billion | MarketsandMarkets", "url": "https://www.prnewswire.com/news-releases/autoinjectors-market-worth-1-7-billion--marketsandmarkets-301840949.html", "time_published": "20230602T170000", "authors": ["MarketsandMarkets"], "summary": "CHICAGO, June 2, 2023 /PRNewswire/ -- The autoinjectors industry is set to experience significant growth in the near future as a result of several factors. With the rise in chronic diseases and the increasing need for self-administration of medication, autoinjectors have emerged as a convenient ...", "banner_image": "https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.413559"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.351754, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.021937", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLTX", "relevance_score": "0.021937", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis  ( IONS )  Posts Two-Year Upbeat Data From HAE Drug Study", "url": "https://www.zacks.com/stock/news/2103417/ionis-ions-posts-two-year-upbeat-data-from-hae-drug-study", "time_published": "20230602T163500", "authors": ["Zacks Investment Research"], "summary": "Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.202932", "ticker_sentiment_score": "0.376758", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGND", "relevance_score": "0.268294", "ticker_sentiment_score": "0.101083", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.119124", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.331765", "ticker_sentiment_score": "0.220693", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis Pharmaceuticals  ( IONS )  Up 19.3% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2103298/ionis-pharmaceuticals-ions-up-193-since-last-earnings-report-can-it-continue", "time_published": "20230602T153140", "authors": ["Zacks Investment Research"], "summary": "Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.134258, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.054114", "ticker_sentiment_score": "0.100757", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.265666", "ticker_sentiment_score": "0.233085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.054114", "ticker_sentiment_score": "0.100757", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech Is Taking On Bristol In Cancer Treatment - Could It Win?", "url": "https://www.investors.com/news/technology/bntx-stock-pops-as-it-takes-on-bristol-in-hard-to-treat-cancer-treatment/", "time_published": "20230602T151100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "BNTX Stock Pops As It Takes On Bristol In Hard-To-Treat Lung ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-BioNTech-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.062955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.076115", "ticker_sentiment_score": "0.378713", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.278688", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIIB", "relevance_score": "0.076115", "ticker_sentiment_score": "0.378713", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNTX", "relevance_score": "0.818966", "ticker_sentiment_score": "-0.094248", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease", "url": "https://www.investors.com/news/technology/biogen-stock-jumps-into-buy-zone-on-a-key-win-in-alzheimers-treatment/", "time_published": "20230601T200900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biogen ( BIIB ) stock jumped into a buy zone Thursday after Medicare officials said they would reimburse patients for the cost of Alzheimer's treatments that target an abnormal protein called beta amyloid.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/07/Stock-biogen-05-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.230441, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.16849", "ticker_sentiment_score": "0.191437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BHVN", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.087097", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.084722", "ticker_sentiment_score": "0.158217", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.605266", "ticker_sentiment_score": "0.3945", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top 2% Biotech Comes 'Out Of Stealth Mode' On A Four-Day Sprint", "url": "https://www.investors.com/news/technology/bhvn-stock-runs-up-for-the-fourth-day-as-it-comes-out-of-stealth-mode/", "time_published": "20230601T200800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "BHVN Stock Exits 'Stealth Mode' And Hits A Record High Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-biohavenpharma-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.16311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BHVN", "relevance_score": "0.73822", "ticker_sentiment_score": "0.223303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.11894", "ticker_sentiment_score": "0.086748", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.11894", "ticker_sentiment_score": "0.086748", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.11894", "ticker_sentiment_score": "0.162133", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.11894", "ticker_sentiment_score": "0.086748", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.11894", "ticker_sentiment_score": "0.086748", "ticker_sentiment_label": "Neutral"}]}, {"title": "US to require patient data for payment of Leqembi, similar Alzheimer's drugs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/medicare-cover-new-alzheimers-drug-after-full-approval-2023-06-01/", "time_published": "20230601T183300", "authors": ["Julie Steenhuysen"], "summary": "US to require patient data for payment of Leqembi, similar ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/V2AEYRPI2JN2LMQGKSSKXI7QWA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.160374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.119532", "ticker_sentiment_score": "0.040054", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059935", "ticker_sentiment_score": "0.086307", "ticker_sentiment_label": "Neutral"}]}, {"title": "BNGO: Is Now the Time to Buy Bionano Genomics  ( BNGO ) ?", "url": "https://stocknews.com/news/bngo-alks-biib-gild-is-now-the-time-to-buy-bionano-genomics-bngo/", "time_published": "20230601T175605", "authors": [], "summary": "Bionano Genomics, Inc. ( BNGO ) is a genome analysis software provider that enables genomics labs to analyze and interpret data across a range of platforms. The company's revenue saw a significant jump in the recent past, increasing at CAGRs of 46.4% and 25.3% over the past three and five years, ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_1551788306-3-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.107846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.784632", "ticker_sentiment_score": "0.186392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALKS", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer", "url": "https://www.prnewswire.com/news-releases/abilita-bio-changes-name-to-abilita-therapeutics-and-appoints-joel-edwards-as-chief-business-officer-301839467.html", "time_published": "20230601T110000", "authors": ["Abilita Therapeutics"], "summary": "Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2090208/Abilita_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252499, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.065685", "ticker_sentiment_score": "0.033201", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.065685", "ticker_sentiment_score": "0.033201", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.065685", "ticker_sentiment_score": "0.033201", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cassava  ( SAVA )  Up on Progress With Alzheimers Disease Study", "url": "https://www.zacks.com/stock/news/2101565/cassava-sava-up-on-progress-with-alzheimers-disease-study", "time_published": "20230530T160600", "authors": ["Zacks Investment Research"], "summary": "Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.120831, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRTA", "relevance_score": "0.183895", "ticker_sentiment_score": "0.092469", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.123209", "ticker_sentiment_score": "0.282067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAVA", "relevance_score": "0.123209", "ticker_sentiment_score": "0.093637", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Recombinant DNA Technology Market Report 2023: Increasing Number of Chronic Diseases Drives Growth", "url": "https://www.prnewswire.com/news-releases/global-recombinant-dna-technology-market-report-2023-increasing-number-of-chronic-diseases-drives-growth-301835829.html", "time_published": "20230527T014500", "authors": ["Research and Markets"], "summary": "Global Recombinant DNA Technology Market Report 2023 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.152528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.065957", "ticker_sentiment_score": "0.116556", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Unusual Options Activity For May 26 - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/markets/options/23/05/32598541/biogen-unusual-options-activity-for-may-26", "time_published": "20230526T160257", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Biogen BIIB. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_10252.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.180453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.767792", "ticker_sentiment_score": "0.267763", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alkermes  ( ALKS )  Up 3.7% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2100372/alkermes-alks-up-37-since-last-earnings-report-can-it-continue", "time_published": "20230526T153141", "authors": ["Zacks Investment Research"], "summary": "Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.167905, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.368773", "ticker_sentiment_score": "0.286998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.251032", "ticker_sentiment_score": "0.064733", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Alzheimer's drug could bring hope to patients, but could be out of reach for people on Medicare", "url": "https://www.marketwatch.com/story/new-alzheimers-drug-could-bring-hope-to-patients-but-could-be-out-of-reach-for-people-on-medicare-8b128e70", "time_published": "20230525T155000", "authors": ["Jessica Hall"], "summary": "The Food and Drug Administration is set to announce soon whether it will grant full approval to lecanemab for the treatment of Alzheimer's.", "banner_image": "https://images.mktw.net/im-788699/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.03458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.069094", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen Inc.  ( BIIB )  Up 4.7% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2099759/biogen-inc-biib-up-47-since-last-earnings-report-can-it-continue", "time_published": "20230525T153100", "authors": ["Zacks Investment Research"], "summary": "Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default224.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998287"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.083827, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.029545", "ticker_sentiment_score": "0.074363", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.541149", "ticker_sentiment_score": "0.235743", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical", "url": "https://www.zacks.com/stock/news/2098801/zacks-industry-outlook-highlights-amphastar-dr-reddys-and-teva-pharmaceutical", "time_published": "20230524T083400", "authors": ["Zacks Investment Research"], "summary": "Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c4/390.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.153898, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMPH", "relevance_score": "0.087185", "ticker_sentiment_score": "-0.083513", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.029113", "ticker_sentiment_score": "0.060772", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.029113", "ticker_sentiment_score": "0.092798", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.029113", "ticker_sentiment_score": "0.060772", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Generic Drug Stocks to Watch Amid Macro Headwinds", "url": "https://www.zacks.com/commentary/2098340/3-generic-drug-stocks-to-watch-amid-macro-headwinds", "time_published": "20230523T120100", "authors": ["Zacks Investment Research"], "summary": "The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/2584.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.151717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMPH", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.098265", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.030292", "ticker_sentiment_score": "0.051993", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.030292", "ticker_sentiment_score": "0.084235", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.030292", "ticker_sentiment_score": "0.051993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen  ( NASDAQ:BIIB )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/05/22/biogen-nasdaqbiib-coverage-initiated-at-stocknews-com.html", "time_published": "20230522T114302", "authors": ["Defense World Staff"], "summary": "StockNews.com began coverage on shares of Biogen ( NASDAQ:BIIB - Get Rating ) in a report released on Thursday. The firm issued a strong-buy rating on the biotechnology company's stock. A number of other research analysts have also recently commented on the company.", "banner_image": "https://www.marketbeat.com/logos/biogen-inc-logo.jpg?v=20221024141534", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.910869"}], "overall_sentiment_score": 0.281597, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.04882", "ticker_sentiment_score": "0.063655", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIO", "relevance_score": "0.04882", "ticker_sentiment_score": "0.063655", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.04882", "ticker_sentiment_score": "0.051385", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.097457", "ticker_sentiment_score": "0.06024", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.801457", "ticker_sentiment_score": "0.455986", "ticker_sentiment_label": "Bullish"}]}, {"title": "Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic", "url": "https://www.prnewswire.com/news-releases/marketing-authorisation-application-for-lecanemab-submitted-in-great-britain-bioarctic-301830416.html", "time_published": "20230522T030300", "authors": ["BioArctic"], "summary": "Marketing Authorisation Application for lecanemab submitted in ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.219913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.580544", "ticker_sentiment_score": "0.323414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.150516", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clinical Project Manager  ( CPM )  Beginner Training Course", "url": "https://www.prnewswire.com/news-releases/clinical-project-manager-cpm-beginner-training-course-301829578.html", "time_published": "20230520T000000", "authors": ["Research and Markets"], "summary": "DUBLIN, May 19, 2023 /PRNewswire/ -- The \"Clinical Project Manager ( CPM ) Beginner\" training has been added to ResearchAndMarkets.com's offering. If you are looking to enter the field of clinical research, this CPD-accredited is for you.", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.195609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.072655", "ticker_sentiment_score": "0.033182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.072655", "ticker_sentiment_score": "0.033182", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.072655", "ticker_sentiment_score": "0.033182", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.072655", "ticker_sentiment_score": "0.158298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.072655", "ticker_sentiment_score": "0.158298", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32491391/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-5-500-today", "time_published": "20230519T180024", "authors": ["Benzinga Insights"], "summary": "Biogen BIIB has outperformed the market over the past 15 years by 4.24% on an annualized basis producing an average annual return of 11.87%. Currently, Biogen has a market capitalization of $44.53 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) , Denali Therapeutics  ( NASDAQ:DNLI ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32483099/analysts-say-these-2-mid-cap-biotechs-have-2x-potential", "time_published": "20230519T175626", "authors": ["MarketBeat"], "summary": "On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel narrowly recommended approval for the company's gene therapy for Duchenne Muscular Dystrophy ( DMD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/19/national-cancer-institute-hmqtsqzhpzu-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.049424", "ticker_sentiment_score": "0.075288", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.179564", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SRPT", "relevance_score": "0.049424", "ticker_sentiment_score": "0.20214", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.098659", "ticker_sentiment_score": "0.099601", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.049424", "ticker_sentiment_score": "0.031001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.049424", "ticker_sentiment_score": "0.031001", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.049424", "ticker_sentiment_score": "0.051446", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049424", "ticker_sentiment_score": "-0.146402", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.049424", "ticker_sentiment_score": "-0.146402", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.049424", "ticker_sentiment_score": "0.09267", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.049424", "ticker_sentiment_score": "0.09267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Pharma, Biotech and Diagnostics Co-development Partnering Deals Analysis Report 2023 with a Directory of Deals - Comprehensive Access to Actual Co-development Contracts", "url": "https://www.prnewswire.com/news-releases/global-pharma-biotech-and-diagnostics-co-development-partnering-deals-analysis-report-2023-with-a-directory-of-deals---comprehensive-access-to-actual-co-development-contracts-301829437.html", "time_published": "20230519T141500", "authors": ["Research and Markets"], "summary": "Global Pharma, Biotech and Diagnostics Co-development ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.268101, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market", "url": "https://www.fool.com/investing/2023/05/19/1-major-advantage-biogen-may-have-over-eli-lilly/", "time_published": "20230519T121500", "authors": ["David Jagielski"], "summary": "Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732639%2Fbuffett17-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.043939, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.172097", "ticker_sentiment_score": "-0.167755", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ESALF", "relevance_score": "0.172097", "ticker_sentiment_score": "0.070545", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.43789", "ticker_sentiment_score": "-0.11496", "ticker_sentiment_label": "Neutral"}]}, {"title": "Canadian Solar Reports First Quarter 2023 Results", "url": "https://www.prnewswire.com/news-releases/canadian-solar-reports-first-quarter-2023-results-301828321.html", "time_published": "20230518T100000", "authors": ["Canadian Solar Inc."], "summary": "GUELPH, ON, May 18, 2023 /PRNewswire/ -- Canadian Solar Inc. ( \"Canadian Solar\" or the \"Company\" ) ( NASDAQ: CSIQ ) today announced financial results for the first quarter ended March 31, 2023. \u2022 66% increase in solar module shipments year-over-year ( \"yoy\" ) to 6.1 GW, in line with guidance of ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.904684"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PGPGF", "relevance_score": "0.022018", "ticker_sentiment_score": "0.153733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TOPCF", "relevance_score": "0.01101", "ticker_sentiment_score": "0.192234", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADSK", "relevance_score": "0.01101", "ticker_sentiment_score": "0.155397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.01101", "ticker_sentiment_score": "0.155397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSIQ", "relevance_score": "0.163984", "ticker_sentiment_score": "0.046225", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.01101", "ticker_sentiment_score": "0.155397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.01101", "ticker_sentiment_score": "-0.086393", "ticker_sentiment_label": "Neutral"}]}, {"title": "The War Over Whether Medicare Should Pay For The New Anti-Alzheimer's Drugs", "url": "https://www.forbes.com/sites/howardgleckman/2023/05/17/the-war-over-whether-medicare-should-pay-for-the-new-anti-alzheimers-drugs/", "time_published": "20230517T192646", "authors": ["Howard Gleckman"], "summary": "Unless Medicare widely covers anti-Alzheimer's drugs, they will be unaffordable for the vast majority of consumers.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64652a14a88356f3a776b700/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.00244, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.046184", "ticker_sentiment_score": "0.084539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046184", "ticker_sentiment_score": "0.084539", "ticker_sentiment_label": "Neutral"}]}, {"title": "We're starting a new position in one of the Big 3 global medical imaging and diagnostics companies", "url": "https://www.cnbc.com/2023/05/17/were-starting-a-new-position-in-a-medical-imaging-and-diagnostics-leader.html", "time_published": "20230517T173053", "authors": ["Jeff Marks", "Jim Cramer"], "summary": "This company operates in an $84 billion total addressable market that the company sees growing to around $100 billion by 2024.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107090852-1658244731556-NUP_198367_00786_copy.jpg?v=1684344653&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.998333"}], "overall_sentiment_score": 0.250949, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.109622", "ticker_sentiment_score": "0.120303", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.073209", "ticker_sentiment_score": "0.110168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.073209", "ticker_sentiment_score": "0.110168", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.036643", "ticker_sentiment_score": "0.105451", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.537702", "ticker_sentiment_score": "0.344722", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.073209", "ticker_sentiment_score": "0.110168", "ticker_sentiment_label": "Neutral"}]}, {"title": "Virtualware rewards its employees with more than 52,000 shares during its first month as a listed company on the Paris Stock Exchange", "url": "https://www.globenewswire.com/news-release/2023/05/17/2671266/0/en/Virtualware-rewards-its-employees-with-more-than-52-000-shares-during-its-first-month-as-a-listed-company-on-the-Paris-Stock-Exchange.html", "time_published": "20230517T151300", "authors": ["Virtualware"], "summary": "PARIS and BILBAO, Spain, May 17, 2023 ( GLOBE NEWSWIRE ) -- Virtual reality company Virtualware ( EPA:MLVIR ) has distributed in its first month of trading a total of 52,602 shares among most of its employees, with a total value of more than 315,612 euros.", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.486418, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HTHIF", "relevance_score": "0.115232", "ticker_sentiment_score": "0.132715", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.115232", "ticker_sentiment_score": "0.132715", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.115232", "ticker_sentiment_score": "0.132715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.115232", "ticker_sentiment_score": "0.132715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.115232", "ticker_sentiment_score": "0.132715", "ticker_sentiment_label": "Neutral"}]}, {"title": "CENTOGENE Reports Full Year 2022 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/05/16/2670546/0/en/CENTOGENE-Reports-Full-Year-2022-Financial-Results.html", "time_published": "20230516T222500", "authors": ["Centogene NV"], "summary": "CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 ( GLOBE NEWSWIRE ) -- Centogene N.V. ( Nasdaq: CNTG ) ( \"we\" or the \"Company\" ) , the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9db085f4-b57e-4d19-84cf-62bc960c1d57", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.206637, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CNTG", "relevance_score": "0.278641", "ticker_sentiment_score": "0.224363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TWST", "relevance_score": "0.016738", "ticker_sentiment_score": "0.121407", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.016738", "ticker_sentiment_score": "0.121407", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.016738", "ticker_sentiment_score": "0.121407", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.016738", "ticker_sentiment_score": "0.121407", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Biogen  ( BIIB )  Stock is Up 12.6% This Year So Far", "url": "https://www.zacks.com/stock/news/2095822/heres-why-biogen-biib-stock-is-up-126-this-year-so-far", "time_published": "20230516T135600", "authors": ["Zacks Investment Research"], "summary": "Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.141223, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.182047", "ticker_sentiment_score": "0.099361", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.182047", "ticker_sentiment_score": "-0.101418", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUP", "relevance_score": "0.241085", "ticker_sentiment_score": "0.080882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.061159", "ticker_sentiment_score": "0.199105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.557075", "ticker_sentiment_score": "0.02096", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alcami Appoints Laurent Boer as General Manager of Biostorage and Pharmaceutical Support Services.", "url": "https://www.prnewswire.com/news-releases/alcami-appoints-laurent-boer-as-general-manager-of-biostorage-and-pharmaceutical-support-services-301825973.html", "time_published": "20230516T133000", "authors": ["Alcami Corporation"], "summary": "Alcami Appoints Laurent Boer as General Manager of Biostorage ... PR ...", "banner_image": "https://mma.prnewswire.com/media/344471/Alcami_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.340702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.017051", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.017051", "ticker_sentiment_label": "Neutral"}]}, {"title": "Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease", "url": "https://www.globenewswire.com/news-release/2023/05/15/2669467/0/en/Health-Canada-Accepts-New-Drug-Submission-for-Lecanemab-as-Treatment-for-Early-Alzheimer-s-Disease.html", "time_published": "20230515T233000", "authors": ["Biogen Inc."], "summary": "TOKYO and CAMBRIDGE, Mass., May 15, 2023 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\" ) announced today that Health Canada has ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.173979, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.024297", "ticker_sentiment_score": "0.060009", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.048572", "ticker_sentiment_score": "0.083122", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.024297", "ticker_sentiment_score": "0.081503", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.497175", "ticker_sentiment_score": "0.223732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.285249", "ticker_sentiment_score": "0.072732", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Denali Therapeutics Are Up Monday", "url": "https://www.fool.com/investing/2023/05/15/why-shares-of-denali-therapeutics-are-up-monday/", "time_published": "20230515T203143", "authors": ["Jim Halley"], "summary": "Analysts maintained their buy ratings on the clinical-stage biotech company.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732443%2Ftsla.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.016862, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.029706", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.265378", "ticker_sentiment_score": "0.10816", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.029706", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly Is On Track For A Blockbuster Alzheimer's Drug; What's Next?", "url": "https://www.investors.com/news/technology/eli-lilly-stock-why-version-alzheimers-treatment-could-become-a-blockbuster-in-2025/", "time_published": "20230515T175000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Eli Lilly Stock: Why Version 1.0 In Alzheimer's Treatment Could ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.207179, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.615462", "ticker_sentiment_score": "0.379671", "ticker_sentiment_label": "Bullish"}, {"ticker": "ESALF", "relevance_score": "0.115232", "ticker_sentiment_score": "0.169605", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.33628", "ticker_sentiment_score": "0.125055", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson's Disease", "url": "https://www.benzinga.com/pressreleases/23/05/g32401310/nature-publishes-work-demonstrating-clinical-ink-technology-sensitivity-to-parkinsons-disease", "time_published": "20230515T173043", "authors": ["Globe Newswire"], "summary": "Winston Salem, NC, May 15, 2023 ( GLOBE NEWSWIRE ) -- Clinical ink, a global life science technology company, announces the publication of \"Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study\" in npj Parkinson's Disease.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.070231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.109956", "ticker_sentiment_score": "0.021888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium", "url": "https://www.prnewswire.com/news-releases/recurrent-energy-signs-aggregation-deal-for-100-mw-of-solar-energy-in-texas-with-industry-consortium-301824300.html", "time_published": "20230515T110000", "authors": ["Canadian Solar Inc."], "summary": "Recurrent Energy Signs Aggregation Deal for 100 MW of Solar ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.304299, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADSK", "relevance_score": "0.112929", "ticker_sentiment_score": "0.276942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.140896", "ticker_sentiment_score": "0.206224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSIQ", "relevance_score": "0.277433", "ticker_sentiment_score": "0.080423", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.112929", "ticker_sentiment_score": "0.181378", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BiomX Reports First Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/05/15/2668546/0/en/BiomX-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html", "time_published": "20230515T103000", "authors": ["BiomX"], "summary": "Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis ( \"CF\" ). Results from Part 2 Expected in Third Quarter of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2545774a-e366-4eba-a284-7aca7de3708d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}], "overall_sentiment_score": 0.080388, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMRN", "relevance_score": "0.023533", "ticker_sentiment_score": "0.030946", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.023533", "ticker_sentiment_score": "0.030946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html", "time_published": "20230515T093200", "authors": ["Brandessence Market Research and Consulting Private Limited"], "summary": "Report Forecasts Promising Future for Alzheimer's Disease Market ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.172476, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACIU", "relevance_score": "0.017394", "ticker_sentiment_score": "-0.017349", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHYOF", "relevance_score": "0.017394", "ticker_sentiment_score": "0.117319", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.03478", "ticker_sentiment_score": "0.017283", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.017394", "ticker_sentiment_score": "-0.017349", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.017394", "ticker_sentiment_score": "-0.017349", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.03478", "ticker_sentiment_score": "0.124339", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.017394", "ticker_sentiment_score": "0.117319", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.017394", "ticker_sentiment_score": "0.117319", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.017394", "ticker_sentiment_score": "-0.017349", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.017394", "ticker_sentiment_score": "0.117319", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.017394", "ticker_sentiment_score": "0.112745", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.069495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UZS", "relevance_score": "0.017394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Promising new Alzheimer's drugs present patients with tough choices", "url": "https://www.axios.com/2023/05/15/alzheimers-drugs-patients-risks-medicare-fda", "time_published": "20230515T063442", "authors": ["Caitlin Owens", "https://www.axios.com/authors/caitlin", "https://www.axios.com/authors/ogonzalez", "Oriana Gonz\u00e1lez"], "summary": "Promising clinical trial results from another new Alzheimer's drug haven't put to bed questions about how much the treatments actually benefit patients, and whether their strong points outweigh their safety risks.", "banner_image": "https://images.axios.com/6R47z_cZDHYOR0EvealgK8pfznY=/0x0:1920x1080/1920x1080/2023/05/12/1683922162654.jpg?w=1920", "source": "Axios", "category_within_source": "Economy", "source_domain": "www.axios.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.134457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.040622", "ticker_sentiment_score": "-0.003954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040622", "ticker_sentiment_score": "0.072431", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win", "url": "https://www.fool.com/investing/2023/05/14/these-2-pharma-stocks-might-face-off-soon-but-they/", "time_published": "20230514T121500", "authors": ["Alex Carchidi"], "summary": "There's no rule that says a market must have only one winner.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732171%2Fneurologist-shows-patient-a-brain-scan-image.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.012074, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.351985", "ticker_sentiment_score": "-0.04786", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.103778", "ticker_sentiment_score": "-0.080198", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates", "url": "https://www.cnbc.com/2023/05/12/alzheimers-disease-leqembi-could-cost-medicare-5-billion-per-year.html", "time_published": "20230512T185357", "authors": ["Spencer Kimball"], "summary": "The authors said the estimated cost of Leqembi to Medicare are conservative, and spending on the Alzheimer's treatment may increase more than anticipated.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107240452-16839077782023-01-20t224759z_1083470858_rc2f2w9147j4_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1683917637&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.023936, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.121959", "ticker_sentiment_score": "0.075092", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.061159", "ticker_sentiment_score": "-0.12502", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.121959", "ticker_sentiment_score": "0.075092", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.061159", "ticker_sentiment_score": "-0.12502", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Buy Biogen Stock  ( and 1 to Sell ) ", "url": "https://www.fool.com/investing/2023/05/12/3-reasons-to-buy-biogen-stock-and-1-to-sell/", "time_published": "20230512T141500", "authors": ["David Jagielski"], "summary": "The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F731390%2Fbuffett8-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.260362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.055492", "ticker_sentiment_score": "0.234974", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.596433", "ticker_sentiment_score": "0.389816", "ticker_sentiment_label": "Bullish"}]}, {"title": "Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-alzheimers-drug-leqembi-would-cost-us-medicare-up-5-bln-year-study-2023-05-11/", "time_published": "20230511T194200", "authors": ["Deena Beasley"], "summary": "Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/V2AEYRPI2JN2LMQGKSSKXI7QWA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.018992, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.190667", "ticker_sentiment_score": "0.006109", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.127795", "ticker_sentiment_score": "0.007203", "ticker_sentiment_label": "Neutral"}]}, {"title": "BIIB: 3 Biotech Stocks to Buy Now", "url": "https://stocknews.com/news/biib-alks-vnda-3-biotech-stocks-to-buy-now/", "time_published": "20230511T150816", "authors": [], "summary": "The biotech industry was at the forefront of vaccine development and helped tide over the pandemic. Government initiatives, rapid advancements in agricultural biotechnology, and the inelastic demand for healthcare are the main drivers of the biotech industry's growth.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.23011, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.27063", "ticker_sentiment_score": "0.189969", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VNDA", "relevance_score": "0.156715", "ticker_sentiment_score": "0.122436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.343543", "ticker_sentiment_score": "0.159905", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal", "url": "https://www.fool.com/investing/2023/05/11/heres-why-eli-lillys-alzheimers-drug-could-be-the/", "time_published": "20230511T140700", "authors": ["David Jagielski"], "summary": "Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F731423%2Fstock-market-crash-plunge-dollar-newspaper-invest-dow-sp-500-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.162855, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.263942", "ticker_sentiment_score": "0.19747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.199584", "ticker_sentiment_score": "0.048343", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should iShares Morningstar Mid-Cap Value ETF  ( IMCV )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2093943/should-ishares-morningstar-mid-cap-value-etf-imcv-be-on-your-investing-radar", "time_published": "20230511T102008", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.300265, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.060848", "ticker_sentiment_score": "0.114009", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.181137", "ticker_sentiment_score": "0.224214", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOW", "relevance_score": "0.121343", "ticker_sentiment_score": "0.068087", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.121343", "ticker_sentiment_score": "0.068087", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEM", "relevance_score": "0.121343", "ticker_sentiment_score": "0.068087", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NEM", "relevance_score": "0.060848", "ticker_sentiment_score": "0.06", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( BIIB )  - Analyzing Biogen's Short Interest - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/short-sellers/23/05/32327721/biib-analyzing-biogens-short-interest", "time_published": "20230510T203032", "authors": ["Benzinga Insights"], "summary": "Biogen's BIIB short percent of float has risen 7.59% since its last report. The company recently reported that it has 2.00 million shares sold short, which is 1.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Hyper-Personalized Medicine Market Expected to Generate a Revenue of $5,886.50 Billion and Rise at a CAGR of 11.7% over the 2022-2031 Timeframe [280-Pages] | Information by Research Dive", "url": "https://www.benzinga.com/pressreleases/23/05/g32315607/global-hyper-personalized-medicine-market-expected-to-generate-a-revenue-of-5-886-50-billion-and-r", "time_published": "20230510T130500", "authors": ["Globe Newswire"], "summary": "New York, USA, May 10, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global hyper-personalized medicine market is anticipated to garner a revenue of $5,886.50 billion and rise at a CAGR of 11.7% during the analysis timeframe from 2022 to 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.243692, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXAS", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.053153", "ticker_sentiment_score": "0.269869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DHR", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer", "url": "https://www.globenewswire.com/news-release/2023/05/10/2665341/0/en/Cerevel-Therapeutics-Appoints-Susan-Altschuller-Ph-D-as-Chief-Financial-Officer.html", "time_published": "20230510T103000", "authors": ["Cerevel Therapeutics"], "summary": "Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a08b2b75-1208-494e-96a4-a7f98dc0328a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.15392, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CERE", "relevance_score": "0.243585", "ticker_sentiment_score": "0.283331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.070621", "ticker_sentiment_score": "0.062264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32310471/cerevel-therapeutics-appoints-susan-altschuller-ph-d-as-chief-financial-officer", "time_published": "20230510T103000", "authors": ["Globe Newswire"], "summary": "Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.151486, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CERE", "relevance_score": "0.206685", "ticker_sentiment_score": "0.243947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.069596", "ticker_sentiment_score": "0.062213", "ticker_sentiment_label": "Neutral"}]}, {"title": "Denali  ( DNLI )  Q1 Earnings Miss Estimates, Pipeline in Focus", "url": "https://www.zacks.com/stock/news/2092620/denali-dnli-q1-earnings-miss-estimates-pipeline-in-focus", "time_published": "20230509T172400", "authors": ["Zacks Investment Research"], "summary": "Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.044869, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.256314", "ticker_sentiment_score": "0.074818", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.376194", "ticker_sentiment_score": "0.06953", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.317254", "ticker_sentiment_score": "-0.016795", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.256314", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors - Voyager Therapeutics  ( NASDAQ:VYGR ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32282893/voyager-therapeutics-announces-appointment-of-george-scangos-ph-d-to-board-of-directors", "time_published": "20230509T105500", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass., May 09, 2023 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.170501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXEL", "relevance_score": "0.089965", "ticker_sentiment_score": "0.089278", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045054", "ticker_sentiment_score": "0.036673", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.045054", "ticker_sentiment_score": "0.046448", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.17879", "ticker_sentiment_score": "0.05394", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.089965", "ticker_sentiment_score": "0.089278", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.045054", "ticker_sentiment_score": "0.036673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/05/09/2664203/36461/en/Voyager-Therapeutics-Announces-Appointment-of-George-Scangos-Ph-D-to-Board-of-Directors.html", "time_published": "20230509T105500", "authors": ["Inc.", "Voyager Therapeutics"], "summary": "CAMBRIDGE, Mass., May 09, 2023 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( NASDAQ: VYGR ) , a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors.", "banner_image": "https://ml.globenewswire.com/Resource/Download/3fe5c08d-e9d5-4ef6-944b-503007d056b0", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.172877, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXEL", "relevance_score": "0.084871", "ticker_sentiment_score": "0.089348", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042496", "ticker_sentiment_score": "0.037496", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.042496", "ticker_sentiment_score": "0.048168", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.210092", "ticker_sentiment_score": "0.062633", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.084871", "ticker_sentiment_score": "0.089348", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.042496", "ticker_sentiment_score": "0.037496", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for Biogen - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/news/23/05/32266928/pe-ratio-insights-for-biogen", "time_published": "20230508T150039", "authors": ["Benzinga Insights"], "summary": "In the current market session, Biogen Inc. BIIB stock price is at $314.35, after a 1.17% decrease. However, over the past month, the company's stock increased by 10.81%, and in the past year, by 61.20%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.040303, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "0.359014", "ticker_sentiment_score": "-0.01009", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks", "url": "https://www.zacks.com/stock/news/2091538/the-zacks-analyst-blog-highlights-exxon-mobil-costco-wholesale-activision-blizzard-biogen-and-arista-networks", "time_published": "20230508T125400", "authors": ["Zacks Investment Research"], "summary": "Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a0/810.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.253638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.246167", "ticker_sentiment_score": "-0.001867", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.083251", "ticker_sentiment_score": "-0.002104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.165598", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.324139", "ticker_sentiment_score": "0.189912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.165598", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.398781", "ticker_sentiment_score": "0.354128", "ticker_sentiment_label": "Bullish"}]}, {"title": "After weight loss, Alzheimer's may be next frontier for drugs like Ozempic", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/after-weight-loss-alzheimers-may-be-next-frontier-drugs-like-ozempic-2023-05-08/", "time_published": "20230508T101100", "authors": ["Natalie Grover"], "summary": "After weight loss, Alzheimer's may be next frontier for drugs like ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TMB2SR6WF5ODTCNRTO6MFIXALQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064505, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ESALF", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.036002", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042421", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.036002", "ticker_sentiment_label": "Neutral"}]}, {"title": "Where Will Eli Lilly Be in 3 Years?", "url": "https://www.fool.com/investing/2023/05/08/where-will-eli-lilly-be-in-3-years/", "time_published": "20230508T095700", "authors": ["Alex Carchidi"], "summary": "The pharmaceutical giant is likely to grow quickly as it is entering a new age of contested markets.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F730975%2Fa-digital-rendering-of-a-computer-chip-being-plugged-into-a-circuit-board.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.213068, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.459624", "ticker_sentiment_score": "0.288973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.054236", "ticker_sentiment_score": "0.040003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.054236", "ticker_sentiment_score": "0.040003", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Things About Eli Lilly That Smart Investors Know", "url": "https://www.fool.com/investing/2023/05/08/3-things-about-eli-lilly-that-smart-investors-know/", "time_published": "20230508T090500", "authors": ["Alex Carchidi"], "summary": "There are quite a few details to keep track of with this company, and they all matter.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F730975%2Fa-digital-rendering-of-a-computer-chip-being-plugged-into-a-circuit-board.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.149688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.369685", "ticker_sentiment_score": "0.252615", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.063933", "ticker_sentiment_score": "0.134318", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.063933", "ticker_sentiment_score": "0.134318", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.063933", "ticker_sentiment_score": "0.134318", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.063933", "ticker_sentiment_score": "0.134318", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.063933", "ticker_sentiment_score": "-0.029181", "ticker_sentiment_label": "Neutral"}]}]}